Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - GAMG [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - hTERT-RPE1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - JURKAT [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - OE19 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - SuSa [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" "Single Cell Type RNA - Alveolar cells type 1 [NX]" "Single Cell Type RNA - Alveolar cells type 2 [NX]" "Single Cell Type RNA - B-cells [NX]" "Single Cell Type RNA - Basal glandular cells [NX]" "Single Cell Type RNA - Basal keratinocytes [NX]" "Single Cell Type RNA - Bipolar cells [NX]" "Single Cell Type RNA - Cardiomyocytes [NX]" "Single Cell Type RNA - Cholangiocytes [NX]" "Single Cell Type RNA - Ciliated cells [NX]" "Single Cell Type RNA - Club cells [NX]" "Single Cell Type RNA - Collecting duct cells [NX]" "Single Cell Type RNA - Cone photoreceptor cells [NX]" "Single Cell Type RNA - Cytotrophoblasts [NX]" "Single Cell Type RNA - Distal tubular cells [NX]" "Single Cell Type RNA - Ductal cells [NX]" "Single Cell Type RNA - Early spermatids [NX]" "Single Cell Type RNA - Endothelial cells [NX]" "Single Cell Type RNA - Enterocytes [NX]" "Single Cell Type RNA - Erythroid cells [NX]" "Single Cell Type RNA - Exocrine glandular cells [NX]" "Single Cell Type RNA - Extravillous trophoblasts [NX]" "Single Cell Type RNA - Fibroblasts [NX]" "Single Cell Type RNA - Glandular cells [NX]" "Single Cell Type RNA - granulocytes [NX]" "Single Cell Type RNA - Hepatocytes [NX]" "Single Cell Type RNA - Hofbauer cells [NX]" "Single Cell Type RNA - Horizontal cells [NX]" "Single Cell Type RNA - Intestinal endocrine cells [NX]" "Single Cell Type RNA - Ito cells [NX]" "Single Cell Type RNA - Kupffer cells [NX]" "Single Cell Type RNA - Late spermatids [NX]" "Single Cell Type RNA - Leydig cells [NX]" "Single Cell Type RNA - Macrophages [NX]" "Single Cell Type RNA - Melanocytes [NX]" "Single Cell Type RNA - monocytes [NX]" "Single Cell Type RNA - Mucus-secreting cells [NX]" "Single Cell Type RNA - Muller glia cells [NX]" "Single Cell Type RNA - Pancreatic endocrine cells [NX]" "Single Cell Type RNA - Paneth cells [NX]" "Single Cell Type RNA - Peritubular cells [NX]" "Single Cell Type RNA - Proximal tubular cells [NX]" "Single Cell Type RNA - Rod photoreceptor cells [NX]" "Single Cell Type RNA - Sertoli cells [NX]" "Single Cell Type RNA - Smooth muscle cells [NX]" "Single Cell Type RNA - Spermatocytes [NX]" "Single Cell Type RNA - Spermatogonia [NX]" "Single Cell Type RNA - Suprabasal keratinocytes [NX]" "Single Cell Type RNA - Syncytiotrophoblasts [NX]" "Single Cell Type RNA - T-cells [NX]" "Single Cell Type RNA - Undifferentiated cells [NX]" "Single Cell Type RNA - Urothelial cells [NX]" ABCB1 "ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1" ENSG00000085563 "ATP binding cassette subfamily B member 1" P08183 7 87503633-87713323 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport Translocase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 57.8;intestine: 49.6" "Cell type enhanced" "Detected in many" 13 "Cholangiocytes: 104.4;Enterocytes: 174.5;Paneth cells: 77.2" "Cancer enhanced" "Detected in many" "renal cancer: 14.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 19.2" "Group enriched" "Detected in many" 8 "NK-cells: 11.4;T-cells: 19.2" "Cell line enhanced" "Detected in some" "CACO-2: 30.1;HEK 293: 9.3;HEL: 16.7;Hep G2: 8.2;RPTEC TERT1: 11.5;SH-SY5Y: 36.8" "CAB001716, HPA002199, HPA074614" Enhanced Approved "Nucleoplasm,Plasma membrane,Focal adhesion sites" NA NA "Nucleoplasm, Plasma membrane" "Focal adhesion sites" "CAB001716: , HPA002199: AB_1844428, HPA074614: " "unprognostic (5.38e-3)" "unprognostic (2.45e-2)" "unprognostic (1.42e-1)" "unprognostic (1.06e-1)" "unprognostic (2.25e-2)" "unprognostic (9.99e-5)" "unprognostic (2.23e-3)" "unprognostic (5.65e-3)" "unprognostic (1.14e-1)" "unprognostic (5.17e-2)" "prognostic favorable (3.33e-4)" "unprognostic (5.19e-1)" "prognostic favorable (2.95e-4)" "unprognostic (2.06e-1)" "unprognostic (1.50e-1)" "unprognostic (3.83e-1)" "unprognostic (6.12e-2)" 2.6 57.8 9.4 3.2 11.5 1.2 3.4 5.1 10.5 5.5 22.7 3.8 2.0 14.4 9.4 3.5 2.0 3.2 9.0 1.8 9.2 6.6 19.1 15.6 3.8 2.2 9.4 5.7 2.2 1.5 1.7 1.3 3.1 11.1 2.7 10.7 7.6 1.5 2.1 1.1 1.3 49.6 5.7 9.0 2.4 1.7 1.3 8.6 0.1 2.4 1.4 2.2 2.6 5.9 1.9 0.0 0.1 0.0 11.4 19.2 1.5 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 30.1 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 9.3 16.7 1.9 8.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 11.5 0.1 0.4 36.8 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.9 0.0 0.4 3.2 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 7.8 0.0 19.2 0.4 2.0 4.7 0.0 1.9 1.2 4.8 0.1 11.4 0.0 0.0 0.0 1.5 9.4 11.5 5.1 10.5 9.2 6.6 9.4 5.7 11.1 8.6 0.0 4.8 5.9 0.1 0.7 0.6 2.8 104.4 1.4 1.2 47.1 0.0 5.0 5.0 10.2 21.6 23.1 174.5 23.3 1.6 0.1 0.5 0.1 3.5 32.6 0.4 0.0 0.0 3.7 1.2 2.5 0.9 0.8 0.0 0.0 8.9 0.0 11.4 77.2 0.0 44.0 0.9 0.0 0.8 0.5 0.4 0.5 8.2 27.3 1.7 0.1 ABCB4 "GBD1, MDR2, MDR3, PFIC-3, PGY3" ENSG00000005471 "ATP binding cassette subfamily B member 4" P21439 7 87401697-87480435 "Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Lipid transport, Transport" Translocase "Disease mutation, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "liver: 93.2" "Cell type enriched" "Detected in some" 6 "Hepatocytes: 235.3" "Cancer enriched" "Detected in some" 11 "liver cancer: 16.3" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 6 "memory B-cell: 4.9;naive B-cell: 11.4" "Lineage enriched" "Detected in many" 8 "B-cells: 11.4" "Group enriched" "Detected in some" 5 "SH-SY5Y: 12.0;WM-115: 22.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA049395, HPA053288" Enhanced Approved "Nucleoplasm,Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Nucleoplasm, Plasma membrane, Actin filaments" "Focal adhesion sites" "HPA049395: AB_2680745, HPA053288: AB_2682102" "unprognostic (7.92e-2)" "unprognostic (8.87e-2)" "unprognostic (1.97e-1)" "unprognostic (1.90e-1)" "unprognostic (8.95e-2)" "unprognostic (1.06e-2)" "unprognostic (2.35e-3)" "unprognostic (9.91e-2)" "unprognostic (3.53e-1)" "unprognostic (1.19e-1)" "unprognostic (2.44e-3)" "unprognostic (8.43e-2)" "unprognostic (2.83e-2)" "unprognostic (8.01e-3)" "unprognostic (7.12e-2)" "unprognostic (2.11e-2)" "unprognostic (2.47e-1)" 0.5 4.1 0.2 4.3 0.2 0.2 0.3 0.1 1.1 0.2 0.6 0.4 0.0 0.0 0.1 0.2 0.6 0.1 0.3 4.0 0.3 0.2 0.4 93.2 0.1 4.1 0.3 0.2 0.3 0.1 0.0 0.5 0.0 0.3 0.3 0.4 0.8 0.4 0.1 2.9 0.6 1.2 1.6 0.5 5.2 0.2 0.5 0.4 0.1 0.4 4.2 3.2 0.6 0.5 11.4 1.4 0.0 0.0 0.0 0.1 0.2 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.1 2.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.5 0.3 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 12.0 0.0 0.6 2.2 0.5 0.2 0.5 0.0 0.2 1.6 0.1 0.0 0.0 0.0 2.8 0.2 0.0 22.9 0.0 0.0 0.0 0.0 0.0 0.1 4.9 0.0 0.1 1.4 11.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.2 0.2 0.1 1.1 0.3 0.2 0.3 0.2 0.3 0.4 0.0 0.3 23.1 0.0 0.9 0.0 9.3 0.0 0.0 0.0 1.8 0.0 0.9 0.0 0.1 0.6 0.8 0.1 0.0 0.0 0.2 1.5 0.0 0.0 235.3 0.5 36.5 0.0 5.5 5.4 0.2 0.0 0.0 10.1 0.0 0.0 0.0 0.1 0.0 0.4 0.5 0.0 0.0 0.9 0.5 0.1 0.4 0.1 0.0 0.0 0.0 AC093827.5 ENSG00000285458 "Uncharacterized protein C4orf36 " Q96KX1 4 86886472-86936178 "Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "No human protein/transcript evidence" "Evidence at transcript level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in some" 18 "Alveolar cells type 1: 11.9;Ciliated cells: 14.7;Club cells: 3.4;Distal tubular cells: 5.0" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 12.2" HPA057434 Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA057434: AB_2683438" 2.0 2.0 4.4 0.9 8.1 1.5 3.4 1.0 4.5 2.0 1.3 9.7 2.2 1.6 1.8 3.7 2.2 1.6 1.1 6.8 4.6 3.0 0.8 1.5 0.3 8.9 3.7 1.8 1.2 3.3 1.6 1.6 5.8 2.5 1.8 2.6 2.0 2.4 4.8 5.1 1.6 3.0 8.9 1.2 2.1 3.2 8.2 0.0 3.9 2.4 0.3 1.6 0.0 2.0 2.8 3.3 1.8 2.0 3.1 0.6 2.9 1.8 0.9 1.3 2.8 2.5 1.4 2.7 2.8 0.9 1.4 1.3 4.9 0.5 2.5 1.8 2.3 2.0 1.3 1.6 1.1 2.3 1.0 2.3 2.2 1.3 1.6 3.6 1.5 1.7 4.2 0.9 3.2 1.5 0.8 1.2 1.6 12.2 0.5 0.9 1.5 1.4 2.1 2.8 1.2 2.9 1.2 2.6 2.9 2.1 1.0 1.8 2.1 2.1 2.4 1.4 3.8 2.6 1.0 2.3 3.1 1.0 1.6 4.4 2.0 4.0 1.9 1.7 1.2 1.6 1.7 1.5 2.0 1.8 2.5 1.6 1.4 2.0 1.5 2.0 1.9 3.1 3.3 2.0 1.3 2.8 0.7 0.6 11.9 1.9 0.0 0.0 0.0 0.0 0.0 0.0 14.7 3.4 0.0 0.0 0.0 5.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ACTN1 ENSG00000072110 "Actinin alpha 1" P12814 14 68874143-68979440 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Actin-binding "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Extravillous trophoblasts: 304.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 71.8" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004303, HPA006035" Approved Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA 780000000 "Plasma membrane, Actin filaments, Focal adhesion sites" "CAB004303: AB_626633, HPA006035: AB_1078095" "unprognostic (4.40e-2)" "unprognostic (1.03e-3)" "unprognostic (2.49e-2)" "unprognostic (1.96e-1)" "unprognostic (1.19e-1)" "prognostic unfavorable (2.49e-4)" "unprognostic (6.19e-3)" "prognostic unfavorable (7.63e-5)" "unprognostic (3.62e-1)" "unprognostic (3.23e-2)" "unprognostic (3.16e-2)" "unprognostic (1.71e-1)" "prognostic unfavorable (9.08e-10)" "unprognostic (2.87e-2)" "unprognostic (2.00e-1)" "unprognostic (6.05e-3)" "prognostic unfavorable (8.00e-4)" 27.6 10.8 18.7 33.1 28.4 31.0 38.8 4.1 20.0 30.5 101.8 3.1 43.7 11.6 80.3 24.6 48.3 38.7 53.3 31.2 9.9 6.2 11.2 20.3 23.9 23.1 4.7 15.0 27.8 12.4 2.3 7.9 22.0 8.7 43.2 26.4 11.1 30.1 72.7 7.1 14.6 25.9 135.4 10.3 19.4 52.3 9.5 9.6 7.0 9.3 9.9 11.3 81.1 53.1 0.0 8.8 71.8 12.5 0.7 22.0 14.9 85.1 26.3 16.2 12.3 28.8 19.1 60.9 75.3 72.2 79.3 59.3 21.0 19.8 0.0 26.5 74.3 32.0 37.2 12.8 79.4 100.3 0.4 3.8 11.6 13.8 17.5 52.0 8.3 1.4 24.3 15.6 49.2 56.1 57.1 43.4 4.8 5.5 0.1 62.1 24.2 0.9 17.7 12.7 21.5 20.1 5.8 30.2 3.2 30.2 22.5 5.8 7.0 65.4 9.9 18.2 51.2 14.8 16.9 54.7 112.7 44.9 13.0 65.5 11.7 4.5 0.3 32.6 11.5 59.2 11.2 12.5 25.6 1.1 5.7 1.4 0.0 4.6 2.5 8.8 0.0 22.0 18.7 71.8 0.7 1.6 0.4 1.8 14.9 18.7 28.4 4.1 20.0 9.9 6.2 4.7 15.0 8.7 9.6 35.7 33.8 3.4 113.1 106.0 70.3 54.6 48.4 36.1 29.6 40.1 231.7 130.6 3.3 153.8 29.8 133.1 4.5 46.7 126.5 304.9 96.9 72.4 7.0 87.3 76.3 17.5 37.0 130.8 82.0 7.0 33.1 65.6 28.7 116.4 48.6 4.7 162.5 31.6 230.9 6.3 85.7 174.6 230.4 9.7 11.7 52.2 56.0 17.5 44.3 58.4 ACTR10 "ACTR11, Arp10, Arp11, HARP11" ENSG00000131966 "Actin related protein 10 homolog" Q9NZ32 14 58200080-58235636 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000699 Approved "Vesicles,Plasma membrane,Focal adhesion sites" NA NA "Vesicles, Plasma membrane, Focal adhesion sites" "HPA000699: " "prognostic unfavorable (3.24e-4)" "unprognostic (4.61e-2)" "unprognostic (6.22e-3)" "unprognostic (2.03e-2)" "unprognostic (4.42e-1)" "unprognostic (1.36e-2)" "prognostic unfavorable (2.71e-5)" "unprognostic (3.20e-1)" "unprognostic (9.30e-2)" "unprognostic (1.53e-1)" "unprognostic (4.86e-1)" "unprognostic (2.36e-1)" "prognostic favorable (8.48e-8)" "unprognostic (1.01e-2)" "unprognostic (2.39e-1)" "unprognostic (2.43e-2)" "unprognostic (8.48e-2)" 31.5 22.8 23.8 12.5 27.2 15.8 23.4 16.2 32.3 16.4 23.3 13.6 16.1 10.1 18.2 18.3 18.3 17.6 14.8 27.3 21.8 28.4 20.5 15.4 17.7 16.7 32.5 26.7 19.4 18.5 19.2 18.9 21.3 33.7 22.2 15.2 14.6 35.8 17.6 21.4 26.4 12.8 21.0 18.5 17.5 14.1 13.8 9.7 14.6 18.2 13.2 14.4 13.7 16.3 7.4 5.9 15.8 9.8 7.2 12.0 5.1 3.4 1.9 3.9 1.6 13.4 6.5 2.0 2.7 3.1 4.5 5.3 2.9 4.0 5.1 3.9 5.7 2.5 3.5 5.1 4.0 6.1 2.8 12.9 2.0 3.7 5.5 11.4 3.5 3.0 8.3 5.9 3.8 7.5 3.7 5.8 3.1 1.6 4.2 8.4 9.4 4.7 13.2 2.0 3.3 18.0 3.2 6.9 3.1 7.9 4.4 2.2 2.5 5.2 4.1 12.7 4.7 7.2 6.0 4.9 4.6 9.4 4.2 2.3 2.4 1.5 5.4 5.0 2.8 2.6 15.8 7.3 10.3 8.4 8.9 12.0 7.4 9.6 8.2 5.3 5.6 10.0 10.2 9.9 7.2 9.8 5.9 6.7 5.1 23.8 27.2 16.2 32.3 21.8 28.4 32.5 26.7 33.7 9.7 56.6 43.6 39.5 61.8 47.4 67.4 72.6 38.2 44.2 33.0 48.8 27.5 94.0 106.1 72.0 6.3 50.9 47.7 46.7 52.4 64.0 71.0 55.6 42.7 28.7 68.6 54.0 32.2 47.3 34.9 8.2 81.7 44.1 70.9 56.9 42.7 84.3 64.7 24.6 75.3 91.6 58.2 77.6 61.8 118.4 56.8 56.2 130.4 42.6 34.0 48.5 AFAP1 "AFAP, AFAP-110" ENSG00000196526 "Actin filament associated protein 1" Q8N556 4 7758714-7939926 "Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 9 "Early spermatids: 151.9;Extravillous trophoblasts: 100.0;Late spermatids: 257.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 6.0" "Group enriched" "Detected in many" 5 "granulocytes: 6.0;T-cells: 2.9" "Cell line enhanced" "Detected in many" "TIME: 41.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015642, CAB024712" Enhanced Supported "Actin filaments,Focal adhesion sites,Cytosol" NA NA "Actin filaments, Cytosol" "Focal adhesion sites" "CAB024712: , HPA015642: AB_1844632" "unprognostic (1.12e-1)" "unprognostic (2.78e-2)" "unprognostic (3.97e-1)" "unprognostic (7.29e-2)" "unprognostic (2.02e-1)" "unprognostic (1.93e-1)" "unprognostic (3.30e-1)" "prognostic unfavorable (2.84e-4)" "unprognostic (2.00e-1)" "unprognostic (3.39e-2)" "unprognostic (3.40e-2)" "unprognostic (1.38e-1)" "prognostic unfavorable (8.18e-4)" "unprognostic (1.40e-2)" "unprognostic (1.56e-1)" "unprognostic (1.85e-1)" "unprognostic (2.44e-2)" 14.0 3.9 9.5 11.6 10.2 1.0 15.8 10.3 12.2 11.0 17.8 4.4 6.5 6.7 18.7 6.6 13.1 9.0 14.7 11.0 7.1 5.8 5.2 1.8 8.7 5.3 4.7 6.9 12.1 6.6 31.9 13.0 14.4 5.6 10.3 11.7 12.4 9.6 12.7 5.7 5.8 8.8 32.1 8.3 4.6 8.4 21.7 3.2 3.3 8.6 5.6 6.1 16.2 13.1 0.0 0.0 6.0 0.9 0.0 2.9 1.5 10.1 7.6 5.4 4.3 5.3 9.6 7.2 15.2 22.6 14.7 13.6 2.4 2.4 0.0 5.1 24.7 24.4 4.9 2.8 6.1 9.7 0.2 1.9 0.0 11.0 1.4 14.8 0.0 0.1 5.9 4.6 18.3 12.0 24.4 17.6 1.5 0.2 2.2 7.6 3.3 0.1 0.0 2.3 4.3 14.7 0.0 4.0 0.5 1.6 1.3 10.7 17.9 5.2 3.6 4.1 7.5 1.3 0.1 41.6 18.0 4.0 23.3 7.4 0.0 0.0 0.0 6.4 0.0 20.5 0.0 0.9 6.0 1.1 0.2 1.4 0.0 1.6 1.5 0.0 0.0 2.9 1.3 2.3 0.0 0.1 0.0 1.3 1.5 9.5 10.2 10.3 10.8 7.1 5.8 4.7 6.9 5.6 3.2 6.0 1.3 0.0 7.2 2.6 1.0 4.9 17.8 5.3 9.1 10.4 3.9 4.5 0.0 16.4 151.9 13.7 8.0 0.0 6.7 100.0 15.5 12.1 0.0 0.0 6.9 0.0 13.9 16.5 0.3 257.9 10.3 0.0 1.7 1.0 19.4 9.1 19.5 5.8 11.7 2.6 0.4 6.5 10.3 11.4 8.8 3.8 7.3 3.2 12.4 8.9 AJM1 "ajm-1, C9orf172" ENSG00000232434 "Apical junction component 1 homolog" C9J069 9 136844415-136848801 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 22.7;testis: 15.0" "Cell type enhanced" "Detected in some" 23 "Collecting duct cells: 5.2;Ductal cells: 1.4;granulocytes: 1.1;Pancreatic endocrine cells: 1.0" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 22.7" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 3.9" "Group enriched" "Detected in many" 11 "dendritic cells: 3.9;monocytes: 1.6;T-cells: 1.9" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" HPA021200 Uncertain Approved "Focal adhesion sites,Cytosol" NA NA "Focal adhesion sites, Cytosol" "HPA021200: AB_10601695" "unprognostic (3.30e-3)" "unprognostic (1.67e-1)" "unprognostic (7.68e-3)" "unprognostic (9.54e-2)" "unprognostic (2.34e-1)" "unprognostic (1.08e-2)" "unprognostic (1.27e-2)" "unprognostic (8.00e-2)" "unprognostic (6.29e-2)" "unprognostic (4.33e-1)" "unprognostic (2.72e-3)" "unprognostic (4.34e-2)" "unprognostic (1.05e-1)" "unprognostic (2.71e-3)" "unprognostic (2.94e-1)" "unprognostic (6.07e-3)" "unprognostic (7.27e-2)" 1.1 1.9 4.6 1.3 6.3 1.4 1.1 22.7 7.9 1.1 4.0 1.1 1.1 3.3 1.2 1.1 1.1 0.3 1.1 1.2 4.4 3.1 1.1 1.1 1.1 1.1 2.1 1.1 1.1 7.6 1.1 5.2 1.1 1.1 2.6 1.1 1.1 2.0 2.2 3.9 1.5 4.3 1.1 1.3 3.6 2.3 15.0 1.1 1.1 1.1 1.1 1.1 2.6 1.1 0.2 3.9 0.1 1.6 0.2 1.9 0.8 3.7 3.0 0.4 1.1 0.5 0.4 4.9 3.0 0.5 0.4 0.2 1.0 2.0 2.3 2.6 0.8 1.0 4.2 0.4 1.1 0.0 5.8 2.2 0.6 5.6 0.9 1.7 1.3 4.2 0.9 1.5 0.5 0.3 2.5 0.2 1.1 3.5 1.5 0.7 4.1 0.4 4.5 1.2 3.1 3.9 2.8 0.9 7.3 0.9 0.7 7.4 2.6 1.9 7.6 4.0 0.6 6.0 2.8 3.1 5.0 3.5 1.7 1.8 6.6 4.5 0.8 8.8 4.6 1.2 0.0 1.6 0.1 1.9 1.0 0.4 0.2 0.5 0.9 1.5 0.0 0.2 0.9 0.1 0.2 1.5 3.9 0.1 0.8 4.6 6.3 22.7 6.8 4.4 3.1 2.1 1.1 1.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.5 0.0 1.4 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 1.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 AL132780.3 ENSG00000259132 14 22946270-22982258 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enriched" "Detected in single" 30 "Alveolar cells type 1: 3.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Hep G2: 28.1" HPA029803 Approved Approved "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA029803: AB_10601428" 4.8 6.2 4.5 4.7 5.5 6.6 5.3 3.5 2.4 16.1 7.1 2.3 7.1 5.5 12.4 9.2 16.2 6.6 11.2 6.0 4.6 3.8 20.4 24.5 10.5 7.9 5.3 1.9 11.8 13.8 0.0 3.5 18.1 3.8 13.1 6.1 10.4 5.7 16.0 6.2 8.8 4.5 3.5 4.5 11.3 4.5 6.0 1.9 10.3 22.1 7.7 9.6 5.0 7.9 3.3 5.7 10.2 5.9 1.1 4.1 2.8 4.1 8.9 6.2 2.0 6.1 7.2 4.0 0.7 5.8 3.7 3.8 3.0 3.1 0.0 2.4 6.8 2.1 1.6 2.9 3.1 2.6 0.0 0.7 1.3 6.8 28.1 4.0 3.2 2.6 3.2 8.2 2.9 7.0 8.1 5.1 7.4 0.0 6.1 4.0 16.8 7.0 12.0 3.0 6.9 1.9 3.4 4.4 3.8 10.3 8.4 3.5 2.0 2.8 3.6 1.7 4.5 5.5 7.1 1.0 4.7 3.4 1.9 3.5 6.0 7.3 6.3 1.6 3.2 2.9 0.5 5.9 2.1 2.5 4.2 1.2 2.7 1.8 2.1 5.7 3.3 3.4 1.7 10.2 1.1 2.9 2.6 4.1 2.8 4.5 5.5 3.5 2.4 4.6 3.8 5.3 1.9 3.8 1.9 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ALKBH6 MGC15677 ENSG00000239382 "AlkB homolog 6" Q3KRA9 19 36009120-36014239 "Cancer-related genes, Predicted intracellular proteins" "Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA073835, HPA074340" Approved Supported "Nucleoplasm,Focal adhesion sites" NA NA Nucleoplasm "Focal adhesion sites" "HPA073835: AB_2686637, HPA074340: AB_2686680" "unprognostic (1.90e-3)" "unprognostic (1.82e-1)" "unprognostic (5.16e-3)" "unprognostic (1.12e-2)" "unprognostic (1.24e-1)" "unprognostic (5.86e-5)" "unprognostic (6.21e-2)" "unprognostic (4.53e-2)" "unprognostic (3.95e-1)" "unprognostic (3.56e-2)" "unprognostic (8.78e-4)" "unprognostic (1.77e-2)" "unprognostic (2.31e-5)" "unprognostic (9.34e-2)" "unprognostic (2.15e-1)" "unprognostic (3.82e-1)" "unprognostic (1.05e-3)" 8.4 7.0 14.1 6.4 15.2 6.8 6.3 7.8 18.9 5.8 8.2 7.8 2.5 6.6 6.5 6.6 6.5 8.2 7.7 9.2 13.0 14.9 5.7 12.6 6.8 8.7 14.8 12.5 5.4 3.4 8.2 8.5 6.2 19.5 9.7 4.6 6.5 8.7 9.9 6.3 5.8 6.4 8.5 10.5 8.9 9.6 4.2 4.9 5.7 6.2 3.7 8.4 7.2 4.7 18.1 13.5 29.5 15.0 15.7 19.5 9.4 10.3 11.1 4.2 6.2 6.6 4.0 7.1 10.3 6.9 12.1 12.3 4.6 5.5 9.1 16.5 5.7 6.3 4.1 4.4 11.9 6.4 14.3 8.0 5.2 4.2 4.9 7.5 4.5 16.0 6.0 8.6 10.0 3.4 4.2 8.2 13.9 8.1 6.9 6.5 10.8 10.8 5.9 3.3 10.8 7.2 6.9 5.8 6.5 8.7 4.6 5.1 5.3 7.0 8.5 8.6 6.2 6.7 10.2 3.5 6.3 9.3 14.3 10.0 13.0 7.7 6.4 13.7 5.1 6.7 29.5 11.4 27.3 17.1 15.0 13.0 18.1 15.5 16.1 9.6 14.6 13.2 12.8 9.6 15.7 11.7 13.5 19.5 9.4 14.1 15.2 7.8 18.9 13.0 14.9 14.8 12.5 19.5 4.9 3.0 1.7 11.5 10.4 6.1 6.0 1.4 10.2 0.0 1.2 17.4 0.0 16.3 5.0 9.6 4.7 4.7 7.7 23.3 8.1 13.8 6.9 7.1 0.0 12.9 9.3 9.5 12.6 8.0 4.9 4.0 10.3 7.9 8.5 19.8 9.6 4.9 10.7 14.0 4.2 8.7 3.3 6.5 9.6 3.1 2.5 4.4 15.9 15.8 8.0 8.8 ARAP2 "CENTD1, PARX" ENSG00000047365 "ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2" Q8WZ64 4 35948221-36244509 "Predicted intracellular proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 32.5" "Cell type enhanced" "Detected in many" 8 "Alveolar cells type 1: 142.9;Early spermatids: 113.2;Late spermatids: 89.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CAPAN-2: 12.0;hTCEpi: 11.3;MOLT-4: 10.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035925 Approved Approved "Actin filaments,Focal adhesion sites" NA NA "Focal adhesion sites" "Actin filaments" "HPA035925: AB_10672075" "unprognostic (2.97e-2)" "unprognostic (8.62e-2)" "unprognostic (3.43e-3)" "unprognostic (1.04e-1)" "unprognostic (8.86e-2)" "unprognostic (2.72e-3)" "unprognostic (1.09e-1)" "unprognostic (3.78e-3)" "unprognostic (2.04e-1)" "unprognostic (2.45e-2)" "unprognostic (2.72e-3)" "unprognostic (2.96e-1)" "unprognostic (4.48e-2)" "unprognostic (4.54e-2)" "unprognostic (3.43e-2)" "unprognostic (1.57e-1)" "unprognostic (6.72e-2)" 5.2 2.5 16.3 9.1 27.5 32.5 5.2 4.8 20.8 4.2 5.1 18.3 0.3 8.5 3.5 4.1 12.7 3.5 9.2 2.5 16.0 9.5 3.9 8.8 12.7 13.7 24.4 12.1 1.9 6.8 8.2 5.1 3.5 18.4 2.9 5.8 0.7 5.8 3.3 1.4 16.1 8.2 4.4 15.3 10.4 5.8 5.9 32.0 26.4 22.4 4.0 10.2 6.2 7.2 2.4 1.7 0.6 5.8 8.6 5.7 0.7 7.3 0.6 0.7 0.3 0.0 0.0 3.7 0.0 0.0 0.0 0.0 3.6 12.0 3.5 2.9 0.3 0.0 2.8 1.1 5.8 0.0 0.0 6.6 0.1 2.4 0.2 1.5 4.6 0.0 0.4 11.3 0.0 2.5 4.4 0.0 9.7 0.2 0.6 0.0 3.1 10.7 3.8 0.8 5.1 2.3 5.5 0.0 4.0 8.3 7.5 6.5 0.0 0.4 1.8 2.4 0.4 5.0 1.4 0.0 2.0 6.7 0.0 1.0 0.0 0.0 6.8 0.8 5.3 1.7 0.0 0.8 0.0 5.7 2.7 5.3 2.4 3.2 3.9 0.4 1.4 1.1 2.9 0.6 8.6 5.8 1.7 1.5 0.7 16.3 27.5 4.8 20.8 16.0 9.5 24.4 12.1 18.4 32.0 142.9 21.8 22.6 24.0 34.8 0.3 1.7 10.2 20.1 43.3 7.0 0.0 0.1 6.6 7.2 113.2 13.5 14.6 0.0 8.6 0.2 4.5 28.3 9.2 3.8 7.3 0.0 2.9 3.1 32.3 89.9 2.6 17.8 5.0 16.2 9.2 5.4 15.9 17.5 0.7 4.1 1.0 0.0 1.4 3.2 1.9 59.0 0.7 42.4 6.4 46.4 ARHGAP4 "C1, KIAA0131, p115, RhoGAP4, SrGAP4" ENSG00000089820 "Rho GTPase activating protein 4" P98171 X 153907367-153934999 "Predicted intracellular proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 44.8;lymphoid tissue: 48.4" "Cell type enhanced" "Detected in many" 7 "Hofbauer cells: 71.1;Kupffer cells: 73.8;Macrophages: 43.6;T-cells: 48.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 26.2;Karpas-707: 26.9;MOLT-4: 25.3;RPMI-8226: 49.8;THP-1: 24.3;U-698: 23.2;U-937: 21.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001012, HPA001083" Enhanced Approved "Nucleoplasm,Focal adhesion sites" NA NA "Focal adhesion sites" Nucleoplasm "HPA001012: AB_1078201, HPA001083: AB_1078199" "unprognostic (3.54e-2)" "prognostic favorable (3.94e-5)" "prognostic unfavorable (1.97e-5)" "unprognostic (5.79e-2)" "unprognostic (9.42e-2)" "prognostic favorable (3.31e-4)" "unprognostic (5.72e-3)" "unprognostic (1.39e-1)" "unprognostic (3.27e-1)" "unprognostic (1.37e-1)" "unprognostic (7.81e-3)" "unprognostic (1.45e-1)" "prognostic unfavorable (2.49e-4)" "unprognostic (8.47e-3)" "unprognostic (2.01e-1)" "unprognostic (1.03e-1)" "unprognostic (1.99e-1)" 7.0 4.8 5.3 24.3 5.8 44.8 5.0 4.5 3.2 3.1 6.5 5.2 2.1 6.0 3.9 7.0 4.4 5.2 6.5 4.2 4.5 3.2 7.4 4.9 13.4 29.1 5.2 0.9 2.6 2.3 0.9 3.5 9.0 4.8 4.2 3.0 5.7 7.5 1.8 1.6 1.8 18.0 3.9 5.9 48.4 4.9 3.6 4.2 43.2 4.2 1.6 29.0 7.1 3.6 10.8 17.7 18.7 30.5 8.5 15.7 12.6 0.4 0.1 0.2 1.7 0.0 0.0 0.7 0.2 0.1 0.0 0.0 0.1 12.5 26.2 1.6 0.0 0.2 0.2 1.3 0.0 0.0 7.1 1.0 10.2 0.1 0.5 1.1 18.6 17.3 0.0 0.1 0.0 0.1 0.1 2.6 6.6 0.0 26.9 0.1 1.3 25.3 0.3 0.8 0.1 0.0 12.0 3.5 49.8 0.1 0.2 2.4 3.6 0.2 0.6 0.2 0.3 5.9 24.3 0.5 0.1 0.3 0.2 0.1 16.3 13.9 23.2 0.2 21.7 0.0 5.1 14.1 18.7 15.7 23.1 10.9 10.8 11.2 12.4 14.1 10.4 10.1 10.1 12.0 8.5 30.5 17.7 12.6 12.6 5.3 5.8 4.5 3.2 4.5 3.2 5.2 0.9 4.8 4.2 8.9 33.9 40.2 0.5 3.1 9.8 30.4 2.5 13.4 4.5 17.4 3.9 1.7 5.0 0.7 0.1 10.6 3.9 0.0 0.6 1.2 2.1 0.4 33.5 0.5 71.1 3.2 4.6 4.3 73.8 0.0 0.9 43.6 10.1 12.6 2.1 1.3 0.1 0.0 0.0 0.6 4.4 0.0 0.9 0.5 4.9 1.5 1.1 48.4 3.9 0.4 ARL14EP "ARF7EP, C11orf46, FLJ38968" ENSG00000152219 "ADP ribosylation factor like GTPase 14 effector protein" Q8N8R7 11 30323051-30338227 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039634, HPA048127" Approved Supported "Nucleoplasm,Vesicles,Focal adhesion sites,Cytosol" NA NA "Vesicles, Focal adhesion sites, Cytosol" Nucleoplasm "HPA039634: AB_2676606, HPA048127: AB_2680277" "prognostic favorable (2.50e-5)" "unprognostic (8.93e-2)" "unprognostic (6.19e-3)" "unprognostic (1.34e-1)" "unprognostic (1.67e-1)" "unprognostic (3.09e-1)" "prognostic unfavorable (5.26e-4)" "unprognostic (2.50e-2)" "unprognostic (6.50e-3)" "unprognostic (5.76e-2)" "unprognostic (8.86e-2)" "unprognostic (1.04e-1)" "unprognostic (8.57e-3)" "unprognostic (1.60e-1)" "unprognostic (3.47e-1)" "unprognostic (4.50e-2)" "prognostic favorable (7.49e-4)" 13.9 21.5 24.5 12.9 29.1 6.3 18.7 22.7 23.4 17.0 14.5 8.0 22.4 8.7 18.1 22.7 11.1 15.8 12.4 20.5 17.7 15.5 16.5 17.6 10.3 23.5 15.5 20.5 20.1 15.0 33.4 28.6 10.6 15.1 19.0 10.3 9.0 17.0 19.9 28.0 11.6 12.5 18.3 16.0 18.2 14.4 14.5 15.0 11.6 23.3 13.9 19.1 16.1 15.1 17.6 12.7 5.5 9.6 24.4 28.7 11.2 5.8 8.5 9.5 8.3 15.6 17.0 4.8 11.5 14.5 10.4 11.6 4.7 2.2 23.8 7.9 8.2 11.6 9.9 13.8 9.7 14.8 18.9 17.1 7.2 6.7 8.2 24.6 12.8 8.3 17.6 19.6 4.9 18.7 15.2 11.4 9.9 11.3 13.0 18.1 5.6 11.6 10.6 11.0 13.1 11.9 10.2 23.2 9.7 13.9 8.1 10.9 11.6 8.9 12.0 14.1 8.9 12.7 7.3 10.0 12.0 6.4 23.5 10.9 20.4 11.6 15.5 11.4 8.0 11.4 5.5 9.6 3.0 12.1 9.4 28.7 17.6 14.8 13.4 12.7 14.0 13.7 13.1 1.7 24.4 7.0 9.1 9.5 11.2 24.5 29.1 22.7 23.4 17.7 15.5 15.5 20.5 15.1 15.0 26.8 28.1 30.5 38.1 11.0 32.2 57.0 17.8 34.8 20.5 24.4 13.7 14.7 64.6 23.3 99.1 24.8 6.3 0.0 19.6 10.7 22.3 27.7 26.6 24.2 22.8 30.2 13.9 12.9 24.3 44.0 25.3 30.9 25.3 43.3 10.0 34.4 19.0 9.7 23.7 27.2 28.6 12.9 24.1 60.6 33.2 9.7 9.3 28.9 10.4 24.4 ARL2 ARFL2 ENSG00000213465 "ADP ribosylation factor like GTPase 2" P36404 11 65014113-65022184 "Predicted intracellular proteins" "Cell cycle" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 8 "Late spermatids: 847.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" HPA044610 Supported Approved "Nucleoplasm,Nucleoli,Golgi apparatus,Focal adhesion sites,Cytosol" NA NA Nucleoplasm "Nucleoli, Golgi apparatus, Focal adhesion sites, Cytosol" "HPA044610: AB_10964207" "unprognostic (9.23e-2)" "unprognostic (3.66e-1)" "unprognostic (1.43e-1)" "prognostic unfavorable (4.58e-4)" "unprognostic (1.61e-1)" "unprognostic (5.08e-2)" "unprognostic (1.07e-3)" "unprognostic (2.34e-1)" "unprognostic (9.85e-3)" "unprognostic (6.43e-2)" "unprognostic (6.87e-3)" "prognostic favorable (7.70e-4)" "unprognostic (2.15e-2)" "unprognostic (1.85e-1)" "unprognostic (1.60e-1)" "unprognostic (4.39e-1)" "unprognostic (1.24e-2)" 39.6 32.0 37.3 17.7 78.7 19.8 26.8 16.1 46.5 21.2 23.5 34.7 13.4 23.9 26.8 20.2 23.7 35.2 22.4 52.6 34.8 32.7 33.8 6.6 23.1 14.8 36.1 38.2 27.2 29.9 22.5 15.4 25.5 32.7 25.3 15.5 30.3 26.9 33.1 78.3 19.6 23.4 28.2 44.9 16.7 18.9 31.4 28.7 7.9 26.3 23.6 12.9 24.7 22.8 43.7 37.8 18.7 21.8 21.0 40.7 34.7 36.1 57.7 17.9 26.4 48.6 36.9 16.3 17.8 41.3 25.6 25.3 16.3 25.0 14.0 34.1 25.1 39.0 23.3 18.8 31.4 12.2 14.6 29.5 14.1 26.0 24.6 37.2 17.1 12.8 29.0 26.3 21.3 47.8 37.4 34.0 16.9 33.2 26.1 17.2 42.8 14.1 38.5 28.0 17.2 47.1 7.5 19.6 33.6 27.5 15.8 33.3 18.8 15.3 15.9 50.2 17.6 16.6 21.0 25.6 48.3 16.3 38.3 18.4 9.0 12.6 8.6 22.8 24.7 39.2 10.2 21.8 18.7 34.8 21.2 37.6 43.7 32.2 33.6 27.6 37.3 36.8 40.7 2.8 21.0 12.4 37.8 20.6 34.7 37.3 78.7 16.1 46.5 34.8 32.7 36.1 38.2 32.7 28.7 20.8 35.8 37.0 78.1 72.4 72.3 89.8 50.9 32.1 52.4 78.5 27.5 165.9 227.1 118.2 362.1 147.4 126.8 46.7 66.9 164.2 116.5 55.8 93.5 17.1 87.0 65.2 80.0 119.1 47.3 847.8 66.4 70.8 168.7 138.9 56.4 119.5 81.6 95.1 66.8 340.4 40.2 64.7 111.8 98.4 65.3 72.4 89.7 39.2 87.9 60.9 ARMC5 FLJ13063 ENSG00000140691 "Armadillo repeat containing 5" Q96C12 16 31458080-31467166 "Disease related genes, Predicted intracellular proteins" "Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Hepatocytes: 23.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NB-4: 35.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041524, HPA063706" Approved Approved "Nucleoplasm,Focal adhesion sites,Cytosol" "Intracellular and membrane" NA NA "Nucleoplasm, Cytosol" "Focal adhesion sites" "HPA041524: AB_10796676, HPA063706: AB_2685098" "unprognostic (1.37e-1)" "unprognostic (1.68e-3)" "unprognostic (8.22e-3)" "unprognostic (9.96e-2)" "unprognostic (2.59e-1)" "unprognostic (2.94e-3)" "unprognostic (4.09e-2)" "unprognostic (6.14e-3)" "unprognostic (2.37e-1)" "unprognostic (1.11e-1)" "prognostic favorable (1.97e-6)" "unprognostic (4.70e-2)" "unprognostic (3.60e-2)" "unprognostic (1.99e-2)" "unprognostic (2.34e-2)" "unprognostic (1.57e-1)" "unprognostic (1.45e-1)" 8.3 8.1 6.6 8.1 11.6 35.3 8.4 13.1 13.6 5.3 5.7 7.8 5.5 9.7 9.1 6.0 8.4 7.1 4.9 6.6 8.4 7.5 6.7 16.1 8.4 7.3 8.9 5.4 8.6 9.3 9.2 9.4 7.3 9.1 7.2 2.9 6.5 10.4 5.8 14.2 13.2 8.3 4.5 5.9 8.6 8.0 6.0 8.9 6.8 9.9 6.8 5.3 5.1 16.8 4.0 10.0 2.8 3.1 9.8 4.9 3.2 2.9 4.7 2.1 3.0 1.3 1.0 5.3 3.9 1.7 2.3 1.9 4.4 3.1 2.9 8.2 2.2 2.3 4.5 2.4 3.5 0.4 4.1 6.0 1.3 7.1 10.1 2.5 8.8 8.9 2.4 4.0 2.3 0.6 2.6 3.5 4.9 6.5 7.1 1.6 7.4 3.3 35.4 3.3 1.3 3.0 5.9 3.0 10.8 1.7 3.5 6.7 5.9 3.6 4.9 2.7 1.3 3.2 10.5 6.5 5.0 3.7 2.0 3.2 6.5 5.6 1.8 3.3 7.4 3.5 2.8 3.1 0.9 4.9 1.6 4.1 4.0 3.8 3.8 4.1 3.5 3.4 3.8 1.8 9.8 1.7 10.0 4.6 3.2 6.6 11.6 13.1 13.6 8.4 7.5 8.9 5.4 9.1 8.9 6.0 14.7 4.5 7.9 5.8 3.9 5.6 10.2 1.4 7.9 0.0 5.9 6.2 3.3 4.7 1.0 8.5 10.3 0.0 4.0 4.6 5.8 5.6 9.2 23.6 5.3 12.7 7.5 6.2 4.8 0.0 4.0 3.0 1.7 2.8 5.2 6.8 3.3 3.6 5.3 3.7 5.2 0.0 6.4 3.9 6.1 5.5 9.6 5.0 3.8 4.8 ASAH2 ENSG00000188611 "N-acylsphingosine amidohydrolase 2" Q9NR71 10 50182778-50248610 "Enzymes, Predicted intracellular proteins" "Apoptosis, Lipid metabolism, Sphingolipid metabolism" Hydrolase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 17 "intestine: 43.9" "Cell type enhanced" "Detected in many" 9 "Late spermatids: 6.0;Muller glia cells: 10.2;Sertoli cells: 6.5" "Low cancer specificity" "Detected in single" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low cell line specificity" "Detected in many" HPA061171 Supported Approved "Focal adhesion sites" "Intracellular and membrane" NA NA 1200000 "Focal adhesion sites" "HPA061171: AB_2684442" "unprognostic (3.59e-2)" "unprognostic (3.63e-2)" "unprognostic (1.66e-1)" "unprognostic (3.84e-2)" "unprognostic (3.66e-1)" "unprognostic (4.48e-2)" "unprognostic (2.25e-2)" "unprognostic (1.08e-1)" "unprognostic (1.65e-2)" "unprognostic (4.33e-2)" "unprognostic (2.17e-1)" "unprognostic (1.14e-1)" "unprognostic (8.29e-2)" "unprognostic (1.86e-2)" "unprognostic (5.64e-2)" "unprognostic (3.22e-1)" "unprognostic (1.02e-3)" 0.3 1.1 0.6 0.2 0.9 0.0 0.5 0.5 1.3 1.7 0.5 43.9 0.7 0.3 0.7 0.5 0.2 0.9 0.5 1.4 0.6 1.6 0.4 0.2 1.2 1.4 1.5 0.3 1.0 0.4 0.5 0.3 0.9 0.2 0.8 0.7 33.4 0.7 0.6 0.2 2.5 1.1 0.6 0.1 1.0 0.5 0.9 0.9 0.0 0.0 0.0 2.2 0.1 1.8 1.4 1.6 2.2 2.9 1.1 2.0 2.0 1.3 3.8 3.5 1.0 4.6 0.0 2.2 2.7 3.1 1.7 2.1 0.7 4.7 2.3 3.8 1.3 3.8 2.9 1.8 0.4 0.2 0.4 2.6 6.6 7.5 0.5 0.8 0.0 2.5 1.2 2.5 1.5 1.4 0.1 4.8 0.0 4.1 0.0 6.4 1.6 2.1 0.3 2.7 7.3 2.5 1.8 3.3 3.9 1.5 1.0 2.0 1.9 4.4 4.7 6.1 1.9 0.2 0.0 5.5 0.0 1.7 0.0 0.0 0.0 0.7 0.0 2.2 0.9 0.4 1.7 0.0 0.1 1.4 2.1 0.0 0.0 0.0 0.9 0.6 0.1 0.0 0.0 0.0 0.2 0.3 1.8 3.0 0.0 0.0 1.2 0.0 2.0 0.3 0.0 1.1 4.1 0.1 1.3 0.0 1.3 0.2 0.4 0.2 0.0 1.8 0.2 1.6 0.0 0.6 0.0 6.0 1.1 0.0 0.0 0.0 1.2 10.2 1.4 0.0 1.4 0.6 1.8 6.5 0.9 0.9 0.8 0.1 0.2 0.0 0.6 0.1 ASAH2B "ASAH2C, ASAH2L, bA449O16.3, bA98I6.3" ENSG00000204147 "N-acylsphingosine amidohydrolase 2B" P0C7U1 10 50739318-50816495 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in all" "intestine: 27.5" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "PC-3: 19.2" HPA061171 Supported Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA061171: AB_2684442" "unprognostic (6.86e-3)" "unprognostic (1.91e-2)" "unprognostic (7.22e-2)" "unprognostic (1.13e-1)" "unprognostic (8.55e-2)" "unprognostic (1.18e-2)" "unprognostic (5.42e-3)" "unprognostic (5.03e-3)" "unprognostic (2.21e-2)" "unprognostic (1.11e-1)" "unprognostic (3.79e-2)" "unprognostic (1.78e-2)" "unprognostic (2.21e-3)" "unprognostic (2.80e-1)" "unprognostic (1.08e-1)" "unprognostic (1.44e-1)" "unprognostic (1.46e-1)" 2.8 8.3 6.5 3.3 10.7 2.3 4.6 4.4 14.5 4.0 4.5 1.5 3.8 27.5 5.1 6.2 4.4 4.8 4.3 7.8 7.2 9.0 7.3 12.2 3.7 2.9 5.7 8.3 5.6 7.6 8.8 12.8 2.1 7.4 6.3 5.3 7.0 6.6 4.4 5.7 3.0 16.0 4.4 3.9 3.0 6.4 5.2 2.0 2.7 5.6 6.8 4.8 3.8 3.4 1.4 3.2 0.5 0.1 0.7 6.0 1.5 1.9 2.0 3.1 5.2 1.1 2.6 2.5 9.7 5.3 5.9 4.9 6.8 4.9 0.1 3.7 2.1 2.0 2.0 3.6 4.1 4.8 3.7 4.0 1.3 5.8 4.5 3.9 1.7 1.9 3.3 4.8 5.6 8.7 1.9 1.2 0.0 6.2 2.5 4.8 4.3 2.8 0.2 4.0 5.5 19.2 0.1 7.3 2.4 3.5 7.2 6.0 12.1 3.3 4.1 3.4 3.5 6.9 1.2 6.4 2.5 11.6 5.3 11.4 3.0 0.4 0.0 12.8 0.0 4.3 0.5 0.1 0.0 2.2 0.0 6.0 0.7 3.5 2.5 0.0 1.4 4.9 4.5 0.4 0.7 0.1 3.2 3.9 1.5 6.5 10.7 4.4 14.5 7.2 9.0 5.7 8.3 7.4 2.0 3.0 0.6 0.5 0.8 1.4 5.5 4.9 2.5 1.4 1.2 5.2 7.9 1.3 5.0 4.1 0.1 1.5 2.0 0.0 4.1 1.2 1.8 1.1 0.0 6.8 0.3 0.0 6.4 1.8 0.0 0.8 1.7 0.0 1.7 0.0 5.1 4.0 3.3 3.4 1.1 4.1 4.4 0.0 2.1 3.7 1.8 0.4 0.5 2.2 4.1 0.8 ASB16 FLJ30165 ENSG00000161664 "Ankyrin repeat and SOCS box containing 16" Q96NS5 17 44170447-44179083 "Predicted intracellular proteins" "Ubl conjugation pathway" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 38.4;tongue: 17.6" "Cell type enhanced" "Detected in some" 13 "Horizontal cells: 1.6;Ito cells: 1.3;Rod photoreceptor cells: 2.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 13 "cerebellum: 11.4" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-266/70: 12.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA066834 Approved Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA066834: AB_2685732" "unprognostic (2.72e-2)" "unprognostic (8.47e-3)" "unprognostic (4.24e-2)" "unprognostic (1.46e-1)" "unprognostic (1.12e-1)" "unprognostic (5.95e-2)" "unprognostic (2.45e-2)" "unprognostic (2.31e-3)" "unprognostic (1.03e-2)" "unprognostic (6.13e-2)" "unprognostic (7.23e-4)" "unprognostic (5.84e-2)" "unprognostic (3.97e-2)" "unprognostic (8.53e-3)" "unprognostic (7.33e-2)" "unprognostic (2.20e-1)" "unprognostic (1.07e-3)" 0.9 0.6 0.2 1.3 0.3 1.2 0.5 11.4 0.7 0.6 1.2 0.3 0.9 1.3 1.3 1.9 1.1 1.0 0.6 12.6 0.7 0.4 0.8 0.4 0.7 1.9 0.6 0.2 1.1 7.0 1.6 1.8 0.3 0.8 1.7 0.0 2.7 1.2 0.1 38.4 1.9 1.3 4.1 0.2 1.8 1.3 0.6 0.3 0.0 0.9 17.6 1.1 1.6 1.5 4.4 2.9 9.6 2.4 4.0 4.5 2.7 2.1 4.1 4.9 4.6 0.0 0.0 4.0 4.5 0.0 0.0 0.0 3.1 2.4 3.3 2.8 0.0 1.0 5.1 0.0 0.0 0.0 5.1 7.3 2.1 7.1 3.4 0.0 2.2 6.6 0.0 0.0 0.0 0.0 1.3 0.0 5.0 3.8 8.3 0.0 3.5 2.6 4.1 1.5 0.8 4.9 8.3 4.8 4.9 0.0 3.3 5.1 2.8 2.1 0.6 0.7 1.5 6.4 2.1 2.2 6.2 5.7 3.8 2.8 12.7 6.2 3.1 1.4 3.2 4.1 4.0 2.4 9.6 3.1 2.2 3.7 4.4 3.3 3.0 1.2 3.8 4.5 2.8 7.3 4.0 1.9 2.9 3.2 2.7 0.2 0.3 11.4 0.6 0.7 0.4 0.6 0.2 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.9 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 1.6 0.0 1.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 ASCC2 "ASC1p100, DKFZp586O0223, FLJ21588" ENSG00000100325 "Activating signal cointegrator 1 complex subunit 2" Q9H1I8 22 29788608-29838304 "Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Late spermatids: 128.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001439, HPA052879" Approved Approved "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA "Focal adhesion sites, Cytosol" Nucleoplasm "HPA001439: AB_1078229, HPA052879: AB_2732577" "unprognostic (1.70e-1)" "unprognostic (1.02e-2)" "unprognostic (8.58e-2)" "unprognostic (3.83e-3)" "unprognostic (1.84e-1)" "unprognostic (2.45e-3)" "unprognostic (3.01e-3)" "unprognostic (1.16e-1)" "unprognostic (1.35e-1)" "unprognostic (5.39e-2)" "unprognostic (1.56e-2)" "unprognostic (1.24e-1)" "unprognostic (3.97e-3)" "unprognostic (5.19e-2)" "unprognostic (7.53e-2)" "unprognostic (3.81e-1)" "unprognostic (2.05e-3)" 19.5 24.2 13.1 22.1 15.1 32.3 23.1 13.4 14.0 16.8 16.9 17.9 22.5 16.5 17.1 17.7 31.1 14.6 19.0 17.7 10.8 8.2 15.8 35.3 19.2 20.2 15.4 9.1 16.2 18.4 17.5 20.6 23.2 12.5 20.1 17.8 17.6 22.2 30.9 50.0 21.7 22.3 14.2 12.9 22.7 25.8 41.0 13.0 28.9 21.9 25.0 26.6 19.1 21.2 11.3 21.1 28.5 27.6 17.3 18.8 10.9 19.7 11.5 12.5 16.9 18.8 16.7 18.0 20.6 15.9 21.4 21.5 13.4 10.7 19.7 14.9 19.8 13.6 24.0 16.0 23.4 18.1 25.2 28.0 16.9 14.6 16.0 23.6 30.3 51.5 17.9 21.3 24.3 22.4 12.6 18.7 13.3 17.4 19.2 19.3 24.4 18.5 16.0 9.1 27.9 15.7 22.4 15.4 20.6 13.1 32.7 19.4 17.1 19.1 21.1 15.3 13.4 15.0 15.9 18.4 30.0 5.1 18.1 20.3 23.0 17.5 23.4 17.5 17.0 21.6 18.2 16.7 28.5 18.8 27.6 16.8 11.3 14.2 15.8 21.1 8.9 14.7 14.8 5.1 17.3 22.5 12.0 16.4 10.9 13.1 15.1 13.4 14.0 10.8 8.2 15.4 9.1 12.5 13.0 17.9 14.3 24.0 18.4 26.7 9.0 16.5 25.5 18.7 18.2 38.4 3.9 37.6 10.0 24.0 92.7 20.5 38.5 23.3 21.6 52.8 23.3 15.9 34.6 23.2 27.5 4.8 14.9 17.8 24.8 128.4 28.7 33.0 27.0 22.6 17.2 11.8 22.4 24.6 23.3 15.2 13.6 19.4 16.0 39.1 19.2 34.4 37.1 35.9 20.3 30.8 ATP2C2 "KIAA0703, SPCA2" ENSG00000064270 "ATPase secretory pathway Ca2+ transporting 2" O75185 16 84368527-84464187 "Enzymes, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" Translocase "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 23.0;salivary gland: 35.8" "Cell type enhanced" "Detected in many" 8 "Alveolar cells type 2: 42.2;Ciliated cells: 72.3;Mucus-secreting cells: 62.9;Undifferentiated cells: 69.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 24 "neutrophil: 2.7" "Lineage enriched" "Detected in single" 24 "granulocytes: 2.7" "Cell line enhanced" "Detected in some" "MCF7: 14.5;OE19: 26.0;RT4: 11.4;SK-BR-3: 20.2;T-47d: 6.7" "Low region specificity" "Detected in some" "Not detected" "Not detected" "HPA052262, HPA075812" Approved Approved "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA052262: AB_2681776, HPA075812: AB_2686765" "unprognostic (2.28e-2)" "unprognostic (6.13e-2)" "unprognostic (3.34e-2)" "prognostic favorable (6.20e-6)" "unprognostic (2.04e-1)" "unprognostic (2.41e-2)" "unprognostic (8.36e-2)" "unprognostic (1.72e-1)" "unprognostic (9.92e-2)" "unprognostic (1.89e-2)" "unprognostic (5.08e-2)" "unprognostic (2.16e-1)" "unprognostic (8.37e-3)" "unprognostic (1.17e-1)" "unprognostic (1.02e-1)" "unprognostic (4.32e-4)" "unprognostic (1.39e-1)" 0.3 0.0 2.1 8.0 1.5 6.1 2.5 0.2 2.0 3.5 23.0 0.5 1.9 16.3 1.8 1.9 2.7 4.0 18.8 0.4 1.8 1.9 2.6 0.2 21.9 0.2 1.3 0.7 1.3 0.5 0.0 2.9 4.8 0.7 7.9 21.9 1.0 35.8 0.2 0.9 15.2 14.5 0.5 0.6 0.2 3.4 0.4 0.4 0.3 8.2 2.2 8.1 4.8 7.8 0.0 0.0 2.7 0.0 0.0 0.1 0.0 3.6 0.2 0.4 0.0 0.0 0.0 3.9 0.1 0.0 0.0 0.0 3.4 3.2 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 0.0 0.0 0.0 26.0 0.1 0.0 0.0 0.1 0.0 11.4 2.9 0.0 0.0 20.2 0.1 0.5 6.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 2.1 1.5 0.2 2.0 1.8 1.9 1.3 0.7 0.7 0.4 29.8 42.2 0.0 12.3 0.6 1.4 0.6 2.5 72.3 29.6 0.0 0.0 1.9 0.0 7.2 3.0 0.6 15.4 0.0 2.3 2.2 0.3 21.6 9.2 0.0 0.2 0.0 32.8 0.0 0.0 1.1 0.0 0.7 1.7 0.0 62.9 1.3 3.1 17.3 0.0 1.9 5.6 0.0 0.5 0.7 0.6 1.0 20.1 0.0 69.5 9.5 BTBD7 "FLJ10648, FUP1" ENSG00000011114 "BTB domain containing 7" Q9P203 14 93237550-93333092 "Predicted intracellular proteins" "Developmental protein" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049926, HPA053406" Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA049926: AB_2680956, HPA053406: AB_2682137" "unprognostic (3.36e-1)" "unprognostic (4.36e-2)" "unprognostic (1.04e-2)" "unprognostic (1.01e-1)" "unprognostic (7.74e-2)" "unprognostic (1.16e-1)" "unprognostic (1.67e-2)" "unprognostic (2.69e-1)" "unprognostic (6.55e-2)" "unprognostic (1.31e-1)" "unprognostic (8.97e-3)" "unprognostic (4.34e-2)" "prognostic favorable (1.69e-6)" "unprognostic (7.27e-2)" "unprognostic (1.97e-1)" "unprognostic (4.72e-2)" "unprognostic (9.52e-2)" 11.1 8.4 10.2 11.0 11.6 11.8 9.9 14.1 11.6 11.9 10.4 14.3 10.9 8.2 11.4 8.0 13.2 10.9 10.8 9.6 8.9 5.4 13.3 8.7 10.6 7.5 10.1 7.8 11.6 10.1 26.1 10.2 18.0 10.3 9.2 10.5 8.0 10.8 10.3 13.0 11.3 12.0 11.0 7.4 9.5 8.9 20.0 10.7 9.1 15.4 6.7 9.1 13.5 15.5 1.6 1.7 4.4 1.3 0.5 1.5 0.2 7.5 5.8 7.3 3.9 5.8 7.7 10.5 6.7 6.6 6.0 4.7 5.2 6.5 3.9 5.2 9.9 4.4 7.3 7.1 14.9 10.1 4.6 3.1 4.1 4.4 3.8 2.9 7.0 4.7 6.4 4.6 7.4 8.7 5.4 9.4 3.0 3.9 5.1 8.6 6.7 2.8 2.0 4.7 5.4 7.5 8.0 10.9 1.9 9.2 25.1 9.2 5.6 7.4 3.4 3.2 7.7 6.8 4.8 12.6 5.8 5.6 5.3 5.0 4.0 3.4 4.7 5.2 3.6 6.8 3.1 0.7 4.4 1.4 0.7 0.4 1.5 1.0 1.3 0.6 1.6 0.9 1.0 1.8 0.5 1.3 1.7 1.5 0.2 10.2 11.6 14.1 11.6 8.9 5.4 10.1 7.8 10.3 10.7 47.6 23.0 18.2 23.5 28.7 25.9 17.8 33.1 18.7 14.8 52.4 35.3 18.3 11.6 27.9 34.8 35.0 22.6 0.0 21.2 18.5 27.2 36.7 24.3 15.1 15.3 25.4 27.6 43.6 27.3 37.7 21.9 21.1 10.1 33.3 22.7 29.5 33.2 23.0 37.1 32.3 29.0 12.9 43.2 24.5 32.1 32.2 25.6 19.8 24.7 62.6 C11orf96 AG2 ENSG00000187479 "Chromosome 11 open reading frame 96" 11 43942505-43944338 "Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "ovary: 152.0" "Cell type enhanced" "Detected in many" 19 "Peritubular cells: 445.9;Sertoli cells: 297.5;Smooth muscle cells: 1129.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 9 "SH-SY5Y: 65.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038843 Uncertain Approved "Nucleoplasm,Focal adhesion sites,Cytosol" No NA "Nucleoplasm, Focal adhesion sites, Cytosol" "HPA038843: AB_10673296" "unprognostic (1.55e-1)" "unprognostic (1.33e-1)" "unprognostic (1.28e-2)" "unprognostic (8.15e-3)" "unprognostic (5.49e-2)" "unprognostic (3.42e-3)" "unprognostic (8.11e-3)" "unprognostic (1.15e-2)" "unprognostic (2.46e-2)" "unprognostic (1.02e-1)" "unprognostic (3.01e-1)" "unprognostic (5.98e-2)" "prognostic unfavorable (2.34e-5)" "unprognostic (2.65e-2)" "unprognostic (2.07e-1)" "unprognostic (1.18e-2)" "unprognostic (3.19e-2)" 68.2 81.2 4.9 23.4 17.4 3.4 42.6 2.6 10.5 39.7 32.2 3.3 6.6 12.4 35.1 41.5 16.3 69.3 70.0 34.3 8.8 7.9 17.9 67.7 61.9 4.9 7.6 4.7 152.0 18.1 3.8 14.2 14.6 32.8 28.6 6.2 7.6 2.3 12.8 38.2 10.1 17.2 22.9 15.3 12.7 31.3 41.7 4.2 0.0 16.7 14.0 2.3 62.9 32.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.7 0.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.7 0.0 0.1 0.0 0.0 0.0 0.9 2.0 0.0 0.0 0.2 0.1 0.1 0.1 0.0 0.4 0.0 0.0 0.4 0.6 0.7 0.0 0.0 0.0 0.7 0.8 0.5 0.0 0.3 3.3 0.2 1.4 0.0 0.0 0.7 65.3 0.0 0.0 6.0 1.9 0.0 0.7 0.9 3.1 1.3 0.8 0.0 7.6 0.0 1.0 2.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 17.4 2.6 7.1 8.8 7.9 7.6 4.7 32.8 4.2 6.0 166.6 0.0 14.6 82.5 15.3 5.3 0.0 1.4 2.3 0.0 2.0 1.1 0.0 2.2 3.5 30.5 0.0 0.0 0.5 3.5 142.9 42.4 12.8 2.5 3.3 1.6 0.0 114.8 6.9 5.8 199.6 9.5 165.4 0.0 0.0 2.3 2.8 0.0 445.9 0.0 7.6 297.5 1129.9 1.6 1.4 77.3 2.6 2.5 0.0 35.8 C4orf36 MGC26744 ENSG00000163633 "Chromosome 4 open reading frame 36" Q96KX1 4 86876205-86892422 "Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "No human protein/transcript evidence" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "testis: 14.0" "Group enriched" "Detected in many" 11 "Early spermatids: 140.3;Late spermatids: 253.3" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 4 "basal ganglia: 1.8;cerebral cortex: 1.6;hippocampal formation: 3.3;pons and medulla: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A-431: 5.8;CAPAN-2: 4.6;hTCEpi: 3.8;hTERT-HME1: 5.5" HPA057434 Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA057434: AB_2683438" "unprognostic (2.01e-1)" "unprognostic (2.68e-1)" "unprognostic (7.78e-2)" "unprognostic (4.76e-2)" "unprognostic (7.31e-2)" "unprognostic (5.68e-2)" "unprognostic (5.93e-3)" "unprognostic (2.39e-2)" "unprognostic (5.20e-2)" "unprognostic (2.77e-1)" "unprognostic (2.76e-2)" "unprognostic (2.55e-1)" "prognostic favorable (7.69e-5)" "unprognostic (2.85e-1)" "unprognostic (2.44e-1)" "unprognostic (4.28e-2)" "unprognostic (7.75e-2)" 0.6 0.2 0.1 0.7 1.8 0.0 2.1 0.4 1.6 1.7 0.3 0.7 0.0 0.3 1.0 0.4 1.0 0.4 0.0 1.4 3.3 0.2 0.6 0.5 0.9 0.0 0.2 0.4 1.7 0.5 0.0 2.6 0.2 1.4 1.3 0.3 0.1 0.6 0.3 0.1 4.2 0.1 0.6 0.3 0.8 0.2 14.0 0.0 0.0 0.8 0.0 0.4 0.5 0.8 0.1 0.9 0.3 0.0 0.0 0.1 0.0 5.8 0.5 0.3 0.2 0.0 0.3 1.2 2.9 0.8 0.7 0.0 0.3 4.6 0.0 0.5 0.0 0.1 2.6 0.4 2.6 0.7 0.1 0.4 0.0 0.9 0.0 0.0 0.0 0.0 0.0 3.8 0.0 5.5 0.1 0.0 0.2 0.4 0.1 0.0 2.7 1.8 0.2 0.8 1.2 0.0 1.4 0.0 0.0 0.9 2.4 0.7 1.8 0.8 0.4 0.0 0.5 1.1 0.0 0.0 0.6 1.0 0.3 0.4 0.2 0.9 0.3 0.0 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 0.1 1.8 0.4 1.6 3.3 0.2 0.2 0.4 1.4 0.0 0.0 0.0 3.4 9.5 4.4 4.8 18.1 12.7 0.0 0.0 0.0 9.8 0.9 0.0 0.0 140.3 7.1 10.2 0.0 0.0 1.6 3.8 3.9 0.0 2.4 2.8 1.6 2.9 4.3 5.4 253.3 4.9 1.5 1.7 0.0 7.4 6.3 0.3 9.3 3.2 0.0 6.8 6.5 3.1 3.7 7.0 8.9 8.1 2.2 5.2 3.9 CAPN12 ENSG00000182472 "Calpain 12" Q6ZSI9 19 38730187-38769904 "Enzymes, Predicted intracellular proteins" "Hydrolase, Protease, Thiol protease" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "blood: 24.5;gallbladder: 21.0;liver: 21.8;salivary gland: 34.3" "Cell type enhanced" "Detected in many" 8 "Alveolar cells type 2: 27.1;Cholangiocytes: 50.9;T-cells: 25.4" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in some" "pons and medulla: 2.4" "Group enriched" "Detected in many" 7 "basophil: 24.5;NK-cell: 12.7" "Group enriched" "Detected in many" 7 "granulocytes: 24.5;NK-cells: 12.7" "Cell line enriched" "Detected in some" 5 "HMC-1: 17.6" "Low region specificity" "Detected in single" "Region enhanced" "Detected in single" "hippocampal formation: 3.6" HPA053322 Approved "Nucleoplasm,Focal adhesion sites" NA NA "Focal adhesion sites" Nucleoplasm "HPA053322: AB_2682111" "unprognostic (1.81e-1)" "unprognostic (4.48e-2)" "unprognostic (1.04e-2)" "unprognostic (1.08e-1)" "unprognostic (1.95e-2)" "unprognostic (2.81e-2)" "unprognostic (1.02e-1)" "unprognostic (6.01e-3)" "unprognostic (7.20e-2)" "unprognostic (2.45e-2)" "unprognostic (1.29e-1)" "unprognostic (4.01e-2)" "prognostic unfavorable (5.90e-6)" "unprognostic (7.04e-2)" "unprognostic (4.01e-2)" "unprognostic (3.00e-1)" "unprognostic (4.59e-2)" 0.6 0.4 0.2 4.7 0.2 0.2 0.7 0.2 0.3 4.2 4.1 0.1 5.6 1.2 1.1 1.0 1.2 3.6 21.0 0.7 1.0 0.4 7.1 21.8 2.0 1.8 0.2 0.1 0.4 5.0 0.2 0.7 0.5 2.4 2.2 0.7 0.4 34.3 3.0 0.3 4.5 1.9 0.5 0.4 4.9 1.6 0.6 0.1 0.4 0.4 1.6 5.2 1.5 1.0 1.7 0.0 24.5 0.0 12.7 2.6 0.7 0.2 1.8 0.1 0.0 0.3 0.1 2.2 0.1 0.0 0.0 0.1 3.2 0.1 0.7 0.1 0.0 0.3 1.3 0.0 0.8 0.0 0.1 0.0 0.3 0.7 0.9 0.0 0.0 17.6 0.8 2.5 0.3 0.0 0.0 0.0 0.0 0.5 0.5 0.3 0.3 0.0 0.0 0.5 1.0 0.0 0.0 0.0 0.2 1.9 0.0 0.1 0.0 0.1 0.4 0.1 0.4 0.1 1.4 0.0 0.0 0.1 0.0 0.4 0.9 0.7 0.0 0.1 0.0 0.7 24.5 0.0 1.8 2.6 0.0 2.5 1.5 0.7 1.3 0.0 1.7 0.0 0.6 0.4 12.7 0.0 0.0 0.5 0.7 0.2 0.2 0.2 0.3 1.0 0.4 0.2 0.1 2.4 0.1 11.9 27.1 15.9 8.0 8.4 1.2 0.6 50.9 5.3 5.7 5.2 0.0 1.5 0.0 9.1 0.4 1.8 4.2 0.0 6.3 8.2 1.1 2.3 4.7 12.7 0.9 0.0 3.5 1.3 1.0 0.2 0.6 2.0 3.3 0.0 18.8 1.7 4.0 3.5 0.4 16.5 0.6 0.0 1.7 0.3 2.4 8.3 2.4 25.4 16.4 4.3 CEP135 "CEP4, FLJ13621, KIAA0635" ENSG00000174799 "Centrosomal protein 135" Q66GS9 4 55948871-56033363 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Mental retardation, Primary microcephaly" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 27.1" "Cell type enhanced" "Detected in all" 6 "Early spermatids: 56.2;monocytes: 85.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA073950 Uncertain "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA073950: " "unprognostic (2.75e-1)" "unprognostic (2.71e-2)" "unprognostic (2.48e-2)" "unprognostic (1.06e-2)" "unprognostic (3.63e-1)" "unprognostic (3.42e-2)" "unprognostic (4.65e-3)" "unprognostic (4.78e-3)" "unprognostic (1.83e-3)" "unprognostic (9.89e-3)" "unprognostic (9.50e-2)" "unprognostic (2.27e-1)" "unprognostic (6.02e-9)" "unprognostic (7.55e-2)" "unprognostic (5.54e-2)" "unprognostic (1.95e-1)" "prognostic favorable (6.11e-5)" 5.5 3.0 2.9 13.8 6.0 12.8 5.2 5.1 5.3 8.5 4.6 3.1 7.5 4.3 12.8 4.5 4.7 7.4 4.5 3.4 5.3 3.4 5.7 2.9 7.0 13.0 5.8 3.9 9.6 4.5 4.1 6.9 8.1 4.5 4.4 4.6 2.5 3.7 5.9 2.3 5.4 6.2 7.1 5.5 11.1 3.6 9.3 4.6 27.1 5.0 4.5 10.1 4.8 5.6 9.2 8.7 11.9 4.4 7.1 7.5 2.0 6.9 3.8 10.7 10.0 2.2 4.3 4.6 6.9 4.9 6.4 7.5 4.3 7.3 18.9 5.3 3.1 5.1 3.3 11.1 4.3 12.1 5.1 7.1 6.6 5.7 3.8 2.4 11.9 10.4 3.3 3.4 8.0 5.8 2.9 5.3 9.7 12.1 9.1 6.5 4.2 16.6 7.4 6.7 3.5 4.2 12.1 5.1 3.9 4.6 5.2 7.7 8.1 6.2 4.2 5.1 6.7 5.7 7.7 5.2 8.7 14.2 10.3 12.1 5.0 3.5 12.9 4.4 9.4 10.6 11.9 3.4 4.2 4.7 4.1 4.3 4.6 6.0 4.5 2.1 9.2 7.5 4.8 7.0 7.1 4.4 8.7 3.7 2.0 2.9 6.0 5.1 5.3 5.3 3.4 5.8 3.9 4.5 4.6 6.0 14.3 15.9 7.2 8.0 12.6 7.3 2.5 22.7 14.8 7.0 9.8 15.3 3.3 7.8 56.2 15.3 3.9 23.3 4.7 11.7 5.9 4.3 13.9 1.8 9.0 25.4 5.2 12.3 9.2 11.4 5.5 17.8 5.0 85.6 4.3 4.7 11.0 5.7 7.8 9.0 21.0 6.5 6.6 53.2 43.8 5.8 8.0 16.0 5.2 5.5 CHRNA5 ENSG00000169684 "Cholinergic receptor nicotinic alpha 5 subunit" P30532 15 78565520-78595269 "Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "vagina: 33.9" "Cell type enhanced" "Detected in many" 16 "Extravillous trophoblasts: 9.6;Spermatogonia: 32.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA054381 Approved Approved "Plasma membrane,Focal adhesion sites" NA NA "Focal adhesion sites" "Plasma membrane" "HPA054381: AB_2682468" "unprognostic (2.66e-1)" "unprognostic (1.76e-1)" "unprognostic (2.32e-2)" "unprognostic (3.20e-3)" "unprognostic (6.66e-2)" "unprognostic (1.29e-3)" "unprognostic (7.03e-5)" "prognostic unfavorable (3.64e-5)" "unprognostic (1.34e-2)" "unprognostic (1.31e-2)" "unprognostic (4.52e-2)" "unprognostic (8.97e-2)" "unprognostic (6.50e-11)" "unprognostic (4.37e-1)" "unprognostic (5.39e-1)" "unprognostic (5.44e-2)" "unprognostic (2.22e-1)" 2.9 3.3 1.7 4.4 1.7 0.6 4.9 1.8 1.7 2.7 6.4 0.4 1.6 7.8 4.7 1.9 4.0 1.1 16.3 2.4 1.7 1.8 0.9 1.8 1.4 2.0 1.9 0.3 1.7 11.8 0.0 0.7 2.1 1.2 3.6 7.1 3.5 1.7 0.7 5.8 1.0 6.8 6.1 1.3 1.9 5.3 9.8 0.6 4.5 1.6 2.9 4.4 5.7 33.9 0.9 1.1 3.4 1.6 1.6 1.4 0.7 6.7 17.4 9.5 5.2 1.1 0.8 3.8 4.9 2.4 5.5 10.0 6.6 32.1 4.0 12.2 1.0 14.8 6.0 18.1 7.3 5.6 8.1 21.7 7.4 13.6 6.6 0.6 5.0 10.5 0.3 1.3 1.5 2.0 2.0 10.2 5.6 7.2 5.2 3.5 14.7 6.3 1.7 7.7 13.3 4.8 8.1 10.9 4.0 6.6 16.1 16.0 23.5 11.9 11.6 5.5 5.6 25.8 1.3 2.2 7.5 9.0 5.5 15.5 6.1 25.0 4.5 4.5 8.1 6.9 3.0 1.6 2.5 0.8 1.6 0.4 0.3 0.8 0.5 0.9 0.9 1.4 1.4 3.4 1.6 1.3 1.1 0.3 0.7 1.7 1.7 1.8 1.7 1.7 1.8 1.9 0.3 1.2 0.6 0.0 0.0 0.0 7.8 2.9 1.9 0.8 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.3 1.0 1.0 0.0 0.0 1.8 9.6 0.4 5.2 0.0 0.0 0.9 4.8 3.4 0.0 0.0 1.2 0.3 0.8 1.7 0.0 6.3 0.2 0.7 0.0 0.4 0.2 0.5 0.0 2.1 3.2 32.1 1.4 0.8 1.3 1.5 2.7 CNTD1 "CNTD, FLJ40137" ENSG00000176563 "Cyclin N-terminal domain containing 1" Q8N815 17 42798792-42811587 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 11 "testis: 31.0" "Group enriched" "Detected in many" 12 "Ciliated cells: 80.3;Early spermatids: 53.3;Late spermatids: 75.8;Spermatocytes: 135.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "neutrophil: 2.7" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "A-431: 6.3;ASC diff: 4.3;SiHa: 3.3;T-47d: 2.4" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA023324 Approved "Nucleoplasm,Plasma membrane,Focal adhesion sites" NA NA Nucleoplasm "Plasma membrane, Focal adhesion sites" "HPA023324: AB_1848931" "unprognostic (5.92e-2)" "unprognostic (1.99e-3)" "unprognostic (3.66e-2)" "unprognostic (2.13e-2)" "unprognostic (1.25e-1)" "unprognostic (6.29e-3)" "unprognostic (6.61e-2)" "unprognostic (1.09e-2)" "unprognostic (7.82e-2)" "unprognostic (6.18e-2)" "unprognostic (1.36e-2)" "unprognostic (2.07e-1)" "unprognostic (5.89e-7)" "unprognostic (1.52e-1)" "unprognostic (1.90e-1)" "unprognostic (2.35e-1)" "unprognostic (1.81e-4)" 0.2 0.1 0.7 0.0 1.4 0.0 1.6 0.2 1.7 0.2 0.6 0.4 0.0 0.0 0.1 0.9 0.1 0.5 0.0 0.1 1.5 0.3 1.2 0.1 0.3 0.0 0.5 0.8 0.3 0.8 0.0 0.1 0.0 0.9 1.1 1.5 0.1 0.5 0.0 0.2 0.1 0.2 0.7 0.8 0.1 2.3 31.0 1.6 0.0 0.1 0.0 0.0 0.2 0.1 0.9 0.1 2.7 0.3 0.1 0.3 0.3 6.3 0.7 0.5 1.3 4.3 1.5 0.0 0.0 0.3 0.4 1.4 0.0 0.0 0.0 0.2 1.2 0.0 0.0 0.0 0.0 1.0 0.2 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.6 0.0 0.0 1.1 0.2 0.0 0.4 0.6 1.3 0.0 0.0 0.2 0.6 0.0 0.2 0.0 0.2 0.0 0.4 0.7 0.0 0.0 0.0 3.3 0.3 0.8 0.1 2.4 0.0 0.0 1.4 0.2 0.0 0.0 0.0 0.3 0.1 0.1 0.5 0.4 0.0 0.3 0.0 0.3 0.2 0.3 0.4 0.1 0.0 0.1 0.9 0.0 0.0 2.7 0.1 0.1 0.0 0.0 0.3 0.7 1.4 0.2 1.7 1.5 0.3 0.5 0.8 0.9 1.6 3.0 2.9 0.0 0.4 0.3 1.6 0.8 0.0 80.3 3.4 0.0 0.0 0.2 5.0 0.2 53.3 0.3 0.5 0.0 0.3 0.3 0.6 7.4 5.8 0.9 0.3 6.4 0.0 0.0 1.0 75.8 2.3 0.7 0.0 0.0 4.6 1.2 0.3 0.0 1.1 0.3 0.4 6.5 0.9 135.1 2.7 0.5 0.2 0.5 2.1 0.9 CORO2B "ClipinC, KIAA0925" ENSG00000103647 "Coronin 2B" Q9UQ03 15 68578969-68727806 "Plasma proteins, Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 53.5;fallopian tube: 27.4" "Cell type enhanced" "Detected in many" 11 "Bipolar cells: 32.6;Ciliated cells: 14.7;Cone photoreceptor cells: 35.3;Rod photoreceptor cells: 20.9" "Group enriched" "Detected in many" 8 "glioma: 34.7;melanoma: 21.5" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "memory B-cell: 1.2;naive B-cell: 4.5" "Lineage enriched" "Detected in single" 21 "B-cells: 4.5" "Cell line enhanced" "Detected in many" "ASC diff: 12.9;ASC TERT1: 27.8;HSkMC: 20.0;hTEC/SVTERT24-B: 16.3;U-87 MG: 27.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017960 Enhanced Supported Approved "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA017960: AB_1847167" "unprognostic (1.35e-1)" "unprognostic (2.63e-2)" "unprognostic (2.81e-3)" "unprognostic (4.71e-3)" "unprognostic (3.28e-1)" "unprognostic (8.11e-5)" "unprognostic (4.77e-2)" "unprognostic (1.24e-1)" "unprognostic (3.68e-2)" "unprognostic (1.81e-1)" "unprognostic (1.33e-3)" "unprognostic (4.12e-2)" "unprognostic (1.26e-1)" "unprognostic (1.10e-2)" "unprognostic (5.83e-2)" "unprognostic (3.59e-2)" "unprognostic (1.87e-2)" 10.9 4.4 15.7 3.2 30.1 1.9 4.8 33.7 53.5 6.5 3.4 27.3 0.8 2.4 7.5 3.9 2.7 27.4 6.3 7.2 23.0 15.1 5.5 2.0 5.8 3.5 20.9 18.8 18.4 2.9 1.6 1.5 4.7 23.6 3.2 2.9 11.8 3.4 6.9 3.8 5.6 3.3 8.4 35.0 3.6 2.0 2.2 17.5 0.0 4.6 0.6 1.9 3.0 1.6 4.5 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.3 12.3 1.0 12.9 27.8 0.0 6.2 6.9 1.1 1.5 0.1 1.4 1.5 0.7 1.0 1.7 0.0 0.4 0.1 4.5 0.0 0.5 0.0 0.0 0.6 4.7 0.0 0.1 20.0 0.1 16.3 1.0 9.7 0.4 0.0 0.0 0.0 11.4 0.0 0.0 0.0 3.0 0.0 0.0 1.0 0.0 0.5 1.7 0.0 7.1 0.1 0.1 0.0 3.6 2.4 0.0 1.4 0.1 3.7 4.1 0.7 8.2 0.0 0.0 1.5 27.8 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.2 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.7 30.1 33.7 29.3 23.0 15.1 20.9 18.8 23.6 17.5 0.0 0.0 0.0 0.3 0.9 32.6 1.1 0.0 14.7 0.0 7.0 35.3 0.0 0.0 3.8 0.2 1.5 0.0 0.0 0.5 0.0 2.6 0.1 0.0 0.0 0.2 0.0 3.5 5.5 0.3 0.0 7.2 0.0 6.8 0.0 0.0 9.5 0.4 0.0 0.4 0.0 20.9 6.5 2.3 0.2 0.4 0.6 0.0 0.0 0.0 0.1 CPAMD8 "K-CAP, KIAA1283, VIP" ENSG00000160111 "C3 and PZP like, alpha-2-macroglobulin domain containing 8" Q8IZJ3 19 16892947-17026815 "Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Protease inhibitor, Serine protease inhibitor" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "prostate: 19.3;retina: 23.7;seminal vesicle: 30.5" "Cell type enhanced" "Detected in many" 6 "Alveolar cells type 1: 20.8;Alveolar cells type 2: 21.4;Collecting duct cells: 26.2;Glandular cells: 18.0;Leydig cells: 29.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "classical monocyte: 1.5" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in some" 7 "BEWO: 14.7;EFO-21: 9.5;T-47d: 25.8" "Not detected" "Not detected" "HPA031327, HPA031328, HPA031329, HPA031330" Uncertain Uncertain "Focal adhesion sites" "Secreted to blood" NA NA 180000 "Focal adhesion sites" "HPA031327: AB_2673829, HPA031328: AB_2673830, HPA031329: , HPA031330: AB_10603788" "unprognostic (4.71e-3)" "unprognostic (1.07e-2)" "unprognostic (4.20e-2)" "unprognostic (2.76e-2)" "unprognostic (4.32e-2)" "unprognostic (4.06e-3)" "unprognostic (7.85e-2)" "unprognostic (9.30e-2)" "unprognostic (1.58e-1)" "unprognostic (2.71e-2)" "unprognostic (1.62e-1)" "unprognostic (4.24e-2)" "unprognostic (8.69e-2)" "unprognostic (1.01e-3)" "unprognostic (2.08e-1)" "unprognostic (8.45e-2)" "unprognostic (1.80e-2)" 3.1 1.3 1.0 0.4 2.3 0.2 3.6 0.6 2.3 5.3 0.4 2.9 6.5 0.2 1.5 8.2 0.6 0.6 0.4 7.0 1.2 1.3 8.9 0.5 11.5 1.5 4.9 0.4 0.6 0.4 3.5 2.0 3.1 5.1 19.3 0.0 23.7 1.1 30.5 1.7 0.4 0.4 0.4 5.6 1.1 0.1 0.9 2.8 0.9 11.6 1.4 0.4 1.2 1.4 0.2 0.0 0.6 1.5 0.1 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 14.7 0.0 0.1 0.0 0.0 0.0 0.0 0.3 9.5 0.2 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.0 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 2.2 0.5 0.0 0.0 1.4 0.0 0.1 0.4 2.0 0.0 0.0 0.0 0.4 0.0 0.1 25.8 0.1 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.5 0.6 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 1.0 2.3 0.6 2.3 1.2 1.3 4.9 0.4 5.1 2.8 20.8 21.4 0.0 10.1 0.8 0.4 4.8 2.5 1.4 12.5 26.2 0.0 6.4 0.0 0.6 1.5 8.6 0.0 0.0 0.0 5.0 2.4 18.0 2.3 0.0 2.6 0.0 0.0 12.9 6.6 3.6 29.1 1.5 0.0 0.0 0.4 0.0 0.9 0.8 6.0 0.0 0.0 0.0 2.8 5.4 1.0 0.5 5.0 0.0 0.0 3.4 CUTA "ACHAP, C6orf82" ENSG00000112514 "CutA divalent cation tolerance homolog" O60888 6 33416442-33418317 "Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016787, HPA064369" Uncertain Approved "Plasma membrane,Focal adhesion sites" "Secreted to blood" NA NA 35000000 "Plasma membrane, Focal adhesion sites" "CAB016787: , HPA064369: AB_2685248" "unprognostic (7.03e-2)" "unprognostic (5.44e-2)" "unprognostic (4.56e-2)" "unprognostic (8.91e-2)" "unprognostic (1.86e-1)" "unprognostic (1.03e-1)" "unprognostic (1.98e-2)" "prognostic favorable (8.50e-4)" "unprognostic (1.87e-1)" "unprognostic (2.78e-2)" "unprognostic (1.27e-3)" "unprognostic (1.91e-1)" "unprognostic (5.55e-2)" "unprognostic (9.90e-2)" "unprognostic (1.54e-1)" "unprognostic (7.94e-2)" "unprognostic (2.74e-1)" 26.6 65.6 47.9 28.3 60.1 33.5 47.6 37.7 73.7 47.7 37.9 36.8 53.9 42.1 40.1 78.5 30.5 46.0 48.8 49.6 45.2 44.9 46.3 61.6 39.0 77.4 46.5 37.8 57.7 66.6 43.8 86.1 45.7 39.8 38.8 28.9 34.2 74.3 69.7 34.6 32.7 37.2 32.4 47.0 36.0 38.7 27.3 31.6 52.2 69.7 30.3 31.3 42.6 28.9 56.5 31.4 27.1 32.0 49.9 69.8 60.8 43.8 26.3 42.1 53.3 31.7 31.2 20.4 40.1 75.1 77.6 82.7 26.2 27.4 31.0 31.2 45.9 56.4 26.8 27.3 40.8 43.8 26.2 60.5 32.3 43.6 68.6 41.3 25.1 24.6 41.3 34.5 37.3 31.5 54.0 20.8 32.9 39.6 63.1 56.7 34.1 38.0 53.5 37.7 38.0 34.7 41.8 25.1 81.9 53.4 19.1 82.4 42.0 24.0 41.8 72.8 25.2 30.7 52.8 22.9 42.0 35.7 29.8 41.8 62.0 61.6 33.9 36.3 55.6 34.1 27.1 32.0 16.5 45.7 22.9 63.2 56.5 67.6 52.7 31.4 44.2 68.5 53.2 4.6 49.9 16.8 27.1 69.8 60.8 47.9 60.1 37.7 73.7 45.2 44.9 46.5 37.8 39.8 31.6 122.1 105.5 178.5 242.5 204.8 84.5 113.4 239.5 131.2 121.7 300.1 64.8 309.8 240.4 162.1 64.8 93.9 157.7 23.3 122.9 203.5 204.8 237.5 167.3 299.7 277.3 73.1 280.4 131.3 162.9 285.6 185.2 150.2 300.3 80.2 266.0 150.8 114.3 196.4 180.0 440.5 69.0 90.5 220.1 100.6 65.6 201.4 203.1 245.2 291.8 203.9 DCAF6 "IQWD1, PC326" ENSG00000143164 "DDB1 and CUL4 associated factor 6" Q58WW2 1 167935783-168075843 "Predicted intracellular proteins" "Ubl conjugation pathway" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 155.9" "Group enriched" "Detected in all" 4 "Cardiomyocytes: 200.2;Early spermatids: 375.8;Late spermatids: 573.8;monocytes: 176.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054305 Supported "Nucleoplasm,Focal adhesion sites" NA NA "Nucleoplasm, Focal adhesion sites" "HPA054305: AB_2682444" "unprognostic (1.54e-1)" "unprognostic (2.11e-1)" "unprognostic (1.42e-1)" "unprognostic (2.31e-1)" "unprognostic (2.20e-1)" "unprognostic (1.19e-1)" "unprognostic (5.42e-2)" "unprognostic (1.81e-1)" "unprognostic (1.51e-1)" "unprognostic (2.12e-1)" "unprognostic (1.74e-1)" "unprognostic (3.20e-2)" "unprognostic (9.21e-2)" "unprognostic (7.06e-2)" "unprognostic (6.00e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-1)" 10.6 17.0 10.9 7.8 12.2 6.2 8.8 10.5 17.8 10.2 11.5 3.9 8.4 6.2 9.5 11.4 9.3 7.7 8.2 43.8 7.6 5.5 9.5 26.2 7.3 4.8 5.2 11.5 8.3 6.1 10.8 11.3 7.8 6.5 10.5 8.7 5.7 10.3 11.9 155.9 6.4 7.8 10.2 4.8 5.9 9.8 21.5 4.8 7.8 8.2 27.3 7.3 9.1 7.3 6.2 7.7 12.5 13.9 4.4 7.2 5.0 23.0 11.0 6.1 9.9 20.3 28.9 21.6 23.6 35.4 16.8 25.1 18.3 19.5 19.1 13.8 30.5 8.0 17.4 9.6 17.7 23.8 10.8 10.2 20.3 16.8 13.1 16.4 9.1 9.7 20.5 17.9 15.9 13.3 25.6 18.3 6.1 22.9 15.8 24.7 5.3 10.1 8.3 3.9 12.9 12.3 7.8 12.7 14.8 41.9 11.3 9.0 7.2 18.9 17.4 12.9 13.4 29.7 11.2 25.8 16.8 10.5 16.2 9.7 17.0 13.8 14.9 22.4 7.8 6.8 6.0 7.0 12.5 6.7 9.6 7.2 6.2 5.4 5.8 7.7 4.5 5.0 6.4 7.2 4.4 13.9 4.6 6.1 5.0 10.9 12.2 10.5 17.8 7.6 5.5 5.2 11.5 6.5 4.8 53.6 33.4 19.8 24.8 51.4 13.4 200.2 45.9 60.2 53.4 24.4 21.6 61.0 14.9 25.7 375.8 29.8 24.8 46.7 16.9 26.6 39.2 32.0 18.5 81.0 17.8 4.8 20.3 25.8 28.6 573.8 53.2 22.6 35.4 176.7 27.3 14.6 18.0 28.1 45.6 26.9 16.7 32.3 37.1 78.4 58.9 34.8 68.0 20.8 28.8 23.7 DLGAP4 "DAP4, KIAA0964, SAPAP4" ENSG00000080845 "DLG associated protein 4" Q9Y2H0 20 36306336-36528637 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-138 MG: 64.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054105, HPA056378" Approved Approved "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA "Nucleoplasm, Cytosol" "Focal adhesion sites" "HPA054105: AB_2682381, HPA056378: " "unprognostic (1.11e-1)" "unprognostic (1.42e-1)" "unprognostic (9.00e-2)" "prognostic unfavorable (2.24e-5)" "unprognostic (1.35e-1)" "unprognostic (1.37e-1)" "prognostic unfavorable (3.73e-6)" "unprognostic (1.23e-1)" "prognostic favorable (9.88e-5)" "unprognostic (1.28e-1)" "unprognostic (2.18e-2)" "unprognostic (8.45e-2)" "prognostic unfavorable (2.48e-4)" "unprognostic (1.07e-1)" "unprognostic (1.13e-1)" "unprognostic (1.37e-1)" "unprognostic (1.53e-1)" 18.8 16.6 25.7 14.3 32.9 4.5 18.0 16.2 31.9 19.0 20.1 9.0 14.9 13.5 23.1 13.1 16.8 18.5 17.0 25.9 23.7 12.7 10.2 11.0 21.6 9.8 9.5 20.7 18.9 30.2 7.7 10.2 16.9 8.8 15.7 10.1 15.4 19.3 21.2 58.0 27.1 13.6 27.2 6.8 14.5 12.2 12.6 10.9 8.3 13.8 16.8 10.8 29.0 15.0 16.1 13.5 19.5 13.1 6.9 12.5 9.1 14.1 12.9 15.8 13.0 15.0 24.6 15.9 21.4 19.6 21.0 14.6 19.4 9.1 4.0 11.6 30.0 18.6 13.7 4.2 21.9 15.7 6.4 1.5 9.1 6.6 13.1 21.7 3.6 7.9 16.2 17.0 24.8 17.4 16.3 20.6 5.7 6.3 11.0 15.8 10.6 7.4 13.9 6.8 10.4 27.6 7.4 4.2 5.5 9.8 7.0 10.4 14.3 14.0 28.5 17.6 16.8 16.3 6.4 20.7 64.1 19.5 27.5 11.7 3.8 2.7 4.3 25.6 4.6 25.1 2.1 12.8 19.5 12.5 13.1 9.8 16.1 11.3 8.7 11.3 14.9 8.8 7.0 18.5 6.9 12.6 13.5 8.7 9.1 25.7 32.9 16.2 31.9 23.7 12.7 9.5 20.7 8.8 10.9 14.9 18.6 15.9 41.2 59.0 31.9 25.0 25.5 17.4 13.6 12.2 7.9 19.6 6.6 45.3 63.3 34.3 19.2 0.0 47.9 41.6 32.7 58.9 11.6 16.3 24.9 69.9 60.7 24.5 18.1 119.1 27.6 21.1 10.1 63.1 29.8 36.4 66.0 24.6 24.8 16.3 27.9 71.1 41.0 13.6 16.2 62.7 46.1 15.0 16.9 46.3 DOK5 "C20orf180, dJ805C22.1" ENSG00000101134 "Docking protein 5" Q9P104 20 54475597-54651171 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 41.3" "Cell type enhanced" "Detected in many" 10 "Distal tubular cells: 33.2;Horizontal cells: 36.5;monocytes: 25.2;Muller glia cells: 60.0" "Group enriched" "Detected in many" 6 "glioma: 18.0;ovarian cancer: 29.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 19.7;ASC diff: 8.0;ASC TERT1: 6.8;hTEC/SVTERT24-B: 8.2;U-138 MG: 31.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054460, HPA065235" Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA054460: AB_2682495, HPA065235: AB_2685441" "unprognostic (2.69e-1)" "unprognostic (1.49e-1)" "unprognostic (8.90e-2)" "prognostic unfavorable (8.99e-7)" "unprognostic (1.02e-1)" "unprognostic (1.72e-2)" "unprognostic (5.88e-4)" "unprognostic (5.12e-2)" "unprognostic (4.51e-3)" "unprognostic (2.97e-1)" "unprognostic (2.69e-2)" "unprognostic (1.49e-1)" "unprognostic (6.49e-2)" "unprognostic (4.23e-3)" "unprognostic (3.08e-1)" "unprognostic (4.56e-2)" "unprognostic (1.99e-2)" 3.5 2.7 15.5 2.3 11.0 0.6 2.0 1.4 14.8 1.8 1.3 6.6 0.4 1.0 2.1 1.0 2.4 13.6 10.6 18.1 11.0 12.5 3.6 3.2 1.0 1.2 8.4 6.2 2.4 1.9 0.9 1.2 2.4 7.3 1.6 1.4 7.6 1.7 1.5 41.3 0.6 1.1 3.5 5.4 0.9 0.9 2.2 6.4 0.0 5.9 6.4 1.0 3.6 3.5 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 19.7 0.0 8.0 6.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 2.6 0.0 8.2 0.0 0.3 1.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 2.0 4.2 0.0 5.2 0.0 0.0 0.0 0.2 1.2 0.0 0.0 0.0 31.2 2.0 0.9 0.0 0.0 0.0 0.1 1.4 0.0 2.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.5 11.0 1.4 12.6 11.0 12.5 8.4 6.2 7.3 6.4 0.0 0.0 0.0 1.0 0.2 9.7 5.9 17.8 0.0 0.0 10.4 5.9 0.2 33.2 16.2 1.9 2.3 0.0 0.0 1.0 0.5 11.2 0.9 0.0 0.0 21.8 36.5 0.0 9.8 0.3 3.1 2.3 1.1 0.0 25.2 0.0 60.0 3.5 0.0 1.1 0.0 7.4 0.0 2.0 0.6 0.4 0.4 0.7 0.0 0.0 0.4 DOK6 "DOK5L, HsT3226, MGC20785" ENSG00000206052 "Docking protein 6" Q6PKX4 18 69401055-69849087 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 22.1" "Cell type enriched" "Detected in some" 7 "Bipolar cells: 239.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 10.4;Hep G2: 10.9;RPMI-8226: 10.5;SCLC-21H: 4.8;SH-SY5Y: 10.9;SuSa: 8.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041099, HPA063534" Approved Approved "Focal adhesion sites,Cytosol" NA NA "Focal adhesion sites, Cytosol" "HPA041099: AB_2677299, HPA063534: AB_2685032" "unprognostic (5.83e-2)" "unprognostic (1.39e-1)" "unprognostic (2.06e-1)" "unprognostic (1.21e-1)" "unprognostic (2.77e-2)" "unprognostic (2.59e-1)" "unprognostic (1.55e-1)" "unprognostic (1.90e-2)" "unprognostic (8.62e-2)" "unprognostic (5.99e-2)" "unprognostic (1.04e-2)" "unprognostic (4.60e-3)" "unprognostic (2.13e-4)" "unprognostic (2.30e-3)" "unprognostic (2.88e-2)" "unprognostic (4.49e-3)" "unprognostic (1.09e-3)" 2.1 1.6 21.3 1.6 11.3 0.6 1.3 6.8 22.1 3.8 1.5 0.9 0.3 1.0 3.0 1.4 1.7 1.7 5.8 10.2 19.2 9.2 8.7 4.4 4.2 1.2 13.7 13.1 4.2 0.7 3.4 1.1 9.9 14.0 3.5 1.3 5.5 1.7 4.2 0.6 1.2 1.3 6.6 2.7 1.8 1.3 2.8 2.7 0.0 4.1 0.0 1.2 5.2 6.6 0.0 0.0 0.0 0.0 0.9 0.9 0.4 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.2 0.0 10.4 0.0 0.0 0.0 0.0 0.0 0.0 1.2 1.0 0.0 10.9 0.3 0.0 0.2 0.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 10.5 0.0 0.0 4.8 10.9 0.0 0.0 0.0 8.1 0.0 0.0 0.0 4.1 0.6 0.0 1.5 0.3 0.0 0.0 3.1 0.0 3.2 0.0 0.0 0.0 0.9 0.0 0.6 0.0 0.2 0.4 0.0 0.0 0.1 0.5 0.0 0.9 0.0 0.0 0.3 0.4 21.3 11.3 6.8 17.1 19.2 9.2 13.7 13.1 14.0 2.7 0.0 0.0 0.0 0.1 0.2 239.6 6.5 0.0 0.0 2.3 0.0 13.7 0.0 1.7 0.0 32.5 0.7 0.0 0.0 0.0 0.0 5.3 0.1 0.0 1.0 0.0 9.5 0.0 0.0 0.3 23.0 1.4 0.3 0.0 0.0 0.0 4.1 0.0 0.0 6.3 7.8 12.7 0.0 2.7 0.7 0.1 0.5 0.0 0.0 0.0 0.1 EIF2B2 "EIF-2Bbeta, EIF2B" ENSG00000119718 "Eukaryotic translation initiation factor 2B subunit beta" P49770 14 75002911-75012366 "Disease related genes, Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Disease mutation, Leukodystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Syncytiotrophoblasts: 138.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005841, CAB037105, HPA048028" Enhanced Approved "Nucleoplasm,Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" Nucleoplasm "CAB037105: AB_1840834, HPA005841: AB_1078725, HPA048028: AB_2680235" "unprognostic (1.10e-1)" "unprognostic (4.41e-2)" "unprognostic (5.70e-2)" "unprognostic (6.71e-2)" "unprognostic (7.64e-2)" "unprognostic (3.45e-3)" "prognostic unfavorable (2.26e-6)" "unprognostic (1.48e-1)" "unprognostic (1.23e-1)" "unprognostic (1.65e-2)" "unprognostic (4.95e-2)" "unprognostic (1.01e-1)" "prognostic favorable (2.95e-4)" "unprognostic (4.15e-2)" "unprognostic (2.74e-1)" "unprognostic (1.44e-1)" "unprognostic (3.28e-2)" 11.8 20.1 11.6 9.2 12.3 9.1 11.6 11.0 16.4 13.2 13.9 13.2 9.2 9.8 11.6 15.8 14.3 10.4 12.6 15.0 11.5 12.0 19.6 18.8 10.3 11.6 13.6 11.4 12.3 12.9 32.3 11.9 20.4 15.7 13.6 12.2 11.7 11.1 14.8 29.0 12.5 13.1 11.0 14.8 12.1 10.9 20.1 11.0 17.7 33.4 11.2 12.7 14.9 9.7 4.2 5.1 7.7 3.9 6.5 8.1 4.8 5.1 6.3 5.1 5.8 5.9 4.9 6.8 3.3 5.5 6.5 7.6 7.9 5.3 4.6 2.1 5.2 4.1 3.9 7.9 7.7 9.8 2.8 5.9 4.0 5.5 5.4 7.7 3.0 4.8 4.5 7.4 8.3 8.6 5.6 22.3 4.0 3.6 4.5 13.9 15.2 4.7 3.7 3.6 6.4 9.3 3.0 6.0 3.8 9.2 6.2 5.5 4.4 3.5 5.0 7.4 6.6 8.1 2.8 5.7 5.0 4.9 2.2 4.2 7.7 6.3 5.4 5.5 3.7 3.8 7.7 3.9 2.8 6.7 3.9 5.6 4.2 5.9 5.4 5.1 4.1 4.4 4.6 2.2 6.5 3.7 4.2 8.1 4.8 11.6 12.3 11.0 16.4 11.5 12.0 13.6 11.4 15.7 11.0 17.9 8.6 15.1 16.5 15.8 25.7 16.1 28.1 10.7 14.8 24.4 43.2 42.7 34.9 31.8 7.6 18.8 14.3 0.0 28.8 47.0 15.5 14.3 20.8 10.5 29.7 27.0 15.0 12.9 16.5 7.8 14.7 14.0 13.5 34.3 9.1 24.2 26.4 12.4 15.2 35.2 27.5 25.8 21.2 39.0 22.8 19.2 138.4 13.8 17.8 15.9 EMC4 "FLJ90746, MGC24415, PIG17, TMEM85" ENSG00000128463 "ER membrane protein complex subunit 4" Q5J8M3 15 34224999-34230156 "Predicted intracellular proteins, Predicted membrane proteins, Transporters" Apoptosis "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026868, HPA053440" Approved Supported "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA026868: AB_2672032, HPA053440: AB_2682151" "unprognostic (8.99e-2)" "unprognostic (1.59e-1)" "unprognostic (7.68e-2)" "unprognostic (3.29e-2)" "unprognostic (9.23e-2)" "unprognostic (1.29e-3)" "unprognostic (3.25e-1)" "unprognostic (3.61e-2)" "unprognostic (1.65e-1)" "unprognostic (1.78e-3)" "unprognostic (1.33e-1)" "unprognostic (2.20e-2)" "unprognostic (2.52e-1)" "unprognostic (5.42e-2)" "unprognostic (4.20e-2)" "unprognostic (2.96e-1)" "unprognostic (1.97e-2)" 36.3 34.3 43.5 23.4 48.3 25.4 35.2 34.9 54.3 33.5 32.2 31.0 25.7 27.5 33.5 54.3 36.2 35.4 28.4 38.5 39.4 40.6 39.1 47.5 27.1 24.5 41.7 42.8 35.3 45.2 29.1 29.5 41.5 48.6 32.5 30.1 32.8 38.9 34.7 95.1 29.6 27.9 30.1 36.7 27.2 31.2 26.4 32.0 26.9 34.6 41.2 29.0 28.9 32.6 71.6 53.3 65.7 59.4 60.3 65.9 78.0 31.9 67.2 28.3 36.6 36.9 33.6 26.0 36.7 42.2 45.4 39.5 43.7 28.5 12.7 48.6 42.4 39.9 61.6 28.7 36.0 32.6 38.7 27.8 24.0 62.0 40.1 44.7 36.3 24.1 33.7 34.4 33.0 37.2 32.4 37.5 38.9 29.9 50.6 39.5 36.4 28.8 38.9 31.7 43.2 44.1 26.7 25.8 35.9 43.2 50.4 37.3 45.6 27.3 40.1 19.4 21.5 26.8 43.2 28.5 41.7 28.6 35.8 37.3 44.9 63.5 32.4 50.8 43.4 35.2 65.7 52.3 54.5 53.0 54.0 57.9 71.6 59.5 63.4 52.2 54.6 60.8 59.8 29.1 60.3 59.4 53.3 65.9 78.0 43.5 48.3 34.9 54.3 39.4 40.6 41.7 42.8 48.6 32.0 50.6 63.2 53.6 84.9 81.4 33.7 52.6 50.9 116.4 81.9 62.8 17.7 127.8 106.1 146.0 74.2 81.8 39.4 0.0 149.7 140.0 89.5 80.2 84.5 75.5 101.4 17.5 50.0 54.0 38.3 16.6 93.2 68.5 96.2 106.4 60.1 89.7 146.5 66.8 85.2 85.7 30.5 84.1 115.4 137.4 96.5 96.1 118.5 65.3 63.0 96.2 ENAH "FLJ10773, MENA, NDPP1" ENSG00000154380 "ENAH, actin regulator" Q8N8S7 1 225486835-225653142 "Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 61.0" "Low region specificity" "Detected in all" "HPA028448, HPA028696" Enhanced Enhanced "Plasma membrane,Focal adhesion sites,Cytosol" NA NA 18000 "Plasma membrane, Focal adhesion sites, Cytosol" "HPA028448: AB_10600766, HPA028696: AB_10611249" "unprognostic (2.56e-2)" "unprognostic (8.03e-2)" "unprognostic (1.09e-1)" "unprognostic (4.35e-2)" "unprognostic (5.61e-3)" "unprognostic (2.85e-1)" "unprognostic (1.21e-3)" "unprognostic (2.30e-1)" "unprognostic (2.23e-1)" "unprognostic (9.22e-2)" "unprognostic (4.71e-3)" "unprognostic (2.14e-1)" "unprognostic (2.24e-3)" "unprognostic (8.84e-2)" "unprognostic (5.83e-2)" "unprognostic (7.92e-2)" "unprognostic (2.93e-2)" 19.2 17.4 15.8 11.9 17.0 0.6 11.1 7.6 17.6 17.8 24.4 15.3 39.9 9.3 21.9 19.9 16.7 11.8 29.0 18.2 16.7 15.3 5.8 5.9 13.8 3.5 13.7 11.3 24.3 16.7 22.5 10.3 13.5 12.7 26.4 8.0 3.3 14.5 44.9 20.2 8.2 8.0 61.4 13.4 17.3 21.0 18.5 17.2 5.3 6.8 11.4 3.5 35.3 21.9 2.1 0.4 1.0 0.3 0.5 0.4 0.0 20.5 16.5 20.5 18.5 8.0 10.6 26.4 22.9 11.0 13.8 10.5 10.6 7.6 8.7 61.0 35.3 12.4 18.2 23.9 8.6 13.2 0.1 14.8 9.1 14.7 14.2 24.0 1.0 0.3 16.3 10.4 17.9 22.9 11.3 10.9 2.5 0.6 0.4 13.6 4.0 4.1 1.0 34.5 5.4 15.0 6.2 28.9 0.2 6.3 15.9 20.2 16.3 44.9 17.2 15.1 16.3 20.4 1.3 21.2 35.9 26.4 29.8 45.3 1.0 2.5 5.9 19.7 1.1 18.3 1.0 0.3 0.2 0.4 0.1 0.3 0.6 0.4 0.3 0.0 2.1 0.4 0.4 1.0 0.5 0.2 0.4 0.2 0.0 15.8 17.0 7.6 13.7 16.7 15.3 13.7 11.3 12.7 17.2 11.9 31.2 2.2 136.9 114.6 7.8 109.0 56.0 123.1 56.9 21.0 58.9 50.3 3.3 71.8 67.2 59.1 5.1 0.0 86.5 13.1 84.6 122.2 4.7 9.6 9.4 15.9 39.7 22.1 1.8 19.9 53.8 7.0 79.2 5.4 28.6 30.0 72.6 14.4 158.7 10.5 19.1 90.5 115.4 8.0 40.0 117.2 50.6 0.0 23.0 87.2 EVI2B "CD361, D17S376, EVDB" ENSG00000185862 "Ecotropic viral integration site 2B" P34910 17 31303766-31314112 "CD markers, Predicted membrane proteins" Proto-oncogene "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 133.6;lymphoid tissue: 72.8" "Cell type enhanced" "Detected in many" 16 "B-cells: 217.4;Kupffer cells: 447.5;Macrophages: 274.7;T-cells: 178.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 133.6" "Group enriched" "Detected in all" 4 "granulocytes: 133.6;monocytes: 34.3" "Cell line enhanced" "Detected in many" "Daudi: 24.2;HHSteC: 19.9;HL-60: 27.3;HMC-1: 38.5;Karpas-707: 27.3;NB-4: 21.6;RPMI-8226: 39.9;THP-1: 34.4" "Low region specificity" "Detected in all" HPA007436 Enhanced Approved "Nucleoplasm,Plasma membrane,Focal adhesion sites" NA NA Nucleoplasm "Plasma membrane, Focal adhesion sites" "HPA007436: AB_1848307" "unprognostic (1.07e-2)" "unprognostic (1.20e-2)" "unprognostic (5.97e-2)" "unprognostic (4.09e-3)" "unprognostic (2.99e-2)" "unprognostic (1.41e-2)" "unprognostic (3.06e-1)" "unprognostic (3.36e-2)" "unprognostic (1.93e-2)" "unprognostic (1.48e-1)" "unprognostic (1.78e-2)" "unprognostic (2.34e-1)" "prognostic unfavorable (2.05e-4)" "unprognostic (1.56e-2)" "unprognostic (3.32e-2)" "unprognostic (8.64e-2)" "unprognostic (2.73e-2)" 15.0 3.6 4.4 37.7 5.8 44.0 4.2 1.7 4.4 3.7 10.7 6.5 0.3 6.0 2.8 4.8 7.1 4.7 8.1 6.7 6.4 4.4 7.8 7.1 38.5 37.5 10.2 2.6 3.8 2.7 0.4 2.1 4.8 7.8 5.3 8.1 2.5 6.6 1.5 2.3 2.4 23.3 4.2 22.0 72.8 8.0 3.7 6.7 26.1 4.0 3.0 43.0 13.0 7.6 18.6 14.6 133.6 34.3 4.1 16.4 19.8 0.1 0.1 0.0 0.0 1.9 2.5 0.0 0.2 1.7 2.0 3.7 0.0 0.9 24.2 0.0 1.5 7.5 0.1 0.0 0.3 2.2 0.0 0.0 0.5 0.0 0.0 19.9 27.3 38.5 4.6 0.0 1.1 1.5 0.6 1.9 2.0 0.3 27.3 5.7 0.0 7.9 21.6 0.0 0.0 0.0 13.9 0.1 39.9 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 34.4 2.1 0.5 0.0 0.2 1.9 5.3 0.2 5.3 2.5 9.4 0.6 78.9 30.5 74.5 8.2 23.2 7.9 18.6 12.6 10.6 14.6 14.3 9.7 9.1 133.6 4.1 34.3 8.4 16.4 19.8 4.4 5.8 1.7 4.4 6.4 4.4 10.2 2.6 7.8 6.7 0.0 17.9 217.4 0.6 4.7 0.2 0.4 2.5 4.0 11.4 1.8 0.0 0.5 0.0 0.0 5.3 2.7 0.2 0.0 0.0 0.5 2.8 0.3 78.7 1.7 88.8 0.0 0.0 9.8 447.5 4.7 0.0 274.7 35.4 10.8 0.0 0.0 0.7 0.0 0.4 0.7 0.8 19.4 4.1 0.3 0.5 3.1 0.2 178.5 0.0 1.1 EXD3 "FLJ20433, LOC54932, mut-7" ENSG00000187609 "Exonuclease 3'-5' domain containing 3" Q8N9H8 9 137306896-137423262 "Predicted intracellular proteins" "Exonuclease, Hydrolase, Nuclease" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 13 "granulocytes: 63.2;Late spermatids: 57.2;Paneth cells: 178.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 21.6" "Low region specificity" "Detected in all" HPA047395 Approved Approved "Actin filaments,Focal adhesion sites" NA NA "Focal adhesion sites" "Actin filaments" "HPA047395: AB_10962864" "unprognostic (2.91e-1)" "unprognostic (5.67e-2)" "unprognostic (1.75e-3)" "prognostic favorable (4.30e-4)" "unprognostic (1.88e-1)" "unprognostic (1.70e-1)" "unprognostic (6.65e-2)" "unprognostic (1.37e-1)" "unprognostic (2.54e-2)" "unprognostic (1.10e-1)" "unprognostic (2.50e-3)" "unprognostic (1.72e-2)" "unprognostic (5.21e-2)" "unprognostic (7.99e-3)" "unprognostic (2.05e-1)" "unprognostic (8.67e-2)" "unprognostic (5.05e-2)" 9.7 10.9 8.0 10.1 11.1 8.4 10.4 11.9 12.4 11.2 15.5 16.5 14.9 22.8 10.2 17.5 11.1 11.5 14.1 10.5 8.7 7.9 11.8 7.3 12.3 8.0 9.5 11.2 11.1 13.3 8.3 13.8 8.3 11.0 14.0 8.9 13.9 17.5 11.4 15.9 17.4 20.6 15.8 7.4 16.3 14.3 5.1 9.1 1.7 11.4 6.8 7.8 10.0 10.8 4.0 5.3 10.8 6.0 5.3 8.5 3.6 5.7 4.9 2.4 6.8 2.0 3.0 5.7 2.9 3.3 2.5 3.9 3.3 12.4 2.5 7.9 2.1 6.3 10.7 0.7 3.1 0.8 5.8 5.9 2.0 8.7 5.1 6.2 1.4 21.6 3.4 4.3 2.2 1.9 7.3 8.6 0.0 4.7 4.6 2.1 15.4 0.1 4.9 2.8 12.6 3.4 4.4 2.0 17.2 5.1 3.3 3.3 6.0 2.8 6.0 2.7 2.9 9.7 6.4 10.7 3.5 3.4 5.5 4.3 6.1 2.7 2.1 6.7 4.5 6.6 10.8 5.0 10.6 3.5 6.0 4.0 3.9 6.0 3.3 5.3 4.0 4.8 3.7 1.2 5.3 5.8 3.4 8.5 3.6 8.0 11.1 11.9 12.4 8.7 7.9 9.5 11.2 11.0 9.1 0.0 4.6 0.5 9.4 5.3 13.3 4.5 5.1 5.3 6.8 7.0 13.7 8.3 8.3 6.2 13.5 11.3 39.9 0.0 9.8 2.8 5.3 8.7 63.2 5.5 7.6 20.6 7.0 16.5 4.9 57.2 5.5 5.1 3.3 2.8 22.2 8.6 6.3 178.5 7.4 10.3 10.3 12.9 7.1 2.8 9.4 7.9 3.3 6.9 28.5 7.4 FABP3 "FABP11, H-FABP, MDGI, O-FABP" ENSG00000121769 "Fatty acid binding protein 3" P05413 1 31365625-31376850 "Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins" Transport "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "heart muscle: 420.9;skeletal muscle: 129.4" "Cell type enriched" "Detected in many" 6 "Cardiomyocytes: 2447.6" "Cancer enhanced" "Detected in all" "renal cancer: 92.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 5 "ASC TERT1: 120.7" "Low region specificity" "Detected in all" "CAB017830, HPA055754" Enhanced Uncertain "Golgi apparatus,Plasma membrane,Focal adhesion sites" NA NA 1640000 4400000 "Focal adhesion sites" "Golgi apparatus, Plasma membrane" "CAB017830: , HPA055754: AB_2682909" "unprognostic (2.07e-2)" "unprognostic (2.50e-2)" "unprognostic (1.32e-3)" "unprognostic (1.73e-2)" "unprognostic (2.05e-1)" "unprognostic (1.62e-1)" "unprognostic (6.07e-3)" "unprognostic (1.04e-1)" "unprognostic (6.86e-2)" "unprognostic (1.18e-1)" "unprognostic (2.85e-1)" "unprognostic (1.67e-1)" "prognostic favorable (1.54e-7)" "unprognostic (5.80e-3)" "unprognostic (3.45e-1)" "unprognostic (7.38e-3)" "unprognostic (9.76e-3)" 2.3 5.2 8.1 0.7 6.0 0.5 22.7 1.4 14.6 3.9 1.3 0.8 3.4 0.7 6.8 5.3 3.1 2.8 1.1 420.9 11.0 5.3 21.3 1.9 4.3 1.3 9.8 6.0 2.2 0.4 0.3 0.7 1.1 13.7 5.0 1.5 3.0 4.4 14.0 129.4 0.9 0.6 13.0 3.4 3.9 3.6 2.0 1.3 0.1 1.7 31.6 2.2 2.5 2.5 1.4 0.5 0.0 0.9 0.2 0.9 0.6 0.1 0.0 3.3 0.2 23.1 120.7 1.1 0.9 8.9 0.1 3.2 0.2 0.9 0.2 12.8 2.5 0.0 0.3 0.9 0.0 0.1 0.1 0.5 0.4 1.1 2.4 1.5 0.2 0.0 10.7 0.0 2.4 0.0 0.3 0.0 0.1 0.2 0.0 1.1 0.0 0.0 0.2 6.1 0.0 0.4 0.1 1.2 0.0 2.9 0.0 0.3 0.0 0.5 0.0 13.9 7.1 0.1 1.4 0.3 0.2 0.1 2.1 0.2 0.1 0.4 0.1 0.5 0.1 0.3 0.0 0.4 0.0 0.9 0.9 0.6 0.2 0.5 0.5 0.5 1.4 0.0 0.9 0.0 0.2 0.1 0.4 0.6 0.6 8.1 6.0 1.4 13.3 11.0 5.3 9.8 6.0 13.7 1.3 0.0 1.7 0.8 1.0 3.2 3.1 2447.6 5.1 2.7 2.3 26.2 2.0 2.1 383.0 0.3 2.1 0.8 0.0 0.0 0.3 1.3 14.9 3.8 1.1 0.0 96.1 7.9 0.0 3.7 20.0 4.2 6.4 17.6 8.5 0.0 0.0 2.7 0.5 3.6 7.4 399.5 8.1 0.0 32.3 0.3 0.1 2.6 1.4 1.0 0.1 5.2 FAM222A "C12orf34, FLJ14721" ENSG00000139438 "Family with sequence similarity 222 member A" Q5U5X8 12 109714228-109770507 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 37.9" "Cell type enhanced" "Detected in many" 13 "Cone photoreceptor cells: 31.4;Early spermatids: 23.4;Horizontal cells: 73.1;Rod photoreceptor cells: 48.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in many" 4 "SH-SY5Y: 51.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA040181, HPA058774" Uncertain Approved "Nucleoplasm,Plasma membrane,Focal adhesion sites,Mitochondria" NA NA "Nucleoplasm, Plasma membrane" "Focal adhesion sites, Mitochondria" "HPA040181: AB_10796448, HPA058774: " "unprognostic (8.59e-3)" "prognostic favorable (1.82e-5)" "unprognostic (1.43e-1)" "unprognostic (1.57e-1)" "unprognostic (1.92e-1)" "unprognostic (2.05e-2)" "unprognostic (1.46e-2)" "unprognostic (1.03e-1)" "unprognostic (6.66e-2)" "unprognostic (8.17e-2)" "prognostic favorable (4.81e-4)" "unprognostic (1.15e-1)" "unprognostic (4.16e-2)" "prognostic favorable (8.59e-4)" "unprognostic (3.93e-2)" "unprognostic (2.77e-1)" "unprognostic (1.24e-1)" 1.8 16.0 7.3 2.3 17.4 2.0 3.0 15.1 25.5 1.6 3.3 37.9 0.0 10.0 1.5 2.7 2.1 1.4 2.6 4.4 11.7 9.6 7.7 2.7 1.8 1.7 23.2 7.9 7.8 6.9 1.5 13.1 1.3 15.1 2.3 3.0 10.3 7.3 2.1 2.8 4.7 5.1 1.8 27.8 6.3 8.0 17.4 23.0 0.0 1.4 0.0 2.1 1.4 2.4 0.2 0.6 0.9 0.2 0.0 0.2 0.0 0.9 1.3 0.7 1.6 0.4 0.0 0.5 0.2 0.1 0.7 0.1 12.0 0.2 0.1 1.0 0.3 0.7 0.5 0.8 0.0 0.2 7.7 1.8 1.5 0.4 2.7 0.1 1.1 1.6 0.0 0.0 0.1 0.0 0.2 0.0 0.8 0.5 0.2 0.1 4.8 0.3 1.5 1.3 1.4 2.4 1.0 3.5 0.5 1.5 0.6 8.5 51.4 1.1 1.6 3.4 0.2 1.9 1.3 0.1 0.2 1.4 0.6 1.0 1.3 1.7 1.0 0.1 0.8 1.7 0.0 0.2 0.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.0 7.3 17.4 15.1 13.7 11.7 9.6 23.2 7.9 15.1 23.0 0.0 0.0 0.5 0.6 1.9 21.6 6.1 2.5 0.0 0.0 1.8 31.4 0.1 6.6 1.4 23.4 0.8 0.6 0.0 0.7 0.1 1.7 1.4 0.0 1.3 0.3 73.1 7.5 0.0 0.0 11.0 1.1 0.3 6.8 0.0 4.1 10.0 0.8 0.0 0.4 0.6 48.4 0.0 1.4 0.7 2.6 1.6 0.7 0.0 0.8 0.2 FBLIM1 "CAL, FBLP-1, migfilin" ENSG00000162458 "Filamin binding LIM protein 1" Q8WUP2 1 15756607-15786594 "Predicted intracellular proteins" "Cell adhesion, Cell shape" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Peritubular cells: 180.0;Sertoli cells: 142.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 54.1;TIME: 84.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA025287, HPA072750" Approved Enhanced "Nucleoli fibrillar center,Cell Junctions,Focal adhesion sites" NA NA "Cell Junctions, Focal adhesion sites" "Nucleoli fibrillar center" "HPA025287: AB_1848443, HPA072750: AB_2686554" "unprognostic (4.10e-2)" "prognostic unfavorable (4.07e-4)" "unprognostic (2.26e-1)" "unprognostic (5.33e-2)" "unprognostic (2.46e-2)" "unprognostic (1.52e-1)" "unprognostic (9.33e-2)" "unprognostic (8.77e-3)" "prognostic unfavorable (6.15e-4)" "unprognostic (2.02e-1)" "unprognostic (1.67e-1)" "unprognostic (1.09e-1)" "prognostic unfavorable (8.64e-4)" "unprognostic (8.33e-2)" "unprognostic (3.01e-1)" "unprognostic (1.08e-1)" "unprognostic (8.21e-2)" 11.6 6.0 1.7 12.8 1.4 0.0 10.1 0.8 1.3 21.5 36.6 1.4 26.8 24.6 30.3 15.8 17.8 16.5 60.2 21.7 1.2 1.0 18.2 3.0 14.7 16.1 1.8 1.6 36.0 13.0 13.9 3.8 21.5 2.3 26.7 15.7 9.0 13.0 26.5 4.1 6.2 62.8 18.7 1.3 22.7 18.9 22.3 0.9 1.3 10.3 7.4 6.3 24.7 16.9 1.8 1.3 4.6 1.2 1.6 1.2 0.3 6.5 3.7 3.3 0.1 0.8 1.7 4.5 11.2 17.9 8.3 6.7 1.2 9.9 0.0 24.3 18.0 14.4 12.7 2.4 25.7 4.1 0.0 1.2 0.0 0.9 6.3 21.6 0.0 0.1 8.5 17.2 6.9 16.5 17.2 54.1 0.4 0.2 1.6 2.8 0.1 0.1 0.1 3.4 10.3 4.8 0.0 0.0 0.2 10.4 4.5 0.0 8.0 5.9 0.7 1.3 7.2 1.4 0.1 84.4 11.0 1.5 0.1 5.1 0.1 0.2 0.1 1.6 0.0 0.1 4.6 1.2 1.0 0.7 0.5 0.6 1.0 0.7 0.7 0.4 1.8 1.1 1.2 3.5 1.6 0.7 1.3 0.4 0.3 1.7 1.4 0.8 1.3 1.2 1.0 1.8 1.6 2.3 0.9 11.9 21.5 5.2 54.8 76.6 3.5 30.9 45.9 12.0 29.6 15.7 5.9 5.8 0.0 80.2 2.4 18.4 138.3 0.0 46.9 102.1 26.9 24.2 17.4 1.8 5.3 1.6 44.1 38.1 0.6 1.8 74.2 10.4 13.5 3.6 47.1 10.0 88.8 84.2 180.0 1.2 5.1 142.3 66.2 2.3 1.8 54.8 16.2 6.1 40.4 47.2 FBXO28 "CENP-30, Fbx28, FLJ10766, KIAA0483" ENSG00000143756 "F-box protein 28" Q9NVF7 1 224114087-224162047 "Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003289 Supported "Nucleoplasm,Focal adhesion sites" NA NA Nucleoplasm "Focal adhesion sites" "HPA003289: AB_2666879" "unprognostic (4.91e-2)" "unprognostic (5.57e-2)" "unprognostic (1.78e-2)" "unprognostic (1.03e-1)" "unprognostic (1.33e-2)" "unprognostic (1.43e-1)" "unprognostic (2.12e-1)" "unprognostic (8.25e-2)" "unprognostic (2.03e-1)" "unprognostic (7.09e-2)" "unprognostic (5.09e-3)" "unprognostic (2.60e-1)" "unprognostic (1.98e-3)" "unprognostic (9.46e-2)" "unprognostic (1.71e-1)" "unprognostic (1.41e-1)" "unprognostic (2.61e-1)" 17.4 13.1 16.4 14.9 19.7 12.1 19.6 22.5 21.6 18.7 15.9 15.0 13.1 13.3 16.2 13.3 22.2 14.1 15.1 15.0 15.3 15.6 21.4 26.6 14.0 14.9 15.9 13.6 18.7 13.4 25.7 16.2 15.8 20.2 16.5 17.1 11.9 16.6 14.9 24.6 32.3 14.4 15.7 15.6 16.1 13.7 11.9 15.5 19.4 15.7 13.1 16.1 17.5 20.0 10.3 10.0 14.7 8.9 10.9 11.0 5.7 14.1 6.3 9.8 10.4 10.3 11.8 16.1 14.3 11.7 9.7 9.3 8.6 11.1 6.8 14.8 13.0 6.2 12.5 14.4 13.9 16.8 9.6 16.1 8.6 7.9 6.2 12.8 16.3 11.4 11.5 16.8 14.0 25.6 11.4 16.1 8.9 14.1 9.8 17.4 4.6 8.4 8.3 23.3 18.8 13.5 9.0 14.0 12.8 18.3 9.4 15.9 17.0 14.9 22.9 15.9 10.7 12.1 16.4 18.4 12.1 9.2 15.1 26.9 10.7 12.6 10.7 15.0 8.0 23.4 8.9 8.7 14.7 7.8 8.1 10.1 10.3 8.2 9.6 10.0 10.2 8.3 9.1 5.3 10.9 8.9 4.7 11.0 5.7 16.4 19.7 22.5 21.6 15.3 15.6 15.9 13.6 20.2 15.5 6.0 8.8 12.3 21.3 30.5 18.7 10.6 7.6 6.7 11.4 10.4 21.6 12.1 8.3 10.9 19.1 14.2 10.6 23.3 9.8 11.5 11.0 18.7 13.9 22.2 12.3 17.5 17.7 9.8 16.3 11.5 12.0 13.9 27.0 10.8 14.0 10.1 13.4 10.5 12.4 17.9 18.4 12.9 11.3 26.0 26.5 34.3 19.2 17.5 11.9 27.2 FCHSD2 "KIAA0769, SH3MD3" ENSG00000137478 "FCH and double SH3 domains 2" O94868 11 72836745-73142261 "Predicted intracellular proteins" "Endocytosis, Protein transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Ito cells: 45.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RPMI-8226: 54.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038545, HPA038546" Uncertain Supported "Nuclear speckles,Plasma membrane,Actin filaments,Focal adhesion sites" Yes No "Plasma membrane" "Nuclear speckles, Actin filaments, Focal adhesion sites" "HPA038545: AB_2676074, HPA038546: AB_10673013" "unprognostic (1.80e-2)" "unprognostic (1.50e-2)" "prognostic favorable (1.71e-4)" "unprognostic (1.63e-1)" "unprognostic (3.14e-2)" "unprognostic (2.62e-3)" "unprognostic (1.41e-2)" "unprognostic (2.62e-1)" "unprognostic (1.27e-2)" "unprognostic (2.56e-1)" "unprognostic (3.69e-2)" "unprognostic (6.16e-2)" "unprognostic (2.89e-3)" "unprognostic (2.02e-1)" "unprognostic (4.70e-1)" "unprognostic (2.92e-1)" "unprognostic (1.23e-1)" 18.5 15.1 28.4 41.5 27.8 19.0 26.5 16.9 25.2 13.2 11.4 17.0 6.8 7.0 12.7 10.2 9.7 11.5 18.1 19.2 24.8 21.4 10.6 13.3 26.2 31.7 19.7 12.1 26.3 9.2 10.2 7.6 24.1 17.6 11.2 11.2 12.5 11.1 11.7 7.4 7.0 14.4 16.4 15.6 30.8 10.1 17.4 26.3 19.2 11.9 4.8 33.0 17.9 11.3 16.8 19.0 11.6 4.8 1.1 2.4 2.0 5.2 4.5 9.3 12.2 3.8 9.5 8.7 9.3 19.9 5.7 4.8 3.5 7.7 28.5 11.5 11.9 5.5 7.5 5.4 5.4 7.6 9.8 2.8 22.9 5.1 11.5 9.8 11.2 2.9 5.7 6.0 5.6 6.8 12.5 13.6 9.9 5.0 18.5 7.3 5.6 13.5 19.3 2.0 5.6 5.5 20.7 14.5 54.2 9.0 7.0 4.7 6.6 3.4 6.4 12.1 4.4 4.6 8.2 17.6 18.3 7.1 12.7 2.9 17.8 9.9 25.3 3.1 18.7 5.3 11.0 4.8 10.5 1.7 3.1 1.2 13.0 1.8 2.0 4.8 16.8 2.1 2.4 11.6 1.1 1.6 19.0 1.8 2.0 28.4 27.8 16.9 20.2 24.8 21.4 19.7 12.1 17.6 26.3 8.9 12.3 31.6 4.7 7.6 11.3 15.3 10.2 2.7 5.7 3.5 23.6 9.4 1.7 4.1 5.8 26.5 1.1 23.3 5.3 7.7 6.1 3.0 2.3 10.0 15.9 9.5 4.6 45.4 25.4 8.2 10.0 19.2 5.0 15.4 6.2 8.3 4.0 5.1 15.6 3.3 16.1 6.5 21.5 7.5 10.9 5.1 10.1 7.5 4.2 3.8 FCMR "FAIM3, TOSO" ENSG00000162894 "Fc fragment of IgM receptor" O60667 1 206904386-206923247 "Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Immunity "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 99.6;intestine: 30.1;lymphoid tissue: 84.9" "Group enriched" "Detected in many" 11 "B-cells: 125.3;T-cells: 41.7" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "B-cells: 99.6;T-cells: 60.0" "Group enriched" "Detected in some" 5 "RPMI-8226: 53.0;U-266/70: 26.7" "Not detected" "Not detected" "Not detected" "Not detected" HPA003910 Approved Approved "Nucleoplasm,Focal adhesion sites,Cytosol" "Secreted to blood" NA NA 2400000 "Focal adhesion sites, Cytosol" Nucleoplasm "HPA003910: AB_1078798" "prognostic favorable (4.23e-4)" "unprognostic (1.16e-3)" "unprognostic (7.48e-2)" "unprognostic (3.06e-3)" "unprognostic (2.04e-1)" "unprognostic (2.69e-3)" "unprognostic (1.15e-1)" "unprognostic (4.85e-3)" "unprognostic (1.03e-1)" "unprognostic (3.97e-1)" "unprognostic (3.23e-2)" "unprognostic (2.01e-1)" "unprognostic (8.15e-3)" "unprognostic (8.06e-2)" "unprognostic (2.12e-2)" "unprognostic (3.74e-2)" "unprognostic (5.05e-3)" 15.5 0.6 0.5 42.9 0.5 2.9 1.5 0.4 0.4 0.8 2.5 0.4 0.3 1.2 1.2 0.8 3.4 1.3 2.6 1.0 0.5 0.5 2.4 1.5 3.9 77.2 0.5 0.0 1.3 0.7 0.0 0.9 0.8 0.2 1.4 2.3 1.3 10.1 0.3 1.9 0.6 30.1 0.4 0.6 78.8 2.8 0.5 0.0 51.8 1.8 1.2 84.9 8.5 1.2 99.6 1.4 5.3 0.4 18.4 60.0 28.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 1.9 0.1 0.1 0.0 0.0 3.4 0.0 0.1 0.3 0.1 0.0 0.4 0.2 0.0 0.1 0.0 0.4 0.0 0.8 0.0 0.0 0.0 0.3 0.1 0.6 0.0 0.0 2.7 0.0 7.4 0.0 0.1 1.0 0.1 0.0 0.0 0.0 1.7 0.2 53.0 0.0 0.1 0.0 0.0 1.0 0.2 5.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.0 26.7 1.9 7.4 0.3 0.0 0.2 0.5 0.2 0.2 20.3 0.4 26.4 80.3 28.1 26.2 0.2 99.6 49.5 33.3 5.3 18.4 0.3 1.4 60.0 28.2 0.5 0.5 0.4 0.4 0.5 0.5 0.5 0.0 0.2 0.0 0.0 4.6 125.3 3.9 0.0 0.0 3.0 7.6 1.4 2.3 0.0 0.0 0.0 0.0 1.3 0.1 0.1 0.0 0.0 2.6 0.1 0.6 2.6 0.0 1.1 3.8 0.0 0.0 5.5 5.1 0.0 0.3 1.2 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.3 0.0 0.0 0.3 0.1 1.0 0.0 0.0 41.7 1.2 7.1 FERMT2 "KIND2, mig-2, PLEKHC1, UNC112B" ENSG00000073712 "Fermitin family member 2" Q96AC1 14 52857268-52952435 "Predicted intracellular proteins" "Cell adhesion, Cell shape, Wnt signaling pathway" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 12 "MAIT T-cell: 3.8" "Lineage enriched" "Detected in single" 39 "T-cells: 3.8" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA040505, HPA072965" Uncertain Supported "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA 58000 "Focal adhesion sites" "Nucleoplasm, Cytosol" "HPA040505: AB_10673300, HPA072965: " "unprognostic (4.38e-2)" "unprognostic (4.25e-2)" "unprognostic (8.00e-3)" "unprognostic (2.42e-2)" "unprognostic (2.51e-2)" "unprognostic (4.89e-3)" "unprognostic (2.50e-2)" "unprognostic (1.92e-1)" "unprognostic (4.21e-2)" "unprognostic (1.07e-1)" "unprognostic (3.58e-1)" "unprognostic (1.99e-1)" "unprognostic (3.87e-2)" "unprognostic (3.96e-3)" "unprognostic (7.69e-2)" "unprognostic (3.14e-1)" "unprognostic (1.73e-3)" 45.9 7.2 15.5 12.3 14.3 0.1 24.4 7.9 12.8 24.1 36.6 12.7 16.0 4.2 41.6 14.2 20.6 22.2 22.2 21.8 18.3 7.5 18.4 35.3 18.1 5.4 15.0 9.1 23.3 6.7 5.8 7.2 37.9 10.7 24.1 11.5 11.0 7.1 41.3 14.5 5.0 11.0 56.7 12.9 11.7 21.4 10.2 15.5 0.6 13.3 6.2 2.1 49.5 16.5 0.0 0.0 0.0 0.0 0.0 3.8 0.0 4.8 4.3 22.8 10.4 37.3 30.7 19.0 32.6 21.1 38.8 24.5 7.3 3.9 0.0 11.1 33.3 7.6 2.1 17.7 2.4 29.2 0.0 4.9 6.8 19.5 8.6 47.9 0.1 2.8 29.5 5.2 21.3 28.3 17.7 20.0 3.7 0.1 34.4 29.0 5.9 1.6 0.1 14.4 0.0 11.3 0.8 23.2 0.0 13.6 4.5 1.4 29.3 34.5 7.7 8.0 24.2 6.7 0.2 25.0 30.6 21.0 24.3 12.0 5.1 6.1 0.1 7.0 0.0 7.3 0.0 0.0 0.0 0.1 0.0 3.8 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.5 14.3 7.9 12.4 18.3 7.5 15.0 9.1 10.7 15.5 71.5 50.2 0.0 111.7 16.6 32.8 53.2 20.4 14.7 37.5 38.4 35.3 69.7 26.6 48.1 59.4 87.9 0.0 0.0 28.6 138.3 102.2 34.3 56.6 71.6 9.0 14.3 0.0 120.9 9.2 20.6 69.3 6.2 43.9 8.2 0.0 57.0 23.6 0.0 164.4 37.4 57.4 148.8 146.8 3.4 10.0 7.0 85.8 4.3 0.0 35.6 FHL2 "DRAL, SLIM3" ENSG00000115641 "Four and a half LIM domains 2" Q14192 2 105357712-105438513 "Predicted intracellular proteins" "Transcription, Transcription regulation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "heart muscle: 312.0;ovary: 80.7" "Cell type enhanced" "Detected in many" 9 "Basal glandular cells: 732.1;Extravillous trophoblasts: 503.8;Leydig cells: 525.0;Peritubular cells: 986.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "granulocytes: 7.8;T-cells: 4.6" "Cell line enhanced" "Detected in many" "LHCN-M2: 79.9;RPTEC TERT1: 73.7" "Group enriched" "Detected in many" 4 "amygdala: 34.7;basal ganglia: 20.4;cerebral cortex: 51.8;hippocampal formation: 36.9;olfactory region: 18.3" "Low region specificity" "Detected in many" "HPA005922, HPA006028, CAB008368" Enhanced Enhanced "Actin filaments,Focal adhesion sites" NA Yes "Actin filaments, Focal adhesion sites" "CAB008368: AB_591383, HPA005922: AB_1078860, HPA006028: AB_1078858" "unprognostic (1.04e-1)" "unprognostic (1.63e-3)" "unprognostic (3.30e-1)" "unprognostic (3.42e-2)" "unprognostic (5.89e-2)" "prognostic unfavorable (2.01e-4)" "unprognostic (2.80e-2)" "unprognostic (1.02e-3)" "unprognostic (1.81e-1)" "unprognostic (2.42e-2)" "unprognostic (3.34e-2)" "unprognostic (8.11e-2)" "prognostic unfavorable (6.42e-5)" "unprognostic (2.06e-1)" "unprognostic (3.49e-1)" "unprognostic (9.92e-3)" "unprognostic (4.73e-2)" 8.3 9.8 1.5 5.7 3.6 1.5 8.9 0.8 5.6 16.3 10.5 1.4 5.1 6.0 14.8 12.1 9.2 6.8 16.5 312.0 2.5 0.4 5.5 7.8 2.1 2.7 0.9 3.0 80.7 1.6 0.2 4.1 16.7 1.1 12.8 7.4 18.5 6.2 8.7 9.4 5.6 16.9 11.9 0.8 3.9 12.7 13.4 0.7 3.1 6.6 16.9 5.1 18.1 7.6 1.4 1.3 7.8 0.8 1.5 4.6 2.6 22.5 5.3 3.1 0.1 10.1 12.8 29.6 42.8 11.3 27.5 33.1 9.5 35.3 0.0 3.6 52.1 34.0 7.0 4.6 38.9 31.4 0.9 3.5 15.8 6.5 7.1 40.0 0.0 3.5 26.6 21.4 43.2 28.8 55.2 56.0 2.6 4.1 1.3 79.9 0.8 3.6 0.1 6.5 15.8 16.7 0.0 4.8 0.6 73.7 16.0 0.1 1.0 16.0 7.2 11.1 3.2 9.0 0.5 26.9 20.0 20.3 22.1 34.4 0.4 0.0 0.1 31.9 0.0 20.6 7.8 0.8 1.0 2.2 0.4 1.5 1.1 1.8 3.6 0.7 1.4 1.4 2.9 4.5 1.5 0.3 1.3 4.6 2.6 1.5 3.6 0.8 5.6 2.5 0.4 0.9 3.0 1.1 0.7 8.9 6.1 0.0 732.1 416.1 8.9 221.1 15.3 12.0 54.6 27.9 2.0 150.7 3.3 97.9 3.5 21.5 61.9 0.0 105.2 503.8 71.2 120.1 10.3 9.2 22.4 0.0 55.8 20.9 1.2 4.9 525.0 6.6 21.9 4.6 119.3 1.5 144.0 32.8 986.1 15.3 12.4 213.4 132.8 6.6 21.1 259.6 149.4 5.0 30.8 351.4 GAS7 "KIAA0394, MGC1348" ENSG00000007237 "Growth arrest specific 7" O60861 17 9910609-10198551 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 86.2" "Cell type enhanced" "Detected in many" 6 "Early spermatids: 49.9;Kupffer cells: 62.0;Late spermatids: 52.5" "Cancer enhanced" "Detected in all" "melanoma: 54.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 17.6" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 9 "WM-115: 110.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004838, HPA064678" Enhanced Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Plasma membrane" "Actin filaments, Focal adhesion sites" "HPA004838: AB_2667263, HPA064678: AB_2685319" "unprognostic (1.68e-2)" "unprognostic (2.84e-3)" "unprognostic (1.80e-1)" "unprognostic (1.28e-3)" "unprognostic (1.15e-1)" "unprognostic (1.01e-2)" "unprognostic (7.32e-2)" "unprognostic (7.16e-2)" "unprognostic (2.88e-1)" "unprognostic (1.50e-2)" "unprognostic (2.48e-1)" "unprognostic (1.79e-1)" "unprognostic (1.94e-3)" "unprognostic (6.48e-2)" "unprognostic (8.78e-2)" "unprognostic (3.08e-2)" "prognostic unfavorable (6.89e-4)" 19.1 6.5 22.1 15.4 40.3 18.7 10.8 86.2 64.7 22.6 9.3 33.4 1.7 5.2 9.7 4.4 17.0 12.6 11.5 23.1 25.8 15.0 1.5 2.1 9.9 5.9 28.1 25.0 5.9 2.8 1.4 1.7 11.0 14.2 3.7 8.7 7.7 4.0 8.2 3.9 21.2 7.4 16.3 33.8 10.0 4.2 11.8 22.2 2.7 2.5 2.7 7.2 11.7 7.8 0.4 3.6 11.0 17.6 2.8 2.1 4.4 0.0 0.1 0.1 0.2 3.4 4.9 0.0 0.1 0.0 0.5 0.2 0.0 0.0 1.3 0.4 1.3 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.3 0.1 1.1 0.3 10.1 0.9 0.0 1.0 0.0 0.0 0.0 8.7 0.0 0.1 0.0 0.0 10.7 3.2 0.5 0.4 0.0 2.8 0.0 9.8 0.0 0.0 0.0 0.6 0.0 0.0 12.7 4.7 0.5 5.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 7.1 110.2 0.4 17.6 10.8 2.1 4.7 0.7 0.3 0.2 1.0 3.6 0.4 0.2 1.0 11.0 2.8 3.1 0.6 0.0 4.4 22.1 40.3 86.2 38.8 25.8 15.0 28.1 25.0 14.2 22.2 0.0 6.2 3.2 3.8 7.3 34.5 11.3 0.0 26.8 1.2 5.2 25.5 1.1 0.0 0.6 49.9 7.0 0.0 0.0 0.0 1.1 43.4 1.6 17.3 0.5 34.5 0.0 0.0 7.4 62.0 52.5 9.5 29.6 32.1 1.0 0.0 8.0 0.3 0.0 1.8 0.0 30.3 0.0 5.2 1.1 6.1 14.4 1.6 7.5 0.0 4.3 GIT1 ENSG00000108262 "GIT ArfGAP 1" Q9Y2X7 17 29573469-29594054 "Plasma proteins, Predicted intracellular proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Early spermatids: 78.6;Late spermatids: 70.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004059, HPA004186" Enhanced Supported "Focal adhesion sites,Mitochondria,Cytosol" NA NA 53000 "Focal adhesion sites, Cytosol" Mitochondria "HPA004059: AB_1078966, HPA004186: AB_1078967" "unprognostic (3.66e-1)" "unprognostic (4.46e-2)" "unprognostic (3.24e-2)" "unprognostic (6.30e-3)" "unprognostic (1.46e-1)" "unprognostic (1.08e-1)" "prognostic unfavorable (2.54e-6)" "unprognostic (3.00e-3)" "unprognostic (2.79e-1)" "unprognostic (5.23e-2)" "unprognostic (2.12e-2)" "unprognostic (3.08e-1)" "unprognostic (8.48e-2)" "unprognostic (5.56e-2)" "unprognostic (7.30e-2)" "unprognostic (2.10e-1)" "unprognostic (1.69e-1)" 13.0 8.5 34.0 11.1 38.1 8.0 9.4 18.9 43.4 7.8 9.8 15.6 2.2 11.6 10.0 5.3 13.2 14.0 10.2 12.2 41.5 16.4 7.0 3.7 12.0 12.6 19.2 21.8 13.6 14.3 10.2 8.1 13.8 15.0 8.4 6.9 7.8 11.9 10.3 10.0 20.2 10.9 8.7 11.9 11.1 9.5 42.9 19.8 10.8 11.0 4.5 9.7 9.8 7.5 1.8 4.7 3.0 6.0 5.6 4.9 3.6 17.5 29.4 14.5 25.8 11.6 7.3 16.8 8.7 8.6 10.5 9.4 11.9 6.6 13.3 14.0 11.4 18.8 29.1 15.2 22.4 5.4 17.1 18.2 9.6 14.4 10.6 14.1 12.1 7.9 8.9 25.8 12.1 18.9 15.0 19.5 17.8 7.8 11.5 7.5 18.1 38.2 16.3 10.8 17.8 7.0 29.1 19.4 19.9 9.5 9.7 30.5 26.1 12.3 28.6 43.0 10.8 14.0 16.2 24.0 10.0 14.5 22.0 17.5 9.6 13.2 14.5 16.5 10.4 16.8 0.3 3.6 3.0 4.7 6.0 2.2 1.8 4.5 4.9 4.7 1.7 3.7 2.7 1.2 5.6 3.7 4.0 2.9 3.6 34.0 38.1 18.9 43.4 41.5 16.4 19.2 21.8 15.0 19.8 3.0 1.0 13.7 6.2 24.2 14.0 7.6 0.0 8.1 1.2 5.2 9.8 4.4 1.7 7.1 78.6 27.4 16.3 0.0 8.1 6.7 8.8 8.0 1.1 2.1 7.3 11.1 14.3 14.7 7.8 70.1 13.3 9.2 8.5 4.6 14.3 9.7 8.1 10.5 9.9 5.0 9.3 12.9 5.1 10.4 10.9 24.6 3.0 7.7 13.7 6.7 GPBP1L1 SP192 ENSG00000159592 "GC-rich promoter binding protein 1 like 1" Q9HC44 1 45627304-45688113 "Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028593 Approved Approved "Nucleoplasm,Plasma membrane,Focal adhesion sites,Cytosol" NA NA Nucleoplasm "Plasma membrane, Focal adhesion sites, Cytosol" "HPA028593: AB_10602906" "unprognostic (1.39e-1)" "unprognostic (8.41e-2)" "unprognostic (1.44e-3)" "unprognostic (6.60e-2)" "unprognostic (6.35e-2)" "unprognostic (1.97e-3)" "unprognostic (2.42e-3)" "unprognostic (9.79e-2)" "unprognostic (3.91e-2)" "unprognostic (1.94e-3)" "unprognostic (1.12e-2)" "unprognostic (4.11e-1)" "unprognostic (1.25e-2)" "unprognostic (6.63e-2)" "unprognostic (4.51e-1)" "unprognostic (7.56e-3)" "unprognostic (6.13e-2)" 29.9 20.5 16.9 21.2 23.7 24.9 25.2 24.4 18.6 27.4 36.9 33.3 29.7 31.6 26.3 23.8 34.8 22.5 19.7 23.9 17.3 17.0 30.2 38.9 28.3 29.1 33.2 12.4 24.7 46.9 24.4 36.6 25.7 22.1 26.4 37.2 29.8 33.5 35.3 29.6 31.0 58.0 25.7 28.2 30.6 26.2 33.2 27.2 40.5 37.7 30.3 35.4 32.5 27.5 13.5 17.8 29.8 22.1 20.0 20.0 15.4 15.8 9.8 17.1 18.1 20.2 19.7 23.4 12.6 21.0 18.3 23.1 9.8 17.8 22.0 16.5 17.3 19.3 16.6 18.7 19.0 23.3 25.1 13.3 28.5 11.4 15.2 27.8 28.4 26.5 14.3 41.6 14.3 41.0 24.7 23.1 28.3 24.3 19.6 20.8 8.5 25.2 25.6 24.3 21.4 11.2 16.6 22.2 16.1 21.0 15.7 21.1 14.1 20.8 30.8 32.1 34.8 14.0 33.6 19.6 13.2 13.9 14.2 19.1 19.2 17.8 16.2 13.9 23.8 13.8 16.4 16.6 29.8 17.8 21.2 18.9 13.5 17.6 17.4 17.8 11.5 19.4 18.9 17.7 20.0 22.1 10.2 20.0 15.4 16.9 23.7 24.4 18.6 17.3 17.0 33.2 12.4 22.1 27.2 56.6 19.5 31.8 35.2 57.7 23.3 41.7 45.9 16.0 29.6 57.6 33.4 23.0 43.1 29.6 10.8 38.3 66.9 46.7 33.6 29.3 24.3 50.8 58.8 72.6 22.6 35.0 36.8 31.9 45.9 13.4 19.0 33.1 21.9 23.4 66.9 16.0 42.8 46.0 20.1 45.1 32.3 19.4 35.3 70.7 75.4 59.2 38.0 35.1 54.0 53.8 GUCA1C GCAP3 ENSG00000138472 "Guanylate cyclase activator 1C" O95843 3 108907792-108953895 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "heart muscle: 10.2;pancreas: 31.0;retina: 15.7" "Cell type enriched" "Detected in some" 6 "Cone photoreceptor cells: 117.8" "Cancer enriched" "Detected in single" 7 "pancreatic cancer: 0.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 84 "RPTEC TERT1: 18.0" HPA041597 Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA041597: AB_10795501" "unprognostic (7.56e-2)" "unprognostic (6.56e-2)" 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.2 0.7 0.0 0.5 0.0 0.0 0.0 0.7 0.0 0.7 31.0 0.0 0.2 0.0 0.5 0.0 0.0 15.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.7 0.0 0.0 0.0 0.0 0.0 2.8 1.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.2 0.7 0.0 0.7 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 7.4 5.5 0.0 0.0 0.0 0.0 117.8 0.0 0.0 0.0 9.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.0 8.2 0.5 0.0 0.0 0.0 19.2 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 HAUS4 "C14orf94, FLJ20424" ENSG00000092036 "HAUS augmin like complex subunit 4" Q9H6D7 14 22946228-22957161 "Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "monocytes: 42.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA029803, HPA071195" Approved Supported "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA029803: AB_10601428, HPA071195: " "unprognostic (8.47e-3)" "unprognostic (3.52e-1)" "unprognostic (6.47e-2)" "unprognostic (7.59e-2)" "unprognostic (3.08e-2)" "unprognostic (1.73e-1)" "unprognostic (7.54e-2)" "unprognostic (4.32e-3)" "unprognostic (2.92e-2)" "unprognostic (2.87e-2)" "unprognostic (7.70e-2)" "unprognostic (8.66e-2)" "unprognostic (3.00e-2)" "unprognostic (6.94e-2)" "unprognostic (3.16e-1)" "unprognostic (1.96e-1)" "prognostic unfavorable (2.24e-4)" 17.2 16.7 11.0 28.8 15.0 29.8 22.3 9.9 15.6 20.3 24.0 13.8 22.3 15.3 17.8 20.7 25.4 16.9 30.6 19.5 12.3 8.3 16.8 17.9 24.0 30.6 17.7 9.2 33.8 29.1 17.5 9.8 12.1 13.4 19.1 16.9 14.2 22.0 19.2 14.4 21.7 24.9 23.3 17.6 24.5 19.3 12.2 17.4 33.7 23.2 17.2 21.2 18.9 19.5 14.0 35.3 34.5 28.2 7.8 15.4 15.3 25.8 17.6 20.4 20.1 15.0 18.8 30.6 13.0 17.4 14.2 20.0 12.6 30.9 50.0 6.2 7.8 10.5 26.1 10.8 15.5 12.0 13.4 8.1 16.8 12.4 30.7 13.7 21.5 28.0 12.8 30.1 6.1 18.6 17.7 24.7 29.2 11.7 25.0 15.2 19.9 23.5 19.1 10.7 20.6 17.9 22.5 24.5 19.2 12.3 14.2 8.2 13.3 18.6 19.3 11.4 9.2 16.8 17.4 13.6 13.0 16.8 9.4 11.4 26.5 22.7 23.2 6.1 24.4 7.4 2.1 28.2 5.8 5.8 18.3 7.8 14.0 10.9 8.3 35.3 11.6 15.4 11.8 34.5 7.8 11.3 9.9 14.6 15.3 11.0 15.0 9.9 15.6 12.3 8.3 17.7 9.2 13.4 17.4 20.8 5.0 11.0 5.1 11.0 0.4 0.8 20.4 10.7 5.7 1.8 0.0 10.2 5.0 13.0 0.2 5.8 8.7 0.0 23.7 11.7 5.8 2.6 3.5 3.9 15.2 0.0 7.5 7.4 24.9 0.0 5.2 13.2 5.0 42.3 17.3 3.9 20.7 17.5 3.9 4.9 0.3 0.0 5.2 2.5 5.4 9.7 6.9 7.9 30.1 5.4 HENMT1 "C1orf59, FLJ30525, HEN1" ENSG00000162639 "HEN methyltransferase 1" Q5T8I9 1 108648290-108661526 "Enzymes, Predicted intracellular proteins" "RNA-mediated gene silencing" "Methyltransferase, RNA-binding, Transferase" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.8;testis: 45.2" "Group enriched" "Detected in many" 4 "Spermatocytes: 118.4;Spermatogonia: 74.4;T-cells: 38.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "JURKAT: 25.7;MOLT-4: 23.6;NB-4: 26.4;U-937: 34.8" "Low region specificity" "Detected in many" "Region enriched" "Detected in single" 15 "cerebellum: 18.1" "HPA028464, HPA028497" Uncertain Approved "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA028464: AB_10600103, HPA028497: AB_10601552" "unprognostic (1.82e-1)" "prognostic favorable (2.56e-4)" "prognostic favorable (9.95e-4)" "unprognostic (2.92e-3)" "unprognostic (1.91e-1)" "unprognostic (3.88e-3)" "unprognostic (2.01e-2)" "unprognostic (1.49e-1)" "unprognostic (7.01e-2)" "unprognostic (1.25e-1)" "unprognostic (2.95e-1)" "unprognostic (1.19e-1)" "prognostic unfavorable (2.48e-5)" "unprognostic (2.53e-1)" "unprognostic (2.43e-1)" "unprognostic (2.18e-1)" "unprognostic (1.65e-1)" 3.5 2.2 6.7 5.1 10.2 7.7 5.5 3.6 11.6 6.1 4.4 4.2 1.4 3.4 2.8 3.4 1.9 1.8 4.5 3.1 9.5 10.1 1.8 1.4 4.9 9.8 8.2 5.6 3.8 1.5 0.6 3.9 3.8 10.7 2.7 6.6 1.3 2.4 2.6 2.0 2.6 5.2 2.5 6.9 8.0 3.2 45.2 2.5 10.3 1.7 1.2 7.3 5.5 1.6 5.4 10.6 18.2 12.0 22.9 28.8 15.9 5.8 3.0 0.2 0.0 0.2 0.2 0.0 1.4 0.5 3.5 0.5 8.8 9.3 0.0 3.2 2.6 0.0 0.0 0.0 0.0 2.2 1.9 0.0 15.0 11.3 0.0 3.0 8.8 13.4 2.9 0.1 0.7 0.0 0.0 0.7 25.7 0.0 6.7 0.1 14.9 23.6 26.4 8.7 4.7 1.3 10.3 0.0 0.5 0.0 6.4 14.7 0.0 12.6 3.5 0.0 0.9 0.0 19.8 0.1 0.0 11.7 6.4 0.0 4.1 5.1 0.0 0.0 34.8 0.1 16.0 8.8 18.2 28.8 10.1 26.0 5.4 14.2 26.0 10.6 2.9 11.8 21.7 8.6 22.9 12.0 8.5 13.1 15.9 6.7 10.2 3.6 11.6 9.5 10.1 8.2 5.6 10.7 2.5 0.0 0.6 0.0 1.4 1.4 3.8 1.5 17.8 1.4 1.2 5.2 0.0 10.4 3.3 2.8 8.7 2.6 3.9 0.0 1.2 16.4 3.1 0.6 6.9 0.4 14.0 0.0 4.7 6.7 11.7 17.0 4.6 8.5 1.7 7.2 2.5 2.0 1.9 6.8 2.8 0.7 2.6 6.5 2.8 118.4 74.4 1.4 4.3 38.3 5.6 2.5 HRASLS "H-REV107, HRASLS1" ENSG00000127252 "HRAS like suppressor" 3 193241125-193277738 "Predicted membrane proteins" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in many" 7 "skeletal muscle: 40.9;testis: 42.1" "Cell type enriched" "Detected in many" 4 "Early spermatids: 449.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 7 "neutrophil: 1.7" "Lineage enriched" "Detected in single" 7 "granulocytes: 1.7" "Cell line enhanced" "Detected in some" "HAP1: 8.7;NTERA-2: 7.6;PC-3: 16.8;RH-30: 7.4;SCLC-21H: 15.3;U-2 OS: 9.3;U-251 MG: 11.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051179 Uncertain Approved "Focal adhesion sites,Cytosol" No No "Focal adhesion sites" Cytosol "HPA051179: AB_2681375" "unprognostic (3.01e-2)" "unprognostic (4.21e-2)" "unprognostic (7.93e-3)" "unprognostic (4.82e-3)" "unprognostic (2.79e-1)" "unprognostic (1.87e-1)" "unprognostic (9.97e-3)" "unprognostic (9.68e-3)" "unprognostic (1.84e-1)" "unprognostic (3.55e-1)" "unprognostic (1.77e-4)" "unprognostic (5.09e-2)" "unprognostic (1.38e-5)" "unprognostic (1.61e-2)" "prognostic favorable (4.36e-4)" "unprognostic (2.98e-3)" "unprognostic (1.13e-2)" 0.6 1.1 1.8 0.2 3.1 0.1 1.0 0.6 3.3 0.5 0.6 1.7 0.0 0.1 0.6 3.1 2.4 0.5 0.2 4.3 2.0 1.1 0.6 0.6 0.5 0.1 1.5 2.1 0.6 0.8 0.5 0.7 0.1 2.4 0.5 0.1 3.1 6.1 0.5 40.9 1.7 0.6 0.7 0.6 0.6 0.6 42.1 1.7 0.2 3.7 6.2 0.2 0.5 0.6 0.0 0.2 1.7 0.1 0.0 0.0 6.2 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.1 0.0 1.5 0.3 0.0 0.1 0.0 0.1 0.0 3.7 0.0 8.7 0.2 0.4 0.0 3.9 4.5 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 7.6 0.2 16.8 0.0 7.4 0.0 2.5 0.0 15.3 2.9 1.0 2.2 0.0 1.4 4.4 0.0 0.1 0.0 9.3 0.0 11.7 0.0 0.0 0.0 4.8 0.0 2.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 6.2 1.8 3.1 0.6 3.3 2.0 1.1 1.5 2.1 2.4 1.7 0.0 0.0 0.0 0.1 0.9 10.8 10.6 2.5 0.0 1.2 0.0 31.4 0.7 0.0 0.7 449.3 0.6 0.0 0.0 0.2 0.8 0.4 0.1 0.0 0.0 0.1 1.6 0.0 0.0 0.3 85.3 6.9 0.8 1.7 0.0 0.0 1.6 0.5 0.0 4.6 0.1 5.6 0.0 0.4 112.1 25.2 5.4 0.3 0.0 0.0 0.0 HSH2D "ALX, FLJ14886, HSH2" ENSG00000196684 "Hematopoietic SH2 domain containing" Q96JZ2 19 16134028-16158575 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 47.4;lymphoid tissue: 33.8" "Cell type enhanced" "Detected in many" 14 "B-cells: 71.7;T-cells: 40.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in all" "basophil: 47.4" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 13.2;HL-60: 13.7;HMC-1: 18.9;NB-4: 44.6;RPMI-8226: 20.0;U-266/84: 12.9;U-937: 43.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA036616 Approved "Plasma membrane,Focal adhesion sites,Cytosol" NA NA "Plasma membrane" "Focal adhesion sites, Cytosol" "HPA036616: AB_10671962" "unprognostic (1.69e-1)" "unprognostic (2.97e-2)" "prognostic unfavorable (9.46e-6)" "unprognostic (1.06e-1)" "unprognostic (5.50e-3)" "unprognostic (5.21e-3)" "unprognostic (9.35e-2)" "unprognostic (4.78e-2)" "unprognostic (4.21e-3)" "unprognostic (9.96e-2)" "unprognostic (1.57e-2)" "unprognostic (2.22e-2)" "prognostic unfavorable (6.49e-6)" "unprognostic (9.17e-3)" "unprognostic (6.18e-2)" "unprognostic (3.21e-2)" "prognostic favorable (3.47e-5)" 1.2 1.1 1.2 31.5 1.1 19.2 1.2 1.1 1.1 1.4 8.9 0.0 5.2 5.5 1.1 6.2 2.0 1.5 10.3 1.2 1.1 1.1 1.3 1.5 6.0 16.7 1.0 0.0 1.1 4.8 0.9 3.7 2.3 0.3 2.2 4.0 1.0 8.8 5.2 1.1 1.1 12.1 0.7 1.1 21.8 5.4 1.1 0.0 8.5 1.7 2.4 33.8 4.7 1.1 14.5 6.0 47.4 8.4 19.0 4.3 3.6 4.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.7 7.0 13.2 0.2 0.0 0.2 0.2 0.0 0.1 0.0 0.7 0.0 0.2 0.1 0.8 0.0 13.7 18.9 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 12.4 0.0 2.8 0.0 44.6 0.0 1.7 0.0 0.9 0.0 20.0 0.1 1.8 0.0 0.0 0.0 0.4 0.1 0.0 0.1 5.1 0.0 0.0 0.0 0.0 0.0 1.9 12.9 7.3 0.0 43.8 0.0 47.4 3.7 23.0 4.3 5.0 3.9 14.5 1.9 2.8 6.0 8.6 1.8 2.3 43.7 19.0 8.4 1.8 2.9 3.6 1.2 1.1 1.1 1.1 1.1 1.1 1.0 0.0 0.3 0.0 3.0 9.9 71.7 0.7 0.2 0.0 0.6 2.5 4.0 4.5 5.2 0.0 2.1 0.0 5.3 0.0 0.0 13.5 0.0 4.4 3.1 0.4 4.3 5.8 0.0 1.1 0.0 8.1 1.8 1.5 0.0 0.0 2.5 10.1 2.8 14.1 0.0 6.8 10.5 0.0 0.3 0.0 0.0 0.3 0.0 0.5 0.1 2.9 40.6 7.7 3.2 IGFLR1 "FLJ22573, TMEM149, U2AF1L4" ENSG00000126246 "IGF like family receptor 1" Q9H665 19 35738801-35742453 "Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 121.2;liver: 46.2;lymphoid tissue: 40.7" "Cell type enriched" "Detected in many" 5 "monocytes: 187.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "plasmacytoid DC: 121.2" "Lineage enriched" "Detected in all" 4 "dendritic cells: 121.2" "Cell line enhanced" "Detected in many" "HMC-1: 22.3;Karpas-707: 17.1;U-266/70: 22.5" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA012369 Uncertain Approved "Focal adhesion sites" "Intracellular and membrane" NA NA "Focal adhesion sites" "HPA012369: AB_1858095" "unprognostic (5.97e-3)" "prognostic favorable (6.55e-4)" "unprognostic (1.94e-1)" "unprognostic (5.42e-2)" "unprognostic (8.31e-3)" "unprognostic (2.34e-4)" "unprognostic (6.71e-2)" "unprognostic (1.74e-2)" "unprognostic (1.87e-2)" "prognostic favorable (1.59e-5)" "unprognostic (1.44e-3)" "unprognostic (3.52e-1)" "unprognostic (8.72e-12)" "unprognostic (2.74e-1)" "unprognostic (1.22e-1)" "unprognostic (2.29e-1)" "unprognostic (3.32e-3)" 5.3 7.3 4.5 17.8 7.6 10.1 4.1 2.0 5.3 3.1 5.0 3.8 0.0 5.6 2.6 4.7 3.4 4.5 5.9 5.8 4.5 3.1 17.0 46.2 8.5 40.7 7.7 1.6 4.5 6.9 1.1 3.4 3.8 5.6 4.0 5.4 2.2 7.4 1.8 3.9 4.6 8.4 3.5 5.4 20.2 6.3 3.5 4.5 14.6 10.0 3.2 19.3 8.0 4.9 22.3 121.2 28.6 26.5 18.1 17.4 16.3 1.3 6.5 2.3 5.4 0.8 1.2 1.3 1.5 0.7 1.2 3.1 1.9 1.6 2.8 2.1 0.4 0.4 1.0 1.3 1.3 0.6 2.1 3.3 10.0 2.7 6.8 1.9 1.3 22.3 1.8 0.8 2.3 0.5 0.9 1.2 5.0 3.0 17.1 0.3 5.5 3.1 10.5 1.6 5.9 1.7 3.8 2.2 5.2 1.1 2.4 1.6 3.1 2.1 1.5 1.1 1.1 2.4 5.4 0.3 2.8 1.3 1.7 2.5 22.5 4.7 1.7 3.3 3.8 2.1 16.2 26.5 23.6 13.3 22.2 15.2 22.3 15.4 12.6 33.9 21.8 13.9 11.1 28.6 18.1 15.5 121.2 17.4 16.3 4.5 7.6 2.0 5.3 4.5 3.1 7.7 1.6 5.6 4.5 0.0 15.7 9.9 0.3 0.6 0.2 0.6 2.5 6.7 9.1 0.0 0.0 0.4 1.7 1.6 0.0 0.5 0.8 0.0 3.6 1.5 0.7 0.3 38.1 16.4 13.3 0.0 2.9 2.5 14.3 0.2 0.0 28.0 5.0 187.6 1.7 1.2 1.5 0.0 0.0 4.4 0.1 0.0 0.9 0.5 0.5 0.6 0.2 8.5 1.2 0.0 IGSF5 JAM4 ENSG00000183067 "Immunoglobulin superfamily member 5" Q9NSI5 21 39745407-39802096 "Predicted membrane proteins" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "heart muscle: 5.8" "Cell type enriched" "Detected in some" 9 "Syncytiotrophoblasts: 95.4" "Cancer enhanced" "Detected in some" "testis cancer: 2.3" "Cell type enriched" "Detected in single" 5 "neutrophil: 2.2" "Lineage enriched" "Detected in single" 5 "granulocytes: 2.2" "Cell line enhanced" "Detected in many" "T-47d: 10.8" "Low region specificity" "Detected in all" HPA057282 Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA057282: AB_2683395" "unprognostic (1.06e-1)" "unprognostic (2.53e-1)" "unprognostic (7.06e-2)" "unprognostic (9.73e-5)" "unprognostic (1.56e-2)" "unprognostic (3.15e-1)" "unprognostic (1.41e-1)" "unprognostic (2.18e-2)" "unprognostic (2.09e-1)" "unprognostic (8.35e-2)" "unprognostic (9.61e-2)" "unprognostic (4.01e-1)" "unprognostic (4.18e-1)" "unprognostic (3.75e-2)" "unprognostic (6.89e-2)" "unprognostic (1.07e-2)" 0.0 2.0 0.9 0.0 3.4 0.1 1.3 0.1 0.7 1.1 0.3 0.2 0.9 3.4 0.0 0.9 0.3 5.8 1.2 2.3 0.3 0.3 0.1 0.2 1.3 1.5 2.5 0.3 1.5 4.3 2.4 0.9 0.9 0.4 0.0 0.6 0.1 0.4 0.7 0.3 0.6 1.5 0.8 0.2 0.5 0.2 0.4 0.3 2.2 0.4 0.0 0.4 0.0 1.3 0.7 4.5 1.1 4.4 3.6 1.2 0.8 1.2 1.3 2.0 0.7 1.3 1.4 1.2 1.7 1.7 1.2 1.5 3.0 2.5 2.3 2.1 1.4 3.3 0.5 2.8 1.9 0.6 3.2 5.5 2.9 3.2 2.2 0.6 0.7 2.6 0.9 1.7 1.6 0.3 0.6 2.5 1.1 0.8 0.7 2.0 0.8 1.9 1.9 2.0 0.5 1.2 3.0 1.8 2.1 10.8 1.1 0.4 2.0 2.3 1.0 1.8 1.0 0.8 0.9 1.1 1.4 2.0 0.1 0.4 0.4 0.4 0.0 0.2 0.1 0.3 0.1 0.1 0.4 0.1 0.2 2.2 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.3 8.7 0.0 0.0 0.0 1.8 0.0 0.9 5.0 0.3 11.1 0.0 0.0 0.0 0.2 0.9 0.0 0.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 4.5 0.3 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.4 2.7 0.1 0.0 0.2 0.5 0.1 0.0 95.4 0.0 0.0 0.9 IL1RL1 "DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1" ENSG00000115602 "Interleukin 1 receptor like 1" Q01638 2 102311502-102352037 "Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Hydrolase, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "kidney: 49.7;lung: 77.2;placenta: 95.0" "Cell type enriched" "Detected in many" 11 "granulocytes: 477.2" "Cancer enhanced" "Detected in many" "thyroid cancer: 7.9" "Group enriched" "Detected in many" 5 "basal ganglia: 11.4;cerebral cortex: 6.6;hippocampal formation: 5.6;midbrain: 3.8;pons and medulla: 14.6" "Group enriched" "Detected in some" 59 "basophil: 17.1;eosinophil: 17.0" "Lineage enriched" "Detected in single" 59 "granulocytes: 17.1" "Group enriched" "Detected in some" 6 "HHSteC: 55.4;HMC-1: 82.4;HUVEC TERT2: 40.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA007406, HPA007917" Uncertain Supported "Plasma membrane,Focal adhesion sites,Cytosol" "Secreted to blood" NA NA 19100000 1700000 "Plasma membrane" "Focal adhesion sites, Cytosol" "HPA007406: AB_1079128, HPA007917: AB_1079129" "unprognostic (7.25e-2)" "unprognostic (9.72e-2)" "unprognostic (1.44e-1)" "unprognostic (3.28e-2)" "unprognostic (5.28e-2)" "unprognostic (1.98e-2)" "unprognostic (3.25e-3)" "unprognostic (2.07e-1)" "unprognostic (2.77e-1)" "unprognostic (4.50e-2)" "unprognostic (8.58e-2)" "unprognostic (9.74e-2)" "unprognostic (1.44e-1)" "unprognostic (1.32e-2)" "unprognostic (1.60e-2)" "unprognostic (1.17e-1)" "unprognostic (4.60e-3)" 10.7 7.5 1.4 2.0 11.4 0.9 6.9 0.5 6.6 2.6 3.1 0.1 0.1 1.3 1.7 0.9 2.7 0.8 7.8 16.6 5.6 1.8 49.7 6.2 77.2 1.4 3.8 0.0 0.7 2.8 0.8 1.8 95.0 14.6 1.9 2.3 1.0 0.7 5.7 2.8 1.1 2.0 3.3 5.0 1.0 6.7 0.8 0.3 0.0 5.6 0.7 0.9 6.0 2.6 0.0 0.0 17.1 0.0 0.2 0.2 0.0 0.2 0.0 0.1 0.0 3.4 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.3 0.0 1.3 0.1 0.0 0.0 9.7 0.1 0.1 55.4 0.4 82.4 1.1 0.3 1.3 8.9 0.1 40.2 0.0 0.2 0.1 0.1 0.0 0.1 1.8 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 3.3 0.1 0.1 0.7 0.1 0.0 0.0 0.0 0.1 0.1 0.1 17.1 0.0 17.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.4 11.4 0.5 6.6 5.6 1.8 3.8 0.0 14.6 0.3 8.9 22.8 0.0 15.1 7.6 0.0 1.8 0.0 12.0 13.6 1.8 0.0 0.0 0.0 0.0 0.2 29.2 0.0 0.0 0.4 0.1 4.2 8.9 477.2 0.0 0.0 0.0 0.0 44.2 0.3 0.9 0.9 11.2 3.3 0.0 0.0 0.0 21.7 0.0 0.0 0.0 0.2 38.8 5.2 0.0 0.0 4.4 0.0 4.3 0.0 11.1 ILK ENSG00000166333 "Integrin linked kinase" Q13418 11 6603708-6610874 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004041, HPA048437" Enhanced Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" NA NA 130000000 "Plasma membrane, Focal adhesion sites" Nucleoplasm "CAB004041: AB_2127050, HPA048437: AB_2680391" "unprognostic (1.78e-1)" "unprognostic (2.26e-2)" "unprognostic (5.26e-2)" "unprognostic (2.12e-2)" "unprognostic (7.57e-2)" "unprognostic (1.01e-1)" "unprognostic (6.19e-3)" "unprognostic (5.25e-3)" "unprognostic (1.49e-2)" "unprognostic (9.65e-2)" "unprognostic (2.64e-1)" "unprognostic (8.12e-2)" "prognostic favorable (2.44e-4)" "unprognostic (4.01e-3)" "unprognostic (9.27e-2)" "unprognostic (2.42e-1)" "unprognostic (6.36e-3)" 20.9 17.6 11.0 22.3 11.9 7.5 37.0 9.4 14.6 40.2 75.1 14.7 41.9 13.5 75.4 25.2 35.7 33.2 41.1 35.1 11.1 9.2 21.6 15.1 21.9 18.9 11.5 14.0 24.2 22.3 20.4 10.9 22.2 11.5 39.9 24.6 19.3 19.4 89.9 18.5 12.4 22.2 103.5 10.6 20.2 33.2 14.2 11.0 8.2 17.5 14.1 13.6 60.8 25.9 19.5 45.9 76.5 49.4 45.3 25.8 63.7 23.9 18.5 29.2 10.1 45.2 32.1 13.3 35.3 69.8 41.8 51.0 19.3 28.3 9.0 9.4 57.7 41.0 19.3 16.3 29.9 42.0 15.7 14.8 13.0 17.7 15.0 30.3 10.4 14.9 30.8 14.1 28.2 21.6 42.9 39.8 7.8 11.9 10.7 54.5 18.0 9.2 17.8 18.4 20.4 21.8 9.6 15.3 9.6 30.6 19.2 5.1 11.5 16.7 23.1 19.4 29.8 16.1 11.9 46.0 52.5 23.7 21.7 17.1 7.8 4.8 12.7 38.9 15.7 24.4 48.3 49.4 76.5 25.8 47.9 25.1 19.5 23.3 24.4 45.9 17.1 14.7 18.5 31.7 45.3 44.4 18.5 25.7 63.7 11.0 11.9 9.4 14.6 11.1 9.2 11.5 14.0 11.5 11.0 41.7 17.0 28.3 58.4 44.9 13.9 0.3 66.2 18.7 15.9 54.1 7.9 94.6 49.7 120.2 46.5 56.1 64.4 46.7 108.6 153.9 93.0 39.7 29.0 24.9 111.6 7.9 36.5 84.1 50.9 110.9 66.2 80.3 81.0 196.6 43.0 50.2 101.4 57.5 138.6 74.7 29.6 155.2 137.9 31.1 15.7 37.8 92.0 54.3 41.7 41.9 INPP5E "CORS1, JBTS1, pharbin, PPI5PIV" ENSG00000148384 "Inositol polyphosphate-5-phosphatase E" Q9NRR6 9 136428619-136439823 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Lipid metabolism" Hydrolase "Ciliopathy, Disease mutation, Joubert syndrome, Mental retardation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA065758 Approved Supported "Nucleoplasm,Golgi apparatus,Focal adhesion sites" NA NA "Golgi apparatus, Focal adhesion sites" Nucleoplasm "HPA065758: AB_2685554" "unprognostic (1.99e-1)" "unprognostic (8.68e-2)" "unprognostic (1.87e-2)" "unprognostic (1.23e-2)" "unprognostic (4.00e-1)" "unprognostic (6.92e-2)" "unprognostic (9.60e-3)" "unprognostic (3.21e-1)" "unprognostic (5.81e-2)" "unprognostic (2.65e-2)" "prognostic favorable (1.82e-4)" "unprognostic (2.03e-1)" "unprognostic (3.04e-2)" "unprognostic (3.76e-1)" "unprognostic (5.48e-2)" "unprognostic (4.64e-1)" "unprognostic (2.66e-2)" 14.3 11.2 14.9 15.3 10.4 8.9 19.2 19.9 19.1 10.5 10.7 11.5 11.1 10.3 13.1 10.1 8.4 17.2 9.4 11.9 12.6 12.0 10.2 9.0 10.1 13.5 8.4 12.3 14.7 11.6 11.4 12.3 9.8 13.2 9.9 5.2 11.0 14.4 12.9 11.6 18.2 10.7 10.7 6.6 19.4 8.6 15.2 10.3 8.5 12.5 6.2 10.7 8.8 19.3 2.6 1.0 1.9 0.5 0.0 2.4 0.6 6.2 7.2 8.5 8.4 4.3 5.6 10.5 7.5 4.4 5.8 3.7 7.4 4.4 7.8 7.7 6.3 8.3 17.5 3.7 5.1 2.2 24.3 14.7 5.2 12.4 4.9 7.3 6.1 8.5 6.0 4.8 6.4 5.7 6.9 5.6 10.0 8.8 7.2 4.9 10.3 7.8 13.4 5.5 3.9 12.0 14.3 6.5 5.8 5.2 6.1 8.9 8.0 7.2 6.8 5.2 6.1 10.9 9.1 8.0 17.9 6.7 7.2 13.0 7.8 6.3 3.3 9.2 5.4 6.5 0.0 0.5 1.9 2.0 0.0 1.3 2.6 2.3 1.5 0.5 1.7 0.8 1.6 0.4 0.0 0.3 1.0 2.4 0.6 14.9 10.4 19.9 19.1 12.6 12.0 8.4 12.3 13.2 10.3 3.0 5.8 2.9 1.5 4.8 7.1 4.1 7.6 6.7 3.4 3.5 2.0 2.0 1.7 4.5 0.3 5.8 2.8 0.0 4.8 2.0 3.9 2.0 9.2 3.0 2.6 14.3 5.8 2.5 3.8 0.7 6.9 3.5 5.0 4.6 2.9 8.5 5.3 0.0 5.3 2.2 11.4 0.0 4.8 9.8 7.8 4.3 0.7 4.3 4.3 1.6 ITGAV "CD51, MSK8, VNRA, VTNR" ENSG00000138448 "Integrin subunit alpha V" P06756 2 186590065-186680901 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.7" "Group enriched" "Detected in many" 4 "granulocytes: 7.7;monocytes: 2.3" "Cell line enhanced" "Detected in many" "RT4: 71.7;SuSa: 62.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002499, HPA004856" Supported Approved "Focal adhesion sites,Cytosol" NA NA 750000 "Focal adhesion sites, Cytosol" "CAB002499: AB_563594, HPA004856: AB_1846316" "unprognostic (4.03e-2)" "unprognostic (5.17e-3)" "unprognostic (1.22e-2)" "unprognostic (5.22e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (2.08e-4)" "unprognostic (1.48e-2)" "unprognostic (6.95e-2)" "unprognostic (2.89e-1)" "prognostic unfavorable (5.07e-4)" "unprognostic (5.84e-2)" "unprognostic (2.67e-2)" "prognostic unfavorable (1.05e-6)" "unprognostic (2.61e-1)" "unprognostic (9.11e-2)" "unprognostic (8.07e-2)" 23.2 22.1 17.9 18.3 21.8 3.1 25.8 16.7 23.1 22.9 13.6 23.4 11.6 8.4 26.0 11.4 14.2 14.5 25.2 40.7 16.8 12.3 51.5 9.5 20.6 7.6 24.2 11.6 35.4 18.7 65.0 11.0 29.6 22.1 16.5 11.9 83.4 17.9 15.9 13.1 21.5 10.1 29.6 33.0 12.1 17.3 11.2 17.0 7.8 33.1 10.9 11.1 17.6 17.9 0.3 0.9 7.7 2.3 0.4 1.1 0.5 9.3 11.1 7.4 23.7 27.3 18.5 28.3 18.3 14.8 6.5 6.5 9.7 32.2 0.0 36.1 20.6 22.7 11.7 3.8 17.2 9.4 1.8 3.4 2.2 14.6 13.3 10.8 1.5 1.4 13.4 8.2 14.4 12.3 39.0 15.4 1.1 2.1 4.7 17.2 3.7 0.9 1.3 5.6 5.6 5.6 0.0 15.2 1.2 16.8 71.7 1.5 4.6 21.1 6.5 7.7 62.1 5.1 4.3 46.8 40.2 12.6 8.2 15.4 1.1 1.9 1.0 16.2 0.6 19.8 7.7 1.1 1.6 1.0 2.3 0.7 0.3 0.5 0.8 0.9 0.1 0.5 0.5 0.5 0.4 1.2 0.4 1.1 0.5 17.9 21.8 16.7 17.3 16.8 12.3 24.2 11.6 22.1 17.0 26.8 18.5 2.4 54.8 114.0 118.2 124.7 73.9 12.0 20.5 73.3 72.6 46.9 1.7 78.4 0.5 50.4 13.2 0.0 89.0 21.8 61.3 83.9 49.5 15.8 26.1 14.3 7.0 34.4 33.9 1.6 17.8 18.2 43.9 20.8 18.9 82.5 120.4 18.2 24.4 16.5 54.8 32.3 47.2 0.7 1.4 90.7 33.2 6.9 11.4 48.6 ITGB1 "CD29, FNRB, GPIIA, MDF2, MSK12" ENSG00000150093 "Integrin subunit beta 1" P05556 10 32900319-33005792 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Ductal cells: 1163.1;Pancreatic endocrine cells: 917.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTERT-RPE1: 196.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003434, HPA059297, HPA069003" Enhanced Supported "Endoplasmic reticulum,Plasma membrane,Focal adhesion sites" NA NA 540000000 "Plasma membrane, Focal adhesion sites" "Endoplasmic reticulum" "CAB003434: AB_303570, HPA059297: AB_2732634, HPA069003: AB_2732125" "unprognostic (3.07e-2)" "prognostic unfavorable (5.01e-4)" "unprognostic (8.67e-2)" "unprognostic (4.36e-1)" "unprognostic (1.20e-2)" "unprognostic (3.87e-2)" "unprognostic (1.60e-2)" "prognostic unfavorable (3.36e-6)" "unprognostic (3.22e-1)" "unprognostic (2.36e-3)" "unprognostic (3.68e-3)" "unprognostic (2.42e-1)" "unprognostic (1.02e-3)" "unprognostic (1.25e-2)" "unprognostic (2.23e-1)" "unprognostic (2.48e-1)" "unprognostic (3.08e-2)" 95.2 30.6 13.7 32.1 19.7 9.7 107.7 6.5 14.8 55.1 61.3 17.0 80.2 20.2 84.2 56.2 59.9 45.0 49.8 68.7 15.0 14.4 47.3 85.8 55.4 34.5 23.0 11.1 47.4 37.4 17.6 35.2 83.3 19.5 53.1 32.2 18.6 30.3 76.2 58.0 19.5 42.3 109.3 30.1 59.8 45.4 26.9 18.8 12.7 36.8 27.6 19.4 92.7 47.4 31.3 9.1 4.3 27.1 21.9 68.4 26.2 45.6 67.0 36.2 40.1 87.3 75.2 31.6 153.5 89.0 73.1 66.9 15.0 106.9 12.3 27.8 128.7 48.0 31.9 10.9 87.3 81.6 12.1 8.8 14.8 31.9 17.5 61.5 3.3 14.7 76.2 47.8 76.9 31.3 196.1 89.8 6.1 10.2 5.4 120.5 7.5 5.7 3.3 8.0 13.9 34.0 3.7 26.8 2.2 104.2 13.2 8.6 21.4 47.8 8.1 34.4 61.5 10.9 11.9 100.4 94.2 54.7 66.9 51.1 5.0 1.1 6.9 69.4 14.1 36.9 1.6 9.8 4.3 25.5 17.8 6.0 31.3 54.6 37.5 9.1 8.6 7.1 19.1 2.3 21.9 27.1 3.7 68.4 26.2 13.7 19.7 6.5 14.8 15.0 14.4 23.0 11.1 19.5 18.8 318.6 128.6 76.4 295.7 485.6 32.6 175.3 242.0 164.6 252.5 214.6 29.5 156.7 11.6 1163.1 4.3 314.7 83.6 70.0 355.7 460.3 265.1 177.2 86.6 221.3 161.3 36.5 185.6 387.9 152.7 9.7 235.6 174.3 325.6 83.0 81.4 76.8 917.0 113.2 565.7 64.3 45.2 627.3 497.4 10.0 63.7 149.1 183.8 106.6 98.8 257.2 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5128183 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Kupffer cells: 36.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 40.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 40.8" "Group enriched" "Detected in many" 5 "ASC diff: 19.4;HDLM-2: 27.4;HEL: 56.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" No No Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708" "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 19.8 8.8 11.5 19.0 10.5 19.0 17.7 14.7 14.4 17.8 10.6 7.0 10.3 7.2 14.8 13.6 12.4 13.4 14.6 27.6 10.3 6.7 7.7 5.6 16.1 19.4 7.0 10.5 15.9 6.7 10.1 7.5 12.0 10.0 12.0 7.4 9.4 7.2 7.4 14.4 19.0 12.3 10.4 11.7 21.5 14.1 10.1 9.0 13.6 8.6 6.5 13.5 13.9 15.6 2.1 9.6 40.8 7.5 3.4 2.1 2.5 2.5 1.5 1.5 2.5 19.4 5.0 0.4 3.5 3.0 2.7 1.8 0.1 0.8 0.1 0.8 2.1 2.2 0.9 1.6 2.1 2.0 27.4 0.5 56.1 3.0 0.7 4.0 3.8 2.9 4.1 0.9 1.1 1.8 3.3 2.5 2.0 4.0 6.5 4.8 0.9 0.9 5.4 1.3 1.3 1.7 1.9 2.8 0.8 2.0 1.3 1.7 0.9 1.0 1.5 1.1 1.6 0.8 6.7 5.1 4.1 1.4 4.2 2.4 1.2 2.3 0.5 5.3 1.9 2.0 40.8 7.5 13.4 2.1 7.3 1.7 2.1 1.6 1.2 9.6 1.9 0.9 1.1 7.1 3.4 5.8 3.6 1.6 2.5 11.5 10.5 14.7 14.4 10.3 6.7 7.0 10.5 10.0 9.0 14.9 6.4 6.9 2.8 8.7 7.4 22.0 0.0 5.3 7.9 7.0 7.9 1.8 1.7 3.0 7.4 8.7 3.9 23.3 3.4 0.8 7.0 1.7 13.9 1.6 11.9 7.9 2.9 4.9 36.0 5.3 21.9 27.7 5.0 16.2 4.2 12.2 5.4 14.4 31.5 2.5 11.1 0.0 5.0 14.9 5.7 7.3 2.9 5.0 3.3 4.1 KLF11 "MODY7, TIEG2, Tieg3" ENSG00000172059 "Kruppel like factor 11" O14901 2 10042849-10054836 "Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Diabetes mellitus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Early spermatids: 120.7;Suprabasal keratinocytes: 75.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 25.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058276 Supported "Nucleoplasm,Nuclear bodies,Focal adhesion sites,Cytosol" Yes No Nucleoplasm "Nuclear bodies, Focal adhesion sites, Cytosol" "HPA058276: AB_2683664" "unprognostic (9.66e-3)" "unprognostic (1.87e-1)" "unprognostic (1.59e-1)" "unprognostic (1.06e-2)" "unprognostic (3.02e-3)" "unprognostic (2.63e-3)" "unprognostic (6.34e-2)" "unprognostic (1.04e-2)" "unprognostic (1.67e-1)" "unprognostic (1.04e-1)" "unprognostic (3.17e-3)" "unprognostic (3.08e-2)" "unprognostic (2.48e-3)" "unprognostic (8.96e-2)" "unprognostic (3.44e-1)" "unprognostic (1.07e-2)" "unprognostic (9.24e-2)" 28.7 9.1 2.5 7.0 3.5 11.8 33.1 8.2 4.4 12.9 13.0 5.1 10.8 3.5 12.8 11.7 8.3 11.2 11.6 19.4 2.9 2.3 12.7 27.9 14.6 15.9 5.5 2.4 13.7 38.3 7.3 2.4 9.9 3.4 13.9 4.7 9.2 11.3 10.9 14.0 19.1 7.7 30.4 3.5 16.1 10.2 16.7 2.7 1.5 9.1 8.5 5.6 11.1 42.7 2.9 6.6 1.7 12.7 5.4 2.7 3.8 3.7 1.8 4.4 0.4 3.1 5.5 10.7 4.4 4.5 2.5 2.6 4.3 8.8 0.0 8.0 5.3 10.2 0.9 3.8 3.4 1.7 25.9 2.9 1.9 5.4 0.8 3.0 7.9 12.6 8.6 12.7 4.8 1.3 6.5 2.2 0.7 5.2 17.5 2.5 4.4 0.0 1.4 7.1 3.0 3.8 4.2 0.1 7.3 6.1 4.7 5.7 3.5 6.7 13.9 12.9 7.3 3.2 10.8 6.2 11.1 9.3 8.3 1.4 15.9 18.9 10.2 2.9 2.1 5.9 0.0 6.9 1.7 2.6 11.0 0.8 2.8 1.7 1.8 6.6 2.9 0.5 1.0 0.2 5.4 12.7 0.3 2.7 3.8 2.5 3.5 8.2 4.4 2.9 2.3 5.5 2.4 3.4 2.7 6.0 5.8 3.2 13.5 53.8 5.2 2.8 7.6 5.3 7.9 7.0 5.9 2.4 24.9 7.7 120.7 16.6 3.1 0.0 7.4 3.3 9.7 13.1 8.1 34.1 11.6 3.2 6.8 43.0 29.9 21.5 13.6 21.1 28.7 3.6 6.8 2.3 8.2 0.0 15.6 5.3 4.7 32.3 44.3 14.1 35.0 75.4 6.9 5.7 7.4 9.5 LASP1 "Lasp-1, MLN50" ENSG00000002834 "LIM and SH3 protein 1" Q14847 17 38869859-38921770 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ion transport, Transport" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 124.5" "Cell type enhanced" "Detected in many" 8 "Late spermatids: 467.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012072, CAB022049" Enhanced Supported "Plasma membrane,Focal adhesion sites,Cytosol" NA NA 26000000 "Plasma membrane, Cytosol" "Focal adhesion sites" "CAB022049: , HPA012072: AB_1852714" "unprognostic (1.23e-1)" "unprognostic (2.09e-2)" "unprognostic (1.77e-1)" "prognostic unfavorable (4.57e-4)" "unprognostic (1.47e-1)" "unprognostic (3.03e-2)" "prognostic unfavorable (2.41e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-1)" "unprognostic (9.60e-2)" "unprognostic (9.87e-3)" "unprognostic (1.01e-1)" "unprognostic (9.65e-3)" "unprognostic (1.29e-3)" "unprognostic (3.95e-2)" "unprognostic (1.60e-3)" "unprognostic (4.53e-2)" 51.2 20.0 23.8 40.3 22.4 45.4 35.5 15.5 25.7 23.6 57.4 16.3 18.7 54.4 23.4 24.1 22.4 20.8 48.3 15.2 18.4 23.3 33.1 47.5 33.3 44.2 20.0 14.3 28.4 30.1 10.1 17.6 40.0 16.1 18.9 38.6 24.2 22.4 24.1 10.7 18.3 124.5 21.3 12.2 43.1 39.5 13.9 12.9 40.5 18.3 18.7 33.7 22.0 28.3 6.4 13.9 34.0 19.9 17.3 16.5 13.1 35.4 73.9 21.6 19.1 31.8 34.5 37.3 44.6 43.6 47.0 34.6 22.0 38.6 16.2 37.3 68.9 26.7 56.5 9.8 33.9 41.2 11.8 5.3 7.7 21.4 38.3 30.2 17.8 23.4 30.6 11.9 39.8 11.3 29.4 31.5 10.0 13.1 5.4 65.4 11.7 21.1 27.5 10.8 31.2 18.5 11.9 11.5 20.4 57.7 31.2 3.2 7.9 26.5 27.9 23.1 41.8 44.0 21.8 55.0 28.2 41.2 33.0 27.0 14.0 18.4 12.6 29.8 16.0 33.9 9.9 14.8 16.8 16.5 17.1 11.3 6.4 8.4 11.0 13.9 6.3 7.2 10.9 34.0 17.3 19.9 10.7 10.7 13.1 23.8 22.4 15.5 25.7 18.4 23.3 20.0 14.3 16.1 12.9 38.7 25.9 38.3 19.5 37.2 55.7 0.8 66.2 32.1 19.4 69.8 9.8 4.3 14.9 58.2 85.5 48.9 225.0 0.0 65.7 33.5 47.6 22.3 51.8 85.9 75.8 25.4 83.1 70.6 116.7 467.6 48.1 58.0 33.7 52.3 91.2 21.1 95.7 106.3 37.4 62.1 22.0 64.7 29.7 2.1 4.1 24.8 5.4 60.9 75.9 23.8 LDB3 "CMD1C, KIAA0613, PDLIM6, ZASP" ENSG00000122367 "LIM domain binding 3" O75112 10 86668449-86736068 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cardiomyopathy, Disease mutation, Myofibrillar myopathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 21 "heart muscle: 213.9;skeletal muscle: 329.7;tongue: 110.3" "Cell type enriched" "Detected in some" 41 "Cardiomyocytes: 1579.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "HSkMC: 5.9;hTERT-RPE1: 5.8;SCLC-21H: 9.6;SK-MEL-30: 4.6" "Low region specificity" "Detected in all" HPA048955 Enhanced Supported "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA 450000 "Focal adhesion sites, Cytosol" Nucleoplasm "HPA048955: AB_2680568" "unprognostic (1.60e-1)" "unprognostic (9.01e-2)" "unprognostic (4.87e-2)" "unprognostic (6.92e-2)" "unprognostic (5.55e-2)" "unprognostic (1.50e-2)" "unprognostic (2.57e-2)" "unprognostic (1.36e-1)" "unprognostic (2.79e-2)" "unprognostic (7.61e-2)" "unprognostic (2.54e-3)" "unprognostic (3.55e-2)" "unprognostic (4.72e-4)" "unprognostic (3.07e-2)" "unprognostic (1.60e-1)" "unprognostic (1.62e-2)" "unprognostic (3.16e-1)" 6.4 0.4 0.9 1.3 1.6 0.2 0.5 0.1 1.3 2.8 2.3 0.0 4.9 0.4 4.2 9.9 9.9 1.3 1.0 213.9 1.7 1.0 0.3 0.2 0.4 0.2 2.6 0.0 1.5 0.3 0.3 0.1 0.5 0.0 4.4 0.8 4.7 7.6 3.1 329.7 0.3 1.2 3.6 6.7 0.2 0.7 0.5 0.0 0.0 2.8 110.3 10.2 1.9 0.9 0.9 0.6 1.8 0.4 0.6 0.6 0.0 0.3 0.2 0.4 3.1 0.4 0.1 0.3 0.4 0.3 0.1 0.2 0.3 0.3 0.2 0.6 0.0 0.7 0.4 0.2 0.0 0.1 0.9 0.7 0.7 0.9 0.1 0.1 0.1 1.6 5.9 0.5 0.1 0.0 5.8 0.0 0.7 0.2 1.8 0.3 1.5 0.4 0.2 0.4 0.4 0.3 0.0 2.0 0.1 0.0 1.1 9.6 1.8 0.3 0.2 4.6 1.4 0.3 0.2 0.0 0.3 0.5 0.4 0.1 0.2 0.6 0.4 0.7 0.3 0.5 1.8 0.4 0.4 0.4 0.3 0.4 0.3 0.3 0.3 0.2 0.9 0.5 0.6 1.4 0.6 0.4 0.6 0.3 0.0 0.9 1.6 0.1 0.6 1.7 1.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.9 1.7 1579.0 0.0 0.0 0.0 1.8 0.0 0.1 0.0 0.0 18.3 0.7 0.0 0.0 1.0 0.0 0.7 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 13.2 10.3 0.4 1.7 0.0 0.0 1.0 0.1 0.0 6.3 0.0 3.4 38.8 33.0 0.6 1.0 0.0 0.0 0.0 0.0 0.1 LIMA1 EPLIN ENSG00000050405 "LIM domain and actin binding 1" Q9UHB6 12 50175788-50283546 "Predicted intracellular proteins" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Basal glandular cells: 458.2;Basal keratinocytes: 492.0" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 73.6" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 85.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023871, HPA052645" Enhanced Enhanced "Plasma membrane,Actin filaments,Focal adhesion sites,Cytosol" NA NA 160000 "Plasma membrane, Actin filaments" "Focal adhesion sites, Cytosol" "HPA023871: AB_1852875, HPA052645: AB_2681898" "unprognostic (6.22e-2)" "unprognostic (9.39e-3)" "unprognostic (8.13e-2)" "unprognostic (1.42e-1)" "unprognostic (8.08e-2)" "prognostic unfavorable (1.76e-6)" "unprognostic (1.63e-1)" "unprognostic (2.29e-1)" "unprognostic (2.28e-2)" "unprognostic (2.65e-1)" "unprognostic (1.28e-3)" "unprognostic (6.27e-2)" "prognostic favorable (2.79e-4)" "unprognostic (7.12e-2)" "unprognostic (9.26e-3)" "unprognostic (1.46e-1)" "unprognostic (1.43e-1)" 50.3 19.8 6.6 22.3 6.8 0.9 34.1 73.6 6.6 30.9 49.2 10.4 21.3 35.2 31.1 22.1 25.0 18.0 31.1 12.6 6.6 5.1 29.3 11.1 23.3 11.8 7.2 4.1 21.1 12.4 12.4 18.6 42.0 15.4 28.2 42.8 20.7 27.0 22.1 10.5 16.3 90.5 33.8 10.4 23.6 30.3 11.8 6.0 12.1 17.0 20.7 18.0 41.8 21.4 0.6 4.4 1.3 2.1 5.8 13.6 2.7 24.5 0.7 7.8 11.5 36.2 36.3 29.7 61.7 43.5 49.7 39.8 9.3 36.2 1.1 5.7 85.0 16.7 28.0 7.0 57.0 43.6 15.6 7.4 10.3 2.8 3.2 23.2 3.6 14.6 24.3 16.8 17.4 50.3 15.0 17.4 4.6 7.1 5.0 16.0 4.2 4.5 1.1 4.0 13.0 3.3 4.5 19.2 0.3 11.5 29.3 5.9 12.6 8.4 17.1 26.4 8.7 8.1 2.2 27.1 21.3 16.4 19.7 10.0 2.7 0.3 4.5 23.2 4.1 9.1 0.1 0.2 1.3 6.4 1.0 2.5 0.1 8.1 7.8 4.4 0.6 3.3 5.9 0.1 5.8 2.1 1.1 13.6 2.7 6.6 6.8 73.6 5.6 6.6 5.1 7.2 4.1 15.4 6.0 41.7 69.6 5.7 458.2 492.0 15.2 4.8 91.7 64.3 190.0 113.4 151.2 92.0 13.3 118.0 57.4 79.0 270.8 0.0 268.0 306.1 86.4 160.9 24.3 17.8 31.1 6.4 118.0 121.5 12.4 9.6 69.9 18.4 86.0 15.4 122.6 21.8 175.8 221.0 72.9 21.7 85.9 64.7 111.9 28.1 7.0 254.8 53.5 31.6 178.0 293.9 LIMD1 ENSG00000144791 "LIM domains containing 1" Q9UGP4 3 45555394-45686338 "Plasma proteins, Predicted intracellular proteins" "RNA-mediated gene silencing, Transcription, Transcription regulation" Repressor "Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Alveolar cells type 1: 35.7;B-cells: 31.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA064220, HPA071736" Approved Supported "Nucleoplasm,Focal adhesion sites" NA NA "Nucleoplasm, Focal adhesion sites" "HPA064220: AB_2685216, HPA071736: " "unprognostic (2.77e-1)" "unprognostic (3.22e-2)" "unprognostic (5.43e-2)" "unprognostic (7.78e-2)" "unprognostic (6.53e-2)" "unprognostic (2.07e-2)" "unprognostic (9.44e-2)" "unprognostic (1.53e-2)" "unprognostic (1.11e-1)" "unprognostic (2.42e-1)" "unprognostic (6.88e-2)" "unprognostic (2.11e-3)" "prognostic favorable (6.73e-5)" "unprognostic (8.02e-2)" "unprognostic (3.06e-2)" "unprognostic (2.86e-2)" "unprognostic (6.61e-3)" 12.6 7.0 4.8 14.9 5.5 6.2 13.9 2.5 6.0 10.2 9.7 8.1 13.0 8.4 14.4 12.0 10.4 9.6 10.9 11.5 5.1 4.1 8.3 16.6 24.8 17.1 9.2 2.2 7.6 24.5 11.3 5.5 11.7 9.4 12.1 9.2 20.2 19.1 8.2 25.2 8.3 12.2 12.5 6.8 16.4 11.4 6.2 6.4 20.3 17.9 10.7 24.9 12.9 18.9 6.7 8.8 4.1 5.5 1.1 1.6 1.0 7.4 14.2 5.2 7.0 4.6 9.0 10.4 7.2 10.1 7.7 6.7 6.7 3.9 0.9 4.8 6.6 15.7 5.1 11.0 5.9 6.4 15.7 6.7 8.3 11.2 5.5 4.7 7.4 10.7 3.7 4.9 11.4 6.0 5.6 6.7 8.6 6.9 23.5 7.6 4.9 9.0 4.7 8.4 6.0 13.7 4.5 6.0 11.3 4.0 13.3 2.4 4.7 6.1 11.1 7.2 5.6 6.7 6.7 11.9 8.5 7.7 8.5 7.6 22.5 28.9 3.7 18.5 6.8 9.2 4.1 1.4 1.4 1.6 3.1 1.0 3.9 1.3 1.4 1.4 6.7 1.4 1.4 1.6 1.1 5.5 8.8 1.3 1.0 4.8 5.5 2.5 6.0 5.1 4.1 9.2 2.2 9.4 6.4 35.7 20.6 31.3 5.1 2.6 1.5 14.2 12.7 10.7 13.6 7.0 2.0 5.1 1.7 6.0 1.0 4.3 5.9 0.0 4.6 10.3 4.8 9.5 3.5 16.3 14.1 6.4 6.4 9.8 15.3 0.2 10.9 9.0 5.0 1.0 16.0 7.0 5.6 3.5 3.2 3.0 1.0 6.5 8.0 0.7 4.1 1.9 4.5 7.4 8.8 3.6 LIMS1 "PINCH, PINCH1" ENSG00000169756 "LIM zinc finger domain containing 1" P48059 2 108534355-108687246 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 89.8" "HPA058455, HPA061230" Approved Supported "Focal adhesion sites,Cytosol" NA NA 130000000 Cytosol "Focal adhesion sites" "HPA058455: AB_2683723, HPA061230: AB_2684456" "unprognostic (1.79e-1)" "unprognostic (8.82e-3)" "unprognostic (5.66e-2)" "unprognostic (1.17e-2)" "unprognostic (1.52e-1)" "unprognostic (4.23e-2)" "unprognostic (1.08e-3)" "unprognostic (1.09e-1)" "unprognostic (8.96e-2)" "unprognostic (1.18e-1)" "unprognostic (5.95e-3)" "unprognostic (2.09e-1)" "prognostic unfavorable (7.88e-4)" "unprognostic (7.51e-2)" "unprognostic (8.60e-3)" "unprognostic (1.43e-2)" "unprognostic (2.11e-1)" 39.3 26.3 7.8 18.3 13.3 14.9 21.5 3.9 9.6 18.1 16.9 14.4 38.2 8.3 21.9 21.7 18.4 16.9 16.5 20.2 8.0 7.5 20.8 18.0 26.3 21.2 13.3 4.6 18.3 10.6 6.6 13.6 19.0 10.8 15.8 9.5 11.0 13.8 43.6 54.0 11.2 17.9 18.8 16.7 24.3 13.0 9.3 10.7 20.2 13.1 15.0 25.5 21.1 16.1 4.4 14.2 45.6 34.0 8.8 20.9 29.6 9.4 10.6 4.2 5.0 7.0 10.2 20.3 10.6 12.2 8.2 8.4 18.4 20.5 9.2 32.5 13.6 12.3 6.1 6.3 10.9 11.1 22.6 11.4 48.1 7.5 9.7 16.0 8.9 89.8 9.8 10.1 21.8 18.0 9.9 29.8 8.1 16.9 12.8 25.3 7.8 8.6 6.6 8.3 6.2 10.9 11.0 14.6 7.4 15.7 17.2 7.6 10.3 16.7 7.1 7.4 5.8 3.7 8.5 40.0 37.5 17.1 8.3 21.7 12.5 16.6 13.1 31.3 10.2 9.5 38.3 16.9 45.6 4.3 28.7 7.8 4.4 18.5 5.7 14.2 3.5 5.0 1.8 8.0 8.8 34.0 1.8 20.9 29.6 7.8 13.3 3.9 9.6 8.0 7.5 13.3 4.6 10.8 10.7 92.3 47.6 42.2 53.7 65.8 24.9 55.7 28.1 57.6 58.0 27.9 51.1 39.0 33.2 68.5 16.9 170.7 21.7 0.0 207.4 109.7 78.3 62.8 99.3 29.3 188.7 14.3 113.4 48.5 145.2 7.9 75.4 215.0 42.2 86.6 18.6 60.5 98.7 14.0 82.7 38.3 18.9 64.7 105.6 36.4 43.6 67.2 23.3 45.9 29.9 55.5 LIMS2 "PINCH-2, PINCH2" ENSG00000072163 "LIM zinc finger domain containing 2" Q7Z4I7 2 127638381-127681786 "Disease related genes, Predicted intracellular proteins" "Disease mutation, Limb-girdle muscular dystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 114.4" "Cell type enhanced" "Detected in many" 12 "Cardiomyocytes: 67.6;Endothelial cells: 62.4;Ito cells: 124.0;Peritubular cells: 46.7;Smooth muscle cells: 49.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 17.1" "Group enriched" "Detected in many" 14 "B-cells: 17.1;T-cells: 8.2" "Cell line enhanced" "Detected in many" "BJ hTERT+: 12.1;fHDF/TERT166: 13.2;HHSteC: 15.9;MOLT-4: 18.0;TIME: 37.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058340 Enhanced Supported "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA058340: AB_2683683" "unprognostic (2.51e-2)" "unprognostic (1.25e-1)" "unprognostic (5.82e-3)" "unprognostic (4.51e-2)" "unprognostic (9.25e-2)" "unprognostic (3.49e-1)" "prognostic favorable (6.53e-7)" "unprognostic (3.98e-2)" "unprognostic (3.73e-1)" "unprognostic (2.29e-1)" "unprognostic (3.78e-2)" "unprognostic (8.86e-2)" "unprognostic (3.33e-1)" "unprognostic (4.60e-3)" "unprognostic (3.64e-2)" "unprognostic (1.77e-1)" "unprognostic (4.00e-2)" 21.9 4.4 3.4 16.7 4.5 0.2 17.9 1.5 5.8 31.7 83.5 4.6 18.1 6.5 49.9 17.4 28.3 23.8 31.8 40.2 4.2 1.8 11.7 8.0 20.1 4.9 3.7 4.3 8.2 2.9 2.6 2.8 11.6 6.4 30.6 6.6 20.4 8.0 45.1 12.5 5.7 16.9 114.4 4.0 21.6 25.6 6.8 2.7 11.5 9.3 6.5 4.5 65.1 44.9 17.1 0.8 0.3 0.2 0.0 8.2 1.9 0.3 0.7 0.2 0.0 2.1 0.5 0.2 8.8 12.1 9.4 8.8 2.3 0.0 0.0 5.1 13.2 0.5 0.0 0.1 0.0 2.0 0.0 0.3 0.0 5.6 1.6 15.9 0.0 0.0 0.1 0.0 3.6 0.1 5.2 6.6 7.2 0.0 0.0 4.4 0.0 18.0 0.4 0.6 0.0 1.1 4.1 0.8 0.4 0.6 0.0 0.0 0.1 1.6 0.8 0.3 3.3 0.3 0.0 37.8 0.0 6.4 8.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.1 0.0 0.1 0.2 0.0 10.7 3.9 0.8 0.1 17.1 8.2 3.3 0.3 0.0 0.1 0.8 5.2 1.9 3.4 4.5 1.5 5.8 4.2 1.8 3.7 4.3 6.4 2.7 20.8 9.6 4.9 0.2 8.4 0.0 67.6 2.5 1.4 2.3 0.0 0.0 0.5 0.0 0.8 1.3 62.4 0.0 0.0 0.2 10.4 16.2 0.1 2.3 14.0 0.9 0.0 0.0 124.0 7.2 1.4 18.4 3.4 10.1 0.0 0.0 0.1 0.7 0.0 46.7 0.0 1.0 25.8 49.1 0.5 1.4 5.8 0.8 1.3 0.0 0.3 LIMS3 ENSG00000256977 "LIM zinc finger domain containing 3" P0CW19 2 109898428-109924868 "Predicted intracellular proteins" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "blood: 11.9;endometrium 1: 9.7" "Cell type enhanced" "Detected in some" 11 "Cardiomyocytes: 1.7;Club cells: 1.2;Distal tubular cells: 1.7;Exocrine glandular cells: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "eosinophil: 11.9" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HEL: 9.8;HMC-1: 29.8" HPA058455 Uncertain Approved "Focal adhesion sites,Cytosol" NA NA Cytosol "Focal adhesion sites" "HPA058455: AB_2683723" "unprognostic (2.23e-2)" 1.2 2.8 0.5 2.2 0.5 0.0 1.0 0.8 0.5 1.0 0.7 0.3 4.2 0.2 9.7 2.8 1.2 7.1 0.9 2.6 0.5 0.5 2.6 0.6 0.8 2.8 0.6 0.3 2.2 0.7 0.3 2.4 5.6 0.3 1.0 0.8 0.6 2.2 0.6 3.0 0.8 0.5 1.2 0.6 0.6 0.7 3.7 0.3 0.3 1.0 0.3 0.3 2.6 0.7 0.7 2.5 11.9 5.5 1.1 6.2 8.0 0.0 0.1 1.3 1.5 0.5 0.4 0.0 1.5 0.0 0.2 0.7 1.5 0.0 0.0 4.7 0.3 3.1 0.8 0.0 1.8 1.3 2.4 0.0 9.8 0.5 0.9 1.4 1.7 29.8 2.2 1.1 1.1 1.3 0.0 2.4 0.0 2.0 1.6 3.3 0.1 0.0 0.2 1.6 0.9 0.6 1.8 3.1 1.0 0.8 1.5 0.4 3.6 4.0 0.0 0.8 0.0 0.0 0.5 7.3 6.4 5.9 3.3 0.3 0.0 0.0 1.9 0.8 0.0 1.9 4.7 3.3 11.9 0.9 5.5 1.5 0.7 5.0 1.7 2.5 0.2 0.9 0.3 0.7 1.1 5.2 0.2 6.2 8.0 0.5 0.5 0.8 0.5 0.5 0.5 0.6 0.3 0.3 0.3 0.0 0.3 0.0 0.1 0.1 0.0 1.7 0.0 0.0 1.2 0.0 0.0 0.0 1.7 0.0 0.0 0.3 0.0 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 LIMS4 LIMS3L ENSG00000256671 "LIM zinc finger domain containing 4" P0CW20 2 110446640-110473075 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in single" 26 "Exocrine glandular cells: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+: 2.7;HHSteC: 2.5;hTEC/SVTERT24-B: 4.9;HUVEC TERT2: 2.8;U-138 MG: 5.3" HPA058455 Uncertain Uncertain "Focal adhesion sites,Cytosol" NA NA Cytosol "Focal adhesion sites" "HPA058455: AB_2683723" "unprognostic (2.12e-1)" 4.0 4.1 0.0 0.3 0.0 0.6 1.5 0.0 0.3 0.3 0.6 0.3 4.1 0.3 0.3 3.7 0.3 3.5 0.0 0.0 5.5 2.7 0.8 0.3 0.0 1.9 2.2 0.3 0.8 0.6 0.3 0.3 0.3 0.3 5.6 0.4 0.3 0.3 0.0 0.3 0.3 1.3 1.1 0.3 0.3 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.5 2.7 0.2 0.7 0.7 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 4.9 0.0 0.0 2.8 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 5.3 0.2 0.0 0.2 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 LMLN "Gp63, LMNL1, Msp" ENSG00000185621 "Leishmanolysin like peptidase" Q96KR4 3 197960200-198043720 "Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, Cell division, Mitosis" "Hydrolase, Metalloprotease, Protease" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Ciliated cells: 32.1;Early spermatids: 29.2;Spermatocytes: 29.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016481, HPA028844" Uncertain Supported "Focal adhesion sites,Cytosol" NA NA Cytosol "Focal adhesion sites" "HPA016481: AB_1852955, HPA028844: AB_10602347" "unprognostic (2.54e-1)" "unprognostic (3.15e-1)" "unprognostic (7.63e-2)" "prognostic favorable (6.77e-4)" "unprognostic (1.14e-2)" "unprognostic (1.19e-1)" "unprognostic (1.30e-1)" "unprognostic (4.07e-2)" "unprognostic (1.94e-1)" "unprognostic (2.31e-1)" "unprognostic (6.36e-2)" "unprognostic (2.98e-1)" "unprognostic (4.82e-3)" "unprognostic (8.78e-2)" "unprognostic (7.65e-2)" "unprognostic (1.01e-1)" "unprognostic (1.63e-1)" 3.9 4.9 5.2 2.5 11.0 2.3 4.5 6.1 9.1 6.2 3.5 5.8 14.3 2.2 4.8 20.3 3.5 9.3 5.1 5.9 5.7 7.4 6.6 3.7 8.1 3.5 5.6 8.9 6.5 6.1 8.8 15.0 3.9 11.6 4.6 4.1 5.4 4.2 11.7 3.7 6.5 2.3 4.0 5.5 3.0 3.9 27.0 4.4 1.2 7.6 3.0 2.6 3.5 3.7 1.9 1.9 0.8 2.4 1.8 2.4 1.2 6.5 2.5 2.9 3.5 5.8 8.2 2.5 3.4 3.1 6.1 5.1 2.4 2.4 2.1 15.8 2.4 13.3 2.5 2.7 2.7 9.0 0.3 2.0 1.2 2.1 1.8 3.6 3.6 1.8 3.9 6.1 7.6 5.0 3.6 2.6 5.3 6.3 4.0 5.9 4.8 2.2 3.2 3.3 4.7 5.9 2.5 0.7 2.2 6.3 1.7 4.8 1.4 4.7 4.2 3.4 3.5 11.0 2.8 5.7 7.6 1.1 9.1 5.7 7.1 13.7 0.6 10.8 6.4 6.8 0.2 0.6 0.5 1.2 2.4 1.7 1.9 0.8 1.6 1.9 1.1 2.2 2.4 0.8 1.8 0.9 0.5 0.0 1.2 5.2 11.0 6.1 9.1 5.7 7.4 5.6 8.9 11.6 4.4 14.9 11.3 1.9 1.5 1.8 7.7 9.2 2.5 32.1 13.6 8.7 15.7 2.5 0.0 2.5 29.2 2.5 1.0 0.0 2.3 2.1 3.3 1.9 2.3 2.4 4.2 7.9 4.6 4.3 2.8 18.6 4.4 2.0 3.3 0.0 3.1 7.7 1.8 0.0 5.3 3.7 16.3 0.0 3.2 29.2 24.7 1.5 2.4 1.3 2.3 1.3 LPP ENSG00000145012 "LIM domain containing preferred translocation partner in lipoma" Q93052 3 188153284-188890671 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 127.8;urinary bladder: 105.1" "Cell type enhanced" "Detected in all" 11 "Early spermatids: 514.4;Late spermatids: 1329.9;Smooth muscle cells: 529.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 18.0" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 29.5;EFO-21: 36.6;U-698: 61.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011133, HPA017342" Enhanced Enhanced "Focal adhesion sites,Cytosol" NA NA 520000 "Focal adhesion sites, Cytosol" "HPA011133: AB_1853247, HPA017342: AB_1853249" "unprognostic (1.50e-1)" "unprognostic (4.97e-3)" "unprognostic (1.41e-1)" "unprognostic (2.18e-1)" "unprognostic (1.86e-1)" "unprognostic (4.05e-1)" "unprognostic (2.43e-3)" "unprognostic (7.97e-2)" "unprognostic (2.17e-1)" "unprognostic (5.56e-2)" "unprognostic (3.44e-3)" "unprognostic (2.10e-1)" "unprognostic (2.57e-3)" "unprognostic (2.25e-2)" "unprognostic (6.86e-2)" "unprognostic (2.82e-3)" "unprognostic (1.48e-1)" 19.6 4.2 2.7 29.5 2.8 3.1 12.5 3.0 2.7 42.2 29.9 2.1 19.6 5.0 68.6 14.9 59.7 10.0 37.9 9.3 2.6 2.8 10.9 5.3 11.4 6.0 2.8 1.6 26.1 4.4 4.7 3.2 5.2 3.0 37.7 12.8 8.5 7.0 28.4 11.6 5.9 17.2 127.8 3.2 9.5 12.1 30.7 1.5 5.1 5.4 4.2 7.8 105.1 38.3 5.9 4.9 18.0 4.5 4.3 5.0 1.4 7.7 7.1 5.2 3.5 11.3 11.7 5.6 5.1 6.5 3.7 2.5 12.9 3.7 29.5 36.6 11.4 4.6 3.3 1.5 3.4 9.4 3.2 1.7 1.4 5.5 3.4 4.8 0.6 1.7 8.3 4.8 8.3 7.2 5.4 6.2 1.6 0.0 0.6 6.5 2.4 1.5 0.6 2.1 4.9 2.3 1.9 3.9 0.1 4.1 8.2 0.3 0.0 10.9 3.6 6.1 9.0 2.8 2.4 13.4 8.6 6.6 6.1 12.5 0.0 1.1 61.0 4.3 1.3 7.7 0.8 4.5 1.9 5.0 4.2 3.2 2.9 4.3 3.6 2.4 5.9 2.3 2.9 18.0 4.3 4.0 4.9 1.6 1.4 2.7 2.8 3.0 2.7 2.6 2.8 2.8 1.6 3.0 1.5 83.4 55.0 41.3 72.1 69.3 7.7 101.6 99.3 40.2 83.0 66.3 13.7 35.7 24.9 114.3 514.4 83.0 142.7 23.3 78.6 20.6 102.9 124.2 17.4 84.7 36.8 4.8 74.4 114.2 61.5 1329.9 208.5 76.2 75.9 36.1 86.3 27.1 104.6 158.4 448.3 61.0 7.4 329.8 529.6 8.1 6.6 59.6 15.6 39.5 123.5 109.3 LPXN LDPL ENSG00000110031 Leupaxin O60711 11 58526871-58578220 "Predicted intracellular proteins" "Cell adhesion, Transcription, Transcription regulation" Activator "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 42.0;lymphoid tissue: 75.1" "Cell type enhanced" "Detected in many" 6 "granulocytes: 51.8;Kupffer cells: 53.4;Macrophages: 67.3;T-cells: 74.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ hTERT+: 40.0;HMC-1: 67.0;Karpas-707: 57.4;U-2197: 40.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043741, CAB046478, HPA061441" Enhanced Supported "Nuclear speckles,Focal adhesion sites,Cytosol" No No "Focal adhesion sites" "Nuclear speckles, Cytosol" "CAB046478: AB_10603113, HPA043741: AB_2678647, HPA061441: AB_2684518" "unprognostic (1.61e-3)" "unprognostic (6.91e-2)" "unprognostic (6.54e-2)" "prognostic favorable (8.81e-4)" "unprognostic (5.16e-2)" "unprognostic (2.07e-3)" "unprognostic (2.16e-2)" "unprognostic (8.87e-3)" "unprognostic (5.18e-2)" "unprognostic (3.96e-2)" "unprognostic (2.39e-2)" "unprognostic (3.05e-1)" "unprognostic (3.60e-3)" "unprognostic (1.91e-1)" "unprognostic (5.25e-2)" "unprognostic (2.55e-1)" "unprognostic (2.41e-3)" 16.3 5.6 5.1 34.2 4.7 4.2 5.1 3.5 4.9 4.4 6.7 9.0 4.1 5.1 6.5 5.9 3.8 4.7 7.2 3.9 5.2 5.1 6.3 7.1 19.7 37.2 6.3 2.5 6.6 5.6 3.9 4.8 2.6 5.0 5.7 9.6 6.2 7.6 5.1 2.1 3.7 16.0 4.7 11.4 32.2 5.7 5.9 4.9 75.1 6.8 4.4 52.9 11.2 3.9 19.9 36.5 3.8 19.1 20.1 42.0 20.9 0.3 0.4 0.4 0.7 1.5 1.9 0.2 10.0 40.0 2.5 4.5 0.0 1.0 29.2 0.4 12.1 1.8 0.3 0.3 27.2 10.5 12.7 0.1 1.3 0.2 0.1 2.6 7.9 67.0 1.5 0.6 34.5 4.5 2.4 16.1 17.9 0.3 57.4 20.2 0.2 27.6 9.9 0.3 0.4 9.1 0.4 0.5 25.1 1.6 14.0 0.2 0.3 0.4 0.6 3.9 0.6 0.5 2.3 15.7 6.3 1.8 40.3 8.9 3.7 3.5 28.7 14.6 7.1 14.2 1.7 19.1 3.1 28.2 11.0 42.0 19.9 29.0 32.4 36.5 11.5 22.6 26.8 3.8 20.1 5.6 33.1 38.7 20.9 5.1 4.7 3.5 4.9 5.2 5.1 6.3 2.5 5.0 4.9 0.0 7.0 47.0 4.0 8.7 3.4 1.6 0.0 4.0 2.3 0.0 3.9 2.3 3.3 2.2 22.9 8.0 4.7 0.0 4.9 1.1 4.5 3.3 51.8 6.7 46.1 1.6 5.8 2.5 53.4 6.2 1.7 67.3 18.6 36.9 2.9 4.1 2.8 4.9 3.5 4.2 4.7 6.5 4.1 7.4 4.1 8.4 2.1 74.6 5.2 26.4 LRCH4 "LRN, LRRN1" ENSG00000077454 "Leucine rich repeats and calponin homology domain containing 4" O75427 7 100574011-100586153 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Early spermatids: 153.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 45.7;NB-4: 70.7" "Low region specificity" "Detected in all" "HPA037667, HPA037668" Enhanced Approved "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA "Nucleoplasm, Focal adhesion sites, Cytosol" "HPA037667: AB_10671882, HPA037668: AB_10672910" "unprognostic (2.41e-1)" "unprognostic (2.53e-2)" "prognostic unfavorable (1.61e-7)" "unprognostic (8.32e-3)" "unprognostic (2.76e-2)" "unprognostic (3.96e-3)" "unprognostic (8.98e-3)" "unprognostic (3.72e-2)" "unprognostic (2.52e-1)" "unprognostic (5.51e-2)" "unprognostic (2.63e-3)" "unprognostic (7.81e-2)" "unprognostic (1.95e-1)" "unprognostic (1.77e-1)" "unprognostic (1.40e-2)" "unprognostic (7.96e-2)" "unprognostic (1.26e-2)" 11.4 15.2 14.5 32.0 25.7 52.7 13.8 19.7 22.2 12.0 14.0 16.4 11.8 22.0 12.3 9.6 14.4 14.0 15.9 10.2 16.2 9.1 16.1 12.2 20.8 39.1 25.8 13.1 23.7 17.3 8.9 22.8 26.4 19.2 14.6 7.2 18.3 23.5 13.0 15.8 15.0 27.8 8.1 25.7 54.5 14.9 43.3 23.1 31.1 20.0 6.8 25.2 9.9 12.0 5.9 6.2 24.2 8.4 1.4 7.3 2.9 7.9 4.5 4.5 4.0 2.7 2.1 8.6 7.7 3.5 4.5 3.7 7.5 11.7 5.8 8.7 2.3 4.8 6.9 2.2 3.2 1.3 5.7 6.0 6.6 5.3 3.5 8.6 11.4 45.7 3.5 3.5 3.8 2.1 2.9 4.6 15.2 8.2 11.9 3.2 15.0 13.1 70.7 4.7 7.4 5.3 14.6 3.7 7.1 3.5 2.8 5.9 8.8 3.7 11.8 9.0 6.1 7.9 24.9 7.2 6.2 11.3 8.6 4.6 12.1 5.7 5.2 4.8 28.3 10.6 12.6 8.4 11.9 5.2 6.8 4.7 4.7 5.1 5.9 6.2 5.9 7.3 5.9 24.2 1.4 4.7 5.9 5.2 2.9 14.5 25.7 19.7 22.2 16.2 9.1 25.8 13.1 19.2 23.1 8.9 16.7 24.7 13.8 10.6 13.6 0.7 25.5 6.7 6.8 21.0 39.3 33.4 13.3 27.1 153.1 9.5 22.2 0.0 21.3 11.2 9.5 12.1 18.5 11.3 30.3 12.7 5.8 15.4 53.4 19.7 23.0 33.3 13.5 52.3 12.9 15.5 23.1 14.0 9.6 6.2 29.9 19.4 12.2 42.6 28.7 10.0 86.4 42.9 11.0 14.2 MISP "C19orf21, Caprice, DKFZp686H18209, MISP1" ENSG00000099812 "Mitotic spindle positioning" Q8IVT2 19 751126-764318 "Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "gallbladder: 24.6;intestine: 63.8" "Group enriched" "Detected in many" 5 "Enterocytes: 892.4;Paneth cells: 434.9" "Cancer enhanced" "Detected in many" "colorectal cancer: 133.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 37.2;HaCaT: 27.6;hTCEpi: 25.9;MCF7: 19.0;OE19: 23.2;SK-BR-3: 42.0" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049511, HPA062232" Enhanced Enhanced "Plasma membrane,Focal adhesion sites" No No "Plasma membrane, Focal adhesion sites" "HPA049511: AB_2680798, HPA062232: AB_2684719" "unprognostic (7.48e-2)" "unprognostic (2.04e-1)" "unprognostic (1.44e-1)" "unprognostic (3.99e-2)" "unprognostic (1.02e-1)" "unprognostic (6.50e-2)" "unprognostic (1.78e-3)" "unprognostic (1.64e-2)" "unprognostic (8.64e-2)" "unprognostic (1.49e-1)" "unprognostic (2.56e-3)" "unprognostic (2.09e-1)" "unprognostic (1.19e-3)" "unprognostic (6.78e-3)" "unprognostic (2.29e-1)" "unprognostic (4.80e-1)" "unprognostic (5.27e-2)" 0.5 0.1 0.3 7.9 0.3 0.0 0.7 0.2 0.2 1.5 42.8 0.2 0.2 45.9 0.7 0.8 0.4 2.4 24.6 0.2 0.5 0.2 6.9 0.4 6.8 0.2 0.3 0.3 2.2 2.0 0.0 4.2 2.1 0.2 2.2 13.0 0.2 0.5 0.5 0.2 0.3 63.8 0.7 0.2 0.2 5.8 0.2 0.2 0.3 0.2 0.8 0.2 1.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.0 37.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 12.8 13.7 3.2 3.6 0.0 0.0 27.6 0.0 11.6 0.0 0.0 0.0 0.0 14.6 3.9 0.0 0.0 0.5 0.0 25.9 0.1 1.4 0.0 0.0 0.0 0.0 0.1 0.0 19.0 0.0 0.2 0.0 23.2 7.6 0.0 0.1 0.3 9.3 10.3 0.4 0.1 13.2 42.0 0.0 0.0 9.1 0.0 0.0 0.0 4.7 0.5 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.2 0.5 0.2 0.3 0.3 0.2 0.2 35.7 10.1 2.2 4.0 0.1 0.0 0.4 2.5 26.8 15.9 10.4 0.0 0.3 1.7 48.8 0.4 0.0 892.4 0.0 41.8 2.6 0.3 34.5 9.2 0.0 0.1 0.0 55.7 0.0 0.0 0.7 0.0 0.8 0.0 1.0 139.5 0.0 94.0 434.9 0.0 21.7 0.0 0.0 0.0 0.0 1.5 0.3 1.7 0.0 93.0 40.9 MMP28 "EPILYSIN, MM28, MMP-25, MMP-28" ENSG00000271447 "Matrix metallopeptidase 28" Q9H239 17 35756249-35795707 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Basal keratinocytes: 34.2;Enterocytes: 39.1;Mucus-secreting cells: 31.9;Paneth cells: 47.6;Urothelial cells: 34.5" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 7.2;naive CD8 T-cell: 5.9" "Lineage enriched" "Detected in many" 5 "T-cells: 7.2" "Cell line enriched" "Detected in some" 7 "HaCaT: 28.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA057288, HPA057890" Approved "Nucleoplasm,Focal adhesion sites" "Secreted to extracellular matrix" NA NA Nucleoplasm "Focal adhesion sites" "HPA057288: , HPA057890: " "unprognostic (7.99e-3)" "unprognostic (3.27e-1)" "unprognostic (2.20e-1)" "unprognostic (1.01e-1)" "unprognostic (7.52e-2)" "unprognostic (1.63e-1)" "unprognostic (6.90e-2)" "unprognostic (1.09e-2)" "unprognostic (1.51e-1)" "unprognostic (1.99e-1)" "prognostic unfavorable (6.28e-6)" "unprognostic (9.37e-2)" "unprognostic (1.31e-1)" "unprognostic (8.87e-2)" "unprognostic (1.74e-1)" "unprognostic (1.76e-2)" "unprognostic (3.27e-3)" 8.0 1.6 1.8 2.7 3.7 0.5 4.3 0.0 5.1 1.7 7.3 1.6 1.4 3.0 3.2 4.8 4.3 1.5 12.3 0.5 2.8 0.8 0.2 10.3 0.4 0.0 2.9 0.1 1.3 0.5 0.0 0.7 1.3 2.9 4.1 2.7 0.1 2.1 0.6 4.5 9.3 4.3 0.2 0.6 7.2 13.4 0.2 0.0 4.2 4.4 2.5 5.5 2.2 1.1 1.5 0.1 0.2 1.3 7.2 0.9 0.1 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.1 0.7 0.0 0.1 28.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.1 0.0 0.0 0.0 2.6 0.0 0.1 0.0 0.2 0.2 0.0 0.1 0.0 0.2 0.1 0.2 0.0 3.9 0.2 0.6 0.0 0.0 0.0 1.6 0.2 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 2.0 1.1 0.4 1.7 0.1 0.9 7.2 5.9 0.1 1.3 0.2 1.5 0.0 0.9 26.8 20.8 0.0 5.1 34.2 0.4 1.0 2.5 5.3 5.7 7.0 0.0 0.0 0.0 0.1 5.0 8.1 39.1 0.0 0.3 0.0 1.6 1.8 0.0 0.0 0.1 1.6 3.5 6.2 0.0 7.1 1.1 0.9 3.3 0.0 31.9 9.1 9.7 47.6 2.8 0.7 0.5 6.5 2.0 0.5 2.5 29.0 0.0 0.7 18.5 34.5 MTSS1L "ABBA, ABBA-1, LOC92154" ENSG00000132613 "MTSS1L, I-BAR domain containing" Q765P7 16 70661204-70686066 "Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 105.5" "Cell type enhanced" "Detected in many" 10 "Extravillous trophoblasts: 36.3;Hepatocytes: 24.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "MAIT T-cell: 2.4;plasmacytoid DC: 2.3" "Group enriched" "Detected in many" 7 "dendritic cells: 2.3;T-cells: 2.4" "Cell line enhanced" "Detected in many" "Hep G2: 62.0;HHSteC: 61.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048531, HPA066469" Approved Supported "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA048531: AB_2680430, HPA066469: AB_2685671" "prognostic unfavorable (2.85e-4)" "unprognostic (8.85e-2)" "unprognostic (7.01e-2)" "unprognostic (5.99e-2)" "unprognostic (3.21e-1)" "unprognostic (2.98e-1)" "unprognostic (1.86e-1)" "unprognostic (1.82e-1)" "unprognostic (5.30e-2)" "unprognostic (1.31e-1)" "unprognostic (5.59e-3)" "unprognostic (3.88e-1)" "unprognostic (2.92e-3)" "unprognostic (9.87e-2)" "unprognostic (9.92e-2)" "unprognostic (6.74e-2)" "unprognostic (2.25e-2)" 17.2 13.4 61.9 11.1 47.6 4.9 6.4 68.3 105.5 22.5 15.5 59.5 4.1 8.1 29.5 4.1 27.4 17.5 15.8 16.8 70.3 45.6 6.8 21.7 12.9 5.5 50.2 38.7 14.5 7.9 7.7 5.2 19.0 40.7 15.5 5.2 11.8 16.1 21.6 37.2 15.8 7.8 31.6 53.5 19.2 6.7 6.2 53.3 8.2 4.5 5.2 4.8 20.8 10.0 0.3 2.3 0.2 0.1 0.0 2.4 0.4 13.8 33.4 8.4 8.6 7.0 7.0 31.7 20.9 26.2 18.0 15.0 13.4 8.9 0.1 7.5 32.7 7.1 29.0 9.0 9.1 6.9 0.2 12.1 4.8 28.4 62.0 61.7 7.1 0.2 28.6 20.0 8.3 29.0 7.8 5.9 7.4 18.1 0.3 15.9 34.4 6.8 36.7 7.3 4.7 7.1 14.6 15.6 0.0 15.7 20.8 19.8 13.2 44.7 19.5 5.8 8.3 15.0 14.0 8.8 14.1 16.0 12.7 13.0 5.0 1.2 0.2 12.8 0.2 4.8 0.0 0.1 0.2 0.1 0.0 2.4 0.2 0.0 0.0 0.2 0.3 0.0 0.5 0.0 0.0 0.0 2.3 0.0 0.4 61.9 47.6 68.3 52.3 70.3 45.6 50.2 38.7 40.7 53.3 0.0 1.3 0.0 3.4 5.4 0.0 6.7 0.0 2.7 1.2 1.8 0.0 2.5 3.3 4.3 3.5 2.1 0.0 0.0 0.5 36.3 4.0 4.6 1.1 24.1 7.1 0.0 2.9 13.5 1.6 5.2 4.0 0.0 5.0 0.0 4.5 0.0 0.9 0.0 3.2 1.7 0.0 0.0 5.9 0.5 1.1 5.6 5.1 0.0 1.2 3.9 MYO5A "GS1, MYH12, MYO5, MYR12" ENSG00000197535 "Myosin VA" Q9Y4I1 15 52307283-52529050 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Protein transport, Transport" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.5;parathyroid gland: 47.6" "Cell type enhanced" "Detected in many" 7 "Bipolar cells: 82.8;Melanocytes: 92.8" "Cancer enhanced" "Detected in all" "melanoma: 25.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Karpas-707: 60.0;RPMI-8226: 40.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001356 Enhanced Approved "Focal adhesion sites,Centriolar satellite" NA NA "Focal adhesion sites, Centriolar satellite" "HPA001356: AB_1079441" "unprognostic (1.54e-1)" "unprognostic (1.78e-1)" "unprognostic (6.95e-2)" "unprognostic (2.29e-2)" "unprognostic (1.97e-2)" "unprognostic (3.91e-2)" "unprognostic (2.30e-2)" "unprognostic (6.65e-2)" "unprognostic (7.89e-2)" "unprognostic (4.74e-2)" "unprognostic (9.36e-3)" "unprognostic (1.71e-1)" "unprognostic (5.63e-3)" "unprognostic (3.79e-3)" "unprognostic (1.24e-1)" "unprognostic (7.16e-2)" "prognostic unfavorable (4.22e-4)" 8.4 7.1 16.6 9.5 27.5 15.7 5.5 27.4 34.5 6.2 4.4 7.8 0.4 3.3 4.2 3.2 5.0 3.6 7.3 4.6 15.9 15.4 4.6 2.7 7.3 11.2 15.6 17.6 5.4 4.3 47.6 10.5 5.2 29.3 4.5 5.2 9.9 4.0 3.4 4.1 10.4 3.9 7.7 10.1 7.3 4.1 4.6 7.1 3.1 6.8 2.7 10.3 7.3 4.2 2.3 5.2 6.3 4.4 0.7 4.5 1.9 5.5 9.8 5.2 6.3 5.3 6.5 5.6 10.1 9.1 5.4 4.2 0.9 2.2 5.3 2.6 12.0 7.9 4.6 12.0 10.4 6.7 30.0 2.8 4.9 2.5 1.2 2.7 2.6 4.8 4.3 6.5 7.9 15.8 5.3 31.4 3.5 0.1 60.0 10.4 9.8 2.3 0.3 2.4 0.1 7.8 4.2 8.4 40.7 4.4 4.0 3.8 2.3 9.4 7.8 18.3 4.0 4.1 2.9 15.0 10.9 4.7 5.1 9.8 6.2 13.8 6.4 11.9 7.5 15.7 0.9 4.4 5.4 2.9 3.6 4.5 2.3 2.9 1.9 5.2 1.6 0.5 1.0 6.3 0.7 2.6 3.1 4.1 1.9 16.6 27.5 27.4 34.5 15.9 15.4 15.6 17.6 29.3 7.1 11.9 10.7 12.3 8.4 18.4 82.8 8.7 5.1 9.4 29.6 14.0 37.3 0.5 0.0 4.8 16.0 9.0 0.0 0.0 5.4 0.4 6.0 6.8 22.0 1.0 21.3 25.4 1.2 1.8 24.4 6.4 3.4 39.4 92.8 27.9 0.0 4.5 5.0 0.8 1.8 2.2 27.1 6.5 4.7 8.7 7.0 10.2 0.9 12.9 0.0 7.4 NOB1 "ART-4, MST158, NOB1P, PSMD8BP1" ENSG00000141101 "NIN1/PSMD8 binding protein 1 homolog" Q9ULX3 16 69741867-69754940 "Predicted intracellular proteins" "Endonuclease, Hydrolase, Nuclease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041522, HPA049430, HPA067411" Approved Approved "Focal adhesion sites,Cytosol" NA NA Cytosol "Focal adhesion sites" "HPA041522: , HPA049430: AB_2680764, HPA067411: " "unprognostic (5.11e-2)" "unprognostic (4.49e-2)" "unprognostic (3.15e-1)" "unprognostic (8.61e-3)" "unprognostic (9.45e-2)" "prognostic unfavorable (4.21e-5)" "prognostic unfavorable (8.16e-4)" "unprognostic (3.26e-2)" "unprognostic (3.04e-1)" "unprognostic (7.51e-2)" "unprognostic (1.04e-2)" "unprognostic (1.55e-1)" "unprognostic (1.01e-1)" "unprognostic (1.16e-2)" "unprognostic (1.23e-2)" "unprognostic (1.57e-1)" "unprognostic (1.16e-1)" 18.2 31.6 9.9 14.5 18.0 17.4 18.9 13.4 16.2 18.8 19.4 12.5 12.4 20.3 21.3 15.5 25.4 29.2 19.0 13.3 9.6 9.7 18.4 23.4 13.3 21.3 12.9 7.5 37.5 68.5 13.9 10.1 13.1 13.5 21.5 12.7 13.0 20.4 14.8 26.3 25.1 15.5 18.0 10.1 21.5 20.5 11.6 15.4 23.7 28.9 25.8 29.0 25.6 18.4 21.0 20.3 2.0 15.0 24.5 26.1 17.3 14.8 32.6 7.7 21.8 17.1 27.1 15.3 11.9 16.7 22.4 20.4 36.9 24.5 33.2 18.7 13.2 11.8 22.1 21.1 26.7 13.3 8.3 24.6 12.9 15.4 47.3 30.4 23.8 10.9 34.2 22.8 25.8 33.0 20.9 18.9 20.2 29.4 10.3 11.1 38.9 29.9 47.7 23.6 16.6 19.4 33.2 7.9 41.9 16.6 14.5 20.0 9.9 37.6 13.2 18.6 7.1 14.3 21.6 14.3 15.3 13.9 13.9 19.4 17.0 12.9 58.5 15.3 21.8 16.8 0.1 15.0 2.0 17.6 12.7 24.6 19.4 21.4 16.1 20.3 21.0 23.1 21.0 0.7 24.5 9.5 10.5 26.1 17.3 9.9 18.0 13.4 16.2 9.6 9.7 12.9 7.5 13.5 15.4 3.0 13.1 37.1 60.4 53.2 9.7 4.8 15.3 18.7 46.6 19.2 0.0 58.6 34.9 34.6 8.8 42.1 15.8 23.3 74.6 74.1 39.0 28.3 16.1 13.2 32.4 4.8 9.8 18.4 20.2 5.9 33.9 23.1 20.3 37.9 33.2 10.5 44.9 17.5 40.0 27.6 4.6 25.8 39.2 17.4 28.1 52.1 39.7 37.4 50.6 54.8 NUP214 "CAIN, CAN, D9S46E, N214" ENSG00000126883 "Nucleoporin 214" P35658 9 131125561-131234670 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 131.5" "Cell type enhanced" "Detected in many" 9 "Early spermatids: 225.7;Kupffer cells: 255.0;Late spermatids: 282.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 43.7;neutrophil: 131.5" "Group enriched" "Detected in many" 5 "granulocytes: 131.5;monocytes: 43.7" "Cell line enhanced" "Detected in all" "K-562: 73.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048789 Approved "Nucleoplasm,Vesicles,Focal adhesion sites" NA NA 100000 Nucleoplasm "Vesicles, Focal adhesion sites" "HPA048789: AB_2680521" "unprognostic (1.30e-1)" "unprognostic (9.51e-3)" "unprognostic (9.92e-3)" "unprognostic (1.15e-1)" "unprognostic (7.42e-2)" "unprognostic (8.31e-2)" "unprognostic (1.07e-3)" "unprognostic (2.10e-2)" "unprognostic (3.35e-1)" "unprognostic (4.95e-1)" "unprognostic (6.60e-3)" "unprognostic (1.08e-1)" "prognostic favorable (2.39e-5)" "unprognostic (5.49e-2)" "unprognostic (6.84e-2)" "unprognostic (1.82e-1)" "unprognostic (1.53e-1)" 16.9 10.3 11.5 13.8 13.9 29.4 12.9 13.0 14.4 10.2 11.4 19.8 10.4 9.0 15.0 13.7 16.1 12.1 10.2 9.7 9.5 8.1 19.0 15.1 11.7 13.3 13.2 8.8 14.2 17.0 16.7 16.9 13.0 11.3 11.1 10.8 15.3 13.0 11.1 15.5 17.5 11.7 11.1 14.3 35.8 12.3 63.7 13.3 27.4 11.8 7.6 16.8 10.7 11.2 1.2 16.8 131.5 43.7 1.2 0.8 17.9 6.8 9.8 8.4 5.0 6.8 6.6 8.8 6.1 6.3 8.0 6.5 8.0 5.0 11.1 4.9 8.4 8.3 15.7 11.3 8.0 7.8 8.0 5.5 6.9 14.0 15.6 6.0 10.8 7.5 7.1 7.4 10.2 8.3 5.1 8.1 7.4 73.0 6.4 8.2 12.8 14.2 16.4 9.1 9.9 8.6 5.0 10.6 11.1 9.2 6.3 7.1 7.4 10.2 9.4 5.3 6.3 12.4 27.0 7.0 14.1 7.9 9.2 9.9 5.6 10.9 10.8 6.9 6.5 8.5 3.5 43.7 17.3 0.7 18.4 0.8 1.2 0.7 0.6 16.8 1.1 0.7 0.7 131.5 1.2 15.0 1.5 0.4 17.9 11.5 13.9 13.0 14.4 9.5 8.1 13.2 8.8 11.3 13.3 17.9 19.9 15.2 9.5 7.7 29.6 24.0 15.3 16.0 15.9 22.7 43.2 10.9 8.3 9.1 225.7 14.6 13.6 0.0 13.1 9.3 11.4 11.4 8.1 11.9 75.5 15.9 19.5 18.4 255.0 282.5 21.6 77.0 10.1 15.4 14.3 14.8 12.0 5.8 19.1 6.7 31.6 6.5 8.1 90.1 44.5 9.5 9.2 11.8 16.3 9.3 PALMD "C1orf11, FLJ20271, PALML" ENSG00000099260 Palmdelphin Q9NP74 1 99645943-99694541 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 84.9;skeletal muscle: 106.9" "Cell type enhanced" "Detected in many" 9 "Cardiomyocytes: 153.8;Ciliated cells: 174.0;Endothelial cells: 169.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HUVEC TERT2: 43.5;LHCN-M2: 14.0;TIME: 60.9;U-87 MG: 26.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017959, HPA030549" Supported Supported "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Actin filaments" "Plasma membrane, Focal adhesion sites" "HPA017959: AB_1854949, HPA030549: AB_2673518" "unprognostic (1.48e-2)" "unprognostic (1.15e-2)" "unprognostic (2.05e-2)" "prognostic favorable (9.42e-4)" "unprognostic (7.67e-2)" "prognostic favorable (5.90e-5)" "unprognostic (1.54e-2)" "unprognostic (2.10e-1)" "unprognostic (3.93e-2)" "unprognostic (1.64e-1)" "unprognostic (8.32e-2)" "unprognostic (6.18e-2)" "unprognostic (5.19e-2)" "unprognostic (1.63e-2)" "unprognostic (1.88e-1)" "unprognostic (2.70e-1)" "unprognostic (8.08e-2)" 84.9 18.6 8.3 6.2 4.3 0.0 46.4 1.1 3.7 17.1 6.5 3.9 4.0 1.3 18.6 10.1 16.2 8.7 5.3 59.0 5.6 3.4 5.1 20.9 10.6 3.4 3.9 3.8 17.4 2.2 4.4 4.7 16.8 19.0 8.1 2.6 7.9 34.0 4.4 106.9 18.0 3.5 12.2 4.1 2.3 2.8 7.5 2.2 2.1 3.4 48.2 6.2 6.9 11.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.6 0.7 0.1 3.0 0.0 0.1 0.0 0.0 0.0 0.0 5.7 7.3 0.0 0.0 0.0 1.1 0.5 0.0 0.0 1.2 43.5 0.0 6.1 0.0 14.0 0.1 0.0 0.0 0.0 0.4 1.9 0.0 10.9 0.0 0.0 2.2 0.2 0.1 0.0 2.8 0.0 0.3 0.6 0.0 60.9 0.0 0.1 4.7 0.0 0.0 0.0 0.0 26.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 4.3 1.1 3.7 5.6 3.4 3.9 3.8 19.0 2.2 6.0 9.3 0.0 9.8 34.2 0.2 153.8 35.7 174.0 45.5 3.5 0.0 0.2 5.0 7.1 73.5 169.5 0.0 0.0 0.2 0.4 4.8 4.7 1.1 55.2 0.5 3.2 1.7 58.9 1.3 7.9 8.6 1.7 23.6 0.0 0.0 54.8 2.5 0.0 22.6 0.0 2.1 0.0 6.1 0.5 0.2 40.7 0.2 0.0 0.0 0.7 PARVA "FLJ10793, FLJ12254, MXRA2" ENSG00000197702 "Parvin alpha" 11 12377185-12530801 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "MAIT T-cell: 4.0;memory CD4 T-cell: 1.3" "Lineage enriched" "Detected in single" 40 "T-cells: 4.0" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 53.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005964 Approved Supported "Actin filaments,Focal adhesion sites,Cytosol" NA NA "Actin filaments, Focal adhesion sites" Cytosol "HPA005964: AB_1079569" "unprognostic (3.87e-2)" "unprognostic (7.38e-2)" "unprognostic (3.30e-2)" "prognostic favorable (1.76e-4)" "unprognostic (7.37e-3)" "unprognostic (1.38e-2)" "unprognostic (6.78e-2)" "prognostic unfavorable (8.19e-4)" "unprognostic (1.76e-2)" "unprognostic (2.80e-2)" "unprognostic (1.70e-2)" "unprognostic (9.82e-2)" "unprognostic (6.73e-2)" "unprognostic (6.58e-3)" "unprognostic (1.35e-1)" "unprognostic (1.50e-1)" "unprognostic (3.82e-2)" 30.5 8.3 7.1 14.4 6.5 0.0 44.0 3.9 8.3 29.2 39.2 3.5 25.8 6.9 40.5 17.6 27.0 17.2 35.2 21.3 6.4 5.3 15.3 10.7 13.2 8.5 5.3 7.8 22.7 16.2 10.1 6.3 16.3 5.5 31.7 16.4 18.3 13.4 35.1 6.4 7.7 13.1 55.9 5.0 8.4 24.2 8.4 2.8 0.4 10.5 8.1 5.0 38.8 33.4 0.0 0.0 0.0 0.0 0.0 4.0 0.1 7.7 7.7 7.2 9.3 36.8 28.6 16.7 29.7 30.7 21.0 19.7 5.7 12.1 0.0 9.9 53.9 2.3 4.8 0.1 15.5 25.1 0.1 3.9 0.0 10.9 4.3 28.3 0.0 0.2 22.5 6.3 8.8 13.8 26.1 26.1 0.0 0.0 0.0 31.2 4.6 0.0 0.0 3.3 4.6 6.7 0.0 17.9 0.0 11.6 7.6 1.1 0.0 22.8 9.2 15.3 16.8 4.3 0.2 32.2 25.4 10.6 13.6 8.1 0.0 0.0 0.0 14.1 0.0 27.9 0.0 0.0 0.0 0.5 0.0 4.0 0.0 1.3 0.4 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 7.1 6.5 3.9 8.3 6.4 5.3 5.3 7.8 5.5 2.8 92.3 24.1 1.7 21.5 12.2 1.5 37.0 20.4 69.6 28.4 26.2 0.0 36.9 33.2 52.3 0.4 35.1 27.4 0.0 58.4 78.2 48.2 29.5 4.7 15.3 5.7 0.0 26.0 40.5 1.6 0.9 38.0 2.5 43.9 1.8 21.5 21.4 55.2 21.0 48.8 29.7 2.1 51.8 48.4 1.1 3.4 7.9 15.9 3.8 29.3 20.3 PCDHGA2 PCDH-GAMMA-A2 ENSG00000081853 "Protocadherin gamma subfamily A, 2" Q9Y5H1 5 141338760-141512979 "Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in some" 13 "Bipolar cells: 2.7;Cardiomyocytes: 1.6;Leydig cells: 1.1;Peritubular cells: 2.5" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 9.8;BJ: 5.4;fHDF/TERT166: 6.3;HSkMC: 5.0;hTERT-RPE1: 5.8" "Low region specificity" "Detected in all" "HPA008755, HPA010580, HPA038625" Approved Approved "Nucleoplasm,Nucleoli,Vesicles,Plasma membrane,Focal adhesion sites,Cytosol" NA NA "Vesicles, Plasma membrane" "Nucleoplasm, Nucleoli, Focal adhesion sites, Cytosol" "HPA008755: AB_1079577, HPA010580: AB_2732401, HPA038625: AB_2732480" "unprognostic (2.43e-3)" "unprognostic (2.10e-2)" "unprognostic (1.32e-2)" "unprognostic (4.54e-1)" "unprognostic (2.92e-1)" "unprognostic (1.14e-1)" "unprognostic (3.01e-1)" "unprognostic (2.82e-1)" "unprognostic (1.56e-1)" "unprognostic (1.18e-1)" "unprognostic (9.01e-2)" "unprognostic (4.32e-2)" "unprognostic (8.45e-3)" "unprognostic (9.68e-3)" "unprognostic (1.04e-2)" "unprognostic (1.18e-2)" "unprognostic (2.23e-4)" 5.1 4.3 6.7 2.1 8.0 0.6 4.2 5.2 12.6 6.6 2.6 4.6 1.0 0.9 6.5 5.7 2.4 5.5 5.5 11.1 6.5 4.6 3.3 2.4 4.6 1.1 6.0 2.3 15.3 8.4 9.2 10.6 2.2 7.8 5.3 1.4 13.8 3.3 5.8 2.6 2.9 1.4 5.2 5.6 1.9 2.1 10.4 3.5 0.0 4.3 1.2 1.1 3.2 5.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.3 3.9 9.8 0.1 5.4 2.1 0.5 0.9 0.1 0.1 0.1 0.7 6.3 0.8 0.2 0.0 0.4 1.3 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 5.0 0.2 0.1 0.3 5.8 2.0 0.0 0.0 0.1 0.9 0.0 0.0 0.1 0.0 0.0 0.1 1.4 0.3 0.2 0.8 0.0 0.3 0.7 0.0 3.6 0.1 0.5 0.7 0.0 3.3 0.9 0.5 0.3 0.1 0.0 0.4 0.0 2.3 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.7 8.0 5.2 7.2 6.5 4.6 6.0 2.3 7.8 3.5 0.0 0.0 0.0 0.1 0.0 2.7 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.5 0.3 0.3 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 PCDHGB1 PCDH-GAMMA-B1 ENSG00000254221 "Protocadherin gamma subfamily B, 1" Q9Y5G3 5 141350102-141512979 "Predicted membrane proteins" "Cell adhesion" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in many" 6 "brain: 32.2;pituitary gland: 13.7" "Group enriched" "Detected in some" 17 "Early spermatids: 5.4;Late spermatids: 5.9;Melanocytes: 1.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 14 "naive CD8 T-cell: 1.3" "Lineage enriched" "Detected in single" 14 "T-cells: 1.3" "Cell line enhanced" "Detected in many" "ASC diff: 14.7;ASC TERT1: 7.7;hTERT-RPE1: 8.0;T-47d: 9.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008755, HPA010580, HPA076182" Uncertain Approved "Nucleoplasm,Vesicles,Plasma membrane,Focal adhesion sites,Midbody" Yes No "Vesicles, Plasma membrane" "Nucleoplasm, Focal adhesion sites, Midbody" "HPA008755: AB_1079577, HPA010580: AB_2732401, HPA076182: AB_2686783" "unprognostic (1.53e-2)" "unprognostic (1.94e-3)" "unprognostic (3.21e-1)" "unprognostic (4.38e-3)" "unprognostic (2.98e-1)" "unprognostic (8.36e-3)" "unprognostic (2.37e-1)" "unprognostic (9.57e-2)" "unprognostic (8.57e-2)" "unprognostic (1.06e-1)" "unprognostic (3.44e-2)" "unprognostic (4.78e-2)" "unprognostic (6.33e-2)" "unprognostic (3.15e-2)" "unprognostic (8.75e-2)" "unprognostic (1.93e-1)" "unprognostic (7.63e-3)" 2.3 2.7 8.2 1.4 7.5 1.0 2.1 4.3 32.2 2.5 1.4 9.4 0.1 1.2 3.7 2.0 1.7 1.9 2.1 2.2 7.6 5.7 2.1 1.3 2.4 1.2 5.5 5.0 4.1 2.8 1.4 13.7 1.6 7.0 2.5 1.4 2.6 1.7 3.1 1.1 1.4 1.3 3.0 6.9 1.4 1.2 1.5 5.6 0.0 2.5 0.0 1.2 1.4 1.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.1 2.0 1.8 0.0 14.7 7.7 0.1 1.4 3.6 0.5 0.8 0.2 0.5 0.5 4.7 0.5 3.5 0.6 0.4 0.2 0.5 0.0 0.9 0.0 0.2 1.3 0.2 0.0 0.1 1.2 0.0 0.0 0.0 8.0 0.1 0.0 0.2 0.2 3.3 1.8 0.4 0.3 0.2 0.0 0.0 0.0 2.7 0.1 0.0 0.0 1.1 0.8 0.0 0.9 0.1 1.5 9.6 0.0 1.1 0.2 1.6 1.2 0.0 0.0 2.6 0.3 2.9 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 8.2 7.5 4.3 9.6 7.6 5.7 5.5 5.0 7.0 5.6 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 1.7 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 PDLIM2 ENSG00000120913 "PDZ and LIM domain 2" Q96JY6 8 22578279-22598025 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 81.6" "Cell type enhanced" "Detected in many" 12 "Syncytiotrophoblasts: 663.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" HPA003880 Approved Supported "Actin filaments,Focal adhesion sites" NA NA "Actin filaments, Focal adhesion sites" "HPA003880: AB_1855149" "unprognostic (1.04e-1)" "unprognostic (3.53e-2)" "unprognostic (1.80e-2)" "unprognostic (1.03e-1)" "unprognostic (1.45e-3)" "unprognostic (9.33e-2)" "unprognostic (3.69e-2)" "unprognostic (4.55e-2)" "unprognostic (1.79e-2)" "unprognostic (1.22e-3)" "unprognostic (1.52e-1)" "unprognostic (3.37e-1)" "prognostic unfavorable (1.37e-7)" "unprognostic (6.14e-2)" "unprognostic (8.17e-2)" "unprognostic (3.47e-2)" "unprognostic (3.08e-3)" 10.4 7.0 5.4 10.9 5.9 6.0 10.4 16.2 7.9 19.8 27.6 8.4 7.7 17.8 11.1 11.0 41.1 9.0 19.9 10.1 6.3 5.0 20.9 16.4 26.5 17.2 6.9 7.1 13.1 15.6 2.2 5.7 42.3 10.8 11.2 3.2 11.3 12.4 10.0 53.5 48.8 32.2 16.2 10.1 81.6 5.6 8.5 5.0 7.5 5.5 23.4 21.0 12.7 23.2 9.6 12.4 49.3 20.2 8.7 16.4 10.2 22.9 14.2 9.6 16.9 19.0 32.6 10.9 36.4 27.3 26.2 26.6 16.2 3.8 9.5 10.3 32.8 4.8 11.7 5.4 24.8 5.1 0.0 3.7 2.9 9.3 11.7 24.1 3.3 23.1 34.7 3.1 12.8 3.5 20.7 14.3 5.3 0.8 6.2 17.7 12.1 4.2 3.9 7.9 9.7 1.4 3.4 1.8 1.0 4.6 4.7 3.0 7.2 7.6 20.8 32.9 6.0 7.3 6.7 17.7 28.5 29.4 34.1 16.6 0.1 0.2 3.0 29.4 13.2 20.9 22.7 15.5 49.3 16.4 20.2 14.6 8.4 12.4 16.1 12.4 9.6 8.6 12.2 32.9 8.7 19.4 8.0 12.8 10.2 5.4 5.9 16.2 7.9 6.3 5.0 6.9 7.1 10.8 5.0 71.5 9.6 36.7 11.1 84.4 2.3 7.6 22.9 0.0 18.2 17.4 0.0 44.5 13.3 24.7 0.8 39.4 132.3 23.3 23.2 92.2 139.6 25.2 27.6 40.4 50.0 3.2 1.2 92.7 45.1 1.5 122.3 51.2 45.5 1.8 8.4 19.8 61.5 119.3 205.1 104.7 3.1 58.2 92.0 0.7 4.5 88.1 663.2 89.7 11.3 15.2 PDLIM5 "Enh, LIM" ENSG00000163110 "PDZ and LIM domain 5" Q96HC4 4 94451857-94668227 "Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 129.6;skeletal muscle: 173.0" "Cell type enriched" "Detected in all" 8 "Cardiomyocytes: 1784.7" "Cancer enriched" "Detected in all" 8 "prostate cancer: 132.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in all" 4 "basophil: 51.1" "Lineage enriched" "Detected in all" 4 "granulocytes: 51.1" "Cell line enhanced" "Detected in all" "hTERT-RPE1: 51.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013511, HPA016740, HPA020026" Enhanced Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" NA NA 2200000 "Nucleoplasm, Plasma membrane, Focal adhesion sites" "CAB013511: AB_2533388, HPA016740: AB_1855153, HPA020026: AB_1855154" "unprognostic (6.20e-2)" "unprognostic (1.94e-1)" "unprognostic (2.81e-2)" "unprognostic (1.08e-2)" "unprognostic (6.61e-2)" "unprognostic (2.24e-1)" "unprognostic (1.33e-1)" "unprognostic (2.46e-2)" "unprognostic (7.60e-2)" "unprognostic (2.65e-1)" "unprognostic (1.18e-2)" "unprognostic (1.47e-1)" "unprognostic (1.24e-1)" "unprognostic (2.11e-2)" "unprognostic (3.15e-2)" "unprognostic (1.91e-1)" "unprognostic (1.04e-1)" 11.6 4.8 6.2 4.2 6.1 8.7 9.8 3.4 5.8 12.7 11.0 3.7 7.1 5.6 37.5 12.9 14.0 10.2 11.0 129.6 5.3 5.2 12.9 13.9 5.6 5.3 5.4 4.5 10.3 8.1 3.4 6.8 18.9 10.2 15.3 5.4 12.6 15.3 12.5 173.0 5.6 15.8 22.1 4.9 7.0 5.6 5.5 3.7 1.0 5.3 52.9 9.5 17.7 7.1 3.2 5.6 51.1 12.2 2.7 3.9 3.8 8.2 24.4 9.5 3.7 21.0 14.4 3.7 20.1 16.7 11.5 9.3 22.5 18.3 3.3 20.6 20.1 5.9 8.5 12.9 18.8 19.3 5.8 5.4 12.0 15.9 8.5 30.3 3.9 10.8 19.3 16.6 27.6 21.5 51.4 25.9 3.4 5.1 3.6 24.5 8.1 4.0 1.3 3.2 18.1 10.2 1.9 7.0 2.9 12.9 26.4 4.7 6.3 11.0 25.1 5.6 8.0 2.9 1.2 32.4 30.1 4.8 13.0 12.2 2.5 3.2 3.3 16.4 2.8 7.0 51.1 6.8 5.9 3.8 11.8 3.1 3.2 3.7 3.9 5.6 2.5 2.5 3.2 6.8 2.7 12.2 1.9 3.4 3.8 6.2 6.1 3.4 3.9 5.3 5.2 5.4 4.5 10.2 3.7 41.7 23.4 12.7 232.1 172.6 4.3 1784.7 58.6 30.8 37.5 47.1 29.5 9.2 11.6 82.1 14.6 128.1 146.3 23.3 81.9 91.7 90.4 234.4 50.8 159.4 34.4 1.6 105.0 135.1 57.1 6.8 38.3 60.2 59.1 29.7 89.1 79.1 115.5 83.5 62.6 63.8 35.6 77.6 141.3 13.2 30.2 137.1 19.9 15.0 51.0 185.7 PDLIM7 ENIGMA ENSG00000196923 "PDZ and LIM domain 7" Q9NR12 5 177483394-177497606 "Predicted intracellular proteins" "Differentiation, Osteogenesis" "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 159.6" "Cell type enhanced" "Detected in many" 6 "Ductal cells: 173.8;Exocrine glandular cells: 213.2;Pancreatic endocrine cells: 210.7;Peritubular cells: 209.7;Sertoli cells: 161.7;Smooth muscle cells: 171.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "basophil: 27.2;eosinophil: 20.5;neutrophil: 80.6" "Lineage enriched" "Detected in many" 10 "granulocytes: 80.6" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018794, HPA048815" Approved Enhanced "Actin filaments,Focal adhesion sites" NA NA 7600000 "Actin filaments, Focal adhesion sites" "HPA018794: AB_1855155, HPA048815: AB_2680530" "unprognostic (7.70e-3)" "unprognostic (3.75e-2)" "unprognostic (9.27e-3)" "prognostic unfavorable (5.45e-4)" "unprognostic (1.40e-1)" "unprognostic (3.48e-2)" "unprognostic (9.18e-3)" "prognostic unfavorable (4.07e-4)" "unprognostic (5.01e-2)" "unprognostic (3.10e-1)" "unprognostic (7.24e-2)" "unprognostic (1.88e-1)" "prognostic unfavorable (6.19e-10)" "unprognostic (6.72e-3)" "unprognostic (3.02e-1)" "unprognostic (1.93e-1)" "unprognostic (3.68e-2)" 12.4 5.6 3.7 21.1 9.3 12.5 8.3 0.5 5.9 54.6 76.0 3.2 42.6 9.0 85.0 35.8 33.9 35.5 52.3 11.1 3.8 5.0 8.3 2.4 11.6 8.9 3.5 5.8 28.2 3.1 2.1 10.3 11.5 5.6 42.0 7.6 17.6 9.1 61.7 159.6 5.3 16.5 129.5 3.1 12.7 27.0 11.7 2.4 3.7 5.4 24.9 6.5 67.8 19.6 1.8 4.8 80.6 8.4 0.4 1.4 3.9 24.9 5.0 23.9 18.8 6.5 11.9 24.2 47.9 26.1 27.3 19.6 9.6 22.6 4.5 49.5 29.3 15.0 12.1 3.9 32.4 6.3 6.2 5.8 14.7 16.3 9.0 17.7 7.8 49.6 25.8 5.5 21.8 10.5 38.7 16.3 4.1 10.9 3.2 19.7 19.3 1.4 17.3 16.5 4.8 21.5 29.1 21.3 2.8 18.2 5.1 3.7 7.8 18.7 3.6 9.1 8.4 5.1 7.0 58.6 32.9 35.7 12.5 43.7 0.8 0.9 5.3 15.6 8.4 7.4 27.2 8.4 20.5 0.9 3.9 1.1 1.8 0.6 1.4 4.8 1.0 0.6 0.7 80.6 0.4 4.9 0.3 1.2 3.9 3.7 9.3 0.5 5.9 3.8 5.0 3.5 5.8 5.6 2.4 0.0 1.1 5.9 34.1 12.9 5.2 16.1 5.1 4.0 2.3 24.4 13.7 10.1 21.6 173.8 19.2 30.0 1.3 0.0 213.2 44.5 47.3 13.0 17.3 0.9 64.5 7.9 3.4 50.3 15.5 30.6 41.4 23.5 10.1 34.3 1.9 12.4 210.7 35.1 209.7 6.7 20.4 161.7 171.6 10.9 35.2 13.8 11.8 14.9 1.7 21.1 PKN1 "DBK, MGC46204, PAK1, PKN, PRK1, PRKCL1" ENSG00000123143 "Protein kinase N1" Q16512 19 14433053-14471867 "Enzymes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003982, CAB010278" Approved Approved "Plasma membrane,Focal adhesion sites,Cytokinetic bridge" NA NA "Plasma membrane" "Focal adhesion sites, Cytokinetic bridge" "CAB010278: AB_2163965, HPA003982: AB_1855440" "unprognostic (3.83e-2)" "unprognostic (2.14e-1)" "unprognostic (4.13e-2)" "unprognostic (1.13e-2)" "unprognostic (1.94e-1)" "unprognostic (4.58e-1)" "unprognostic (1.30e-2)" "unprognostic (1.45e-1)" "unprognostic (1.43e-1)" "unprognostic (8.55e-3)" "unprognostic (4.08e-3)" "unprognostic (2.11e-1)" "unprognostic (1.45e-2)" "unprognostic (1.70e-1)" "unprognostic (8.66e-2)" "unprognostic (4.08e-1)" "unprognostic (2.24e-2)" 28.8 19.5 19.1 27.6 26.7 39.6 25.3 21.9 19.2 19.2 26.0 20.9 16.5 10.0 25.4 19.7 16.6 22.2 22.5 38.3 17.1 17.6 17.9 16.3 27.9 42.2 19.5 16.3 21.7 32.3 15.8 18.7 22.7 19.2 22.6 6.9 21.5 22.6 22.7 43.2 7.6 16.9 22.5 19.4 39.7 24.2 21.5 18.9 39.2 17.8 13.8 24.0 22.1 30.5 11.5 17.0 24.1 30.6 13.5 20.7 15.2 37.7 22.5 8.4 17.4 13.6 16.1 13.8 13.6 16.3 14.4 13.8 8.8 21.7 36.1 35.2 23.3 18.0 8.8 13.4 6.0 5.6 29.2 17.4 43.2 14.4 18.6 45.1 17.0 27.1 11.5 4.4 8.7 13.7 16.4 33.4 19.2 19.1 25.1 10.6 15.5 25.5 15.7 15.2 13.7 25.8 34.3 11.5 25.9 7.1 6.2 30.6 43.4 8.4 10.8 22.0 4.2 9.7 29.6 49.9 28.6 12.3 34.6 20.6 33.0 30.0 19.7 18.8 34.1 22.4 15.4 17.3 24.1 20.7 24.2 15.7 10.7 14.0 14.2 17.0 11.5 13.1 14.3 21.3 13.5 30.6 11.1 15.9 15.2 19.1 26.7 21.9 17.3 17.1 17.6 19.5 16.3 19.2 18.9 3.0 2.1 24.5 5.5 3.3 36.7 3.5 25.5 1.4 1.2 33.2 15.7 1.9 1.7 23.7 4.1 29.5 2.6 0.0 25.6 12.9 16.0 10.2 2.3 9.6 49.5 46.1 38.6 51.0 56.2 6.7 18.4 27.1 16.9 29.7 12.0 47.4 49.8 9.5 21.5 12.7 25.3 25.8 16.5 6.3 26.6 2.4 3.1 48.4 6.6 3.2 PLEC "EBS1, PCN, PLEC1, PLTN" ENSG00000178209 Plectin Q15149 8 143915147-143976734 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Actin-binding "Cancer-related genes, Disease mutation, Epidermolysis bullosa, Limb-girdle muscular dystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 144.9" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "PC-3: 73.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003847, HPA025967, HPA029906" Enhanced Supported "Intermediate filaments,Focal adhesion sites,Cytosol" NA NA 7100000 "Intermediate filaments, Cytosol" "Focal adhesion sites" "CAB003847: AB_562198, HPA025967: AB_10601671, HPA029906: AB_10602279" "unprognostic (1.02e-1)" "unprognostic (1.37e-3)" "prognostic unfavorable (4.29e-4)" "unprognostic (2.09e-2)" "unprognostic (1.04e-1)" "unprognostic (1.05e-2)" "unprognostic (1.76e-3)" "prognostic unfavorable (5.33e-4)" "unprognostic (1.72e-3)" "unprognostic (1.13e-2)" "unprognostic (2.85e-3)" "unprognostic (5.48e-2)" "prognostic unfavorable (7.98e-6)" "unprognostic (2.30e-1)" "unprognostic (4.04e-2)" "unprognostic (6.58e-2)" "unprognostic (5.58e-3)" 20.9 11.0 15.9 16.5 13.3 27.9 13.1 15.0 20.7 20.7 17.7 14.6 16.7 13.1 20.2 16.8 25.1 18.2 29.0 23.4 18.9 10.7 11.2 10.9 16.6 15.0 9.9 13.0 18.0 14.0 8.8 12.0 24.2 13.2 17.5 9.8 13.0 17.8 14.8 144.9 36.4 24.1 24.7 11.0 16.9 21.4 6.7 12.7 16.3 9.2 44.2 24.5 20.2 19.2 1.5 3.4 0.8 4.1 0.7 2.9 3.2 16.5 52.1 3.3 4.1 6.1 13.6 11.9 24.4 10.8 6.5 3.6 7.2 17.4 1.7 19.0 35.8 11.6 19.8 2.2 34.1 2.6 12.4 1.8 6.3 52.9 5.9 9.7 2.0 5.3 15.7 6.7 17.5 34.2 5.8 7.6 1.5 3.0 5.4 7.5 29.2 1.2 3.4 2.2 5.2 73.4 0.3 9.6 4.5 10.9 30.8 3.5 3.5 41.6 8.9 4.0 4.5 10.8 2.4 24.3 25.2 45.7 22.2 28.9 0.8 0.6 1.2 24.1 2.7 35.8 0.0 4.1 0.2 1.4 3.8 2.8 1.4 2.7 2.0 3.4 1.5 2.0 1.1 0.8 0.7 2.7 2.8 2.9 3.2 15.9 13.3 15.0 17.3 18.9 10.7 9.9 13.0 13.2 12.7 26.8 17.0 14.3 46.9 95.9 11.5 31.5 35.7 18.7 31.8 38.4 23.6 26.8 0.0 34.1 0.9 56.3 142.5 0.0 17.6 23.1 42.0 88.8 8.1 52.0 34.6 28.6 30.9 54.0 64.5 2.4 41.1 45.0 32.1 26.2 69.7 11.4 96.9 52.6 70.4 3.3 9.5 6.5 55.6 0.5 5.7 67.0 57.7 11.5 29.8 96.8 PNMA1 MA1 ENSG00000176903 "PNMA family member 1" Q8ND90 14 73711783-73714372 "Predicted intracellular proteins" "Tumor antigen" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Spermatocytes: 97.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003817, HPA015007" Enhanced Supported "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA Cytosol "Nucleoplasm, Focal adhesion sites" "HPA003817: AB_1079646, HPA015007: AB_1855502" "unprognostic (2.82e-2)" "unprognostic (3.26e-1)" "unprognostic (9.50e-2)" "unprognostic (1.10e-1)" "unprognostic (2.96e-1)" "prognostic unfavorable (7.49e-5)" "prognostic unfavorable (3.00e-5)" "unprognostic (2.90e-1)" "unprognostic (5.35e-2)" "unprognostic (3.63e-1)" "unprognostic (5.58e-2)" "unprognostic (4.58e-2)" "unprognostic (1.67e-3)" "unprognostic (2.04e-3)" "unprognostic (4.17e-2)" "unprognostic (2.23e-3)" "prognostic unfavorable (4.51e-5)" 19.6 18.0 39.1 11.1 42.4 4.7 17.4 30.4 68.2 16.0 19.3 11.2 15.8 8.2 20.5 32.4 13.9 20.9 14.3 13.1 29.6 33.5 16.4 3.1 8.4 12.5 25.8 39.4 31.8 5.7 6.7 20.9 12.3 27.0 29.0 10.1 8.9 4.6 53.4 5.8 4.5 9.1 29.5 19.8 10.1 10.9 38.1 17.3 6.0 11.0 2.5 7.3 14.8 21.2 3.3 3.6 4.0 4.6 4.8 12.8 6.4 15.0 13.7 23.7 17.6 17.9 19.0 9.8 16.0 9.0 14.7 10.8 12.9 9.4 0.3 11.2 19.4 14.0 10.1 18.2 9.5 15.2 14.3 11.2 8.6 11.5 9.6 19.2 4.7 13.7 16.7 11.5 17.5 11.1 29.0 22.1 9.3 7.4 9.6 19.9 37.0 9.4 11.6 7.1 7.8 48.5 14.9 14.8 0.3 19.3 0.4 28.2 21.6 28.2 6.5 12.6 15.0 31.6 8.1 21.3 29.7 23.9 18.0 12.9 8.5 13.1 4.5 29.3 6.8 9.8 2.6 1.7 4.0 8.4 3.3 5.6 2.9 10.8 8.5 3.6 3.3 10.6 9.7 1.6 4.8 4.6 0.6 12.8 6.4 39.1 42.4 30.4 59.9 29.6 33.5 25.8 39.4 27.0 17.3 6.0 4.0 2.4 6.5 3.4 46.6 16.9 0.0 17.4 3.4 14.0 11.8 6.4 13.3 8.4 68.4 12.6 3.1 0.0 5.9 9.3 17.3 7.4 16.1 0.9 13.5 55.6 18.0 22.1 5.4 42.0 30.2 13.2 18.6 19.8 3.7 60.0 19.1 0.0 79.5 17.9 44.9 71.1 44.2 97.4 36.5 3.3 5.0 13.8 1.7 3.1 PPFIA1 "LIP.1, LIPRIN" ENSG00000131626 "PTPRF interacting protein alpha 1" Q13136 11 70270700-70385312 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 163.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "A-431: 80.2;SK-MEL-30: 46.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017032, HPA042271" Uncertain Supported "Focal adhesion sites,Cytosol" NA NA Cytosol "Focal adhesion sites" "CAB017032: , HPA042271: AB_2677923" "unprognostic (1.89e-1)" "unprognostic (1.28e-2)" "unprognostic (6.27e-2)" "unprognostic (9.92e-2)" "unprognostic (1.18e-1)" "prognostic unfavorable (5.58e-4)" "unprognostic (7.20e-3)" "unprognostic (2.20e-1)" "unprognostic (3.02e-2)" "unprognostic (5.45e-3)" "prognostic unfavorable (8.26e-4)" "unprognostic (1.14e-1)" "prognostic favorable (3.76e-4)" "unprognostic (1.09e-1)" "unprognostic (1.14e-1)" "unprognostic (1.80e-1)" "unprognostic (2.14e-2)" 28.9 18.6 20.9 17.5 20.8 20.8 40.5 22.8 24.1 15.9 18.3 27.7 18.5 15.5 26.2 20.4 19.4 16.9 23.9 19.3 19.7 12.0 18.1 15.5 25.4 15.9 18.9 17.8 21.0 17.7 21.2 34.1 24.9 20.7 13.8 16.3 21.9 19.0 18.5 38.7 24.2 17.8 18.4 30.0 14.7 15.6 29.8 22.5 17.0 25.2 10.0 13.6 18.7 18.6 2.6 2.8 10.0 4.8 1.1 2.2 1.0 80.2 10.8 10.0 6.7 9.3 5.8 10.6 9.4 7.7 11.7 7.8 20.5 7.2 7.5 12.3 7.5 12.0 11.6 8.4 8.1 10.1 5.0 5.9 6.0 11.3 6.5 9.5 7.9 7.4 7.4 13.0 15.1 12.4 9.4 7.5 6.4 10.1 6.1 10.2 10.9 5.4 4.7 5.9 17.1 9.3 6.3 25.1 6.5 5.7 11.0 9.7 6.6 14.0 17.7 46.1 10.8 11.9 8.4 10.3 11.8 9.2 16.3 10.0 7.5 4.7 10.5 9.8 5.5 13.7 0.0 3.6 1.7 1.3 1.9 2.2 2.6 2.2 1.9 2.8 2.3 1.7 1.0 10.0 1.1 4.8 2.8 2.1 1.0 20.9 20.8 22.8 21.4 19.7 12.0 18.9 17.8 20.7 22.5 23.8 49.3 8.8 18.7 24.4 31.5 23.0 22.9 26.8 25.0 17.4 29.5 30.5 10.0 19.2 163.8 25.1 26.3 0.0 17.6 12.0 18.6 32.7 8.1 19.8 21.9 31.8 25.8 20.3 35.7 71.1 25.6 27.2 20.3 20.8 17.6 75.0 27.2 20.3 24.1 18.0 43.9 19.4 21.9 47.9 72.2 29.0 62.1 17.3 16.9 36.9 PRAG1 "DKFZp761P0423, NACK, PEAK2, PRAGMIN, SgK223" ENSG00000275342 "PEAK1 related, kinase-activating pseudokinase 1" Q86YV5 8 8317736-8386498 "Enzymes, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 30.4" "Cell type enhanced" "Detected in some" 11 "Alveolar cells type 1: 8.9;Alveolar cells type 2: 6.2;Cytotrophoblasts: 6.4;Ductal cells: 6.6;Extravillous trophoblasts: 5.5;Hofbauer cells: 14.8;Pancreatic endocrine cells: 5.5" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 27.5;NTERA-2: 17.8;SuSa: 19.0" "Low region specificity" "Detected in all" "HPA011776, HPA012066" Uncertain Uncertain "Nucleoli,Focal adhesion sites" NA NA Nucleoli "Focal adhesion sites" "HPA011776: , HPA012066: AB_1847706" "unprognostic (7.04e-3)" "unprognostic (7.90e-2)" "unprognostic (2.32e-1)" "unprognostic (2.95e-2)" "unprognostic (1.60e-1)" "unprognostic (2.92e-1)" "unprognostic (1.05e-1)" "unprognostic (4.78e-3)" "unprognostic (2.64e-3)" "unprognostic (5.19e-2)" "unprognostic (4.95e-2)" "unprognostic (1.78e-1)" "prognostic favorable (4.81e-4)" "unprognostic (5.27e-2)" "unprognostic (1.23e-1)" "unprognostic (5.04e-2)" "unprognostic (5.22e-3)" 7.6 0.2 6.4 8.8 4.9 0.1 5.4 30.4 7.0 2.4 5.7 1.8 3.2 9.8 0.8 1.7 2.6 5.0 4.0 1.8 2.1 1.3 0.9 4.3 9.1 0.0 1.4 1.7 1.0 2.2 0.0 5.4 1.2 1.5 3.4 0.0 1.7 5.7 5.6 2.8 9.4 0.9 1.4 5.7 3.9 0.7 1.2 1.8 15.4 4.7 6.2 1.5 0.2 3.1 4.6 2.2 1.6 1.3 3.9 0.4 3.3 27.5 3.1 0.4 0.0 0.2 7.8 7.0 1.5 2.8 1.1 13.6 8.0 5.5 4.8 3.3 7.6 12.0 0.5 8.4 0.6 0.2 0.8 0.0 3.3 7.6 3.0 0.8 8.7 0.7 5.5 0.4 1.2 1.6 5.7 0.8 0.0 0.0 2.1 4.6 0.7 2.6 17.8 10.5 7.1 3.5 3.3 1.3 4.1 9.5 1.5 1.0 2.7 7.7 2.7 19.0 6.0 3.4 7.5 0.2 7.4 0.0 1.7 0.4 0.6 7.5 1.7 1.8 4.1 0.0 0.5 2.2 1.2 0.1 0.9 3.1 1.5 0.4 0.7 2.6 3.9 3.2 0.0 1.3 1.6 4.6 0.2 0.4 8.9 6.2 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 6.4 0.0 6.6 0.0 0.0 0.0 0.0 2.7 5.5 0.0 0.0 2.3 0.0 14.8 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 1.8 0.0 0.0 5.5 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 PTK2 "FADK, FAK, FAK1, PPP1R71" ENSG00000169398 "Protein tyrosine kinase 2" Q05397 8 140657900-141002216 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" Angiogenesis "Developmental protein, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001842, CAB004036, HPA029671" Approved Supported "Vesicles,Focal adhesion sites,Cytosol" NA NA 32000 "Focal adhesion sites" "Vesicles, Cytosol" "CAB004036: AB_2269034, HPA001842: AB_1855891, HPA029671: AB_10610288" "prognostic unfavorable (3.21e-4)" "unprognostic (3.86e-2)" "unprognostic (1.95e-1)" "prognostic unfavorable (9.11e-4)" "unprognostic (1.93e-1)" "unprognostic (2.28e-1)" "unprognostic (3.02e-2)" "unprognostic (1.27e-1)" "unprognostic (1.97e-1)" "unprognostic (2.96e-2)" "unprognostic (1.06e-2)" "unprognostic (2.38e-1)" "unprognostic (2.80e-2)" "unprognostic (2.94e-2)" "unprognostic (1.11e-1)" "unprognostic (1.53e-1)" "unprognostic (2.90e-2)" 22.6 20.4 36.0 14.4 42.3 3.1 19.3 20.5 40.8 24.9 17.9 55.7 23.5 14.5 20.2 29.9 14.6 18.7 18.4 20.0 43.5 23.9 22.3 17.0 21.5 13.0 41.4 31.4 19.4 18.2 33.1 13.0 42.1 30.0 19.2 20.7 11.0 21.9 25.5 17.9 13.5 16.3 21.9 38.0 12.2 17.5 21.2 46.1 2.8 22.5 10.2 14.0 22.2 17.8 8.6 7.2 1.8 3.9 5.2 5.7 4.1 14.5 23.1 32.1 11.5 13.5 14.5 20.7 14.4 20.0 13.4 13.2 10.1 12.0 8.8 32.6 18.3 18.9 17.1 18.8 32.8 20.4 0.1 8.8 19.5 12.8 13.9 18.5 0.0 9.2 9.8 16.2 16.8 23.7 35.4 39.6 12.5 19.6 0.2 17.9 25.2 0.2 0.1 12.4 31.5 25.8 12.9 17.6 0.4 28.4 33.1 12.7 15.9 22.4 7.2 14.5 29.6 17.0 0.3 23.9 13.3 25.0 15.6 16.1 0.0 0.1 0.9 17.2 0.1 17.9 1.8 3.9 0.0 0.3 1.6 0.0 6.8 0.8 0.1 5.3 8.6 5.7 2.0 1.7 5.2 0.9 7.2 0.2 4.1 36.0 42.3 20.5 40.8 43.5 23.9 41.4 31.4 30.0 46.1 29.8 24.9 2.7 51.7 29.7 51.6 26.2 33.1 25.4 20.5 52.4 56.9 27.2 19.9 23.3 34.0 35.8 21.0 0.0 20.0 45.5 28.2 67.2 9.2 14.7 6.8 63.5 24.8 33.7 11.7 33.3 22.2 7.9 23.6 1.0 23.1 41.5 33.4 21.0 20.5 22.6 56.8 97.0 121.7 43.2 62.8 22.6 27.8 1.8 21.0 67.4 PWWP2A KIAA1935 ENSG00000170234 "PWWP domain containing 2A" Q96N64 5 160061801-160119423 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 52.7" "Cell type enhanced" "Detected in all" 5 "Bipolar cells: 94.1;Horizontal cells: 89.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046733, HPA058233" Supported "Nucleoplasm,Focal adhesion sites" NA NA Nucleoplasm "Focal adhesion sites" "HPA046733: AB_2679777, HPA058233: AB_2683647" "unprognostic (1.03e-1)" "unprognostic (2.67e-1)" "unprognostic (5.13e-2)" "unprognostic (1.85e-1)" "unprognostic (1.18e-2)" "unprognostic (7.86e-3)" "unprognostic (1.40e-3)" "unprognostic (6.24e-2)" "unprognostic (2.42e-2)" "unprognostic (7.08e-2)" "unprognostic (7.25e-2)" "unprognostic (8.24e-3)" "prognostic unfavorable (3.70e-4)" "unprognostic (2.23e-1)" "unprognostic (3.88e-2)" "unprognostic (1.08e-1)" "prognostic favorable (3.51e-4)" 8.4 9.3 9.5 12.7 22.3 11.9 9.1 52.7 16.0 14.4 13.6 19.9 5.3 9.6 10.8 7.2 8.7 9.5 8.1 7.4 15.9 8.8 10.3 8.6 9.8 12.0 25.2 8.9 10.5 10.5 10.6 15.1 11.2 17.0 11.9 14.7 10.3 8.8 8.4 7.0 14.7 10.6 9.3 13.8 12.5 11.8 6.3 21.3 18.6 9.8 5.8 11.4 10.7 10.1 6.0 2.9 6.0 4.4 1.1 4.9 0.9 10.7 5.2 13.5 11.5 15.1 11.8 19.1 8.6 7.0 7.7 7.9 16.8 21.0 17.4 13.2 6.6 12.6 7.8 11.7 13.5 12.7 18.0 13.0 12.5 9.6 8.6 11.5 12.5 9.5 8.4 6.7 15.5 11.8 17.3 12.3 9.9 9.5 11.3 13.0 9.0 10.7 12.2 15.9 9.2 6.7 16.9 12.0 11.1 9.4 7.7 15.9 11.1 14.5 14.7 15.6 11.5 11.3 13.9 16.4 13.5 9.3 10.0 16.7 13.0 11.6 15.5 8.8 12.7 13.2 6.0 4.4 2.4 2.8 2.0 2.2 6.0 3.0 3.3 2.9 3.7 4.9 2.7 5.0 1.1 2.6 2.7 2.5 0.9 9.5 22.3 52.7 16.0 15.9 8.8 25.2 8.9 17.0 21.3 8.9 14.8 18.5 12.5 28.3 94.1 10.6 10.2 14.7 17.0 19.2 68.7 11.2 14.9 11.6 1.5 15.3 18.4 23.3 9.6 10.5 16.2 15.6 23.1 7.6 7.8 89.0 31.6 12.9 11.0 2.1 51.8 14.6 10.1 12.6 19.4 22.7 13.1 14.4 36.0 5.8 50.6 25.8 22.6 9.7 17.2 22.6 7.8 17.3 20.4 11.2 PXN ENSG00000089159 Paxillin P49023 12 120210439-120265771 "Predicted intracellular proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Extravillous trophoblasts: 124.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 49.5" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003841, HPA051309" Supported Enhanced "Focal adhesion sites,Centrosome,Cytosol" NA NA "Focal adhesion sites" "Centrosome, Cytosol" "CAB003841: AB_562188, HPA051309: AB_2681436" "unprognostic (4.00e-2)" "unprognostic (1.94e-2)" "unprognostic (3.51e-2)" "unprognostic (3.55e-3)" "prognostic unfavorable (1.09e-4)" "prognostic unfavorable (3.72e-5)" "prognostic unfavorable (7.12e-5)" "prognostic unfavorable (1.73e-4)" "unprognostic (3.12e-2)" "unprognostic (9.19e-3)" "unprognostic (2.66e-2)" "unprognostic (1.73e-1)" "unprognostic (2.12e-2)" "unprognostic (3.35e-2)" "unprognostic (2.09e-1)" "unprognostic (1.98e-1)" "unprognostic (2.75e-2)" 35.4 26.2 17.9 26.7 16.5 31.6 45.9 15.5 18.6 25.0 29.0 12.4 31.7 25.6 27.6 30.9 16.0 29.8 31.8 26.2 18.0 7.6 27.6 13.1 35.8 42.9 15.7 8.1 14.8 16.3 17.6 13.9 34.0 15.8 24.9 23.5 24.7 22.1 40.1 98.5 19.7 34.7 44.4 20.3 34.0 20.6 19.8 14.4 9.9 26.7 22.8 11.6 30.1 45.7 0.5 7.6 49.5 12.3 14.4 26.3 14.5 33.2 16.5 5.9 5.9 11.9 31.0 40.1 28.2 24.6 23.0 12.1 19.2 21.0 2.3 18.5 28.6 22.3 23.8 4.1 51.4 18.4 1.8 3.7 0.4 12.2 6.9 17.2 0.5 0.7 15.1 33.6 24.0 27.4 26.0 40.8 6.2 5.9 3.8 44.9 22.1 2.0 0.7 8.4 14.5 57.5 4.9 9.8 2.0 23.6 32.0 9.7 2.9 25.3 7.8 15.2 14.5 19.2 2.7 53.7 16.0 17.5 19.9 33.5 4.0 2.2 0.8 46.0 5.0 31.2 9.8 12.3 13.4 26.3 4.4 14.2 0.5 12.1 17.2 7.6 0.4 9.6 12.8 49.5 14.4 0.2 1.2 9.1 14.5 17.9 16.5 15.5 18.6 18.0 7.6 15.7 8.1 15.8 14.4 53.6 30.4 3.0 29.8 37.5 7.1 11.5 25.5 28.1 35.2 40.1 31.4 31.3 16.6 30.3 1.2 56.8 59.3 0.0 34.6 124.5 18.0 29.6 17.4 15.3 29.4 11.1 52.5 57.1 49.0 1.6 22.5 13.7 25.3 10.0 49.9 6.9 56.8 50.3 17.7 11.6 30.4 6.5 10.5 3.8 8.0 16.9 20.9 28.7 28.4 33.9 RAB24 ENSG00000169228 "RAB24, member RAS oncogene family" Q969Q5 5 177301198-177303744 "Predicted intracellular proteins" "Autophagy, Protein transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 55.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA034945 Uncertain "Focal adhesion sites" No No "Focal adhesion sites" "HPA034945: " "unprognostic (1.03e-2)" "unprognostic (6.81e-2)" "unprognostic (3.05e-2)" "unprognostic (1.59e-1)" "unprognostic (7.86e-2)" "prognostic favorable (6.22e-4)" "prognostic unfavorable (7.56e-5)" "unprognostic (1.28e-1)" "unprognostic (1.78e-2)" "unprognostic (9.66e-2)" "unprognostic (1.43e-3)" "unprognostic (2.79e-2)" "prognostic unfavorable (2.54e-7)" "unprognostic (3.97e-2)" "unprognostic (1.22e-1)" "unprognostic (2.75e-1)" "unprognostic (1.12e-2)" 13.6 19.7 18.3 19.9 20.9 24.6 16.8 25.0 24.2 12.1 13.7 7.5 25.3 15.3 10.9 23.6 21.0 11.9 12.4 12.7 15.4 18.0 16.6 15.2 14.2 15.5 13.1 22.0 16.9 31.4 16.2 26.0 15.6 19.8 15.3 11.0 14.1 23.2 20.8 27.1 19.5 15.6 14.5 10.6 27.6 12.8 5.7 13.1 5.9 18.8 15.1 19.9 11.0 15.9 7.5 14.5 38.0 42.0 7.9 5.1 10.2 2.9 7.9 5.2 10.4 8.5 7.5 10.9 9.1 11.4 11.3 13.7 9.5 3.9 3.2 11.2 7.2 12.6 2.8 7.0 9.8 6.3 55.2 5.6 11.0 8.0 8.1 17.9 6.9 10.0 12.4 8.0 12.0 8.5 16.7 6.9 8.8 8.2 17.5 7.9 11.2 2.5 19.9 3.3 5.9 8.0 1.5 8.6 12.4 7.6 5.2 6.7 9.1 2.8 5.6 23.5 6.6 10.1 17.4 7.6 4.0 6.5 9.1 7.8 13.4 6.3 4.1 7.5 11.2 8.4 8.7 21.4 38.0 5.1 42.0 4.4 7.5 2.5 4.2 14.5 6.8 2.8 4.4 33.0 7.9 40.7 3.2 2.1 10.2 18.3 20.9 25.0 24.2 15.4 18.0 13.1 22.0 19.8 13.1 3.0 10.3 9.9 1.7 4.7 3.1 2.0 0.0 4.0 10.3 1.8 2.0 6.2 3.3 21.3 0.3 4.2 15.7 0.0 17.6 4.6 4.4 1.9 11.5 1.5 3.9 12.7 17.3 8.0 10.0 0.2 4.6 9.1 3.3 1.0 12.6 1.9 16.4 15.2 1.1 5.4 4.4 0.0 4.1 2.4 3.3 5.3 25.6 4.9 12.8 2.0 RAET1E "bA350J20.7, LETAL, ULBP4" ENSG00000164520 "Retinoic acid early transcript 1E" Q8TD07 6 149883375-149898102 "Predicted intracellular proteins, Predicted membrane proteins" Immunity "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "esophagus: 39.7;lymphoid tissue: 22.5;tongue: 19.8" "Cell type enhanced" "Detected in some" 12 "Basal keratinocytes: 1.9;Early spermatids: 5.0;Late spermatids: 4.2;Suprabasal keratinocytes: 5.6" "Cancer enhanced" "Detected in many" "head and neck cancer: 3.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "HBEC3-KT: 15.9;HeLa: 21.8;hTCEpi: 15.8;SiHa: 7.5;U-87 MG: 6.8" HPA054022 Supported "Focal adhesion sites,Cytosol" "Intracellular and membrane" NA NA "Focal adhesion sites" Cytosol "HPA054022: AB_2797250" "unprognostic (1.67e-2)" "unprognostic (2.10e-1)" "unprognostic (3.49e-3)" "unprognostic (1.26e-1)" "unprognostic (1.36e-1)" "unprognostic (2.71e-2)" "unprognostic (1.36e-3)" "unprognostic (4.80e-4)" "unprognostic (1.11e-1)" "unprognostic (3.39e-1)" "unprognostic (1.02e-1)" "unprognostic (1.69e-1)" "unprognostic (7.47e-5)" "unprognostic (2.41e-2)" "unprognostic (3.18e-2)" "unprognostic (3.17e-2)" "unprognostic (1.06e-1)" 1.6 0.5 0.2 0.5 0.2 0.0 1.4 0.2 0.2 10.4 0.3 0.2 0.2 0.2 0.8 0.6 39.7 0.6 0.2 0.2 0.2 0.0 2.8 0.2 0.6 0.2 0.2 0.2 0.6 0.2 0.1 0.2 0.5 0.2 0.4 0.3 0.2 7.0 0.2 0.7 14.6 0.3 0.3 0.2 0.6 0.2 0.5 0.3 0.3 0.2 19.8 22.5 1.3 12.6 0.6 0.4 2.3 0.6 0.5 0.7 0.1 1.5 0.9 0.0 0.0 0.2 1.3 0.1 0.1 0.9 0.1 0.3 0.0 3.7 0.0 2.1 3.1 2.0 1.7 0.0 15.9 0.2 0.4 0.0 0.0 21.8 0.0 0.0 0.0 0.0 0.3 15.8 0.9 3.3 0.5 0.1 0.0 0.0 1.3 0.9 0.1 0.0 0.0 0.1 0.3 0.8 0.0 0.0 0.2 0.3 0.7 0.2 0.0 7.5 2.0 0.0 0.0 1.1 0.0 3.0 1.1 0.4 0.1 0.9 0.0 0.0 0.0 6.8 0.3 0.0 2.0 0.6 0.4 0.4 0.3 0.2 0.2 0.6 0.3 0.1 0.6 0.7 0.4 2.3 0.5 0.2 0.4 0.3 0.1 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.3 0.0 0.0 0.0 0.9 1.9 0.6 0.3 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 5.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 1.8 RALA RAL ENSG00000006451 "RAS like proto-oncogene A" P11233 7 39623483-39708124 "Predicted intracellular proteins, RAS pathway related proteins" "Cell cycle, Cell division, Exocytosis" Hydrolase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Pancreatic endocrine cells: 277.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 78.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047037, HPA065232" Approved Supported "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane" "Focal adhesion sites" "HPA047037: , HPA065232: AB_2685440" "unprognostic (1.20e-3)" "unprognostic (1.03e-2)" "unprognostic (2.91e-1)" "unprognostic (7.73e-3)" "unprognostic (1.98e-2)" "unprognostic (9.14e-2)" "prognostic unfavorable (5.32e-5)" "unprognostic (7.71e-2)" "unprognostic (2.17e-1)" "prognostic favorable (7.46e-4)" "prognostic unfavorable (6.30e-4)" "unprognostic (3.32e-1)" "unprognostic (4.95e-3)" "unprognostic (5.38e-2)" "unprognostic (7.15e-2)" "unprognostic (2.79e-1)" "unprognostic (2.95e-2)" 19.2 25.2 24.7 14.3 24.6 4.8 24.4 16.1 22.0 18.4 22.3 17.2 8.0 23.5 15.7 15.5 44.9 15.0 20.0 13.8 24.7 20.2 15.9 15.4 30.3 14.8 27.6 18.9 17.4 11.6 12.8 14.2 23.7 20.3 12.9 23.6 9.1 18.5 12.7 16.8 19.5 25.5 15.7 36.0 16.0 24.4 12.2 21.9 19.9 13.8 31.0 28.9 15.2 20.8 13.3 16.3 21.5 11.2 15.7 20.4 11.5 20.1 4.6 11.4 9.9 21.8 18.2 7.9 17.7 25.6 16.1 17.9 11.5 9.9 10.4 6.7 13.7 15.1 21.0 16.1 11.5 27.9 9.9 7.6 8.1 7.6 8.4 35.4 14.0 11.5 14.3 14.1 28.7 40.9 20.2 78.1 10.2 16.2 6.9 16.3 6.5 9.8 16.7 32.1 22.1 9.2 12.3 10.3 9.0 16.4 9.4 20.5 19.9 10.9 17.5 12.0 21.5 16.4 15.4 25.0 9.5 8.5 12.0 12.6 12.3 9.5 12.7 10.7 14.6 17.3 21.5 9.8 11.0 9.7 11.2 12.0 11.5 15.7 12.4 16.3 13.3 20.4 17.9 4.5 15.7 8.6 10.6 19.7 11.5 24.7 24.6 16.1 20.8 24.7 20.2 27.6 18.9 20.3 21.9 77.4 36.8 45.3 32.8 80.0 10.9 33.0 45.9 29.4 21.6 22.7 5.9 45.4 18.3 162.0 51.6 66.4 59.6 23.3 107.3 77.4 54.6 33.5 31.1 26.2 97.6 11.1 45.8 69.3 24.5 12.3 44.3 67.7 28.7 146.1 46.5 37.7 277.8 66.0 65.4 28.4 15.8 32.3 24.7 52.6 55.6 95.7 51.8 25.5 51.1 47.7 RAPGEF4 "cAMP-GEFII, CGEF2" ENSG00000091428 "Rap guanine nucleotide exchange factor 4" Q8WZA2 2 172735274-173052893 "Predicted intracellular proteins" Exocytosis "Guanine-nucleotide releasing factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 29.6;brain: 70.9" "Cell type enhanced" "Detected in many" 12 "Cone photoreceptor cells: 43.2;Endothelial cells: 30.4;Ito cells: 23.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in all" 4 "amygdala: 68.3;basal ganglia: 31.5;cerebral cortex: 55.3;hippocampal formation: 70.9;olfactory region: 23.8" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "Karpas-707: 18.0;SCLC-21H: 7.0;U-266/70: 9.3;U-266/84: 18.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004388, HPA028968" Approved Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "CAB004388: AB_670916, HPA028968: AB_2672846" "unprognostic (1.87e-1)" "unprognostic (4.22e-2)" "unprognostic (1.31e-1)" "unprognostic (2.98e-3)" "unprognostic (4.53e-2)" "unprognostic (1.20e-2)" "unprognostic (4.45e-2)" "unprognostic (1.80e-1)" "unprognostic (1.16e-1)" "unprognostic (3.23e-1)" "prognostic favorable (1.32e-4)" "unprognostic (6.32e-2)" "unprognostic (1.46e-3)" "unprognostic (1.97e-2)" "unprognostic (6.18e-2)" "unprognostic (5.70e-2)" "unprognostic (2.93e-1)" 3.3 29.6 68.3 1.6 31.5 0.6 5.2 10.9 55.3 4.9 1.5 5.4 1.0 2.1 6.6 2.7 2.3 2.9 3.7 5.7 70.9 10.2 3.8 24.6 5.4 1.7 10.0 23.8 9.7 2.0 3.2 2.4 2.3 8.6 3.5 1.7 11.3 1.7 2.9 1.4 10.6 1.8 4.3 2.9 0.9 5.4 3.7 11.5 0.0 4.3 0.9 1.8 4.2 1.2 0.4 0.6 1.4 0.6 0.6 0.7 0.1 0.1 0.1 2.7 0.4 0.0 0.2 0.1 0.9 0.5 0.1 0.2 0.0 3.1 0.0 0.2 0.0 0.2 0.5 2.3 0.6 0.3 0.1 4.8 0.4 2.3 0.0 0.0 3.0 0.8 0.0 0.7 0.0 0.0 2.7 2.9 1.3 0.0 18.0 0.1 0.0 0.2 0.2 0.3 1.5 0.3 0.0 0.6 0.0 0.0 5.4 7.0 2.6 0.1 0.1 0.9 1.4 0.1 0.1 0.8 0.1 0.3 0.0 0.2 9.3 18.0 0.0 0.3 0.1 0.2 1.4 0.4 0.4 0.3 0.4 0.6 0.4 0.4 0.3 0.3 0.4 0.6 0.7 1.0 0.6 0.6 0.6 0.3 0.1 68.3 31.5 10.9 55.3 70.9 10.2 10.0 23.8 8.6 11.5 3.0 3.2 0.9 1.0 5.5 2.5 6.7 0.0 0.0 0.0 0.0 43.2 0.1 0.0 0.6 2.1 30.4 0.0 0.0 2.3 0.0 0.9 0.5 0.0 9.9 0.1 1.6 7.5 23.9 1.9 1.1 4.0 0.0 3.3 0.0 0.2 1.2 2.4 0.0 1.4 0.0 8.9 0.0 1.4 0.5 2.0 3.3 0.1 0.0 0.0 0.6 RASAL2 nGAP ENSG00000075391 "RAS protein activator like 2" Q9UJF2 1 178094141-178484147 "Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 7 "Cone photoreceptor cells: 143.3;Rod photoreceptor cells: 179.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 2.1" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "hTERT-HME1: 30.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018805, HPA020453" Enhanced Approved "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA018805: AB_1856085, HPA020453: AB_1856086" "unprognostic (5.55e-3)" "unprognostic (6.49e-2)" "unprognostic (2.65e-1)" "unprognostic (6.33e-2)" "unprognostic (3.40e-2)" "unprognostic (5.59e-2)" "unprognostic (5.91e-2)" "unprognostic (1.72e-2)" "unprognostic (2.91e-1)" "unprognostic (2.92e-2)" "unprognostic (3.16e-3)" "unprognostic (2.03e-1)" "unprognostic (1.06e-2)" "unprognostic (4.98e-2)" "unprognostic (2.45e-1)" "unprognostic (8.36e-2)" "prognostic unfavorable (2.05e-4)" 13.5 3.8 4.2 2.8 5.1 0.4 7.1 2.7 8.5 9.5 4.2 3.7 4.2 2.4 10.9 5.5 24.4 5.8 9.0 15.5 3.8 5.9 7.1 2.7 9.2 1.5 4.0 6.5 6.3 5.0 6.1 6.7 21.2 5.6 5.0 4.3 10.7 9.6 4.5 8.3 7.5 3.3 7.1 3.8 2.9 3.7 9.0 2.7 0.0 5.0 13.1 4.8 5.6 13.2 2.1 0.5 1.4 0.6 0.3 0.1 0.0 16.3 5.4 7.1 2.3 4.8 6.5 9.9 8.2 8.0 7.0 5.3 8.6 8.7 0.0 13.7 8.0 11.5 13.8 5.7 13.1 6.5 0.0 3.1 0.0 5.7 3.4 5.7 2.3 0.3 20.4 2.6 8.3 30.0 7.3 6.3 0.0 0.5 0.0 9.7 1.7 0.0 1.9 5.3 3.1 1.0 0.1 2.9 0.0 3.8 2.2 5.5 2.7 6.4 5.0 5.0 6.3 5.8 2.6 11.9 9.3 9.5 9.7 10.9 3.6 0.0 0.0 7.3 1.2 6.6 1.4 0.4 0.1 0.1 0.3 0.0 0.6 0.0 0.0 0.2 2.1 0.1 0.1 0.8 0.3 0.6 0.5 0.0 0.0 4.2 5.1 2.7 7.1 3.8 5.9 4.0 6.5 5.6 2.7 71.5 11.7 1.4 7.8 14.2 47.0 33.2 17.8 37.5 14.8 15.7 143.3 11.6 5.0 19.0 12.3 41.2 5.2 0.0 10.9 12.1 14.7 18.7 7.0 5.4 15.0 79.4 32.7 43.0 2.5 5.1 18.1 13.1 3.3 12.6 14.6 22.8 23.0 2.9 21.5 5.7 179.6 64.7 27.8 28.6 32.2 21.1 35.0 0.7 12.8 29.3 REXO2 "CGI-114, DKFZP566E144, SFN" ENSG00000076043 "RNA exonuclease 2" Q9Y3B8 11 114439386-114450279 "Predicted intracellular proteins" "Exonuclease, Hydrolase, Nuclease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038450, HPA038451" Enhanced Supported "Nucleoli,Focal adhesion sites,Mitochondria" NA NA 390000 Mitochondria "Nucleoli, Focal adhesion sites" "HPA038450: AB_10672516, HPA038451: AB_10697391" "unprognostic (3.26e-3)" "unprognostic (2.36e-2)" "prognostic favorable (6.51e-4)" "unprognostic (6.84e-3)" "unprognostic (5.80e-3)" "unprognostic (1.06e-1)" "unprognostic (1.40e-3)" "unprognostic (1.78e-1)" "unprognostic (8.18e-3)" "unprognostic (2.49e-2)" "unprognostic (2.17e-3)" "unprognostic (1.02e-1)" "unprognostic (1.73e-2)" "unprognostic (6.75e-2)" "unprognostic (1.23e-1)" "unprognostic (7.69e-2)" "prognostic unfavorable (6.70e-4)" 21.8 31.1 13.5 15.8 14.2 16.2 30.0 14.9 12.6 31.4 36.0 11.2 24.0 8.4 38.4 24.8 33.5 17.7 23.9 64.3 13.3 10.5 35.7 28.6 20.1 13.9 17.0 13.1 28.5 27.7 61.2 24.9 45.0 15.3 32.0 17.7 11.6 61.6 22.8 27.8 22.7 15.8 44.6 15.7 18.6 31.5 29.6 14.5 9.9 20.0 25.2 15.2 34.9 40.6 15.5 28.6 19.0 7.9 18.1 30.5 12.2 27.8 16.2 6.3 16.9 50.7 53.8 15.0 47.3 37.0 23.9 30.5 42.6 47.7 15.3 47.7 41.7 36.3 17.8 14.1 41.8 39.5 14.9 10.9 16.9 22.4 26.5 66.7 12.3 5.4 37.2 40.1 30.2 32.1 42.0 42.7 15.9 31.2 9.4 53.5 6.6 8.9 15.5 19.4 22.3 28.7 7.9 20.6 55.8 34.2 22.7 11.2 7.0 21.7 16.8 19.9 27.5 34.1 6.5 40.4 30.8 36.8 23.7 28.9 7.4 8.8 25.9 21.2 29.1 16.4 19.0 6.0 8.8 14.3 7.9 16.5 15.5 21.6 17.9 7.8 11.7 19.9 16.1 1.5 18.1 7.9 28.6 30.5 12.2 13.5 14.2 14.9 12.6 13.3 10.5 17.0 13.1 15.3 14.5 98.3 49.6 36.3 126.2 123.4 12.0 342.7 43.3 89.7 68.2 90.7 2.0 149.0 235.4 121.0 59.3 101.2 22.2 93.5 62.0 153.2 153.3 156.6 32.2 67.6 83.4 4.8 77.7 89.6 17.6 35.4 195.1 39.5 229.5 53.3 64.2 27.2 110.2 31.6 166.2 264.0 6.7 51.8 115.4 227.9 71.1 142.2 225.1 37.4 70.7 116.6 RTN4R NOGOR ENSG00000040608 "Reticulon 4 receptor" Q9BZR6 22 20241415-20283246 "Disease related genes, Predicted membrane proteins" Receptor "Disease mutation, Schizophrenia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 12.0;brain: 33.2" "Cell type enhanced" "Detected in many" 6 "Muller glia cells: 9.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "MAIT T-cell: 12.0" "Lineage enriched" "Detected in many" 9 "T-cells: 12.0" "Cell line enhanced" "Detected in many" "NB-4: 20.5;REH: 28.8;SCLC-21H: 17.6;SK-MEL-30: 13.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB012443 Supported "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA 1300000 "Plasma membrane, Focal adhesion sites" "Actin filaments" "CAB012443: " "unprognostic (1.28e-1)" "unprognostic (1.28e-2)" "unprognostic (8.29e-2)" "unprognostic (6.58e-2)" "unprognostic (3.49e-1)" "prognostic unfavorable (7.73e-4)" "unprognostic (2.19e-1)" "unprognostic (1.56e-1)" "unprognostic (3.44e-1)" "unprognostic (8.90e-3)" "unprognostic (1.21e-2)" "unprognostic (9.89e-2)" "unprognostic (1.80e-2)" "unprognostic (1.34e-2)" "unprognostic (1.30e-1)" "unprognostic (5.02e-2)" "unprognostic (3.07e-1)" 0.8 1.1 10.9 1.2 7.0 1.3 0.7 33.2 24.6 0.8 1.7 1.2 0.3 3.9 4.9 0.5 0.9 1.3 0.6 1.4 8.8 3.1 0.9 4.0 1.7 1.1 1.4 6.8 1.1 2.7 0.6 1.6 1.1 4.9 1.2 0.6 0.7 1.3 1.2 0.8 5.2 1.8 0.7 2.8 5.9 2.3 1.1 0.5 0.1 1.1 0.4 0.7 0.7 0.7 0.1 1.3 0.0 0.0 0.7 12.0 1.7 4.2 2.0 1.3 3.0 0.0 0.0 0.7 0.4 0.0 0.3 0.1 3.2 1.2 0.2 1.4 0.0 2.1 6.9 0.8 1.8 0.0 0.1 7.4 0.1 1.8 0.4 0.7 0.1 0.2 0.0 2.3 0.0 0.2 0.0 0.0 2.0 0.2 0.2 0.0 5.9 2.2 20.5 4.8 1.2 3.7 28.8 0.0 0.2 0.2 1.8 17.6 2.8 2.0 1.5 13.7 0.3 1.7 0.6 0.0 0.2 8.2 0.0 0.1 0.0 0.5 0.5 0.2 4.2 0.0 0.0 0.0 0.0 5.1 0.0 12.0 0.0 4.5 5.1 0.2 0.1 2.7 5.7 0.0 0.7 0.0 1.3 3.1 1.7 10.9 7.0 33.2 20.1 8.8 3.1 1.4 6.8 4.9 0.5 3.0 0.0 0.0 3.6 4.5 5.3 1.7 0.0 0.0 0.0 0.0 3.9 0.0 0.0 2.4 2.0 1.4 1.3 0.0 3.7 4.3 0.5 3.1 0.0 0.9 1.3 6.4 0.0 0.6 0.0 0.0 0.3 0.0 1.7 1.0 1.4 9.8 2.4 0.0 0.0 0.0 4.8 0.0 0.6 0.0 1.3 4.8 0.0 1.0 1.6 2.6 SCN9A "ETHA, Nav1.7, NE-NA, NENA, PN1" ENSG00000169432 "Sodium voltage-gated channel alpha subunit 9" Q15858 2 166195185-166376001 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Exocrine glandular cells: 27.7;Hofbauer cells: 50.6;Intestinal endocrine cells: 31.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 17 "plasmacytoid DC: 18.6" "Lineage enriched" "Detected in single" 24 "dendritic cells: 18.6" "Cell line enhanced" "Detected in many" "BJ: 17.2;BJ hTERT+: 12.8;HHSteC: 14.8;hTERT-RPE1: 12.0" "Region enriched" "Detected in some" 5 "hypothalamus: 10.9" "Low region specificity" "Detected in all" "CAB013679, HPA061843" Uncertain Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Plasma membrane, Actin filaments, Focal adhesion sites" "CAB013679: , HPA061843: AB_2684625" "unprognostic (2.10e-1)" "unprognostic (2.83e-1)" "unprognostic (1.13e-1)" "unprognostic (8.98e-5)" "unprognostic (1.47e-3)" "unprognostic (9.43e-3)" "unprognostic (2.28e-2)" "unprognostic (2.24e-1)" "unprognostic (2.23e-1)" "unprognostic (3.64e-1)" "unprognostic (1.45e-1)" "unprognostic (2.27e-1)" "prognostic unfavorable (2.30e-5)" "unprognostic (1.69e-3)" "unprognostic (6.74e-2)" "unprognostic (2.46e-2)" "unprognostic (2.46e-1)" 6.6 4.2 3.8 2.8 9.1 4.2 2.7 0.9 4.4 1.8 10.2 0.5 0.1 1.4 0.9 3.8 2.6 1.2 5.8 2.9 2.8 15.9 4.8 8.3 4.5 3.5 4.1 2.3 2.1 4.8 0.6 11.3 9.2 7.3 2.0 7.0 1.7 1.8 1.9 0.9 1.8 4.2 5.2 2.5 12.4 1.7 16.2 0.4 10.3 1.4 1.9 1.2 3.6 1.8 0.0 18.6 0.7 0.1 0.4 0.0 0.0 0.0 1.9 0.1 0.0 7.4 6.5 0.0 17.2 12.8 4.0 1.3 0.5 0.0 0.0 0.0 2.1 0.2 0.0 4.9 0.6 6.6 0.0 1.6 1.3 1.5 1.4 14.8 0.0 0.0 0.4 0.2 6.8 1.3 12.0 0.8 0.9 4.3 5.0 0.6 0.0 2.6 0.0 1.5 0.0 0.5 0.7 2.5 6.5 1.8 7.2 0.8 7.2 0.0 0.0 0.3 3.8 0.2 0.0 0.0 0.0 1.1 0.1 0.3 0.1 0.0 0.0 2.5 0.0 1.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.7 0.4 0.1 18.6 0.0 0.0 3.8 9.1 0.9 4.4 2.8 15.9 4.1 2.3 7.3 0.4 11.9 18.4 0.9 0.2 0.9 0.2 1.6 5.1 4.0 7.9 5.2 0.0 0.2 3.3 14.9 1.7 2.2 11.3 0.0 27.7 0.4 1.2 0.2 3.5 6.0 50.6 0.0 31.7 20.3 1.5 1.9 1.1 4.3 3.3 0.0 14.6 1.3 18.8 8.6 0.0 12.2 0.0 0.0 1.0 0.0 0.4 0.4 0.9 0.0 10.7 0.1 SDC1 "CD138, SDC, SYND1, syndecan" ENSG00000115884 "Syndecan 1" P18827 2 20200797-20225433 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 113.2;placenta: 228.8" "Cell type enhanced" "Detected in many" 9 "Cholangiocytes: 298.1;Hepatocytes: 520.4;Urothelial cells: 356.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 17 "memory B-cell: 3.9" "Lineage enriched" "Detected in single" 40 "B-cells: 3.9" "Cell line enhanced" "Detected in many" "HBEC3-KT: 62.1;hTCEpi: 57.5;U-251 MG: 59.2;U-266/70: 61.4;U-266/84: 129.2" "Group enriched" "Detected in some" 4 "cerebellum: 10.7;olfactory region: 5.9" "Not detected" "Not detected" "CAB002424, HPA006185, HPA067477" Enhanced Approved "Focal adhesion sites" "Secreted to blood" NA NA 63100000 1600000 "Focal adhesion sites" "CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: " "prognostic unfavorable (2.22e-4)" "unprognostic (6.80e-3)" "unprognostic (6.80e-2)" "unprognostic (7.84e-2)" "prognostic unfavorable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (4.02e-2)" "unprognostic (6.32e-2)" "unprognostic (1.70e-1)" "unprognostic (3.66e-1)" "unprognostic (2.27e-3)" "unprognostic (1.79e-1)" "unprognostic (1.63e-1)" "unprognostic (1.94e-2)" "unprognostic (4.27e-1)" "unprognostic (1.62e-2)" "unprognostic (1.52e-1)" 0.8 3.4 0.5 5.4 0.6 0.0 4.5 0.8 0.7 21.4 18.3 0.5 3.5 14.3 2.3 8.7 103.7 1.6 55.3 0.3 0.4 0.5 68.5 113.2 15.8 6.3 1.9 0.4 1.6 7.0 0.6 0.6 228.8 0.7 13.3 6.2 1.5 16.0 5.2 0.5 69.5 21.9 4.3 0.4 3.7 16.3 2.6 0.4 1.5 3.5 62.3 48.4 30.0 37.7 3.9 0.0 0.0 0.0 0.0 0.0 0.5 31.4 17.6 5.6 14.0 1.5 0.2 17.7 8.8 8.5 8.2 7.0 3.7 19.2 0.0 3.2 6.2 4.5 31.1 2.4 62.1 5.5 0.1 1.6 0.0 1.6 18.8 1.3 1.3 0.1 0.8 57.5 7.4 17.6 11.5 0.9 0.0 0.7 12.3 4.4 18.8 0.0 0.3 5.0 24.0 34.2 0.6 2.0 23.8 10.6 47.2 1.6 13.1 6.6 44.8 2.0 2.3 4.4 0.3 1.3 32.7 10.5 1.2 59.2 61.4 129.2 0.1 9.8 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.6 0.8 0.7 0.4 0.5 1.9 0.4 0.7 0.4 86.4 91.4 3.0 135.6 101.2 0.1 0.8 298.1 2.7 63.7 40.1 0.0 2.4 26.6 54.9 0.0 1.1 102.7 23.3 19.0 43.0 9.7 42.4 5.8 520.4 2.2 20.6 10.4 6.7 9.6 0.0 0.6 5.4 20.3 1.0 72.0 0.0 67.3 73.7 1.1 68.3 0.0 0.0 7.1 0.7 12.8 200.1 209.7 4.4 66.5 356.0 SENP1 ENSG00000079387 "SUMO1/sentrin specific peptidase 1" Q9P0U3 12 48042898-48106308 "Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 60.2" "Cell type enhanced" "Detected in many" 10 "Spermatocytes: 64.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011765, HPA046491" Supported "Nucleoplasm,Focal adhesion sites" NA NA Nucleoplasm "Focal adhesion sites" "HPA011765: AB_1079907, HPA046491: AB_2679672" "unprognostic (2.66e-2)" "unprognostic (6.51e-2)" "unprognostic (3.14e-1)" "unprognostic (5.69e-2)" "unprognostic (2.83e-1)" "unprognostic (1.09e-1)" "prognostic unfavorable (7.72e-5)" "unprognostic (6.48e-2)" "unprognostic (2.44e-3)" "unprognostic (8.20e-3)" "unprognostic (2.57e-1)" "unprognostic (2.23e-1)" "prognostic unfavorable (8.37e-4)" "unprognostic (7.61e-2)" "unprognostic (3.02e-1)" "unprognostic (1.01e-1)" "unprognostic (1.28e-1)" 5.7 3.3 3.0 9.0 4.0 8.4 5.2 5.3 3.2 5.5 4.9 3.8 3.5 3.4 6.2 4.3 5.7 5.2 3.8 3.6 2.7 3.3 3.8 3.9 4.3 7.3 3.0 2.3 6.2 4.4 6.1 11.4 8.1 3.0 4.4 4.7 5.1 20.0 4.7 6.8 6.6 4.5 5.8 4.3 6.4 4.5 60.2 3.6 15.0 5.2 4.8 8.3 5.7 6.3 5.3 3.8 7.1 2.6 3.8 5.5 2.3 7.1 9.2 11.5 8.6 3.4 5.1 8.5 7.7 8.6 13.2 10.8 11.3 11.6 19.4 6.7 7.0 5.2 7.0 14.2 6.8 13.5 17.6 6.4 17.0 8.9 5.4 5.7 15.8 11.5 4.1 5.6 11.9 10.6 5.9 6.9 13.2 14.9 9.3 6.8 5.7 19.7 5.0 10.5 4.9 7.0 18.7 12.1 9.5 3.6 8.8 12.1 8.3 11.1 6.8 4.5 6.8 10.7 7.6 6.3 11.2 10.1 6.5 8.1 9.6 15.5 19.0 6.9 36.8 5.1 2.0 1.8 7.1 4.3 2.6 5.5 2.4 4.2 3.9 3.3 5.3 3.6 4.1 3.8 3.8 2.0 3.8 5.0 2.3 3.0 4.0 5.3 3.2 2.7 3.3 3.0 2.3 3.0 3.6 8.9 6.2 5.6 4.2 3.3 8.2 2.1 7.6 5.3 10.3 3.5 3.9 3.1 3.3 3.0 10.2 6.3 2.5 0.0 5.6 2.8 3.7 3.6 5.8 6.6 3.8 14.3 3.4 7.4 10.0 3.3 5.8 4.8 1.7 5.4 3.7 4.8 4.5 2.0 6.3 3.4 8.3 0.0 3.1 64.4 24.9 5.4 2.3 4.4 3.6 3.0 SHROOM4 KIAA1202 ENSG00000158352 "Shroom family member 4" Q9ULL8 X 50591647-50814302 "Disease related genes, Predicted intracellular proteins" "Actin-binding, Developmental protein" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 27.3" "Group enriched" "Detected in many" 5 "Alveolar cells type 1: 23.8;Alveolar cells type 2: 15.2;Endothelial cells: 36.5;Ito cells: 31.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 10 "basophil: 1.6" "Lineage enriched" "Detected in single" 17 "granulocytes: 1.6" "Cell line enhanced" "Detected in some" "EFO-21: 6.1;HUVEC TERT2: 23.3;RH-30: 4.5;RPTEC TERT1: 5.0;TIME: 8.7;WM-115: 4.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010089, HPA010565" Uncertain Approved "Nucleoplasm,Vesicles,Focal adhesion sites" NA NA "Focal adhesion sites" "Nucleoplasm, Vesicles" "HPA010089: , HPA010565: AB_1079961" "unprognostic (2.55e-2)" "unprognostic (1.43e-1)" "unprognostic (5.56e-2)" "prognostic unfavorable (8.37e-4)" "unprognostic (1.34e-1)" "unprognostic (1.60e-2)" "unprognostic (4.30e-3)" "unprognostic (4.55e-2)" "unprognostic (2.13e-1)" "unprognostic (2.93e-1)" "unprognostic (1.52e-1)" "unprognostic (1.14e-1)" "prognostic unfavorable (4.66e-4)" "unprognostic (7.30e-2)" "unprognostic (2.83e-1)" "unprognostic (1.74e-2)" "unprognostic (2.75e-1)" 13.1 3.5 5.9 3.6 12.1 2.4 10.1 1.9 7.7 6.4 2.9 27.3 1.6 2.4 6.8 3.6 5.2 4.3 5.7 8.5 8.3 4.8 9.7 1.9 21.4 1.9 15.9 6.5 2.5 1.9 3.6 3.7 15.3 13.0 3.6 3.0 4.8 3.5 3.7 6.0 3.2 2.6 7.4 19.7 2.1 2.4 1.5 15.8 0.0 6.3 6.7 2.1 4.8 4.4 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 1.5 0.1 0.0 6.1 0.8 0.0 0.6 3.7 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.4 0.0 0.0 0.4 0.0 23.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 4.5 0.0 5.0 2.2 0.1 0.0 0.0 0.8 1.3 3.3 0.0 0.1 8.7 0.0 0.0 0.0 0.6 0.4 0.0 0.0 1.2 0.2 4.5 1.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.9 12.1 1.9 7.7 8.3 4.8 15.9 6.5 13.0 15.8 23.8 15.2 0.0 1.7 3.2 0.1 2.5 0.0 2.7 2.3 5.2 0.0 0.4 3.3 0.6 0.0 36.5 0.3 0.0 0.2 2.3 1.9 0.8 3.5 1.0 0.5 0.0 2.9 31.3 3.8 0.0 1.1 1.5 0.0 0.0 2.3 2.8 1.3 0.0 1.1 2.6 0.3 0.0 1.4 0.0 0.9 2.8 0.2 0.0 2.6 1.4 SIKE1 "FLJ21168, SIKE" ENSG00000052723 "Suppressor of IKBKE 1" Q9BRV8 1 114769479-114780685 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA024177, HPA025726" Supported Approved "Vesicles,Focal adhesion sites" NA NA "Focal adhesion sites" Vesicles "HPA024177: AB_1848798, HPA025726: AB_1848800" "unprognostic (1.38e-1)" "unprognostic (1.90e-1)" "unprognostic (3.53e-2)" "unprognostic (4.52e-3)" "unprognostic (4.10e-1)" "unprognostic (6.04e-2)" "unprognostic (3.37e-3)" "unprognostic (2.11e-1)" "unprognostic (1.72e-2)" "unprognostic (2.52e-2)" "unprognostic (1.94e-2)" "unprognostic (7.91e-2)" "unprognostic (2.38e-2)" "unprognostic (3.86e-2)" "unprognostic (9.06e-2)" "unprognostic (2.95e-3)" "unprognostic (1.05e-1)" 18.3 15.4 14.5 17.4 15.9 15.3 16.4 23.5 16.3 18.3 17.3 14.5 14.2 16.7 17.2 13.4 18.1 14.3 13.4 20.3 14.2 15.1 24.4 22.2 12.3 19.7 21.1 11.2 17.2 17.5 15.4 22.5 17.1 23.2 15.2 17.3 9.3 17.2 13.9 21.1 21.9 17.5 16.4 19.2 20.6 14.5 11.8 17.9 26.0 19.3 17.1 21.2 17.2 14.2 8.1 9.8 12.3 7.6 9.2 10.3 5.3 8.5 2.4 11.4 10.8 13.7 10.9 12.2 7.1 6.7 10.4 14.1 7.5 4.5 16.0 7.0 6.0 4.5 8.3 12.5 8.5 14.1 10.8 7.3 8.8 7.6 7.7 13.0 10.0 7.2 10.7 9.8 7.5 12.1 6.5 9.3 12.6 13.4 10.3 7.9 38.1 17.5 9.0 25.7 4.8 7.4 10.5 23.4 8.1 7.6 7.8 8.7 9.7 11.2 11.0 12.8 10.6 6.6 33.5 6.5 8.7 11.5 14.5 9.9 8.7 7.5 15.7 12.4 15.2 18.7 12.3 6.0 7.4 8.6 6.4 10.3 7.9 8.0 7.4 7.8 8.1 9.3 9.9 4.0 9.2 7.6 9.8 6.2 5.3 14.5 15.9 23.5 16.3 14.2 15.1 21.1 11.2 23.2 17.9 23.8 11.3 20.5 20.8 28.3 9.9 37.2 20.4 8.1 13.6 29.6 9.8 26.2 43.1 24.9 28.0 21.2 22.5 0.0 22.3 29.0 22.4 24.9 19.6 33.5 24.5 7.9 17.9 24.5 15.8 47.2 26.2 19.8 21.9 18.0 20.8 14.1 27.5 20.1 18.7 46.0 14.7 19.4 21.7 28.6 31.3 31.9 30.1 30.9 19.8 19.5 SLC16A8 "MCT3, REMP" ENSG00000100156 "Solute carrier family 16 member 8" O95907 22 38078134-38084093 "Plasma proteins, Predicted membrane proteins, Transporters" "Symport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "retina: 70.9" "Cell type enhanced" "Detected in some" 9 "Leydig cells: 4.0;Melanocytes: 5.0;Spermatogonia: 4.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 6.1;RT4: 4.5;SiHa: 6.5;T-47d: 7.8;U-266/70: 11.5" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA075017 Enhanced Approved "Intermediate filaments,Focal adhesion sites" No NA "Focal adhesion sites" "Intermediate filaments" "HPA075017: AB_2732276" "unprognostic (1.22e-2)" "unprognostic (2.25e-2)" "unprognostic (5.07e-6)" "unprognostic (2.99e-2)" "unprognostic (1.37e-1)" "unprognostic (1.84e-2)" "unprognostic (2.99e-2)" "unprognostic (1.74e-1)" "unprognostic (1.24e-1)" "unprognostic (1.76e-1)" "unprognostic (1.63e-2)" "unprognostic (1.32e-2)" "unprognostic (2.34e-4)" "unprognostic (7.69e-2)" "unprognostic (1.15e-1)" "unprognostic (4.06e-1)" "unprognostic (9.71e-5)" 1.6 2.6 1.9 0.8 5.1 1.2 0.8 0.8 3.3 0.8 0.8 0.8 0.8 0.5 1.3 0.8 1.1 1.2 2.7 2.9 2.7 2.9 0.8 0.8 0.8 0.9 2.8 0.8 0.8 2.1 0.0 2.6 0.8 1.3 4.0 0.0 70.9 10.0 0.8 1.9 4.2 0.8 0.8 3.7 1.8 2.3 2.0 0.8 0.8 0.9 0.8 0.8 1.6 0.8 0.0 0.0 0.0 0.0 0.5 0.6 0.0 1.4 0.7 1.2 0.2 0.0 0.0 6.1 0.5 0.0 0.0 0.0 1.3 3.5 0.4 1.7 0.0 0.1 0.8 0.0 0.0 0.0 0.0 1.9 0.3 1.0 0.1 0.2 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 1.6 0.0 4.0 0.0 0.0 1.4 0.1 0.1 2.0 0.0 0.0 0.0 4.5 2.0 0.3 6.5 0.3 1.0 0.6 7.8 0.2 0.0 0.0 3.6 0.3 0.0 11.5 1.6 0.1 0.0 0.2 0.2 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 1.9 5.1 0.8 1.2 2.7 2.9 2.8 0.8 1.3 0.8 0.0 0.0 0.0 0.5 1.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.8 0.0 0.0 1.3 0.3 1.6 4.0 0.0 5.0 0.0 0.0 0.9 0.2 0.0 2.1 0.0 0.5 0.0 0.9 0.9 4.1 0.6 0.0 0.0 0.0 0.1 SLC4A7 "NBC3, SBC2, SLC4A6" ENSG00000033867 "Solute carrier family 4 member 7" Q9Y6M7 3 27372721-27484420 "Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 48.5" "Group enriched" "Detected in many" 10 "Cone photoreceptor cells: 691.1;Rod photoreceptor cells: 667.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "hTERT-HME1: 38.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB022494, HPA035857" Enhanced Supported "Plasma membrane,Focal adhesion sites,Cytosol" NA NA "Plasma membrane" "Focal adhesion sites, Cytosol" "CAB022494: , HPA035857: AB_10795135" "unprognostic (2.94e-2)" "unprognostic (6.34e-2)" "unprognostic (1.80e-3)" "unprognostic (1.91e-1)" "unprognostic (8.48e-3)" "unprognostic (2.68e-1)" "unprognostic (6.79e-4)" "unprognostic (4.13e-2)" "unprognostic (1.40e-1)" "unprognostic (1.64e-1)" "unprognostic (1.83e-1)" "unprognostic (8.58e-3)" "prognostic unfavorable (7.91e-6)" "unprognostic (1.09e-2)" "unprognostic (6.68e-2)" "unprognostic (1.93e-1)" "unprognostic (7.26e-2)" 14.5 5.0 3.2 10.5 4.6 3.3 17.0 4.0 4.8 10.8 38.2 5.0 8.8 48.5 8.1 12.6 8.4 6.5 12.5 9.3 5.0 3.8 15.3 3.7 9.3 10.3 4.8 1.9 9.0 3.3 2.4 4.4 5.6 4.5 10.3 6.9 20.0 8.3 8.4 5.6 5.6 43.4 18.2 5.8 9.7 7.8 6.1 5.5 6.8 6.3 14.7 15.5 15.0 14.9 1.8 2.0 0.1 0.9 2.4 3.9 0.7 5.9 11.1 10.0 4.6 4.7 8.4 7.1 20.2 9.4 7.8 6.1 3.0 3.1 13.5 1.7 7.8 7.5 2.6 9.5 9.8 12.4 11.4 3.1 6.2 7.6 3.2 8.1 14.0 5.4 6.7 4.3 11.8 38.2 16.5 12.8 8.9 4.1 4.8 16.0 2.1 13.9 3.2 6.6 0.7 11.0 9.5 7.9 2.7 18.3 4.2 2.5 6.3 9.2 6.8 3.1 8.9 15.5 5.4 8.9 18.4 5.1 12.7 15.6 1.8 1.9 7.7 16.1 9.9 8.4 0.0 0.5 0.0 3.0 0.6 2.0 1.2 3.8 3.9 1.4 1.8 1.5 2.7 0.1 2.4 0.9 2.0 3.2 0.7 3.2 4.6 4.0 4.8 5.0 3.8 4.8 1.9 4.5 5.5 0.0 12.8 13.2 28.2 26.1 65.7 18.7 15.3 5.3 25.0 59.3 691.1 4.5 8.3 13.6 6.7 25.3 5.8 0.0 6.2 23.0 30.2 41.3 23.1 5.9 16.9 6.4 36.7 14.7 33.1 5.9 8.3 36.7 33.7 20.8 50.6 45.2 13.6 12.7 9.2 10.5 667.4 38.8 32.8 32.4 21.7 26.8 6.8 33.0 12.2 33.6 SMIM11A "C21orf51, FAM165B, SMIM11" ENSG00000205670 "Small integral membrane protein 11A" P58511 21 34375480-34407866 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in some" 8 "Alveolar cells type 1: 3.0;Ciliated cells: 4.0" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" HPA051321 Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA051321: AB_2681440" "unprognostic (2.62e-2)" "unprognostic (4.28e-2)" "unprognostic (1.27e-1)" "unprognostic (5.86e-3)" "unprognostic (1.90e-1)" "unprognostic (1.66e-1)" "unprognostic (3.04e-1)" "unprognostic (4.48e-2)" "unprognostic (1.13e-1)" "unprognostic (2.74e-1)" "unprognostic (8.84e-2)" "unprognostic (4.83e-3)" 2.1 6.7 7.8 1.4 7.4 1.0 5.0 4.4 9.5 2.9 4.1 2.2 4.3 6.0 1.4 6.3 4.8 8.8 6.9 6.1 5.1 4.5 5.0 3.3 6.7 5.0 3.8 5.2 4.1 2.4 3.7 6.2 4.8 2.9 16.4 2.6 4.6 3.7 6.5 3.7 17.0 1.7 12.1 5.0 4.3 2.2 4.6 6.5 6.3 4.8 3.4 11.8 3.6 7.7 8.9 0.0 6.0 6.3 5.3 0.0 0.0 4.7 5.8 6.1 6.2 7.6 14.8 4.3 0.4 10.2 5.7 0.0 0.1 8.5 27.3 17.1 3.2 0.0 3.6 4.8 3.9 7.3 0.1 9.1 0.0 4.9 5.9 10.3 9.3 13.7 12.5 3.7 5.7 2.2 3.8 12.6 13.9 17.6 4.9 7.2 20.8 2.6 2.4 5.3 10.5 0.1 8.7 12.4 4.5 15.8 5.1 0.0 14.3 1.7 4.1 10.3 10.6 13.0 5.2 4.4 6.9 7.0 0.3 3.0 6.3 1.8 4.8 2.7 4.6 3.4 5.0 6.5 2.5 4.6 2.5 0.7 3.4 1.2 1.2 11.8 3.6 3.0 1.6 0.0 0.3 0.0 0.2 0.0 0.0 4.0 1.2 0.0 0.0 0.3 1.7 1.1 0.4 0.0 0.0 0.0 0.6 0.3 0.0 0.3 0.0 1.1 0.6 0.0 1.2 1.3 0.3 0.0 0.0 1.3 0.0 0.0 0.9 0.2 0.9 0.0 0.4 1.4 0.4 0.0 0.0 0.6 0.6 0.0 0.1 0.0 0.7 0.1 SMIM11B ENSG00000273590 "Small integral membrane protein 11B" Q8TCY0 21 7744962-7777853 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at transcript level" "Evidence at transcript level" "No human protein/transcript evidence" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "blood: 19.7" "Cell type enhanced" "Detected in some" 16 "Alveolar cells type 1: 14.9;Ciliated cells: 20.1;Club cells: 7.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" HPA051321 Uncertain Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA051321: AB_2681440" "unprognostic (1.99e-1)" "unprognostic (1.78e-1)" "unprognostic (1.35e-1)" 2.2 1.9 1.4 1.4 2.5 0.6 1.8 1.0 2.3 2.8 4.9 1.5 0.3 1.1 5.8 4.0 4.0 0.3 2.2 3.4 0.9 0.0 0.2 1.8 0.0 1.1 2.1 5.4 0.8 0.7 0.9 0.8 1.7 0.0 1.1 0.4 1.2 19.7 11.2 10.3 11.6 9.5 17.6 10.5 14.3 0.5 8.6 17.5 13.2 16.2 10.4 8.0 11.5 5.7 6.5 0.5 4.0 12.4 4.8 11.3 9.4 2.1 16.2 12.7 2.5 4.6 9.5 20.3 10.7 8.3 13.8 22.0 8.9 16.1 9.1 6.4 10.7 9.7 3.6 10.2 23.5 20.6 7.5 5.9 10.5 16.6 12.7 10.5 0.1 9.6 5.3 17.8 18.2 3.4 15.7 0.8 16.3 7.6 13.1 5.9 6.7 6.9 9.4 0.4 6.7 3.6 2.4 10.5 9.1 19.2 11.7 29.0 9.2 5.0 11.6 10.3 14.1 8.7 16.1 16.0 14.7 14.8 11.2 19.7 17.6 15.7 3.1 9.5 9.1 10.8 13.9 10.5 14.9 3.5 0.0 0.5 0.0 0.8 0.0 0.0 20.1 7.9 0.0 0.0 0.2 3.3 0.4 0.2 0.0 0.1 0.0 0.3 0.2 0.0 0.2 4.7 0.4 0.4 0.0 0.0 0.6 1.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.4 1.0 0.1 0.0 0.0 0.2 0.4 0.0 0.2 0.0 0.4 0.3 SNX32 "FLJ30934, SNX6B" ENSG00000172803 "Sorting nexin 32" Q86XE0 11 65833641-65856896 "Predicted intracellular proteins" "Protein transport, Transport" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 16.6" "Cell type enhanced" "Detected in some" 12 "Early spermatids: 10.4;Late spermatids: 8.2;Spermatocytes: 4.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "B-cells: 1.0;dendritic cells: 1.2;T-cells: 3.0" "Cell line enhanced" "Detected in some" "HHSteC: 6.1;HSkMC: 8.0;REH: 2.6;SH-SY5Y: 3.1;U-266/70: 9.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041775 Uncertain Uncertain "Cell Junctions,Focal adhesion sites" NA NA "Cell Junctions, Focal adhesion sites" "HPA041775: AB_10797268" "unprognostic (6.74e-4)" "unprognostic (1.06e-1)" "unprognostic (1.67e-2)" "unprognostic (4.50e-5)" "unprognostic (1.00e-1)" "unprognostic (9.28e-2)" "unprognostic (7.30e-2)" "unprognostic (9.17e-3)" "unprognostic (2.70e-1)" "unprognostic (2.87e-1)" "unprognostic (5.08e-2)" "unprognostic (1.52e-1)" "unprognostic (3.64e-4)" "unprognostic (2.14e-1)" "unprognostic (1.14e-1)" "unprognostic (9.80e-2)" "unprognostic (5.36e-2)" 0.8 1.0 9.0 1.1 16.6 1.3 1.3 3.5 16.1 1.6 2.2 1.6 0.0 3.4 2.0 1.3 0.9 2.5 2.8 0.9 10.2 5.0 0.9 0.7 0.8 1.0 3.6 10.9 1.3 0.8 0.8 0.3 0.9 3.4 0.8 1.9 0.1 0.7 0.9 0.6 1.1 1.5 2.0 1.8 0.9 0.9 3.5 3.7 0.0 0.7 0.0 1.3 1.0 0.2 1.0 1.2 0.2 0.3 0.1 3.0 0.4 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 6.1 0.0 0.7 8.0 0.1 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.4 0.0 0.5 0.3 0.1 0.0 0.0 2.6 0.0 2.3 0.1 0.0 0.0 3.1 0.0 0.0 1.7 0.0 0.0 0.4 0.0 0.3 0.0 0.0 0.0 9.3 1.6 0.0 0.7 0.0 0.3 0.0 0.1 0.0 1.2 0.3 3.0 0.3 1.6 1.2 1.2 1.0 1.4 0.6 0.2 0.1 0.0 0.7 1.2 0.4 9.0 16.6 3.5 15.4 10.2 5.0 3.6 10.9 3.4 3.7 0.0 1.1 0.0 0.3 0.3 1.7 0.8 0.0 1.4 1.2 0.0 0.0 0.0 0.0 0.0 10.4 0.5 0.8 0.0 0.0 0.1 0.6 0.1 3.5 0.0 0.3 0.0 0.0 0.6 0.0 8.2 0.3 0.0 1.7 0.0 0.3 0.8 0.1 0.0 1.1 0.2 0.5 0.0 0.3 4.4 1.3 0.4 0.0 0.0 1.2 0.1 SORBS1 "CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12" ENSG00000095637 "Sorbin and SH3 domain containing 1" Q9BX66 10 95311771-95561414 "Predicted intracellular proteins" Transport "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 126.5" "Cell type enriched" "Detected in many" 7 "Cardiomyocytes: 479.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "basophil: 7.6;eosinophil: 2.2" "Lineage enriched" "Detected in many" 6 "granulocytes: 7.6" "Cell line enhanced" "Detected in many" "CACO-2: 15.2;HMC-1: 26.6;SK-MEL-30: 22.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027559, CAB032850, HPA043084" Enhanced Supported "Plasma membrane,Focal adhesion sites,Centrosome" NA NA "Focal adhesion sites" "Plasma membrane, Centrosome" "CAB032850: AB_2286335, HPA027559: AB_10600812, HPA043084: AB_2678307" "prognostic favorable (2.84e-4)" "unprognostic (3.53e-1)" "unprognostic (1.89e-1)" "unprognostic (7.85e-2)" "unprognostic (3.43e-1)" "unprognostic (1.41e-1)" "unprognostic (2.98e-2)" "unprognostic (5.30e-2)" "unprognostic (1.95e-2)" "unprognostic (1.65e-2)" "unprognostic (3.17e-2)" "unprognostic (1.27e-1)" "unprognostic (3.40e-2)" "unprognostic (3.13e-2)" "unprognostic (1.80e-1)" "unprognostic (2.55e-2)" "unprognostic (5.01e-3)" 95.0 6.4 23.0 16.4 21.6 1.8 23.5 16.8 22.5 14.9 70.2 18.7 22.1 8.1 41.8 12.5 45.0 25.1 28.9 83.7 20.9 8.3 5.9 14.7 8.7 1.4 13.4 14.1 9.8 7.3 17.5 3.5 9.9 19.2 42.0 20.0 6.4 7.2 65.7 46.4 6.3 15.5 126.5 20.6 2.9 40.0 5.5 19.3 0.0 4.0 12.7 1.2 63.9 31.4 0.1 0.0 7.6 1.2 0.6 1.0 0.2 0.7 0.7 6.4 1.6 2.4 0.1 0.9 0.2 0.1 0.2 0.0 15.2 5.7 0.0 1.2 0.1 2.4 0.3 1.2 0.3 0.1 1.8 2.3 3.7 0.2 9.1 0.8 0.0 26.6 0.4 0.2 0.3 0.1 0.1 2.6 0.9 6.0 1.2 0.6 0.4 0.0 0.3 3.0 2.8 1.4 0.5 2.2 0.2 7.2 10.0 2.8 2.0 0.9 0.3 22.8 4.6 1.2 0.2 0.2 0.0 2.3 0.1 1.2 0.8 0.2 0.1 2.8 0.2 6.4 7.6 0.2 2.2 0.7 1.2 1.0 0.1 0.3 0.4 0.0 0.1 0.3 0.1 0.2 0.6 0.2 0.0 0.5 0.2 23.0 21.6 16.8 20.7 20.9 8.3 13.4 14.1 19.2 19.3 20.8 18.1 0.5 5.1 10.3 5.9 479.0 12.7 0.0 2.3 1.8 2.0 17.9 3.3 4.4 61.7 19.0 1.0 0.0 2.6 1.9 15.3 5.3 15.1 42.9 2.7 6.4 5.8 38.6 4.9 26.4 6.9 1.1 13.5 1.0 14.0 18.2 2.8 3.5 72.2 4.3 5.4 0.0 64.3 2.8 4.7 10.9 24.7 0.0 5.2 3.3 SORBS3 "SCAM-1, SH3D4, vinexin" ENSG00000120896 "Sorbin and SH3 domain containing 3" O60504 8 22544986-22575788 "Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 12 "Early spermatids: 147.7;Late spermatids: 378.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015849 Approved Approved "Focal adhesion sites,Cytosol" NA NA 6600 Cytosol "Focal adhesion sites" "HPA015849: AB_1857365" "unprognostic (6.15e-3)" "unprognostic (2.09e-2)" "unprognostic (2.34e-1)" "unprognostic (3.90e-3)" "unprognostic (1.72e-1)" "unprognostic (9.30e-2)" "unprognostic (2.51e-2)" "unprognostic (2.44e-2)" "unprognostic (5.83e-3)" "unprognostic (1.70e-1)" "prognostic favorable (4.88e-4)" "unprognostic (4.21e-2)" "unprognostic (3.08e-3)" "unprognostic (7.41e-2)" "unprognostic (1.58e-1)" "unprognostic (1.65e-1)" "prognostic unfavorable (1.53e-5)" 52.2 22.6 25.0 16.8 23.2 3.3 56.5 31.4 27.0 49.3 28.9 21.9 19.2 19.6 40.6 32.0 27.5 33.8 42.8 32.8 27.3 12.8 28.1 41.8 38.9 28.7 21.3 18.0 49.0 21.7 27.0 24.1 43.3 22.8 38.0 23.7 45.8 36.6 34.5 29.5 32.0 34.5 41.9 24.1 28.6 20.4 36.0 21.2 3.4 29.7 36.2 15.7 38.4 44.7 0.8 5.6 0.4 3.2 4.0 17.4 3.3 22.6 28.6 15.6 17.6 25.4 33.9 16.0 23.3 36.2 27.3 17.0 28.9 10.2 0.2 15.9 36.3 11.0 19.5 23.4 21.3 14.2 15.9 10.2 1.9 16.1 13.2 28.9 0.2 0.1 21.3 15.9 9.5 14.0 30.5 21.1 12.1 4.9 0.7 19.4 8.9 1.9 0.7 5.5 3.9 12.0 21.7 10.6 2.1 12.4 4.4 0.9 14.1 11.4 2.8 14.4 17.1 4.7 8.1 32.8 24.3 17.4 17.7 16.4 0.4 0.6 3.0 14.2 5.4 16.4 0.0 1.6 0.4 8.6 3.2 17.4 0.6 9.4 9.9 5.6 0.8 9.7 5.6 0.4 4.0 0.7 1.9 0.4 3.3 25.0 23.2 31.4 27.0 27.3 12.8 21.3 18.0 22.8 21.2 17.9 4.5 3.0 20.1 26.0 2.0 8.0 25.5 9.4 11.4 12.2 0.0 21.8 8.3 18.5 147.7 38.9 46.6 0.0 16.9 25.1 46.3 33.6 17.3 37.5 30.7 4.8 14.0 75.5 27.9 378.2 56.7 18.7 23.6 1.8 35.7 20.2 20.5 48.2 55.2 20.3 3.1 58.2 68.3 5.5 6.1 18.6 17.2 14.1 25.3 21.6 TADA1 "ADA1, hADA1, HFI1, STAF42, TADA1L" ENSG00000152382 "Transcriptional adaptor 1" Q96BN2 1 166856510-166876327 "Predicted intracellular proteins" "Transcription, Transcription regulation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028651 Approved Supported "Nucleoplasm,Focal adhesion sites,Cytosol" No No Nucleoplasm "Focal adhesion sites, Cytosol" "HPA028651: AB_10602476" "unprognostic (9.53e-3)" "unprognostic (2.31e-1)" "unprognostic (1.05e-2)" "unprognostic (4.10e-2)" "unprognostic (1.55e-1)" "unprognostic (7.09e-2)" "unprognostic (5.99e-3)" "unprognostic (7.31e-2)" "unprognostic (3.35e-2)" "unprognostic (1.22e-2)" "unprognostic (1.40e-1)" "unprognostic (1.98e-2)" "unprognostic (3.64e-2)" "unprognostic (2.73e-2)" "unprognostic (6.35e-2)" "unprognostic (1.07e-1)" "unprognostic (1.26e-2)" 6.5 10.6 13.8 7.1 18.5 17.8 10.2 18.2 20.0 11.3 9.1 17.0 3.4 8.3 10.5 8.6 10.1 9.8 6.6 9.2 13.2 14.6 12.9 28.9 6.7 10.1 11.1 14.3 12.7 7.5 11.3 13.7 12.5 15.0 9.2 10.2 13.4 8.7 8.4 10.7 8.5 9.0 8.5 10.8 7.3 8.0 12.0 10.3 16.7 11.5 7.1 10.9 8.6 7.8 13.4 13.0 8.1 8.2 16.2 19.5 15.1 8.2 7.9 14.9 8.8 4.5 5.8 8.9 4.3 5.3 7.3 6.3 7.2 6.7 15.7 8.5 5.1 5.9 6.3 12.0 7.7 5.9 9.9 11.5 5.2 6.8 11.8 6.7 14.6 9.6 4.4 8.9 4.3 11.0 5.2 5.9 11.9 18.5 9.6 5.6 5.7 18.0 11.6 22.7 13.3 8.9 15.2 6.6 19.9 9.7 11.1 9.6 16.8 7.8 10.1 9.1 14.3 13.8 15.4 4.4 6.0 6.9 6.5 9.1 13.6 18.5 29.4 4.1 6.7 5.6 1.8 8.1 8.1 14.0 8.2 15.5 13.1 15.2 15.8 13.0 13.4 19.5 15.3 1.3 16.2 6.2 8.5 14.3 15.1 13.8 18.5 18.2 20.0 13.2 14.6 11.1 14.3 15.0 10.3 8.9 2.4 2.9 4.3 5.5 7.4 9.4 0.0 4.0 4.5 3.5 7.9 5.3 5.0 3.2 3.4 3.7 3.8 0.0 3.5 6.3 4.0 4.4 4.7 17.1 3.7 1.6 6.9 3.7 5.1 1.3 4.0 2.5 1.7 5.4 5.3 6.6 3.0 0.0 2.8 5.0 5.7 0.0 3.8 4.7 12.9 4.4 6.1 5.3 5.1 3.2 TAS2R42 "hT2R55, T2R24, T2R55, TAS2R55" ENSG00000186136 "Taste 2 receptor member 42" Q7RTR8 12 11185993-11186937 "G-protein coupled receptors, Predicted membrane proteins" "Sensory transduction, Taste" "G-protein coupled receptor, Receptor, Transducer" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in single" "brain: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA036149 Uncertain Approved "Nucleoplasm,Actin filaments,Focal adhesion sites" NA NA "Nucleoplasm, Actin filaments" "Focal adhesion sites" "HPA036149: AB_10672080" "unprognostic (2.45e-2)" "unprognostic (4.17e-2)" 0.0 0.7 0.2 0.2 0.4 0.0 0.0 1.0 0.2 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.3 0.1 0.6 0.0 0.7 0.0 0.0 0.4 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.4 0.2 0.4 0.1 0.0 0.0 0.0 0.7 0.4 0.0 0.5 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.5 0.0 0.0 0.1 0.0 0.5 0.0 0.4 0.7 0.1 0.6 0.4 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TATDN3 ENSG00000203705 "TatD DNase domain containing 3" Q17R31 1 212791828-212816626 "Predicted intracellular proteins" "Hydrolase, Nuclease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA032092 Approved Approved "Nucleoplasm,Golgi apparatus,Focal adhesion sites" NA NA Nucleoplasm "Golgi apparatus, Focal adhesion sites" "HPA032092: AB_10671086" "unprognostic (9.81e-2)" "unprognostic (1.57e-2)" "unprognostic (1.20e-1)" "unprognostic (3.17e-1)" "unprognostic (1.46e-1)" "unprognostic (1.74e-1)" "unprognostic (9.38e-2)" "unprognostic (4.16e-2)" "unprognostic (3.80e-1)" "unprognostic (3.88e-2)" "unprognostic (3.34e-3)" "unprognostic (5.02e-3)" "prognostic favorable (1.59e-4)" "unprognostic (1.93e-1)" "unprognostic (2.44e-1)" "unprognostic (3.13e-3)" "unprognostic (2.96e-3)" 13.0 14.8 14.4 10.9 24.7 11.9 11.0 12.5 22.9 7.6 8.8 16.6 6.8 7.0 8.5 15.2 8.3 8.7 8.3 20.7 13.7 15.2 18.3 11.1 8.5 16.2 14.5 18.9 10.1 11.3 12.8 11.9 8.0 22.1 8.0 8.6 11.4 9.4 8.2 29.4 7.4 8.1 11.6 15.5 11.5 11.9 10.5 12.0 11.3 13.1 8.3 10.8 10.6 6.5 15.6 30.1 23.8 24.1 5.3 6.9 8.7 6.6 6.6 5.8 8.6 9.4 14.1 13.4 7.4 8.0 5.9 7.4 1.7 9.4 14.7 7.0 6.3 3.4 4.3 7.1 10.0 6.4 9.0 9.2 7.4 5.5 3.2 10.9 17.7 9.3 11.3 7.2 8.0 19.9 6.4 8.5 21.0 14.4 12.3 6.5 3.1 15.1 5.9 7.8 8.2 4.3 8.7 11.0 26.3 6.1 3.3 12.4 10.6 8.1 13.8 16.2 11.0 14.7 11.0 5.8 4.5 6.0 9.3 7.2 11.0 16.9 24.4 11.6 14.1 6.7 8.5 15.6 23.8 5.5 23.7 4.9 15.6 6.9 6.6 18.4 12.7 5.5 6.6 17.5 5.3 24.1 30.1 6.4 8.7 14.4 24.7 12.5 22.9 13.7 15.2 14.5 18.9 22.1 12.0 6.0 15.2 14.3 8.7 3.9 14.8 33.0 10.2 10.7 3.4 3.5 17.7 10.9 34.9 14.4 7.5 6.3 3.9 0.0 14.5 14.4 6.0 4.5 6.9 5.5 16.4 14.3 9.8 4.3 25.0 2.9 4.9 17.6 13.5 30.7 4.0 14.9 11.0 7.0 4.6 20.7 27.3 6.5 6.9 21.3 16.9 3.9 7.8 10.2 5.8 5.5 TES "DKFZP586B2022, TESS-2, TESTIN" ENSG00000135269 "Testin LIM domain protein" Q9UGI8 7 116210493-116258783 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Alveolar cells type 1: 226.3;Early spermatids: 327.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "EFO-21: 51.4;hTCEpi: 58.1;SK-BR-3: 58.3" "Low region specificity" "Detected in single" "HPA015269, HPA018123" Approved Supported "Plasma membrane,Cell Junctions,Focal adhesion sites,Cytosol" NA NA "Focal adhesion sites, Cytosol" "Plasma membrane, Cell Junctions" "HPA015269: AB_1857899, HPA018123: AB_1857900" "unprognostic (9.81e-2)" "unprognostic (5.53e-3)" "unprognostic (4.79e-2)" "unprognostic (1.31e-1)" "unprognostic (4.01e-1)" "unprognostic (6.08e-3)" "unprognostic (1.84e-3)" "unprognostic (4.81e-3)" "unprognostic (8.81e-3)" "unprognostic (6.19e-3)" "prognostic unfavorable (1.20e-5)" "unprognostic (1.60e-2)" "prognostic favorable (8.71e-5)" "unprognostic (1.50e-1)" "unprognostic (5.47e-2)" "unprognostic (2.36e-2)" "unprognostic (3.86e-1)" 12.1 2.9 1.2 36.4 1.5 8.6 22.1 0.8 1.2 42.4 53.1 1.5 43.9 9.3 47.6 21.2 22.6 19.5 15.3 7.9 1.6 1.4 14.3 4.6 16.8 20.3 1.9 0.7 17.1 12.3 3.1 4.2 21.2 3.3 26.1 16.8 5.0 19.0 50.9 5.2 9.1 27.4 84.5 3.0 19.1 25.2 18.4 0.7 17.1 26.3 11.2 18.4 71.6 33.9 26.8 21.9 56.8 39.6 49.0 40.5 34.7 24.4 5.2 5.9 0.0 2.6 6.7 13.8 12.8 6.2 2.4 2.3 12.9 27.3 0.0 51.4 8.9 0.3 25.2 3.1 18.8 5.9 12.1 10.1 2.4 12.1 6.3 15.7 11.1 0.0 14.9 58.1 8.3 21.1 16.6 6.7 0.0 2.5 8.6 0.6 5.0 0.0 0.1 3.9 28.4 14.9 0.0 0.0 9.6 24.2 9.4 2.7 25.5 18.7 58.3 14.1 17.9 0.0 4.5 11.3 0.1 0.3 18.9 0.1 20.5 9.9 0.2 1.6 5.7 19.4 56.8 20.2 53.4 40.5 32.6 39.0 26.8 31.0 36.6 21.9 23.8 31.0 35.0 10.5 49.0 39.6 5.4 31.5 34.7 1.2 1.5 0.8 1.2 1.6 1.4 1.9 0.7 3.3 0.7 226.3 36.4 52.3 147.2 177.9 2.3 14.5 38.2 84.3 97.8 34.9 11.8 16.7 18.3 104.8 327.4 24.0 101.5 0.0 97.9 69.1 27.0 83.0 17.4 9.9 14.9 1.6 48.4 15.4 52.9 82.2 1.7 62.3 27.0 36.1 57.8 23.0 142.2 58.6 0.4 10.3 12.6 6.5 20.6 18.2 9.7 107.3 24.4 57.4 44.4 125.3 TGFB1I1 "ARA55, Hic-5, TSC-5" ENSG00000140682 "Transforming growth factor beta 1 induced transcript 1" O43294 16 31471585-31477960 "Predicted intracellular proteins" "Differentiation, Wnt signaling pathway" Activator "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 11 "Leydig cells: 85.4;Peritubular cells: 168.3;Sertoli cells: 219.9;Smooth muscle cells: 134.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "basophil: 8.8" "Group enriched" "Detected in many" 4 "granulocytes: 8.8;T-cells: 2.5" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 33.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" CAB020844 Enhanced Supported "Focal adhesion sites,Cytosol" NA NA 13000000 "Focal adhesion sites" Cytosol "CAB020844: " "unprognostic (5.80e-2)" "unprognostic (3.09e-2)" "unprognostic (5.34e-2)" "unprognostic (1.18e-1)" "unprognostic (6.64e-2)" "unprognostic (9.52e-2)" "unprognostic (1.89e-1)" "unprognostic (4.95e-2)" "unprognostic (4.19e-2)" "unprognostic (1.71e-2)" "unprognostic (1.38e-1)" "unprognostic (1.39e-1)" "prognostic unfavorable (6.06e-8)" "unprognostic (1.06e-2)" "unprognostic (6.57e-2)" "unprognostic (2.25e-2)" "prognostic unfavorable (7.73e-5)" 16.8 4.1 1.0 14.4 1.4 0.3 18.5 1.2 1.6 42.9 51.1 1.8 22.1 5.8 80.7 22.7 34.1 28.9 36.2 11.8 0.9 0.7 8.6 2.8 11.2 10.6 1.1 1.3 40.3 2.2 5.1 1.8 11.5 2.3 37.7 10.4 11.1 7.1 34.7 5.7 5.9 12.8 71.9 1.8 11.5 19.6 10.9 0.9 0.7 5.8 7.8 3.6 69.9 23.5 1.3 0.5 8.8 0.0 0.0 2.5 2.3 4.2 5.3 8.7 0.0 8.6 15.8 0.1 22.8 21.4 14.3 9.7 2.2 1.4 0.0 21.5 19.5 9.6 6.3 1.8 4.2 18.8 0.0 0.0 5.0 9.8 1.1 22.0 0.0 6.5 10.2 6.2 8.9 5.3 33.8 9.4 0.0 0.5 0.0 17.4 0.0 0.0 0.5 0.4 0.4 5.4 0.0 10.4 0.0 4.0 2.1 0.0 6.2 8.8 0.0 4.4 7.4 0.0 0.5 25.4 25.8 6.3 7.1 9.9 0.0 0.0 0.0 11.4 0.2 15.8 8.8 0.0 0.1 0.3 0.0 0.5 1.3 1.4 0.2 0.1 0.5 0.2 1.0 0.2 0.0 0.0 0.5 2.5 2.3 1.0 1.4 1.2 1.6 0.9 0.7 1.1 1.3 2.3 0.9 6.0 3.7 0.0 18.4 11.2 0.4 8.1 2.5 0.0 2.3 7.0 0.0 1.2 6.6 27.3 0.9 35.1 1.6 0.0 20.6 1.5 58.4 4.7 5.8 0.0 11.3 0.0 0.0 30.7 0.8 2.1 85.4 3.2 38.8 7.2 4.2 7.1 19.0 0.0 168.3 12.6 1.3 219.9 134.8 1.1 2.7 9.8 1.5 0.5 5.3 4.4 TLE2 "ESG, ESG2, FLJ41188, GRG2" ENSG00000065717 "Transducin like enhancer of split 2" Q04725 19 2997638-3047635 "Predicted intracellular proteins" "Transcription, Transcription regulation, Wnt signaling pathway" Repressor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 85.3" "Cell type enhanced" "Detected in many" 4 "Bipolar cells: 37.8" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 85.3" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 10 "B-cells: 3.1;T-cells: 3.4" "Cell line enhanced" "Detected in many" "AN3-CA: 25.1;RT4: 20.0;T-47d: 14.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049103 Enhanced Supported "Nuclear bodies,Focal adhesion sites" NA NA "Nuclear bodies" "Focal adhesion sites" "HPA049103: AB_2680631" "unprognostic (1.87e-3)" "unprognostic (1.42e-1)" "unprognostic (2.89e-1)" "prognostic favorable (2.51e-4)" "unprognostic (2.23e-1)" "unprognostic (1.01e-1)" "unprognostic (9.87e-3)" "unprognostic (6.40e-3)" "unprognostic (2.44e-1)" "unprognostic (1.81e-2)" "prognostic favorable (2.39e-6)" "unprognostic (2.12e-1)" "prognostic favorable (9.49e-6)" "unprognostic (2.66e-1)" "unprognostic (5.99e-2)" "unprognostic (2.60e-1)" "prognostic favorable (8.88e-4)" 13.4 9.6 9.2 4.6 5.7 1.3 38.3 85.3 16.5 10.9 11.4 4.9 28.6 8.1 15.7 6.6 5.5 13.3 8.5 19.9 5.5 7.6 11.9 3.5 12.5 5.4 8.3 5.3 12.4 16.5 13.8 6.4 7.3 9.7 12.9 4.6 20.6 55.5 27.1 38.5 6.4 5.3 26.2 13.3 10.9 7.4 6.3 4.8 1.1 17.5 5.7 3.2 19.2 27.6 3.1 0.0 0.3 0.0 0.0 3.4 0.7 0.3 1.6 0.1 25.1 4.0 0.7 5.5 0.2 0.0 1.3 0.6 7.8 2.8 0.1 3.5 1.7 0.7 4.4 4.1 1.5 0.3 0.7 1.2 0.0 1.8 0.3 5.1 0.0 0.2 5.6 0.7 2.9 0.0 1.4 10.1 7.1 9.0 0.1 0.1 8.4 0.2 0.1 0.1 0.8 1.6 2.0 1.2 2.3 3.3 20.0 1.3 6.5 1.6 12.5 0.7 0.5 14.6 0.0 6.7 8.2 8.6 0.4 0.2 0.3 0.2 1.6 0.2 1.9 1.5 0.0 0.0 0.3 3.2 0.0 2.3 3.1 2.0 1.0 0.0 0.5 3.4 2.1 0.0 0.0 0.0 0.0 0.7 0.7 9.2 5.7 85.3 16.5 5.5 7.6 8.3 5.3 9.7 4.8 17.9 14.5 0.5 30.2 3.2 37.8 24.4 12.7 5.3 1.2 34.9 2.0 1.3 1.7 9.4 3.3 5.9 3.8 0.0 2.4 3.5 6.9 26.7 0.0 3.0 0.6 1.6 13.3 14.7 0.8 7.6 10.9 1.4 5.0 0.0 12.7 18.3 3.3 8.6 14.2 1.1 2.9 0.0 13.3 1.0 3.4 1.9 5.6 1.5 24.3 27.4 TLN1 "ILWEQ, TLN" ENSG00000137076 "Talin 1" Q9Y490 9 35696948-35732395 "Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002006, HPA004748" Supported Supported "Plasma membrane,Focal adhesion sites,Centriolar satellite,Cytosol" NA NA 3600000000 "Focal adhesion sites, Cytosol" "Plasma membrane, Centriolar satellite" "CAB002006: , HPA004748: AB_1857760" "unprognostic (9.71e-2)" "unprognostic (2.02e-2)" "prognostic unfavorable (5.56e-4)" "unprognostic (1.96e-1)" "unprognostic (5.55e-2)" "unprognostic (2.52e-1)" "unprognostic (3.18e-2)" "unprognostic (5.07e-2)" "unprognostic (1.94e-1)" "unprognostic (6.46e-2)" "unprognostic (1.82e-1)" "unprognostic (1.27e-1)" "prognostic favorable (7.21e-4)" "unprognostic (1.36e-1)" "unprognostic (2.71e-2)" "unprognostic (7.83e-2)" "unprognostic (8.83e-3)" 47.4 23.7 10.9 29.3 16.6 25.1 38.1 9.6 11.8 34.7 64.0 18.8 22.8 13.0 57.4 20.6 41.2 38.3 48.4 30.3 11.1 7.1 30.5 36.1 33.0 26.0 17.9 7.3 39.0 12.8 19.6 14.6 30.4 14.4 39.5 15.5 22.8 14.9 43.6 24.5 16.5 27.6 87.0 12.4 54.1 38.2 17.3 14.1 33.4 20.7 12.5 20.7 72.5 49.6 3.3 6.8 12.7 9.2 4.8 7.1 7.1 11.4 19.2 11.9 16.3 40.9 31.1 13.6 32.0 35.1 31.1 28.2 15.8 5.1 13.9 10.6 59.0 19.7 6.2 13.9 19.9 22.8 31.3 9.0 31.6 24.9 14.0 25.4 19.1 52.8 37.6 9.5 45.7 21.7 42.9 47.6 12.1 10.8 14.3 41.0 5.0 12.8 5.0 9.7 5.2 14.8 17.3 6.9 8.1 15.5 9.2 2.7 11.3 15.6 8.7 10.2 11.3 7.4 13.2 57.3 49.6 19.3 15.1 25.7 5.0 4.9 9.7 38.4 10.3 44.7 6.7 7.0 8.4 7.1 7.8 5.9 3.3 4.2 5.4 5.3 3.2 2.0 4.2 12.7 4.8 9.2 6.8 2.8 7.1 10.9 16.6 9.6 11.8 11.1 7.1 17.9 7.3 14.4 14.1 101.3 67.1 67.7 36.3 35.6 10.9 115.6 40.8 50.9 78.5 50.6 9.8 34.4 19.9 88.6 37.6 106.8 42.8 46.7 54.0 72.5 71.0 43.2 194.8 46.5 103.3 14.3 32.7 76.1 163.8 17.2 92.0 155.9 21.9 147.9 23.2 33.9 81.9 24.6 120.9 45.4 17.3 200.5 199.7 26.8 25.9 23.2 49.2 86.7 23.2 31.2 TLN2 "ILWEQ, KIAA0320" ENSG00000171914 "Talin 2" Q9Y4G6 15 62390526-62844631 "Plasma proteins, Predicted intracellular proteins" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 36.9" "Cell type enhanced" "Detected in many" 5 "Horizontal cells: 46.1;Rod photoreceptor cells: 47.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 29.8;hTERT-HME1: 24.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017194, HPA051828, HPA054787" Enhanced Supported "Focal adhesion sites,Cytosol" NA NA 81000000 "Focal adhesion sites, Cytosol" "CAB017194: , HPA051828: AB_2732570, HPA054787: AB_2732587" "prognostic favorable (6.53e-4)" "unprognostic (2.61e-1)" "unprognostic (9.47e-2)" "unprognostic (8.95e-2)" "unprognostic (3.74e-1)" "unprognostic (1.43e-1)" "unprognostic (8.24e-2)" "unprognostic (9.94e-2)" "unprognostic (1.68e-1)" "unprognostic (6.02e-2)" "unprognostic (2.81e-2)" "unprognostic (1.91e-1)" "prognostic favorable (1.81e-6)" "prognostic favorable (7.74e-4)" "unprognostic (1.34e-1)" "unprognostic (5.79e-2)" "unprognostic (2.30e-1)" 12.5 3.1 7.0 12.1 7.0 2.3 5.3 5.4 18.9 5.6 24.3 4.0 1.7 3.3 6.5 4.2 3.4 3.2 6.3 8.5 6.8 6.0 36.9 1.8 1.9 1.3 6.2 4.2 7.0 3.3 2.3 3.0 2.4 4.5 3.1 5.4 5.5 5.4 1.6 16.9 1.6 16.6 6.9 9.6 0.8 4.1 3.5 1.3 0.9 29.0 4.5 1.3 4.3 7.0 0.0 0.7 0.0 0.1 0.0 0.1 0.0 0.8 2.7 3.9 4.6 29.8 2.8 4.4 6.6 5.2 6.1 6.0 7.2 0.9 2.2 3.0 11.4 10.1 1.1 5.0 1.0 5.3 7.1 0.5 0.2 10.8 4.7 1.0 0.7 0.2 5.2 2.7 8.1 24.2 3.5 0.2 2.8 0.2 0.1 10.1 3.5 0.3 0.3 6.9 12.4 2.0 2.7 9.9 2.7 3.2 5.5 0.9 4.5 5.0 0.5 1.7 8.8 1.4 1.7 1.9 11.0 15.0 17.7 16.8 0.1 0.4 1.4 5.0 1.6 13.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.0 7.0 7.0 5.4 12.9 6.8 6.0 6.2 4.2 4.5 1.3 0.0 2.7 1.3 1.5 2.2 11.7 35.9 2.5 0.0 1.2 26.2 35.3 1.0 10.0 3.4 3.4 4.9 16.5 0.0 3.3 22.8 11.6 1.5 0.0 10.6 4.5 46.1 2.4 4.3 5.6 4.0 10.9 5.1 0.0 1.0 16.7 10.1 2.9 17.3 14.9 25.8 47.3 0.0 7.6 2.6 19.4 1.4 1.1 0.0 27.9 1.4 TM4SF20 "FLJ22800, TCCE518" ENSG00000168955 "Transmembrane 4 L six family member 20" Q53R12 2 227362156-227381995 "Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Autism spectrum disorder" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 86 "intestine: 147.8" "Cell type enhanced" "Detected in some" 23 "Early spermatids: 33.2;Enterocytes: 27.7;Late spermatids: 61.3;Paneth cells: 11.5" "Group enriched" "Detected in many" 6 "colorectal cancer: 5.0;liver cancer: 4.7;pancreatic cancer: 5.5;stomach cancer: 11.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "A549: 7.2;RPMI-8226: 4.5" "Not detected" "Not detected" "Not detected" "Not detected" "HPA051838, HPA063184, HPA065531" Uncertain Supported "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane, Focal adhesion sites" "HPA051838: AB_2681631, HPA063184: AB_2684958, HPA065531: AB_2685506" "unprognostic (4.68e-2)" "unprognostic (1.13e-1)" "unprognostic (8.75e-2)" "unprognostic (4.96e-2)" "unprognostic (2.84e-2)" "unprognostic (1.63e-1)" "unprognostic (2.51e-1)" "unprognostic (2.36e-1)" "unprognostic (2.95e-1)" "unprognostic (1.20e-2)" "unprognostic (1.19e-1)" "unprognostic (3.44e-3)" "unprognostic (7.76e-2)" "unprognostic (2.60e-2)" "unprognostic (3.04e-3)" 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 46.5 0.0 0.0 73.5 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.9 0.0 0.1 0.0 0.1 0.1 147.8 0.2 0.1 0.1 0.1 1.2 0.0 0.0 0.1 0.0 0.0 0.1 0.1 1.1 1.2 1.1 0.5 1.7 0.7 0.0 0.1 7.2 0.2 0.1 0.0 0.0 1.3 0.9 0.1 0.0 0.0 1.4 0.5 0.2 0.1 0.4 0.2 0.2 0.0 0.0 0.1 0.1 0.4 0.0 1.3 0.2 0.0 0.5 0.3 0.0 0.1 0.0 0.0 0.4 0.0 0.4 0.4 0.8 0.3 0.0 0.1 1.6 0.3 0.1 0.1 0.5 0.1 4.5 0.1 0.3 0.6 1.7 1.1 0.1 0.0 0.1 0.3 0.1 0.3 0.6 0.3 2.0 0.2 0.5 0.3 0.4 0.2 0.2 0.2 0.8 0.5 0.1 0.7 0.3 0.3 0.7 0.4 0.4 0.0 1.1 0.7 0.5 1.1 1.7 0.1 1.2 0.4 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.2 0.0 27.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 61.3 0.0 0.0 0.0 0.0 0.6 0.2 0.0 11.5 0.7 0.0 0.2 0.0 0.0 0.5 0.2 0.0 0.0 0.0 1.2 0.0 TMEM139 FLJ90586 ENSG00000178826 "Transmembrane protein 139" Q8IV31 7 143279957-143288048 "Predicted membrane proteins, Transporters" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 25.1;kidney: 22.6;placenta: 28.0" "Cell type enhanced" "Detected in many" 7 "Collecting duct cells: 48.8;Ductal cells: 42.9;Enterocytes: 54.0;Proximal tubular cells: 67.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "intermediate monocyte: 3.2" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "A-431: 9.7;CAPAN-2: 18.3;EFO-21: 12.9;RPTEC TERT1: 32.2;SK-BR-3: 11.3;T-47d: 31.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA036982, HPA036983" Approved Approved "Plasma membrane,Focal adhesion sites" NA NA "Plasma membrane" "Focal adhesion sites" "HPA036982: AB_2675413, HPA036983: AB_10672275" "unprognostic (2.58e-1)" "unprognostic (4.38e-1)" "unprognostic (6.62e-3)" "unprognostic (1.41e-1)" "unprognostic (2.10e-1)" "unprognostic (2.16e-3)" "unprognostic (2.83e-2)" "unprognostic (4.90e-2)" "unprognostic (1.60e-1)" "unprognostic (2.82e-2)" "prognostic unfavorable (1.66e-4)" "unprognostic (2.89e-1)" "prognostic favorable (3.05e-5)" "unprognostic (1.73e-1)" "unprognostic (1.42e-2)" "unprognostic (2.83e-2)" "unprognostic (9.08e-3)" 1.5 2.2 0.9 2.8 1.9 0.0 2.1 0.6 1.6 6.3 14.7 6.0 1.5 22.7 1.6 3.5 0.4 4.6 4.8 2.3 1.6 1.1 22.6 7.8 5.5 0.1 4.2 0.7 0.9 9.6 6.4 2.0 28.0 4.8 1.6 2.9 1.4 6.1 2.2 0.1 1.1 25.1 0.4 13.4 0.8 2.0 3.0 2.1 0.1 8.8 0.4 0.7 2.1 2.4 0.5 0.3 0.9 3.2 0.0 2.0 0.4 9.7 0.7 0.1 0.0 0.0 0.0 6.5 0.1 0.0 0.0 0.0 2.3 18.3 0.1 12.9 0.0 0.8 8.3 0.0 4.2 0.0 0.1 0.0 0.0 1.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.6 0.0 0.2 0.0 0.6 0.7 0.4 0.0 0.2 0.7 0.1 0.1 0.0 32.2 2.5 0.1 0.0 0.5 11.3 0.0 0.2 31.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.9 0.0 3.2 0.0 0.5 1.3 0.8 0.0 0.0 1.1 0.6 0.0 0.0 2.4 0.3 2.0 0.4 0.9 1.9 0.6 1.6 1.6 1.1 4.2 0.7 4.8 2.1 14.9 5.1 0.0 2.4 0.1 0.0 2.0 35.7 2.7 5.7 48.8 0.0 26.6 29.9 42.9 12.0 0.3 54.0 0.0 4.0 4.7 0.3 0.3 0.0 13.4 1.7 0.0 3.5 1.3 0.6 8.8 0.0 0.1 5.0 1.8 4.3 8.3 23.3 23.0 0.0 67.4 0.0 0.0 0.0 0.0 0.1 0.0 5.4 0.0 7.4 1.2 TMEM260 "C14orf101, FLJ20392" ENSG00000070269 "Transmembrane protein 260" Q9NX78 14 56488354-56650606 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "cervix, uterine: 61.0" "Cell type enhanced" "Detected in many" 7 "Early spermatids: 69.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003502 Uncertain Approved "Nucleoplasm,Focal adhesion sites,Cytosol" NA NA "Nucleoplasm, Cytosol" "Focal adhesion sites" "HPA003502: AB_1078314" "unprognostic (4.63e-2)" "unprognostic (2.41e-2)" "unprognostic (1.98e-1)" "unprognostic (1.73e-2)" "unprognostic (2.51e-1)" "unprognostic (3.58e-2)" "unprognostic (2.04e-1)" "prognostic favorable (7.11e-4)" "unprognostic (7.14e-2)" "unprognostic (1.89e-1)" "unprognostic (1.95e-3)" "unprognostic (3.22e-1)" "unprognostic (2.23e-3)" "unprognostic (5.81e-2)" "unprognostic (8.11e-2)" "unprognostic (1.32e-1)" "unprognostic (3.84e-2)" 7.8 7.4 7.3 11.0 10.6 3.8 9.1 13.3 9.9 61.0 8.8 13.7 11.6 8.1 11.8 12.1 6.7 11.4 10.3 6.0 8.9 8.6 10.7 8.7 8.4 8.8 10.8 7.5 14.8 13.6 12.4 17.2 8.7 9.7 8.7 9.1 8.7 7.4 13.0 5.2 8.6 10.7 8.9 12.2 9.2 8.4 10.1 8.3 17.6 12.6 4.6 8.8 10.1 9.7 2.0 4.6 2.9 2.8 6.3 3.5 2.0 7.4 5.2 4.0 8.6 14.4 11.9 7.9 7.9 8.8 5.2 6.3 2.4 5.5 6.0 7.8 5.9 5.9 8.6 9.3 5.8 8.3 7.5 4.7 3.9 2.4 3.3 10.1 5.4 9.4 14.5 10.4 2.9 10.1 9.6 6.8 4.7 4.8 6.5 6.8 4.9 2.8 2.0 3.7 12.2 8.3 4.0 6.4 2.0 8.8 11.0 8.5 4.2 8.9 6.5 5.2 7.9 8.2 8.4 9.5 10.6 4.1 7.9 3.9 3.9 3.1 3.5 6.7 4.0 5.2 0.0 2.8 2.9 3.5 1.9 2.4 1.8 2.4 1.8 2.2 2.0 3.2 2.3 1.4 6.3 1.7 4.6 2.9 2.0 7.3 10.6 13.3 9.9 8.9 8.6 10.8 7.5 9.7 8.3 17.9 12.1 4.2 7.4 4.7 14.2 2.9 0.0 17.4 5.7 21.0 3.9 7.9 1.7 6.8 69.7 4.7 6.3 0.0 3.3 6.5 6.7 8.2 11.5 7.5 5.5 6.4 17.2 8.6 13.9 25.8 14.1 7.8 1.7 5.4 10.8 5.6 5.0 7.0 10.3 3.7 17.1 0.0 4.2 7.9 8.5 4.8 9.3 5.7 10.8 6.8 TMEM35A "FLJ14084, TMEM35" ENSG00000126950 "Transmembrane protein 35A" Q53FP2 X 101078720-101096364 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 33.8;seminal vesicle: 46.4" "Not detected" "Not detected" "Cancer enhanced" "Detected in many" "glioma: 6.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 6.5;HUVEC TERT2: 32.3;SH-SY5Y: 8.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048583 Enhanced Supported Supported "Vesicles,Focal adhesion sites,Cytosol" NA NA Vesicles "Focal adhesion sites, Cytosol" "HPA048583: AB_2680451" "unprognostic (7.98e-2)" "unprognostic (7.22e-2)" "unprognostic (1.21e-2)" "unprognostic (1.35e-2)" "unprognostic (3.02e-2)" "unprognostic (3.89e-3)" "unprognostic (2.77e-2)" "unprognostic (6.66e-3)" "unprognostic (1.05e-1)" "unprognostic (3.34e-3)" "unprognostic (9.20e-2)" "unprognostic (4.72e-2)" "unprognostic (3.49e-4)" "unprognostic (5.91e-2)" "unprognostic (1.85e-1)" "unprognostic (1.48e-2)" "unprognostic (9.37e-3)" 3.6 6.7 12.8 1.7 28.2 0.7 1.3 21.2 28.6 3.3 17.3 2.5 6.8 3.5 7.4 3.9 10.4 4.3 3.6 1.1 14.4 33.8 1.1 0.7 2.6 0.8 12.2 10.0 7.7 0.9 6.1 1.5 0.8 30.0 20.5 9.1 2.9 1.0 46.4 1.3 0.9 4.1 11.8 3.9 1.3 3.4 1.8 2.3 0.0 1.3 0.0 0.9 13.3 2.7 0.2 0.0 0.2 0.1 0.6 0.8 0.4 0.0 0.0 3.4 0.0 2.5 6.5 0.0 0.6 0.4 0.3 0.1 0.0 0.0 0.0 0.0 1.9 0.0 0.0 2.1 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 2.2 0.0 1.1 0.0 4.7 32.3 0.0 0.0 0.0 4.1 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.4 8.3 0.0 0.0 0.0 0.8 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.5 0.2 0.5 0.2 0.0 0.0 0.6 0.4 0.2 0.6 0.1 0.0 0.8 0.4 12.8 28.2 21.2 28.6 14.4 33.8 12.2 10.0 30.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TMEM52B "C12orf59, FLJ31166" ENSG00000165685 "Transmembrane protein 52B" Q4KMG9 12 10170542-10191801 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 23 "kidney: 85.1" "Cell type enriched" "Detected in some" 16 "Distal tubular cells: 603.5" "Cancer enriched" "Detected in some" 5 "renal cancer: 6.9" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "myeloid DC: 3.7" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 8 "CACO-2: 46.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA058096 Enhanced Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA058096: AB_2683603" "unprognostic (1.10e-2)" "unprognostic (7.61e-2)" "unprognostic (1.37e-3)" "unprognostic (1.22e-1)" "unprognostic (1.67e-1)" "unprognostic (5.33e-3)" "unprognostic (1.37e-1)" "unprognostic (8.65e-2)" "unprognostic (7.14e-4)" "unprognostic (2.23e-1)" "unprognostic (6.36e-2)" "unprognostic (7.33e-2)" "unprognostic (3.24e-2)" "unprognostic (5.80e-2)" "unprognostic (5.51e-2)" "unprognostic (1.66e-1)" "unprognostic (3.18e-1)" 0.1 0.0 0.1 0.1 0.6 0.9 0.1 0.1 0.6 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 85.1 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.0 0.1 2.0 0.1 0.1 0.0 0.1 0.5 0.1 0.1 0.0 0.1 0.1 0.5 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.9 3.7 1.4 1.3 0.6 0.5 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.5 1.0 0.0 0.0 0.0 46.3 0.0 0.0 0.0 0.3 2.4 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 6.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 3.4 4.4 0.0 1.6 2.5 0.7 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 2.3 0.0 1.4 1.3 1.0 0.4 0.2 0.4 0.4 0.4 0.5 3.7 0.9 0.5 0.5 1.0 0.6 0.2 0.6 0.4 0.4 0.1 0.6 0.1 0.2 0.2 0.1 0.3 0.1 0.1 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 12.2 0.0 38.1 603.5 0.0 0.4 0.0 0.0 0.0 0.0 1.6 0.2 0.0 0.0 0.0 10.6 0.0 0.0 0.0 0.6 0.0 0.3 4.2 1.7 2.8 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.1 0.2 0.0 16.2 0.0 0.0 0.0 TMEM53 "FLJ22353, NET4" ENSG00000126106 "Transmembrane protein 53" Q6P2H8 1 44635238-44674555 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 38.7;liver: 44.7" "Cell type enriched" "Detected in all" 5 "Late spermatids: 845.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "plasmacytoid DC: 38.7" "Lineage enriched" "Detected in all" 4 "dendritic cells: 38.7" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA021134 Approved Approved "Golgi apparatus,Focal adhesion sites" NA NA "Golgi apparatus" "Focal adhesion sites" "HPA021134: AB_2205162" "unprognostic (5.28e-2)" "unprognostic (2.60e-1)" "unprognostic (5.37e-2)" "unprognostic (4.62e-2)" "unprognostic (3.93e-2)" "unprognostic (1.14e-1)" "unprognostic (2.82e-2)" "unprognostic (2.88e-2)" "unprognostic (2.19e-2)" "prognostic favorable (6.96e-4)" "unprognostic (3.00e-1)" "unprognostic (1.34e-1)" "prognostic favorable (1.02e-5)" "unprognostic (1.15e-3)" "unprognostic (1.84e-2)" "unprognostic (4.07e-2)" "unprognostic (2.29e-2)" 8.3 9.0 6.0 4.4 8.7 6.0 7.0 2.4 11.8 4.9 11.0 8.8 4.6 16.6 5.7 7.2 4.5 5.3 7.6 9.3 6.2 6.1 14.8 44.7 7.3 6.4 6.8 6.2 7.7 5.4 3.3 6.4 4.3 8.0 5.2 7.2 13.9 6.0 3.8 4.2 3.9 16.4 4.5 6.1 4.8 7.7 18.8 4.4 3.6 8.2 3.1 4.0 7.3 3.7 5.3 38.7 3.6 8.6 2.8 3.1 2.8 7.6 8.8 8.0 5.8 10.4 7.9 9.6 2.2 6.7 4.4 6.6 2.8 24.2 2.4 7.3 2.1 17.0 6.9 2.2 4.7 2.3 3.8 5.6 2.8 3.6 13.4 10.4 2.2 10.3 9.3 7.3 8.8 1.9 4.8 2.4 5.5 1.2 3.1 2.6 4.5 2.5 6.5 4.6 5.9 5.2 4.0 1.1 23.6 13.1 8.0 5.6 5.4 2.4 9.6 12.4 5.9 3.0 5.8 1.0 3.2 5.5 4.6 2.8 2.2 2.6 1.3 8.4 5.7 3.7 3.6 5.2 2.3 3.0 8.6 2.6 5.3 3.1 2.5 2.6 5.0 1.5 2.0 0.5 2.8 6.0 38.7 3.0 2.8 6.0 8.7 2.4 11.8 6.2 6.1 6.8 6.2 8.0 4.4 6.0 11.8 2.4 6.7 1.4 5.6 24.6 10.2 18.7 9.1 19.2 3.9 11.6 38.1 14.3 155.5 8.7 50.1 23.3 22.5 13.2 5.6 7.8 5.8 81.3 29.8 17.5 13.8 8.0 8.3 845.8 8.3 7.2 8.5 1.8 18.4 12.9 16.0 56.1 11.7 39.8 12.4 25.8 7.3 5.1 8.3 1.9 7.8 4.1 15.4 10.3 TNFRSF25 "APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR" ENSG00000215788 "TNF receptor superfamily member 25" Q93038 1 6461151-6466195 "Predicted membrane proteins, Predicted secreted proteins" Apoptosis Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 19.2;lymphoid tissue: 26.0;skin 1: 24.1" "Cell type enhanced" "Detected in many" 7 "Suprabasal keratinocytes: 25.0;T-cells: 36.2;Undifferentiated cells: 28.4" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 11 "cerebellum: 19.2" "Cell type enhanced" "Detected in many" "T-reg: 9.5" "Lineage enriched" "Detected in single" 10 "T-cells: 9.5" "Cell line enhanced" "Detected in many" "HDLM-2: 20.2;NB-4: 8.0;RPMI-8226: 19.7" "Group enriched" "Detected in some" 6 "amygdala: 1.2;cerebral cortex: 1.3;hippocampal formation: 2.3" "Not detected" "Not detected" HPA069834 Approved "Nucleoplasm,Plasma membrane,Actin filaments,Focal adhesion sites" "Secreted - unknown location" NA NA "Plasma membrane, Actin filaments, Focal adhesion sites" Nucleoplasm "HPA069834: " "unprognostic (8.09e-3)" "unprognostic (6.91e-3)" "prognostic unfavorable (4.46e-4)" "unprognostic (1.97e-1)" "unprognostic (9.63e-3)" "prognostic favorable (3.09e-4)" "unprognostic (2.16e-1)" "unprognostic (1.46e-1)" "unprognostic (2.04e-1)" "unprognostic (2.07e-1)" "unprognostic (6.01e-2)" "unprognostic (3.98e-2)" "prognostic unfavorable (1.65e-7)" "unprognostic (1.21e-1)" "unprognostic (1.61e-1)" "unprognostic (3.44e-1)" "unprognostic (8.68e-3)" 2.2 1.6 1.2 20.3 1.6 0.4 1.4 19.2 1.8 1.4 13.4 0.7 0.6 2.8 1.2 0.6 4.1 2.4 2.1 2.3 1.8 0.9 1.4 2.3 6.3 13.9 1.1 0.6 1.1 0.6 1.4 14.0 4.1 1.3 1.9 1.3 1.1 10.5 2.3 0.8 24.1 11.2 0.6 0.6 18.9 0.8 1.0 0.8 11.7 1.1 3.2 26.0 3.2 1.5 0.0 0.4 0.0 0.9 0.6 9.5 1.3 1.4 0.3 0.8 1.6 0.0 0.4 0.8 0.6 0.4 0.2 0.0 1.3 2.2 0.0 3.0 0.0 1.0 3.2 0.4 3.7 0.0 20.2 1.5 0.8 1.1 0.0 0.6 0.0 0.0 0.0 2.4 1.2 3.2 1.9 3.2 0.9 0.0 0.0 0.0 1.6 0.0 8.0 1.0 1.1 5.5 0.6 0.2 19.7 0.8 0.5 3.9 5.4 0.0 1.9 0.1 0.3 1.7 2.2 1.7 1.0 1.5 0.0 1.5 0.0 3.6 0.0 1.9 0.0 0.0 0.0 0.0 0.0 1.7 0.3 8.0 0.0 6.9 3.2 0.4 0.0 6.4 1.1 0.0 0.6 0.9 0.0 9.5 1.3 1.2 1.6 19.2 1.8 1.8 0.9 1.1 0.6 1.3 0.8 3.0 5.3 0.5 1.8 21.9 0.8 0.8 2.5 2.7 2.3 1.8 2.0 0.4 0.0 0.1 0.3 5.5 16.9 0.0 0.4 1.6 3.2 1.1 6.9 1.1 3.2 4.8 6.4 9.8 1.6 0.0 2.6 2.1 6.8 1.0 17.6 11.2 0.9 11.5 8.9 0.3 9.3 0.0 0.8 0.5 1.1 25.0 0.1 36.2 28.4 6.7 TNFSF13B "BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20" ENSG00000102524 "TNF superfamily member 13b" Q9Y275 13 108251240-108308484 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Immunity Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 76.5;lymphoid tissue: 39.6" "Cell type enhanced" "Detected in many" 23 "Hofbauer cells: 88.9;Kupffer cells: 144.9;Macrophages: 141.3;monocytes: 457.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 76.5" "Group enriched" "Detected in many" 10 "dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7" "Cell line enriched" "Detected in some" 7 "U-937: 61.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB009188, HPA030526" Enhanced Supported "Vesicles,Plasma membrane,Focal adhesion sites" "Secreted to blood" NA NA 393000 530000 "Plasma membrane" "Vesicles, Focal adhesion sites" "CAB009188: , HPA030526: " "unprognostic (6.48e-2)" "unprognostic (3.05e-3)" "unprognostic (1.38e-1)" "unprognostic (1.90e-1)" "unprognostic (2.61e-2)" "unprognostic (7.99e-2)" "unprognostic (8.19e-2)" "unprognostic (1.37e-1)" "unprognostic (1.63e-1)" "unprognostic (1.02e-2)" "unprognostic (2.64e-2)" "unprognostic (1.21e-1)" "prognostic unfavorable (2.53e-11)" "unprognostic (1.23e-1)" "unprognostic (4.14e-2)" "unprognostic (1.88e-1)" "unprognostic (1.25e-1)" 7.2 8.2 3.0 18.5 8.2 13.2 3.4 1.4 5.2 1.6 4.2 2.1 1.0 7.8 1.2 6.5 3.5 2.9 9.4 9.4 5.7 2.9 3.1 5.0 13.2 39.6 7.2 2.6 2.9 2.7 0.5 2.1 6.4 5.7 3.7 6.4 2.6 5.4 1.8 1.6 1.6 6.8 3.5 11.6 23.5 3.4 1.0 4.9 7.2 5.1 1.7 12.7 8.5 3.8 1.0 31.0 76.5 53.7 0.6 5.3 20.8 0.0 0.1 0.0 0.0 0.2 0.3 0.0 0.1 0.3 0.2 0.8 0.0 0.6 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 4.2 0.0 0.3 0.1 0.0 0.1 3.6 0.1 0.7 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.4 0.0 0.0 1.9 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.1 0.5 0.1 0.0 0.0 0.1 0.1 0.0 8.1 0.0 0.1 0.0 0.0 0.1 3.8 0.1 0.0 3.9 61.0 0.6 1.2 53.7 14.4 0.8 39.8 5.3 0.6 3.5 0.7 31.0 1.0 1.7 0.5 76.5 0.6 31.7 11.5 2.8 20.8 3.0 8.2 1.4 5.2 5.7 2.9 7.2 2.6 5.7 4.9 14.9 17.5 3.7 0.7 6.4 0.3 0.5 12.7 2.7 5.7 5.2 0.0 0.5 1.7 2.0 1.0 1.3 0.5 0.0 29.2 0.9 13.3 1.6 4.7 1.5 88.9 0.0 1.2 4.9 144.9 0.2 4.9 141.3 8.5 457.1 0.2 0.4 1.9 0.0 1.8 1.0 0.0 6.5 5.0 0.1 0.1 4.1 0.9 6.2 1.2 1.3 TNNT2 "CMD1D, CMH2, CMPD2" ENSG00000118194 "Troponin T2, cardiac type" P45379 1 201359008-201377762 "Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins" "Muscle protein" "Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 241 "heart muscle: 679.2" "Cell type enriched" "Detected in many" 289 "Cardiomyocytes: 11884.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 18 "RH-30: 189.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB015371, HPA015774, HPA017888" Enhanced Uncertain "Nucleoplasm,Nucleoli,Focal adhesion sites" No No 50000 "Nucleoplasm, Nucleoli" "Focal adhesion sites" "CAB015371: AB_630390, HPA015774: AB_1858354, HPA017888: AB_1858355" "unprognostic (1.45e-1)" "unprognostic (2.74e-1)" "unprognostic (2.33e-4)" "unprognostic (1.85e-1)" "unprognostic (7.29e-2)" "unprognostic (1.79e-1)" "unprognostic (1.80e-1)" "unprognostic (1.24e-1)" "unprognostic (1.42e-1)" "unprognostic (2.91e-2)" "unprognostic (1.38e-1)" "unprognostic (8.63e-2)" "unprognostic (5.50e-3)" "unprognostic (2.94e-1)" "unprognostic (1.61e-1)" "unprognostic (4.76e-2)" "unprognostic (9.98e-2)" 0.1 0.3 0.1 0.1 0.7 0.0 0.8 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.0 1.2 679.2 0.9 0.0 1.9 0.0 0.7 0.3 0.1 1.1 0.1 0.3 0.0 0.2 0.7 0.1 0.7 0.0 0.0 0.2 0.1 2.0 1.3 0.0 2.8 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 2.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.1 0.0 0.0 0.4 0.5 0.0 0.0 189.8 0.0 0.0 0.0 0.2 0.1 0.0 0.2 0.0 10.5 0.0 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 2.1 0.9 0.0 0.1 1.1 0.1 0.0 3.0 4.0 0.0 1.1 3.1 1.0 11884.8 0.0 0.0 1.2 1.8 0.0 2.3 0.0 0.5 9.4 0.0 1.6 0.0 0.3 0.9 41.1 0.5 0.0 0.0 2.7 0.0 0.0 0.0 0.0 13.6 0.6 0.0 0.0 4.6 0.5 0.0 0.7 0.8 1.1 0.8 0.5 0.0 0.4 0.0 0.2 6.4 3.5 0.0 2.8 1.4 TNS1 "DKFZp586K0617, MXRA6, PPP1R155, TNS" ENSG00000079308 "Tensin 1" Q9HBL0 2 217799588-218010421 "Plasma proteins, Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 153.0" "Cell type enhanced" "Detected in many" 10 "Cardiomyocytes: 299.8;Peritubular cells: 473.8;Sertoli cells: 362.2;Smooth muscle cells: 208.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 1.7" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 46.9;ASC TERT1: 25.6;fHDF/TERT166: 22.2;REH: 24.4;TIME: 21.7" "Low region specificity" "Detected in all" "CAB018774, HPA036089, HPA036090" Approved Enhanced "Focal adhesion sites" NA NA "Focal adhesion sites" "CAB018774: AB_2207032, HPA036089: AB_10796111, HPA036090: AB_10794322" "unprognostic (4.63e-2)" "unprognostic (1.47e-1)" "prognostic unfavorable (2.41e-4)" "unprognostic (4.13e-2)" "unprognostic (5.46e-2)" "unprognostic (2.63e-2)" "unprognostic (1.20e-3)" "unprognostic (7.34e-2)" "unprognostic (2.55e-2)" "unprognostic (1.28e-3)" "unprognostic (5.57e-2)" "unprognostic (9.74e-2)" "unprognostic (4.71e-3)" "unprognostic (5.60e-3)" "unprognostic (2.88e-2)" "unprognostic (7.49e-2)" "prognostic unfavorable (5.19e-4)" 77.6 15.6 5.2 21.1 13.7 9.2 33.5 2.9 8.9 50.0 68.9 17.2 45.6 6.0 61.1 29.8 52.0 31.1 46.7 41.0 6.8 4.8 24.0 9.2 28.9 6.1 15.8 4.1 32.3 14.1 6.0 3.8 14.0 14.3 55.1 11.4 27.6 12.8 63.4 40.8 10.1 17.2 153.0 13.7 17.0 30.0 22.6 12.2 1.5 18.3 9.8 4.0 124.6 53.6 0.2 1.0 0.9 1.7 0.0 0.0 2.9 0.0 0.1 3.0 0.0 46.9 25.6 0.3 7.9 2.6 0.4 0.3 3.4 0.0 0.0 4.6 22.2 0.5 0.5 0.3 0.4 0.2 3.1 0.2 6.7 2.0 0.9 3.5 0.0 0.8 12.1 0.0 8.5 0.0 15.3 11.1 0.0 0.2 0.8 6.6 0.9 0.0 0.4 0.3 0.0 0.1 24.4 5.9 0.3 1.6 0.0 0.7 3.5 1.3 3.4 0.8 2.2 1.1 2.4 21.7 5.7 10.4 5.8 1.7 0.4 0.0 0.0 3.3 0.9 0.4 0.0 0.4 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.9 0.0 0.7 1.0 0.0 2.9 5.2 13.7 2.9 8.9 6.8 4.8 15.8 4.1 14.3 12.2 160.8 81.8 4.6 45.8 14.3 2.7 299.8 33.1 20.1 36.4 14.0 0.0 8.0 6.6 34.4 1.7 55.0 0.0 116.8 16.8 1.1 42.2 8.9 29.0 28.8 13.3 39.7 0.0 74.3 14.9 4.3 157.1 14.6 10.1 0.0 0.0 12.6 16.8 0.0 473.8 20.9 1.4 362.2 208.1 0.7 2.0 10.3 1.6 5.3 0.0 14.9 TNS3 "FLJ13732, H_NH0549I23.2, TEM6, TENS1" ENSG00000136205 "Tensin 3" Q68CZ2 7 47275154-47582558 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Hofbauer cells: 66.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 5.8;intermediate monocyte: 4.7;memory B-cell: 3.7;myeloid DC: 4.0;naive B-cell: 2.9;non-classical monocyte: 4.4;plasmacytoid DC: 5.6" "Group enriched" "Detected in many" 6 "B-cells: 3.7;dendritic cells: 5.6;monocytes: 5.8" "Cell line enhanced" "Detected in many" "A549: 65.8;LHCN-M2: 42.4" "Low region specificity" "Detected in all" "HPA055338, HPA056015" Approved Enhanced "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA055338: AB_2682789, HPA056015: AB_2683010" "unprognostic (1.46e-1)" "unprognostic (2.97e-2)" "unprognostic (1.34e-1)" "unprognostic (7.02e-2)" "unprognostic (9.04e-2)" "unprognostic (1.63e-1)" "unprognostic (1.17e-1)" "unprognostic (2.05e-1)" "unprognostic (8.00e-2)" "unprognostic (3.77e-2)" "unprognostic (3.70e-1)" "unprognostic (6.60e-2)" "prognostic favorable (5.21e-4)" "unprognostic (3.13e-2)" "unprognostic (4.41e-2)" "unprognostic (3.20e-2)" "unprognostic (9.09e-3)" 46.9 18.5 16.4 19.3 12.7 2.8 29.8 8.1 11.7 18.2 15.7 11.4 9.1 9.9 27.4 13.9 7.7 12.3 29.6 13.5 12.1 13.2 27.3 24.9 25.1 37.7 16.0 3.6 22.4 35.5 16.4 5.5 44.9 9.6 15.0 9.3 40.3 36.4 11.7 14.9 6.7 20.7 14.7 11.6 42.7 13.9 9.6 7.8 3.8 23.8 9.6 19.9 12.5 19.3 3.7 5.6 0.8 5.8 0.1 0.2 1.8 6.3 65.8 4.0 6.9 9.2 7.5 12.8 5.8 33.4 5.7 8.8 14.7 8.6 3.2 10.4 21.2 21.5 12.2 6.4 9.5 5.2 0.0 0.4 9.0 9.5 7.8 9.5 0.0 0.1 7.4 4.1 3.3 5.2 37.5 4.5 0.0 0.0 20.3 42.4 3.9 0.0 0.2 3.8 9.2 7.9 2.9 9.8 10.7 19.8 13.1 0.4 8.2 11.5 2.3 6.4 21.1 8.8 6.7 17.9 8.9 7.1 0.1 8.9 13.1 16.9 7.6 2.2 6.3 32.2 0.2 5.8 0.0 0.1 4.7 0.2 3.7 0.0 0.0 4.0 2.9 0.0 0.0 0.8 0.1 4.4 5.6 0.0 1.8 16.4 12.7 8.1 11.7 12.1 13.2 16.0 3.6 9.6 7.8 62.5 12.0 3.7 7.3 4.2 1.4 17.3 33.1 16.0 25.0 29.6 0.0 21.4 1.7 14.4 9.5 6.9 28.0 0.0 15.8 47.3 17.5 2.8 0.0 35.1 66.7 0.0 14.5 40.5 35.8 11.8 5.8 13.7 15.1 11.8 15.6 34.2 21.0 8.6 14.5 11.5 1.4 25.8 8.2 1.7 3.4 2.9 25.1 1.9 15.3 2.1 TRIM62 "DEAR1, FLJ10759" ENSG00000116525 "Tripartite motif containing 62" Q9BVG3 1 33145402-33182059 "Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Horizontal cells: 9.5;Sertoli cells: 6.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 20.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050061 Approved "Vesicles,Focal adhesion sites" NA NA "Vesicles, Focal adhesion sites" "HPA050061: AB_2681001" "unprognostic (1.57e-1)" "unprognostic (4.39e-2)" "unprognostic (2.39e-2)" "unprognostic (2.62e-2)" "unprognostic (1.14e-2)" "unprognostic (5.80e-2)" "unprognostic (5.10e-5)" "unprognostic (2.05e-2)" "unprognostic (1.14e-1)" "unprognostic (4.32e-2)" "unprognostic (3.55e-3)" "unprognostic (3.66e-1)" "prognostic unfavorable (7.08e-5)" "unprognostic (2.14e-1)" "unprognostic (1.10e-1)" "unprognostic (1.05e-1)" "unprognostic (2.05e-3)" 4.8 11.8 10.1 6.4 19.2 9.3 6.2 19.0 13.9 5.6 4.9 31.8 1.6 5.6 4.9 6.9 6.9 5.1 4.9 5.3 12.3 10.5 5.3 2.7 5.6 9.6 28.1 9.1 6.7 4.8 7.5 9.2 19.6 15.4 8.7 5.4 5.0 10.8 7.5 6.7 20.5 5.8 6.9 12.8 8.3 6.5 4.0 23.7 8.7 6.3 5.1 10.4 9.8 7.3 3.0 1.8 6.0 3.5 1.7 8.5 2.1 2.9 2.3 20.7 3.4 5.2 2.3 6.3 2.9 8.7 5.4 4.8 2.4 3.0 4.7 3.2 2.6 2.6 6.0 4.1 3.8 5.2 4.5 3.2 5.4 2.5 1.9 5.0 1.7 13.5 4.5 3.5 7.2 1.8 8.9 5.4 4.3 0.8 3.1 5.5 7.8 5.3 1.7 4.9 3.7 2.9 6.7 10.8 2.2 3.5 7.7 5.0 3.1 3.2 12.2 13.8 12.1 3.4 1.2 5.2 2.3 3.2 6.6 2.2 5.8 2.5 2.3 4.2 3.2 2.8 2.2 2.0 6.0 2.7 3.5 4.6 2.2 4.1 3.7 1.8 3.0 2.8 2.7 4.4 1.7 2.2 0.8 8.5 2.1 10.1 19.2 19.0 13.9 12.3 10.5 28.1 9.1 15.4 23.7 3.0 2.1 0.9 0.7 2.4 2.4 0.6 0.0 0.0 0.0 1.8 0.0 0.8 0.0 1.4 0.5 1.0 1.1 0.0 1.7 1.6 1.3 2.2 1.1 0.6 1.0 9.5 1.7 1.3 1.2 0.0 2.3 1.2 0.0 1.0 2.0 1.4 2.1 0.0 4.6 0.6 0.8 6.5 2.0 1.1 0.4 4.1 1.1 1.9 0.9 1.7 TRIM71 "LIN-41, LIN41" ENSG00000206557 "Tripartite motif containing 71" Q2Q1W2 3 32818018-32897826 "Enzymes, Predicted intracellular proteins" "RNA-mediated gene silencing, Ubl conjugation pathway" "Developmental protein, RNA-binding, Transferase" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lung: 6.5;testis: 11.1" "Cell type enhanced" "Detected in some" 12 "Alveolar cells type 1: 8.9;Extravillous trophoblasts: 13.2;Spermatogonia: 12.6" "Cancer enriched" "Detected in some" 28 "testis cancer: 28.6" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 11.9;BEWO: 36.1;Hep G2: 23.3;NTERA-2: 31.9;SuSa: 30.5" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA038141, HPA038142" Uncertain Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Plasma membrane, Actin filaments, Focal adhesion sites" "HPA038141: AB_2675857, HPA038142: AB_10697240" "unprognostic (2.93e-2)" "unprognostic (4.29e-3)" "unprognostic (1.70e-1)" "unprognostic (1.02e-2)" "unprognostic (2.58e-2)" "unprognostic (3.27e-2)" "unprognostic (2.09e-2)" "unprognostic (1.25e-1)" "unprognostic (3.16e-2)" "unprognostic (3.04e-1)" "unprognostic (1.11e-2)" "unprognostic (3.11e-1)" "unprognostic (4.36e-6)" "unprognostic (3.92e-2)" "unprognostic (9.27e-2)" "unprognostic (8.17e-2)" "unprognostic (4.65e-2)" 0.1 0.0 0.7 0.1 1.9 0.5 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 2.7 0.7 2.2 0.0 6.5 0.0 0.2 0.0 0.1 0.0 0.0 0.5 1.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.1 0.1 11.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.5 0.3 0.0 0.1 0.0 0.0 0.0 11.9 0.0 0.0 0.0 36.1 0.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.6 0.0 23.3 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.0 0.0 0.2 2.5 31.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 30.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.1 0.0 0.2 0.3 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.7 1.9 0.0 0.5 2.7 0.7 0.2 0.0 1.9 0.0 8.9 2.6 0.0 0.0 0.0 0.4 2.8 0.0 1.4 3.4 0.0 0.0 3.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 13.2 0.3 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.9 0.4 0.0 0.0 0.3 12.6 0.0 3.3 0.0 0.0 0.0 TRIP6 "MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1" ENSG00000087077 "Thyroid hormone receptor interactor 6" Q15654 7 100867138-100873454 "Predicted intracellular proteins" "Cell adhesion, Transcription, Transcription regulation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 7.7" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB046454, CAB046460, HPA052813" Approved Supported "Plasma membrane,Focal adhesion sites,Cytosol" NA NA 12000 "Plasma membrane, Focal adhesion sites, Cytosol" "CAB046454: AB_10604048, CAB046460: AB_2303907, HPA052813: AB_2681961" "unprognostic (7.94e-3)" "unprognostic (1.06e-1)" "unprognostic (3.22e-3)" "unprognostic (2.84e-3)" "unprognostic (3.52e-2)" "unprognostic (2.92e-2)" "unprognostic (3.18e-2)" "unprognostic (4.61e-3)" "unprognostic (8.48e-2)" "unprognostic (4.18e-2)" "unprognostic (5.08e-2)" "unprognostic (1.42e-1)" "unprognostic (1.25e-2)" "unprognostic (5.07e-2)" "unprognostic (9.71e-2)" "unprognostic (1.92e-1)" "unprognostic (1.25e-1)" 15.5 14.7 10.9 16.2 11.2 6.0 18.1 4.2 7.3 36.7 14.6 9.4 22.5 4.4 28.2 30.8 27.2 18.5 43.5 14.5 8.7 7.7 21.6 24.1 18.4 5.8 11.7 9.4 22.0 19.2 28.0 6.5 13.6 9.7 22.1 3.9 22.7 23.0 38.2 8.3 23.9 6.5 25.5 9.7 7.9 9.9 17.5 7.8 7.3 26.6 30.6 12.6 25.0 23.6 3.1 7.7 0.2 4.7 0.0 1.7 0.5 27.0 11.2 5.8 27.7 8.8 10.2 29.1 16.9 18.1 23.2 21.8 10.5 31.2 1.1 17.8 19.0 28.9 20.2 8.5 32.5 5.9 3.9 11.5 0.1 18.6 0.1 23.2 13.0 1.6 18.5 21.4 15.4 24.2 13.7 11.9 4.1 17.0 0.2 20.0 47.5 0.2 20.5 20.0 11.1 10.0 10.2 5.8 2.7 14.3 6.7 2.1 0.3 14.1 42.7 16.8 9.0 4.5 16.6 18.2 34.1 32.1 36.9 39.4 0.2 0.4 0.1 21.2 1.6 51.3 0.0 1.9 0.2 0.2 3.0 0.6 3.1 1.5 1.3 3.1 2.5 1.7 0.7 0.2 0.0 4.7 7.7 1.3 0.5 10.9 11.2 4.2 7.3 8.7 7.7 11.7 9.4 9.7 7.8 44.7 35.0 7.5 130.2 117.2 0.0 14.4 38.2 10.7 37.5 57.6 0.0 99.2 68.0 79.4 0.8 30.6 3.6 0.0 73.3 72.2 63.2 50.1 8.1 26.8 40.2 1.6 4.7 19.6 7.0 2.2 60.9 26.5 35.4 31.5 10.3 87.6 78.1 10.5 68.2 104.6 3.3 71.1 72.2 0.9 2.5 85.9 111.1 6.1 17.5 140.8 TRPC7 ENSG00000069018 "Transient receptor potential cation channel subfamily C member 7" Q9HCX4 5 136213320-136365545 "Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 2.2;brain: 1.6;intestine: 1.3;kidney: 1.5;pituitary gland: 2.2;testis: 2.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 1.8;SCLC-21H: 1.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB022592, HPA031126" Uncertain Uncertain "Actin filaments,Focal adhesion sites" NA NA "Focal adhesion sites" "Actin filaments" "CAB022592: , HPA031126: AB_10603221" "unprognostic (1.49e-1)" "unprognostic (2.08e-1)" "unprognostic (3.03e-2)" "unprognostic (2.89e-5)" "unprognostic (3.26e-1)" "unprognostic (2.75e-1)" "unprognostic (9.99e-2)" "unprognostic (1.77e-1)" "unprognostic (6.78e-2)" 0.0 2.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 2.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 USP40 FLJ10785 ENSG00000085982 "Ubiquitin specific peptidase 40" Q9NVE5 2 233475520-233566782 "Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005821 Uncertain Approved "Vesicles,Focal adhesion sites" NA NA Vesicles "Focal adhesion sites" "HPA005821: AB_1080526" "unprognostic (2.19e-1)" "unprognostic (1.04e-1)" "unprognostic (1.13e-1)" "unprognostic (1.33e-1)" "unprognostic (3.70e-1)" "unprognostic (2.15e-1)" "unprognostic (5.30e-2)" "unprognostic (2.25e-1)" "unprognostic (1.80e-2)" "unprognostic (1.18e-1)" "unprognostic (1.96e-1)" "unprognostic (1.26e-1)" "unprognostic (2.22e-1)" "unprognostic (1.45e-1)" "unprognostic (4.09e-2)" "unprognostic (1.90e-2)" "unprognostic (2.53e-2)" 12.5 20.5 11.0 8.2 17.7 3.5 16.1 8.2 13.5 12.4 12.1 26.1 22.5 11.6 16.2 28.1 13.9 13.4 13.2 10.8 11.3 8.5 16.9 15.7 13.9 7.6 22.1 10.1 19.6 17.2 22.8 24.3 16.3 16.5 16.1 11.2 16.4 13.9 19.7 13.6 21.7 15.2 17.1 20.1 11.4 16.3 23.3 18.9 9.8 21.2 9.4 12.0 18.0 11.8 1.9 5.0 0.4 2.8 1.4 2.2 1.4 9.5 11.1 10.2 6.9 15.0 14.1 9.0 9.4 7.3 8.8 9.6 7.9 11.4 0.2 2.8 15.1 22.6 17.0 7.8 16.7 12.6 0.0 5.1 7.5 9.2 13.3 13.1 3.1 5.1 13.4 12.1 12.9 18.2 15.4 10.1 4.6 12.1 1.8 12.3 7.7 3.4 4.7 4.5 9.9 9.0 0.0 21.2 4.4 10.4 15.4 5.6 6.1 7.5 7.8 9.7 8.0 8.8 7.1 9.9 12.2 7.6 5.1 11.4 3.4 2.6 0.4 15.9 5.7 10.6 0.0 2.7 0.0 1.3 2.8 0.6 1.3 1.5 1.3 4.0 1.9 1.9 2.2 0.4 1.4 2.3 5.0 2.0 1.4 11.0 17.7 8.2 13.5 11.3 8.5 22.1 10.1 16.5 18.9 29.8 31.5 3.7 9.6 6.5 18.6 8.9 10.2 24.1 23.9 15.7 23.6 17.1 6.6 7.9 6.7 7.1 10.9 0.0 10.6 8.8 7.4 11.3 9.2 20.9 7.0 22.3 14.5 12.3 10.4 7.8 6.4 6.7 3.3 5.4 9.1 13.0 9.7 8.6 7.8 11.6 20.8 12.9 8.2 31.2 14.9 9.3 13.2 4.4 11.2 7.1 VASP ENSG00000125753 "Vasodilator stimulated phosphoprotein" P50552 19 45506579-45526983 "Plasma proteins, Predicted intracellular proteins" Actin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Extravillous trophoblasts: 388.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 23.6" "Group enriched" "Detected in all" 6 "granulocytes: 23.6;monocytes: 10.4" "Cell line enhanced" "Detected in all" "HMC-1: 65.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004612, HPA005724" Enhanced Supported "Plasma membrane,Cell Junctions,Focal adhesion sites" NA NA 110000000 "Plasma membrane, Cell Junctions, Focal adhesion sites" "CAB004612: AB_2213431, HPA005724: AB_1858721" "unprognostic (3.07e-2)" "unprognostic (1.07e-2)" "unprognostic (4.70e-2)" "unprognostic (7.85e-3)" "unprognostic (8.31e-2)" "unprognostic (1.90e-2)" "prognostic unfavorable (3.49e-5)" "unprognostic (1.66e-3)" "unprognostic (1.58e-1)" "unprognostic (1.30e-2)" "unprognostic (3.64e-3)" "unprognostic (4.39e-1)" "prognostic unfavorable (5.91e-7)" "unprognostic (1.15e-1)" "unprognostic (1.15e-1)" "unprognostic (1.69e-1)" "unprognostic (1.08e-2)" 29.1 10.3 4.9 33.3 5.9 40.3 19.0 3.9 4.7 22.6 38.2 5.3 15.4 28.8 37.5 13.3 34.3 23.8 32.2 21.1 5.2 4.3 17.9 21.1 30.5 44.5 7.7 2.2 22.5 10.5 2.9 7.5 31.5 6.2 26.8 9.8 8.9 12.9 20.3 10.4 13.0 43.7 36.7 4.8 69.2 33.4 14.4 6.6 28.3 11.7 12.8 33.2 39.2 17.5 1.8 2.6 23.6 10.4 2.0 2.1 2.2 15.5 16.4 4.8 8.2 2.4 4.2 12.3 16.1 12.4 11.1 9.7 7.4 32.8 7.2 13.7 12.8 7.4 14.5 1.4 15.9 3.7 21.2 3.7 41.4 8.1 12.5 13.6 15.1 65.0 6.4 9.0 10.4 6.7 9.0 16.5 6.1 24.7 15.7 6.8 13.0 6.9 13.1 8.4 14.6 11.3 5.2 3.0 2.7 9.5 50.0 5.7 4.0 19.1 9.8 11.3 3.2 10.6 26.0 24.6 17.8 18.0 5.7 25.3 8.4 10.1 12.4 12.4 18.5 21.3 5.6 4.0 23.6 2.1 6.5 1.5 1.8 1.7 2.0 2.6 1.7 1.1 1.3 17.1 2.0 10.4 1.0 1.2 2.2 4.9 5.9 3.9 4.7 5.2 4.3 7.7 2.2 6.2 6.6 14.9 24.5 57.0 75.3 87.2 7.9 14.6 30.6 10.7 34.2 31.4 25.5 54.0 14.9 140.2 2.8 53.3 134.7 0.0 86.8 388.2 29.9 56.5 81.9 13.5 148.4 6.4 110.1 45.4 113.3 3.6 24.2 183.9 47.2 67.7 118.7 13.1 143.6 173.9 46.3 13.6 13.6 129.4 84.5 7.5 10.0 68.0 117.9 82.0 102.2 112.6 VCL ENSG00000035403 Vinculin P18206 10 73995193-74121363 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" Actin-binding "Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cardiomyocytes: 304.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ hTERT+: 90.2;hTERT-RPE1: 88.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002131, CAB002453, HPA063777" Enhanced Enhanced "Focal adhesion sites" NA NA 1800000000 "Focal adhesion sites" "CAB002453: AB_564057, HPA002131: AB_1080570, HPA063777: AB_2685121" "unprognostic (8.49e-2)" "unprognostic (1.61e-2)" "unprognostic (3.14e-1)" "unprognostic (6.31e-2)" "unprognostic (3.34e-1)" "unprognostic (9.62e-3)" "unprognostic (2.72e-3)" "unprognostic (2.67e-3)" "unprognostic (3.42e-2)" "unprognostic (1.46e-1)" "prognostic unfavorable (2.75e-4)" "unprognostic (1.29e-1)" "unprognostic (3.68e-2)" "unprognostic (4.03e-2)" "unprognostic (4.02e-2)" "unprognostic (1.89e-1)" "unprognostic (1.37e-3)" 31.9 7.3 4.3 19.0 6.0 8.6 24.4 5.4 5.3 37.9 41.2 6.7 24.4 8.0 72.1 29.2 36.1 27.6 44.8 35.0 4.7 3.9 20.8 6.9 25.9 9.3 3.8 5.5 29.2 12.8 18.1 7.6 22.6 9.6 43.3 18.0 20.2 14.9 38.8 59.1 14.4 20.2 113.1 3.8 23.6 23.6 29.5 3.3 3.0 15.3 20.5 11.7 73.9 26.1 3.7 12.9 21.6 11.3 2.8 9.9 15.6 22.4 15.4 27.9 19.7 35.0 40.8 15.4 29.7 90.2 20.3 23.1 13.8 19.6 1.0 24.8 51.8 13.9 28.9 18.3 14.9 21.5 1.9 7.8 10.7 15.0 5.7 19.2 2.1 16.4 33.7 4.0 27.5 25.1 88.6 27.1 1.8 7.7 2.2 33.8 3.8 0.3 2.5 13.2 10.8 54.5 3.7 14.6 2.8 29.1 29.1 1.0 4.1 16.5 18.7 8.5 25.7 8.6 3.2 36.2 22.2 9.3 10.7 27.7 0.4 0.9 4.4 25.9 6.0 6.2 8.5 7.6 21.6 9.9 10.8 7.0 3.7 4.7 5.1 12.9 1.6 1.8 3.6 7.0 2.8 11.3 5.0 1.2 15.6 4.3 6.0 5.4 5.3 4.7 3.9 3.8 5.5 9.6 3.3 92.3 37.8 11.5 94.3 102.0 13.5 304.7 50.9 28.1 77.3 40.1 80.5 44.5 3.3 59.0 2.3 54.3 61.0 0.0 53.1 67.5 69.7 88.5 33.6 30.6 21.4 15.9 36.8 73.1 36.2 4.7 46.3 28.0 25.3 9.0 29.5 12.2 85.6 31.9 72.2 12.4 35.2 103.5 102.7 14.2 10.9 81.3 33.2 19.8 37.5 76.0 VIPR2 "VPAC2, VPAC2R" ENSG00000106018 "Vasoactive intestinal peptide receptor 2" P41587 7 159028175-159144957 "G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 4 "Muller glia cells: 32.3;Rod photoreceptor cells: 44.5" "Cancer enhanced" "Detected in some" "glioma: 2.8" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 13.1" "Lineage enriched" "Detected in single" 16 "dendritic cells: 13.1" "Cell line enhanced" "Detected in some" "HeLa: 4.2;HMC-1: 6.5;MOLT-4: 8.8;U-266/70: 29.8" "Region enhanced" "Detected in some" "olfactory region: 33.2" "Low region specificity" "Detected in all" HPA062707 Approved Approved "Focal adhesion sites" NA NA "Focal adhesion sites" "HPA062707: AB_2684842" "unprognostic (3.65e-2)" "unprognostic (2.13e-2)" "unprognostic (4.26e-2)" "unprognostic (2.04e-2)" "unprognostic (6.31e-2)" "unprognostic (4.10e-2)" "unprognostic (1.03e-1)" "unprognostic (8.58e-2)" "unprognostic (2.32e-2)" "unprognostic (1.02e-1)" "unprognostic (9.60e-2)" "unprognostic (1.74e-1)" "unprognostic (1.88e-1)" "unprognostic (2.49e-2)" "unprognostic (1.26e-1)" "unprognostic (1.21e-1)" "unprognostic (8.89e-2)" 9.6 1.2 2.1 2.9 1.3 0.6 2.1 0.9 10.2 18.0 10.6 1.5 14.1 2.1 11.5 14.3 3.1 3.3 4.7 13.3 2.6 1.8 1.0 0.6 0.6 3.0 1.9 2.3 10.8 15.7 0.3 2.6 6.4 2.1 8.4 1.5 4.9 1.1 24.0 7.3 0.6 3.9 7.1 2.4 1.1 8.3 2.4 1.1 16.9 0.4 0.7 0.8 5.7 9.9 0.0 13.1 0.1 0.0 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 0.0 0.2 8.8 0.0 0.7 0.0 0.0 2.2 0.1 0.5 0.0 0.0 2.1 1.7 0.1 0.1 0.0 0.2 0.0 0.5 0.0 0.0 0.3 0.0 0.0 29.8 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.1 0.2 0.1 0.0 0.0 13.1 0.0 0.1 2.1 1.3 0.9 10.2 2.6 1.8 1.9 2.3 2.1 1.1 0.0 0.0 0.0 2.2 0.6 1.4 6.7 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.8 0.4 0.0 0.0 5.8 0.0 1.5 1.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.0 9.5 0.0 1.7 0.0 0.0 32.3 0.8 0.0 2.5 0.3 44.5 0.0 8.0 3.7 2.1 0.0 0.0 2.9 0.0 0.1 VTCN1 "B7-H4, B7H4, B7S1, B7X, FLJ22418" ENSG00000134258 "V-set domain containing T cell activation inhibitor 1" Q7Z7D3 1 117143587-117210960 "Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 46.4;epididymis: 29.9;kidney: 27.0;pancreas: 35.9" "Group enriched" "Detected in some" 5 "Collecting duct cells: 52.4;Ductal cells: 73.6;Exocrine glandular cells: 31.1" "Group enriched" "Detected in many" 6 "breast cancer: 55.8;endometrial cancer: 45.2;ovarian cancer: 49.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "SK-BR-3: 74.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA054200 Approved Approved "Plasma membrane,Cell Junctions,Focal adhesion sites" No NA "Plasma membrane" "Cell Junctions, Focal adhesion sites" "HPA054200: AB_2682415" "unprognostic (4.13e-1)" "unprognostic (1.71e-3)" "unprognostic (2.95e-1)" "unprognostic (3.44e-2)" "unprognostic (1.71e-3)" "unprognostic (2.56e-1)" "unprognostic (7.94e-2)" "unprognostic (4.86e-2)" "unprognostic (3.53e-1)" "unprognostic (1.17e-2)" "unprognostic (4.54e-2)" "unprognostic (5.47e-2)" "unprognostic (1.50e-2)" "unprognostic (1.06e-1)" "unprognostic (2.42e-1)" "unprognostic (3.07e-1)" "unprognostic (1.45e-2)" 0.1 0.0 0.1 0.1 0.1 0.0 46.4 0.1 0.1 6.7 0.1 0.1 7.0 0.0 2.6 29.9 0.4 14.2 1.9 0.2 0.1 0.1 27.0 0.9 0.3 0.1 0.1 0.1 4.5 35.9 0.0 1.4 3.0 0.1 1.5 0.0 0.1 17.5 3.6 0.2 2.2 0.1 0.8 0.1 0.1 1.5 2.5 0.1 0.2 0.1 0.5 1.5 2.1 0.7 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.5 0.0 0.0 0.0 13.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.3 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.3 0.0 0.0 74.4 0.0 9.6 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 2.4 0.0 0.0 1.2 0.0 4.0 10.3 52.4 0.0 1.7 0.0 73.6 1.6 0.0 0.0 0.0 31.1 1.1 0.0 1.5 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 3.9 ZBTB8A "BOZF1, FLJ90065, ZBTB8, ZNF916A" ENSG00000160062 "Zinc finger and BTB domain containing 8A" Q96BR9 1 32539427-32605939 "Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Peritubular cells: 33.2;Sertoli cells: 32.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031768, HPA031769, HPA031770" Approved Approved "Nuclear speckles,Focal adhesion sites" NA NA "Nuclear speckles, Focal adhesion sites" "HPA031768: AB_10610568, HPA031769: AB_2674036, HPA031770: AB_2674037" "unprognostic (1.71e-1)" "unprognostic (1.98e-1)" "unprognostic (1.01e-1)" "unprognostic (7.40e-2)" "unprognostic (7.21e-2)" "unprognostic (2.85e-2)" "unprognostic (9.45e-5)" "unprognostic (1.62e-2)" "unprognostic (2.04e-1)" "unprognostic (7.83e-3)" "unprognostic (4.23e-3)" "unprognostic (1.78e-1)" "unprognostic (8.10e-2)" "unprognostic (2.88e-2)" "unprognostic (1.61e-1)" "unprognostic (1.47e-1)" "unprognostic (3.15e-2)" 8.8 4.9 4.4 3.2 5.0 2.3 19.1 11.1 5.9 13.6 6.2 4.8 12.2 3.8 12.7 8.6 7.2 7.8 5.7 6.9 4.4 3.4 5.7 4.4 14.0 1.9 3.3 4.5 8.6 10.9 10.7 8.9 5.5 7.9 7.8 6.2 6.9 9.9 11.4 10.3 4.8 4.2 15.4 5.2 2.7 6.4 6.2 3.5 1.8 11.2 6.6 3.0 9.1 7.6 1.6 2.1 4.1 1.0 2.6 1.0 0.5 6.6 1.9 7.8 8.4 5.6 7.5 5.9 6.7 5.3 6.3 6.4 0.8 5.4 5.4 4.6 7.2 2.8 5.2 7.7 5.3 5.6 1.4 5.2 0.3 6.6 2.9 7.2 1.2 0.4 5.0 7.6 4.6 12.1 6.3 7.0 4.9 1.1 3.9 6.3 6.8 3.6 0.6 7.1 3.3 2.8 6.6 11.4 4.3 3.9 6.9 6.6 6.0 9.3 4.7 8.9 4.3 6.1 3.1 7.2 8.4 6.9 11.5 4.8 7.1 3.4 4.2 5.8 1.4 3.5 4.1 1.0 0.8 0.8 0.6 1.0 0.8 0.7 0.7 0.7 1.6 0.8 0.9 3.8 2.6 0.8 2.1 0.6 0.5 4.4 5.0 11.1 5.9 4.4 3.4 3.3 4.5 7.9 3.5 14.9 14.4 1.5 6.3 3.7 10.5 3.6 5.1 4.0 4.5 7.0 21.6 2.5 1.7 5.7 3.8 12.8 3.5 0.0 4.5 5.1 10.1 7.2 2.3 3.6 1.4 6.4 4.7 20.3 4.0 3.9 18.4 4.8 3.3 1.0 4.5 4.1 5.0 3.5 33.2 2.4 8.7 32.3 11.3 0.9 4.3 3.3 1.3 2.5 8.7 5.4 ZNF185 SCELL ENSG00000147394 "Zinc finger protein 185 with LIM domain" O15231 X 152914442-152973480 "Plasma proteins, Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 93.5;esophagus: 67.6" "Cell type enhanced" "Detected in many" 10 "Pancreatic endocrine cells: 42.4;Suprabasal keratinocytes: 18.4;Urothelial cells: 17.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 21.6" "Group enriched" "Detected in many" 5 "granulocytes: 21.6;monocytes: 13.9" "Cell line enhanced" "Detected in many" "A-431: 31.7;EFO-21: 37.7;HBEC3-KT: 26.2;PC-3: 23.2;TIME: 61.8" "Low region specificity" "Detected in all" "HPA000400, HPA016438" Enhanced Supported "Plasma membrane,Actin filaments,Focal adhesion sites,Cytosol" NA NA 5400 "Plasma membrane, Cytosol" "Actin filaments, Focal adhesion sites" "HPA000400: AB_1080685, HPA016438: AB_1859109" "unprognostic (1.34e-1)" "unprognostic (1.39e-1)" "unprognostic (1.84e-1)" "unprognostic (2.43e-2)" "unprognostic (9.75e-3)" "unprognostic (2.69e-1)" "unprognostic (2.49e-2)" "prognostic unfavorable (1.50e-4)" "unprognostic (7.94e-2)" "unprognostic (6.28e-2)" "prognostic unfavorable (3.30e-5)" "unprognostic (5.18e-2)" "unprognostic (8.12e-2)" "unprognostic (1.99e-1)" "unprognostic (1.37e-1)" "unprognostic (2.10e-1)" "unprognostic (1.60e-1)" 3.9 1.7 1.8 2.0 3.2 0.8 1.8 2.7 2.0 14.3 1.8 1.4 10.7 0.0 3.8 93.5 67.6 3.1 2.0 1.9 1.7 0.8 2.0 1.1 3.3 3.1 2.1 1.1 1.2 0.9 0.1 2.3 4.0 1.7 4.2 0.3 1.3 10.1 28.1 1.5 9.9 1.2 1.4 1.2 3.7 0.8 1.9 2.0 1.2 3.9 1.4 6.6 2.1 22.8 0.4 3.8 21.6 13.9 0.2 0.6 10.2 31.7 6.7 0.6 0.4 0.8 1.1 1.5 1.5 0.1 3.9 0.5 0.2 9.6 0.4 37.7 2.3 0.4 4.5 0.9 26.2 16.3 0.3 0.6 2.0 2.7 1.0 1.9 0.1 0.1 0.8 18.8 0.4 15.4 3.9 20.2 0.4 0.1 0.3 0.1 7.5 0.1 0.1 0.5 8.1 23.2 0.1 0.1 0.2 2.0 3.0 0.2 2.2 0.0 6.0 0.9 6.5 6.2 0.7 61.8 0.2 13.7 0.8 1.1 0.3 0.2 0.2 0.4 2.3 0.4 21.6 13.9 5.7 0.5 12.9 0.3 0.4 0.4 0.6 3.8 0.3 0.6 0.3 9.5 0.2 10.2 2.5 0.5 10.2 1.8 3.2 2.7 2.0 1.7 0.8 2.1 1.1 1.7 2.0 11.9 1.6 0.5 4.9 8.1 0.5 1.0 2.5 2.7 4.5 8.7 2.0 3.2 0.0 8.6 0.2 0.5 0.0 0.0 2.6 4.3 2.8 5.1 1.1 0.0 8.6 0.0 0.0 0.6 8.8 0.0 1.1 4.6 3.3 4.6 2.1 3.0 42.4 0.0 1.1 0.9 0.0 0.0 0.5 2.3 5.3 18.4 0.6 0.0 3.3 17.6 ZYX ENSG00000159840 Zyxin Q15942 7 143381080-143391111 "Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Host-virus interaction" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Kupffer cells: 188.3;monocytes: 174.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 47.5" "Group enriched" "Detected in many" 4 "dendritic cells: 16.5;granulocytes: 47.5;monocytes: 22.1" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004835, CAB009321, HPA073497, CAB075747" Approved Supported "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA 420000000 "Focal adhesion sites" "Plasma membrane, Actin filaments" "CAB009321: AB_2221290, CAB075747: AB_2665753, HPA004835: AB_1080771, HPA073497: AB_2686611" "unprognostic (1.96e-2)" "unprognostic (5.35e-2)" "unprognostic (2.36e-2)" "unprognostic (1.25e-1)" "unprognostic (1.44e-2)" "unprognostic (1.18e-1)" "unprognostic (2.21e-3)" "unprognostic (1.66e-3)" "unprognostic (2.60e-1)" "unprognostic (4.22e-1)" "unprognostic (1.98e-1)" "unprognostic (2.43e-1)" "prognostic unfavorable (7.92e-5)" "unprognostic (1.39e-1)" "unprognostic (8.12e-2)" "unprognostic (1.95e-1)" "unprognostic (6.72e-2)" 52.7 11.7 7.7 39.3 8.8 46.1 34.3 17.5 22.2 61.1 56.8 10.7 20.5 13.6 103.6 38.6 52.3 48.9 58.1 22.7 7.4 7.7 24.7 21.2 52.8 63.0 8.8 8.3 58.1 15.9 63.8 9.1 32.4 15.5 43.8 10.8 17.9 18.8 40.7 28.3 21.1 26.6 74.7 8.5 57.1 28.3 37.4 7.1 24.4 18.9 19.1 26.0 93.7 35.7 0.9 16.5 47.5 22.1 4.1 6.7 9.0 12.8 7.8 10.3 14.4 19.5 43.7 12.3 27.3 32.1 30.0 25.2 26.5 8.3 0.8 10.7 33.3 17.3 10.4 6.3 27.6 14.0 13.7 3.4 20.0 9.2 9.2 34.4 16.1 31.9 46.5 12.3 32.7 11.1 18.6 37.9 1.8 4.9 8.7 31.9 14.4 0.2 32.4 21.6 5.0 50.5 3.0 5.5 1.2 22.7 6.8 0.5 7.8 21.5 20.1 11.2 9.8 2.4 16.1 66.4 35.8 14.7 38.0 28.7 2.8 3.7 2.2 31.8 16.9 23.7 4.9 18.2 12.5 5.9 19.2 4.7 0.9 5.5 6.7 16.5 0.5 3.5 4.0 47.5 4.1 22.1 4.2 5.0 9.0 7.7 8.8 17.5 22.2 7.4 7.7 8.8 8.3 15.5 7.1 6.0 8.3 17.4 144.9 30.0 3.3 10.9 33.1 2.7 27.3 33.2 0.0 28.4 6.6 98.9 1.5 40.4 21.3 0.0 81.4 80.5 41.1 47.9 35.8 26.7 153.1 0.0 36.7 66.9 188.3 4.7 26.4 86.6 13.5 174.9 19.9 15.1 120.5 31.6 51.9 14.7 2.6 84.1 82.1 7.9 9.5 17.7 23.5 54.9 19.6 87.0